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Summary 
This thesis describes the model-based development and validation of an advisor for the 
maintenance of artificially ventilated patients in the intensive care unit (leU). The advisor 
employs fuzzy logic to represent an anaesthetist's decision making process when adjusting 
ventilator settings to safely maintain a patient's blood-gases and airway pressures within desired 
limits. Fuzzy logic was chosen for its ability to process both quantitative and qualitative data. 
The advisor estimates the changes in inspired O2 fraction (FI02), peak inspiratory pressure 
(PEEP), respiratory rate (RR), tidal volume (VT) and inspiratory time (TIN), based upon 
observations of the patient state and the current ventilator settings. The advisor rules only 
considered the ventilation of patients on volume control (VC) and pressure regulated volume 
control (PRVC) modes. 
The fuzzy rules were handcrafted using known physiological relationships and from tacit 
knowledge elicited during dialogue with anaesthetists. The resulting rules were validated using a 
computer-based model of human respiration during artificial ventilation. This model was able to 
simulate a wide range ofpatho-physiology, and using data collected from leu it was shown that it 
could be matched to real clinical data to predict the patient's response to ventilator changes. 
Using the model, five simulated patient scenarios were constructed via discussion with an 
anaesthetist. These were used to test the closed-loop performance of the prototype advisor and 
successfully highlighted divergent behaviour in the rules. By comparing the closed-loop 
responses against those produced by an anaesthetist (using the patient-model), rapid rule-
refinement was possible. The modified advisor demonstrated better decision matching than the 
prototype rules, when compared against the decisions made by the anaesthetist. 
The modified advisor was also tested using data collected from leu. Direct comparisons were 
made between the decisions given by an anaesthetist and those produced by the advisor. Good 
decision matching was observed in patients with well behaved physiology but soon ran into 
difficulties if a patients state was changing rapidly or if the patient observations contained large 
measurement errors. 
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Chapter 1: Introduction 
Hypothesis: Using fuzzy-logic it is possible to construct an advisory system that emulates the 
changes made by an anaesthetist to the ventilator settings. on patients in intensive care (leU). 
Knowledge elicitation and rule-refinement can be improved through the use of a computer-based 
model of a ventilated patient. The model can be used to simulate closed-loop control and provide 
stability analysis of the control rules. This can have advantages over validation made using only 
clinical data, and highlights a design methodology that facilitates future advisor design. 
Artificial ventilation is defined as the provision of minute volume (Mv) of respiration by 
external forces. It is usually required when there is either severe dysfunction of the mechanics of 
breathing, impairment to the patient's respiratory muscles or a need to improve the oxygenation 
ofthe arterial blood. The main situations in which it is employed are; 
1). Resuscitation following acute apnoea (cessation of breathing). 
2). Anaesthesia with paralysis. 
3). Intensive care with failure of one or more vital functions. 
4). Prolonged treatment of chronic ventilatory failure. 
Patients are usually connected to a ventilator using an endotracheal tube via a humidifier, see 
Figure 1.1. The vital functions of the patient (i.e. heart rate, oxygen saturation, cardiac output, 
blood pressure, etc) are recorded using a bedside monitoring system, and accurate measurement 
of arterial and venous blood O2 and CO2 are made using a blood-gas analyser. 
o 
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Figure 1.1: Overview of patient on artificial ventilation. 
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Ventilatory support is continued, until the underlying causes of respiratory failure have been 
resolved. From the start of intubation, the anaesthetist has to maintain the patient's blood-gases 
and airway pressures within safe limits with a view to eventually weaning them from the 
ventilator. This involves adjustment of the ventilator settings in response to the gradual 
improvement or degradation of the patient's condition. It is this decision process that we wish to 
emulate using a fuzzy-logic based advisor. 
The potential benefits of an advisory system for the ventilatory care of patients in ICU have 
been expressed for many years, and previous studies have highlighted advantages in terms of 
improved patient care and anaesthetist training. Many attempts to represent anaesthetists' 
knowledge in ventilatory care have been made, for example Fagan, 1980; Miller, 1985; 
Summers et ai, 1987 and 1988; Singh & Roth, 1988; Sittig, 1988; Farr & Fagan, 1989; 
Hermindezsande, et ai, 1989; Rudowski et ai, 1989; Shahsavar et ai, 1989 and 1991; Arkad et 
ai, 1991; Summers et ai, 1991 and 1992; Miksch et ai, 1993; Fernando et ai, 1995; Dojat et ai, 
1996 and 1997; Snowden et ai, 1997; to name but a few. 
However, increased understanding of the ventilation care problem has led to changes in the 
ventilation strategies employed, causing advisory systems to become outmoded, and no longer 
applicable to new clinical practices. Consequently, new advisor rules need to be constructed and 
re-tested against clinical data to ensure that the advice generated is safe. This is an extremely 
time consuming process since it has to be repeated each time the rules are modified. To make 
matters worse, the data used for validation may contain significant measurement errors, 
complicating any decision comparisons made. Whilst a truly useful system must be able to deal 
with such errors, developing an advisor in this way for complex processes can prove extremely 
labour intensive. Such investment will be wasted when conceptually very different care 
strategies are introduced into ICU. Furthermore, unless the control-loop can be closed between 
the advisor and the process then no guarantee of rule stability can be assured. The rules may 
contain divergent or limit-cycle behaviour that is not detectable using one-off comparisons of 
decision differences. Since clinicians are unlikely to close the control loop until safe control has 
been demonstrated we are left with somewhat of a design dilemma. 
There is a better way - model-based advisor development! If control system design is to keep 
abreast of current care developments then a more rapid method for rule validation is required. 
By constructing a computer-based model of the process, closed-loop control can be simulated 
and the performance of the rules assessed. Because this is closed-loop control (albeit simulated) 
the incidence of rule instability, divergence and limit-cycle behaviour can be rapidly identified 
and resolved. 
With careful selection of the model, virtual patient scenarios can be constructed to represent a 
wide range of respiratory pathology and trauma. These have the advantage of being repeatable 
and free from measurement errors, a quality not possible using clinical data. This allows 
quantitative comparisons to be made between anaesthetists' decisions and those produced by the 
advisor, thus enabling rapid identification of rule errors and the elicitation of tacit knowledge 
that may have been missed during the prototype advisor design. Better still, the efficacy of 
alternative advisor designs can be quantitatively measured. 
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Fuzzy-logic was chosen as the method for rule representation since it is able to process the 
uncertainties of the problem. Its applicability to process control has been widely demonstrated 
and recent work has shown its use in the maintenance of end-tidal Peo2 during mechanical 
ventilation in anaesthesia [Schaublin et ai, 1996] and during high-frequency jet ventilation 
[Noshiro et ai, 1994]. Interacting and conflicting rules can be processed with the same degree of 
ease, due to the simple computational mechanics of fuzzy logic. Also its use of linguistic 
classifiers (e.g. inspired O2 is high) makes the system readily interpretable by an expert (i.e. an 
anaesthetist). The simplicity of rule representation makes for rapid modification and methods 
exist for self-organisation of control rules. This makes it well suited for future design. 
Whilst developing an advisor capable of handling all aspects of ventilatory care is the long term 
objective, this research was restricted to a sub-set of the care-problem in order to prove the 
capabilities and benefits of fuzzy-logic and model-based controller design. The advisor was 
therefore restricted to the maintenance of arterial O2 partial pressure (Pao2), arterial CO2 partial 
pressure (Pae02), pH and peak inspiratory pressure (PIP) via the adjustment of inspired O2 
fraction (FI02), positive end-expiratory pressure (PEEP), respiratory rate (RR), tidal volume 
(VT) and inspiratory-expiratory ratio (I:E), in patients ventilated using continuous mandatory 
ventilation (CMV) and in particular those on volume control (VC) or pressure regulated volume 
control (PRVC) modes. These patients are expected to be well sedated and therefore performing 
no breathing for themselves or indeed triggering any breaths. The patient model was selected to 
meet the requirements of this sub-problem. 
A summary of the thesis chapters is given below; 
Ch 2: Fuzzy Logic and its Application to Control in Biomedicine 
This provides a brief overview of fuzzy logic concepts and principles, followed by a review of 
the previous applications of fuzzy logic to biomedical control with particular reference to 
advisory systems and ventilator management. 
Ch 3: Respiratory Models 
This provides a review of respiratory models with particular reference to their classification and 
suitability for advisor development. Models are grouped according to the process they are 
describing and whether they are theoretically (white-box) or empirically (black-box) based. Also 
described are model-based nomograms that are useful descriptors of physiological behaviour. 
Ch 4: SOP A Vent - Patient Model Development 
The architecture of the patient model is presented together with a detailed description of the 
equations behind it and their sources. This includes explanations of the O2 and CO2 mass 
transport equations and the O2 and CO2 gas dissociation function (GOF) together with the 
computation of their inverse (IGOF). A simple ventilator model is also described, and equations 
for the conversion of gas-volume, gas-fraction and gas flow-rate from observed units and 
conditions to the units and conditions required by the model are presented (e.g. STPD -
standard temperature pressure dry converted to BTPS - body temperature pressure saturated). 
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The functional implementation of the O2 GDF and it validation using clinical data available in 
the literature is discussed, followed by the implementation of its inverse. Methods employed to 
optimise the inverse function, are described. The implementation of the O2 transport equations 
using SIMULINK is presented and its ability to match expected normal blood-gas values is 
demonstrated using patient parameters representative of a healthy male subject. This is repeated 
for the CO2 GDF and CO2 transport equations, and then the behaviour of the integrated O2 and 
CO2 model is examined. This does not constitute the final model and further improvements are 
discussed in the beginning of Chapter 7. 
Ch 5: Clinical Validation of Patient Model 
This chapter describes the attempts to validate the patient-model using data collected from ICU. 
The primary objective was to ascertain whether the model could predict blood-gas responses to 
changes in ventilator settings. Whether this can be achieved depends very much on the quality 
of the data collected and the parametric sensitivity of the model. The first section therefore 
provides a brief review of sensitivity analysis methodology including descriptions of the 
problems that can be encountered and their implications when interpreting sensitivity results. 
The classical sensitivity analysis of the patient-model is then described and the implication of 
the results to clinical measurement and model tuning are discussed. 
Next, the data collection protocols and data processing required to produce all of the inputs of 
the model are described. The method used for tuning the model to match the observed blood-
gases is described and the ability of the model to match blood-gas responses to ventilator 
changes is assessed using qualitative and quantitative techniques. Finally, the possible causes of 
response errors are discussed. 
Ch 6: FA VeM - Advisor Development 
The advisor architecture is presented together with a detailed examination of the choice of 
inference methodology. This is followed by a discussion of techniques used to implement the 
rules, including the need for completeness, the method of fuzzy consequent construction and the 
description of a rule reduction algorithm to reduce computational overheads. 
The development of the F102, PEEP, Mv and VT-RR advisor subsystems is presented in turn, 
highlighting the sources of knowledge and methods employed to elicit them. The F102 rule 
development describes the elicitation of fuzzy classifications for Pa02 from an anaesthetist and 
the use of iso-shunt nomograms to deduce prototype control rules. The evaluation of these rules 
by an anaesthetist is described, and the suitability of the advice generated assessed. The 
modifications made to the control rules based on this assessment are described. PEEP rule 
development is described next with an explanation of the benefits and disadvantages of PEEP 
and how these might be expressed using fuzzy control rules. The F102 and PEEP rules work 
together to provide maintenance of Pa02. 
PaC02 maintenance via the adjustment of Mv is explored and simple control rules proposed. 
The importance of goal-orientated Paco2 maintenance to encapsulate particular ventilation 
requirements such as patients with head injury is discussed. These control rules are then 
extended to include acid-base imbalance. The causes of imbalance are described in detail and 
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the elicitation of pH fuzzy classes using the Henderson-Hasselbalch equation presented. The 
rules are further extended to include consideration of PIP and thus prevent possible barotrauma. 
Finally, the development of rules to correctly convert changes in Mv to changes in RR and/or 
Vr is described. The concept of an ideal RR-Vr relationship is presented together with its use to 
estimate the control rules. The rules are extended to include restrictions due to elevated PIP. 
Ch 7: Closed-loop Advisor Validation 
The prototype rules are then evaluated usmg simulated closed-loop control. This chapter 
highlights the advantages that such an approach has over other validation methods and describes 
its implementation. Before closed-loop validation could be performed, improvements were 
made to the model so that it would respond realistically to changes in ventilator settings. These 
include modelling of pH changes, airway pressures, effects of PEEP and the inclusion of 
relationships governing nominal cardiac output (Q,), O2 consumption (Vo2 ) and CO2 
production ( Veo2)' The equations describing these improvements are presented. 
The use of this improved model to construct virtual patient scenarios with input from an 
anaesthetist is described. These are then used to provide simulated closed-loop evaluation of the 
prototype advisor's performance. Behavioural discrepancies are highlighted and modifications 
made to the rules described. The advisor is then re-evaluated and the level of performance 
improvement assessed. Any remaining decision differences are examined and potential 
solutions discussed. 
Ch 8: Clinical Validation of Advisor 
In the final chapter the modified advisor is validated against real clinical decisions. The causes 
of decision mismatch are explored in detail and possible solutions outlined. Analysis is made 
using both qualitative scoring techniques and statistical measures. 
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Chapter 2: Fuzzy Logic & its Application in Biomedicine 
2.1 Introduction 
Fuzzy logic theory was first developed by Zadeh in 1965, and combines elements of multi-valued 
logic, probability theory and artificial intelligence. It provides the concept of fuzzy linguistic 
variables and uses fuzzy sets to express linguistic rules that can produce a realistic control 
strategy. It is therefore well suited to problems that require human judgement or loose linguistic 
descriptors of the control process, and for controlled systems that have non-linear characteristics 
that are difficult to model mathematically. 
This chapter provides a brief overview of the principles and concepts of fuzzy set representation, 
rule inference and defuzzification. For more detailed explanations of these and other related 
concepts the reader is directed towards the work of Driankov et al (1993) and Yan et al (1994). 
This is followed by a review of fuzzy logic control applications, and is restricted to examples 
occurring in biomedicine. Tong (1977) gives a survey of early FLC applications, and Sugeno (1988) 
describes the use of FLC in industrial processes such as heat exchangers, blast furnaces, waste water 
treatment and train operation. 
2.2 Basics Principles and Concepts of Fuzzy Logic 
Fuzzy logic is a branch of logic that represents membership within a set as a continuous function 
rather than having strict true/false membership. The degree of membership is the certainty 
(expressed as a number from 0 to 1) of a particular observation value belonging to a fuzzy set. 
This enables complex computing tasks with imprecise or fuzzy answers to be processed easily. It 
enables linguistic concepts such as hot and cold to be described mathematically and thus used to 
represent statements such as 'The room temperature is hot' . 
2.2.1 Set Membership and Geometry 
Several different shapes can be used to model linguistic uncertainty, see Figure 2.1. The most 
popular fuzzy set shapes are the triangular and trapezoidal ones, because of their simplicity of 
representation, and ease of computer implementation. The fuzzy singleton is a special class of 
crisp set, with full membership only occurring for a unique observation value. 
The way in which linguistic terms of a fuzzy variable are mapped onto its domain (or universe of 
discourse, UoD) can affect the performance of the controller in a number of ways, see Section 
6.3.2. In order to discuss these influences it is necessary to introduce some definitions of 
parameters which characterise a membership function. 
Peak Value 
This is the point at which the degree of membership for a given linguistic value (P) is 1, i.e. J1 (Xpeak) = 
1, see Figure 2.2. In the case of trapezoidal membership functions the peak value is an interval. 
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J I : 1 I 0 I I J 6 I I 
23 24 2.5 26 27 DC 23 24 2.5 26 27 DC 23 24 2.5 26 27 DC 
fuzzy singleton crisp fuzzy set triangular fuzzy set 
]~ :J C\ :lL I I 
23 24 2.5 26 27 DC 23 24 2.5 26 27 DC 23 24 2.5 26 27 DC 
bell-shaped fuzzy set trapezoidal fuzzy set sigmoid fuzzy set 
Figure 2.1: Different fuzzy set membership functions 
Left and Right Width 
The left width of a membership function II is the length of the interval from the peak value to the 
point when the degree of membership equals zero. Similarly the right width is the interval from 
the peak value to the point to the right of the peak value when II (x) = O. The sum of the left and 
right widths defines the support of II, see Figure 2.2. If the left and right intervals are equal the 
membership function is said to be symmetrical. 
1 
support 
,... . ... 
left width ~ 
Xpeak 
right width 
Figure 2.2: The peak-value, left width, right width and support of a triangular membership function. 
Cross-point 
Usually, neighbouring membership functions on a given VoD intersect, allowing an observation 
to exist in more than one set simultaneously. Let III and 112 be two membership functions 
representing two linguistic values upon the same universe of discourse. A cross-point between III 
and 112 is that value Xcross within the universe of discourse such that; 
(2.1) 
The cross-point level is defined by the degree of membership at III (Xcross) which by definition of 
the cross-point is the same as /.12 (xcross). The cross point ratio is the number of cross-points 
between two neighbouring membership functions. In triangular sets this can only ever be 1 or O. 
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Figure 2.3 illustrates the above definitions in the case of triangular functions. It is important to 
remember that all of the above notions are relevant for any type of membership function. 
J.I 
1 
Xcross 
Cross-point level = 0.4 
Cross-point ratio = 1 
x 
J.I 
1 
No cross-points 
Figure 2.3: Cross-points and cross-point levels of triangular membership functions. 
2.2.2 Fuzzy Inference 
x 
In a fuzzy logic controller (FLC) the possible output actions are defined using a number of IF-
THEN rules. A collection of these rules forms the rule-base or knowledge-base of the FLC. 
Most FLCs use rules that have two inputs (or antecedents) and one output (or consequent). The 
inputs usually considered are the error from a desired set-point and the change in error. The 
output is either the actual control level or the change in control level (increment or decrement). 
Typically the fuzzy inputs and fuzzy outputs are described by seven linguistic sets, ranging 
from positive big to negative big. An example of a simple rule-base might be; 
1). IF (error is zero) AND (change in error is pos itive small) 
THEN (output is negative small). 
2). IF (error is zero) AND (change in error is zero) 
THEN (output is zero). 
3). IF (error is negative small) AND (change in error is zero) 
THEN (output is positive small). 
The controller inputs are used to obtain the contribution of each rule to the final output. This is a 
process known as fuzzy inference. Using what is known as individual-rule based inference, one first 
'fires' each rule with a fuzzy singleton and obtains n scaled or clipped consequent fuzzy sets that are 
aggregated to form the fuzzy output. Scaled sets are produced using Larsen's implication operation 
(also known as MAX-DOT inference) [Kaufman, 1975] and clipped sets are produced using 
Mamdani's implication operation (also known as MAX-MIN inference) [Mamdani et ai, 1981]. This 
process is best clarified graphically using the above rule-base example, see Figure 2.4. 
The firing weight of a rule (as defined by the height of the clipped or scaled fuzzy set) is 
normally obtained using the minimum height of the antecedent memberships. This is known 
as the liaison operator, and other operators include algebraic product, bounded sum, bounded 
product and drastic product. The minimum and algebraic products are the most commonly 
used liaison operators and have different advantages depending upon their application. 
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Algebraic product will produce smaller firing weights than the minimum operator if the input 
memberships are less than 1, see Figure 2.5. 
The final stage of the inference process is to derive a scalar output from the fuzzy aggregated 
output. This is known as defuzzification and is discussed in the next section. 
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fuzzy aggregated output 
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-4 -2 \:1?4~ 
defuzzified 
output 
PS: positive small 
NS: negative small 
Z: zero 
Figure 2.4: Diagram of the fuzzy inference mechanism using (a) scaled fuzzy sets (Larsen's 
implication) and (b) clipped fuzzy sets (Mamdani's implication). 
Z firing weight 
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Figure 2.5: Difference in rule-firing outputs using the minimum and algebraic liaison operators. 
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2.2.3 Defuzzification 
Many methods exist for output defuzzification, but perhaps the most widely used are centre-of-
gravity (CoG) and centre-of sums (CoS). The main function ofthe defuzzification process is to 
take the distributed fuzzy output derived using the inference process (as described above) and 
produce a single output value that can be used to drive the controlled process. 
The CoG method finds the balance point of the aggregated fuzzy output. In this case the aggregated 
fuzzy output is the union of the scaled (or clipped) rule consequents. The CoS method is identical to 
CoG except the aggregated fuzzy output is the sum of the rule consequents, see Figure 2.6. 
-6 6 -6 
CoG CoS 
(a) (b) 
Figure 2.6: Comparison between (a) centre-of-gravity defuzzification method where the 
aggregate is formed by taking the union of the consequent sets and (b) centre-of-sums 
defuzzification method where the aggregate is formed by taking the sum of consequent sets. 
The bold line indicates the aggregated fuzzy output. 
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2.3 Biomedical Applications of Fuzzy Logic 
The following biomedical applications ofFLC have been found and are discussed in more detail below; 
1). Post-surgical control of mean arterial pressure (MAP). 
2). Control of depth of anaesthesia (DO A). 
3). Ventilator control. 
4). Control of Fr02 and isoflurane delivery in minimal flow anaesthesia. 
5). Pace-maker regulation. 
6). Treatment of renal anaemia. 
7). Post-operative pain control. 
2.3 .1 Post-surgical Control of Mean Arterial Pressure 
The fast-acting vasodilator drug sodium nitroprusside (SNP) is used to treat patients who demonstrate 
elevated systemic arterial blood pressure after open-heart surgery. The rapid and powerful action of 
SNP requires the frequent monitoring of mean arterial pressure (MAP), followed by adjustment of 
SNP infusion rate. Ying et al (1992) proposed a closed-loop controller that would relieve nurses of this 
task, leaving them free to perform other duties. A simple 4 rule FLC [ying, 1988] that derived changes 
in SNP infusion rates based upon error from MAP set-point (e) and rate of ehange in error (e ), was 
converted into a set of lOnon-fuzzy control algorithms. This gave a precise analytieal representation of 
the fuzzy controller, a feature not usually possible since most FLC structures are very complex. These 
non-fuzzy algorithms describe the control relationship in terms of the input and output scaling factors 
and the turning point of the fuzzy sets. These were optimised using a Laplace model of the SNPIMAP 
relationship, to give the best generalised control of patients with a wide range of sensitivities to SNP. 
Ruiz et al (1993) produced a much simpler FLC that used 3 trend measures of MAP over 160, 
80 and 20 second observation windows, to determine whether the SNP infusion rate should be 
increased, decreased or maintained. These trends gave an indication of the long-term and short-
term MAP behaviour. Having established the action required, the SNP infusion rate was then 
adjusted using quantitative relationships. This approach was shown to give adequate performance 
with small over and undershooting outside of predefmed limits, and produced significantly better 
performance than manual control. The control algorithm separates the problem into qualitative 
''What to do?" using FLC and quantitative "How much?" using clinically proven relationships. 
2.3.2 Depth of Anaesthesia 
Two areas of anaesthesia control have been explored using FLCs; unconsciousness using inhaled 
anaesthetics, and muscle relaxation using infused neuromuscular block. Unconsciousness is 
considered to be the depth of anaesthesia (DOA) necessary to counteract physiological response 
to surgical stimuli (i.e. the incision of a scalpel). Muscle relaxation on the other hand is necessary 
to prevent potentially fatal involuntary movements in a patient. 
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Unconsciousness Anaesthesia 
Traditionally DOA has been controlled by maintaining systolic blood pressure (SBP) at pre-
anaesthetic levels. Tsutsui & Arifa (1994) described an FLC for the closed-loop control of SBP 
via enflurane anaesthesia. The SBP was sampled every 30 seconds and the current value and 
previous value were used as the inputs to the FLC, with the output being the enflurane percentage 
concentration. Rules were constructed to establish an initial SBP value of MAC-BAR (minimum 
alveolar concentration to block adrenergic response in 50 % of patients [Roizen et ai, 1981 D, and 
maintain it at AD95 (the known value of anaesthetic effective dose for 95 % of patients [Dejong & 
Eger, 1975]). In clinical trials the FLC maintained SBP to within ± 20 % of the pre-anaesthetic 
SBP in 82 % of cases, compared to 83 % using manual control. 
Meier et al (1992) developed a similar FLC for the control of DO A using proportional-integral 
(PI) control. Instead of SBP, the inputs to the FLC were the error from mean arterial pressure 
(MAP) set-point and the integral of the error. The output was the % concentration of isoflurane 
and the integral of the inspired isoflurane fraction. In clinical trials [Zbinden et aI, 1995], the 
FLC outperformed human control at skin incision (maintaining 48.2 % of all MAP values within 
± 10 % of the desired level, compared to 40.4 % using human control) , but performed slightly 
worse during the rest of the operation (78.3 % using FLC and 82.3 % using human control). 
It is questionable whether arterial blood pressure alone provides an accurate measure of the DOA and 
therefore a guarantee of unconsciousness in the patient. This problem was addressed by Shieh et al 
(1998) using a hierarchical control structure based on SAP, heart rate (HR) and end-tidal gas 
concentrations (Et) to adjust desflurane concentration. The first hierarchical level used an FLC to 
control SAP at set-point. The second level used a rule-base to control HR in the stable condition. A 
third level used anaesthetists' experience to tune the SAP set point level when Et reaches upper and 
lower limits. To prevent awareness during anaesthesia a fourth level used the low limit of Et to 
determine the dose of inhaled anaesthetics, and finally an alarm level to warn when SAP and Et are 
going out of safe limits. In clinical trials automatic control was maintained for 89.l5 % of the time, 
with manual control being necessary when the patient's condition fell outside the abilities of the 
controller or the controller was failing to maintain the patient as required. 
Another multi-factorial approach to DOA control was employed by Abbod & Linkens (1998). 
They used fuzzy logic fusion to combine two measures of DOA; auditory evoked response (AER) 
depth of anaesthesia (AER_DOA) and cardio-vascular based DOA (CV _DOA); into a final 
measure of DOA (F _DOA) that was used to control the infusion rate of propofol given to a 
patient. The AER_DOA was based on wavelet analysis of the AER signal and was classified 
using an Adaptive Network Based Fuzzy Inference System (ANFIS) [Jang, 1993]. Using a hybrid 
learning procedure, ANFIS can learn input-output mapping based on human knowledge (in the 
form of IF-TIffiN fuzzy rules). The AER_DOA was classified as awake, light, ok_light, 
ok_deep and deep. The CV _DOA used the same classifications of DOA and was based upon 
observations ofHR and SAP, with the rule-base derived from anaesthetist's experience [Linkens 
et ai, 1996]. The final DOA produced from the fuzzy logic fusion module was fed to the propofol 
plasma concentration controller. This fuzzy logic rule-based controller, used the current target 
concentration and the measured DOA to calculate a new target plasma concentration. From this 
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the drug infusion rate was derived using a 3-compartment patient model with an additional effect 
compartment. The overall DOA control system was validated using a computer simulated patient 
model, describing the pharmacokenetics and pharmacodynamics of propofol in the plasma. The 
outputs of the model were SBP, HR and AER. The results obtained from closed-loop simulations 
showed that the system effectively maintained the patient at clinically acceptable DOA. Clinical 
trials were being undertaken at the time of pUblishing. 
Muscle Relaxant Anaesthesia 
In 1988, Linkens & Mahfouf described a simple FLC for automated drug infusion of atracrium 
for muscle relaxant anaesthesia, where the problem of knowledge elicitation was tackled using 
self-organising fuzzy logic techniques. The efficacy of the controller was investigated via 
extensive simulation studies using a non-linear model of the drug response. Linkens & Abbod 
(1993) discussed the importance of such anaesthesia simulators for the design of supervisory 
rule-based control in the operating theatre. 
Mason et al (1994) described a similar fuzzy controller using a PD + I (proportional. differential 
plus integral) configuration. The rules of the FLC were handcrafted based on simulations 
involving the non-linear atracrium dose-response characteristics. This was assessed clinically 
[Mason et al. 1996] and gave good control performance although the infusion rate appeared 
erratic. An alternative schema, using a self-learning fuzzy logic controller (SLFLC) was proposed 
in 1997 [Mason et al. 1997]. This started with a blank PO (proportional-differential) rule-base and 
adapted the outputs of the fuzzy control rules in real time to match the needs of each individual 
patient. In clinical trials the atracrium infusion rate was observed to be much less erratic than 
when using the earlier simple FLC with a fixed rule-base, and the overall control performance was 
very good. A hierarchical approach to muscle relaxant anaesthesia, similar to that applied to 
desflurane anaesthesia, was considered by Shieh et al (1996 and 1997). 
2.3.3 Ventilator Control 
The use of fuzzy-logic for ventilator control (and this includes advisory systems) has not been 
that widely explored. One of the earliest examples is that of Vasil' eva et al (1989). They used 
an FLC to adjust the inspiratory gas flow (VI) produced by a ventilator in response to changes 
in alveolar pressure (PA(t). A simple model of the lung mechanics during inspiration and 
expiration was used to test the FLC. 
Sun et al (1994) described an FLC for the adj ustment of F102 in ventilated new-born infants. 
The controller utilised rules elicited from neonatologists and was implemented in real-time. 
Clinical trials were being conducted at the time of publication. 
In the 1980s, high-frequency jet ventilation (HFJV) came into vogue. This uses much smaller tidal 
volumes (typically 2.2 to 5.0 mllkg) and higher respiratory frequencies (60 to 300 rpm) than 
conventional mechanical ventilation. Its ability to provide ventilation at much lower inspiratory 
pressures promised much. unfortunately the complex and non-linear relationship between RR, Vr 
and PaC02 made routine application difficult. Noshiro et al (1994) used a fuzzy PI control system 
to successfully regulate end-tidal PC02 (PErC02) in a new HFJV ventilator. They compared the 
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closed-loop response of the FLC and a conventional PI compensator on 11 anaesthetised and 
intubated mongrel dogs. The performance of the two systems was almost identical, however the 
FLC was found to give better generalised control. 
Shaublin et al (1996) described the closed-loop control of end-tidal CO2 content fraction (FE-rCCh) 
via the adjustment of VT and RR, in artificial ventilation during anaesthesia. This was done 
whilst minimising the deviation of VT and RR from normal values of 10 rn1Ikg and 10 rpm 
respectively, and attempting to maintain the plateau airway pressure (Pplat) within suitable limits 
«3 - 4 kPa). Compared with human controllers, the FLC maintained desired FE-rC02 with similar 
precision and stability and gave good dynamic response to set-point changes. The breathing 
pattern, selected by the FLC was within clinically acceptable ranges. However, apart from 
maintaining P plat within acceptable limits, the controller did not adapt the ventilator settings to the 
lung function or lung mechanics of an individual patient, a feature offered by the adaptive 
ventilator controllers of Labscher et al (1994) and Weiler et af (1994). 
Most recently, Ncmoto et al (1999) developed a fuzzy-logic based advisory system (FLBAS) for the 
control of pressure support (PS) ventilation in patients with chronic obstructive pulmonary disease 
(COPD). Pressure support is prescribed for spontaneously breathing patients that are triggering breaths 
for themselves but require additional pressure to aid inflation of the lung because of muscle 
insufficiency or increased work of breathing. It enables the patient to be gradually weaned from 
artificial ventilation by gradually reducing the amount of pressure support (in cmH20) required. 
Nemoto et al used observations of heart rate, arterial O2 saturation (Sao2) and current RR and 
VT settings to determine the percent change in PS required. These observations defined a measure 
of the patient's status and were assigned to a quantity called CONDITION, having four possible 
categories: POOR, QUESTIONABLE, MODERATE and GOOD. A second quantity called 
TREND used observations of RR, change of RR, and change of Sa02 to derive a measure of 
whether the patient's condition is STABLE, IMPROVING, DETERIORATING or CRASHING. 
These were then combined using fuzzy-logic fusion to produce the controller output % PS-
change, labelled as INCREASE A LOT, INCREASE, MAINTAIN and DECREASE. Validation 
of the control rules was only made using retrospective comparison against actual clinical 
decisions made on 13 ICU patients. Consequently, whilst the advisor was found to have generally 
good agreement, there is no evidence of the controller's stability in closed-loop control. 
2.3.4 Miscellaneous Applications 
These have been included to illustrate the breadth of biomedical fuzzy-logic applications, and 
represent applications not falling into the above larger categories. 
Sugiura et al (1991) applied fuzzy-logic to the control of cardiac-pacemaker rate based upon 
observations of RR and body temperature (T BODY). The fuzzy relationship between RR and T BODY 
on intrinsic hear rates were derived using 3 mongrel dogs. The pace-rates calculated using the 
derived fuzzy rules were then compared against the intrinsic heart rates, of 2 different dogs. 
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Carolla et al (1993) reported the use of FLC for the control of alfentanil infusion for post-
operative pain relief. This was achieved using a simulated patient model of drug 
pharmacodynamic relationships. 
Bellazzi et al (1994) described the use of FLC in the delivery of recombinant human 
erythropoietin (r-HuEPO) for the treatment of renal anaemia. Validation was achieved by 
performing a case-simulation study using a multi-compartmental model of the erythropoietic 
response to r-HuEPO. The FLC was able to adapt to patient drug sensitivity. 
Curatola et al (1996) used fuzzy logic to control inspired isoflurane and O2 concentrations during 
minimal flow anaesthesia (MFA). The FLC enabled isoflurane and F102 to be maintained at set 
levels during MFA performed by anaesthetists not trained in minimal flow technique. When using 
MFA the inspired gas concentrations do not correspond with those in the fresh gas because of 
mixing with exhaled alveolar gas, making human control difficult. The FLC was able to 
demonstrate reliable isoflurane and F102 control and reduced anaesthetic gas delivery and costs 
over the human operator. 
Becker et al (1997) described the design and validation of a fuzzy logic based intelligent patient 
monitoring and alann system to ease the cognitive load of anacsthctists during high invasive surgery. 
2.4 Summary & Conclusions 
The basic principles of fuzzy set representation and an overview of the mechanics of individual 
rule-based inference and defuzzification have been described. 
The review of FLC applications highlighted an increased interest in the use of FLCs in 
biomedical applications, and this has led to their clinical acceptance in certain areas. Some simple 
controllers have been developed for the maintenance of artificially ventilated patients, but these 
have been restricted to subsets of the overall care problem. Model-based validation has been 
demonstrated to be of particular benefit for stability analysis and controller optimisation, 
although it has not yet been applied to ventilatory care. 
The next chapter reviews the models suitable for the development of a patient simulator for the 
validation of a fuzzy-logic-based advisor for the ventilation of patients on artificial ventilation. 
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Chapter 3: Review of Respiratory Models 
3.1 Introduction 
This chapter presents a critical review of mathematical models of the human respiratory system, 
placing them within historical context and according to various classification criteria. Particular 
attention is given to those models, or model elements suited to the development of a patient 
simulator for the purpose of advisor validation. The correct choice of model is a trade-off between 
complexity and clinical usefulness. A model with too much complexity becomes difficult to 
implement, whereas over simplification limits the range of physiological behaviour that can be 
represented. Consideration also needs to be given to the estimation of the model parameters to 
match its behaviour to that observed clinically. Again if the model is too complex then this 
becomes increasingly difficult to achieve as the number of unknown parameters increases. 
Classification According to Process 
Historically, models of the human respiratory system have been developed to explain various 
aspects of the process and can be categorised accordingly; 
I). Lung Mechanics: models of the mechanics of breathing being concerned with 
volume, flow and pressure characteristics of the lung system. 
2). Ventilators: models describing artificial mechanical ventilators, often developed 
in conjunction with models of lung mechanics. 
3). Gas Exchange: models concerned with gas exchange in the lungs. Usually only O2 
and CO2 but may also include the transport of N2 (nitrogen) and CO (carbon 
monoxide). 
4). Gas Dissociation: models of the relationship between blood-gas partial pressures 
and contents. 
5). Respiratory Control: models concerned with the self-regulating mechanisms of 
breathing to maintain O2, CO2 and pH homeostasis. 
6). Integrated: a combination of any number of the above model elements, describing 
their interaction to form a cohesive description of the entire respiratory process. 
The lung mechanics, ventilator, gas transport, gas dissociation and respiratory control models 
are known as local models and only deal with part of the respiratory system, whereas the 
integrated models are global. This is not a measure of their complexity, since integrated models 
may contain many simplifications resulting in poor specificity, whilst local models can contain 
deep physiological knowledge that make them comprehensive within their domain of operation. 
16 
Classification According to Method of Implementation 
A number of approaches to model implementation are available and these fall into one of three 
broad categories; 
1). White-Box Models: also known as theoretical models, these are based soundly 
and explicitly upon the underlying physical and chemical processes. 
2). Black-box Models: also known as empirical models, these are concerned with the 
interaction and interdependence of system variables, being mathematically 
representative of the process but imparting little in the way of physical meaning. 
Such models include regression models, neural models and parametric 
identification models. 
3). Grey-box Models: also known as empirico-theoretical models, these cover the 
majority of models, being based where possible upon the underlying physical and 
chemical processes but also dependent upon empirical relationships. 
Usually, model development aims to be as theoretical as possible (white-box modelling) enabling 
interpretation by the widest possible audience. It also helps to identify possible model inadequacies 
and assumptions made in the model, a process often difficult using black-box models. 
3.2 Grey-Box Models 
It is difficult to draw a distinction between gas exchange/transport models and respiratory 
control models, since their development is often dependent and interrelated. However, the 
research has often focused more on either physiological process modelling or ventilatory 
control modelling. More complex models also began to introduce many integrated 
physiological components including lung mechanics and empirical physiological relationships 
describing disease states. The following reviews have therefore been grouped according to the 
process types, however there will inevitably be some overlap between them. 
3.2.1 Respiratory Mechanics Models 
Respiratory mechanics models describe the relationship between inspiratory and expiratory 
flow rates and the pressures generated across the airway and alveolar space. Typically they 
describe the lung mechanics in terms of total flow resistance (R) and total compliance (C), but 
may also include terms describing the properties of the ventilator (if artificial ventilation is 
being considered). Compliance (in I/cmH20) is an indicator of lung and chest-wall elasticity 
and flow resistance (cmH20/l/sec) reflects resistive properties of both the tissue and peripheral 
airways. 
Several studies characterising the main aspects of breathing have been published. These have 
used different lumped-parameter models, ranging from a simple two-element resistance-
compliance linear model to more sophisticated physiological models which include tissue 
viscoelasticity, the inertial effects of the airways and branching networks [Lutchen & Costa, 
1990], to non-linear models [Ben-Haim et ai, 1988]. 
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Barbini et al (1994) compared the Bode diagrams of four lumped-parameter resistance-compliance 
models against those clinically observed on mechanically ventilated patients. They found that the 
simple two-element series R-C model (see Figure 3.la) produced Bode diagrams basically different 
from the clinical responses. This was resolved by the inclusion of an additional parallel compliance 
(Cp), see Figure 3.1b, although no physical meaning was attributed to this new element. 
More complex models have been suggested; a 4-element R-C model [Mead, 1969]; 6-element 
R-C-I model (where I is an inductance component) [Dorkins et aI, 1988] and a 9-element R-C-I 
model [Jackson & Lutchen, 1987]. However, this level of complexity may be useful in 
describing the frequency behaviour of the lungs across the range 0-200 Hz, but does not provide 
any real benefits in terms of clinical understanding. 
R 
O--L=:l-------,I 
o~_-----JI 
(a) 
C 
R 
O---r-C=:l-------,I 
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C 
(b) 
Figure 3.1: Electrical analogues of (a) the simple 2-element R-C airway model and (b) with an 
additional parallel compliance as proposed by Barbini et al (1994). 
3.2.2 Gas Exchange Models 
These models are concerned with descriptions of the gas diffusion between the alveolar space 
and the pulmonary capillaries. They form a key component in integrated model development 
and represent a significant part of the "controlled" process in models of respiratory control. 
The diffusion boundary is usually described in terms of a linear homogenous blood-gas barrier 
offering resistance to diffusion of the gases [Piiper & Scheid, 1981]. This assumes diffusion 
occurs only perpendicular to the barrier and is governed by Fick's law of diffusion. 
Early gas exchange models represented the lung as a single ideal alveolus compartment with a 
ventilation-perfusion ratio of unity CV/Q = 1) [Grodins et ai, 1954]. This was extended to 
include dead space and shunt compartments with V / Q = 00 and V / Q = 0 respectively [Riley & 
Cournard, 1949]. Using this classical gas exchange model it was possible to represent a wide 
range of patho-physiology. However, V / Q varies across the lung in an approximately log-
normal manner [Farhi & Rahn, 1955] and this gives rise to differences in O2 uptake from those 
obtainable using the 3-compartment model. West (1969) examined lung models with 3-1000 
respiratory segments and found that 10-compartments was sufficient to describe this log-normal 
17/ Q distribution. Kelman (1970) used a 25-compartment approximation to the log-normal 
17/ Q distribution. Recently, 4-compartment models of gas exchange have been employed 
[Petros et ai, 1993; Rutledge (1994 & 1995), providing a trade-off between representative O2 
uptake (and CO2 elimination) and clinical usefulness. 
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3.2.3 Gas Dissociation Models 
Models of the relationship between blood-gas tensions (partial pressures) and blood-gas contents 
have been used to bridge the gap between the mass transport blood circulation models (concerned 
with gas contents) and the lung diffusion models that are driven by differences in partial pressure 
between the alveoli and pulmonary capillaries. Similarly, gas partial pressures and not contents 
drive the chemoreceptors for ventilatory control. The relationship between pressure and content of 
each gas was determined early this century by driving off the gases from blood in successive 
steps - hence the term "dissociation curve". 
Oxygen Dissociation Curves 
In 1966 Kelman published an empirical description of the O2 dissociation curve (ODC), suitable 
for computer implementation. It extended the previous work of Adair (1925) and accounted for 
shifts in the position of the curve due to pH, Peo2, temperature and haemoglobin concentration, 
and has widely been accepted to be accurate for the majority of applications. 
However, at lower P02 the curve was found to diverge from experimentally determined values 
and Kelman (1968) corrected for this by switching to a different expression for O2 saturation 
when P02 was below 10 mmHg. 
Ingram & Bloch [1986] developed a very similar algorithm to that of Kelman, using the same 
equation to derive O2 saturation. However shifts in the position of the curve were based upon 
organic phosphate 2,3-diphosphoglycerate (2,3-DPG) concentration in haemoglobin, temperature, 
pH and base excess (BE). Corrections to the pH and BE effects were made according to the 2-3-
DPG levels. Additional shifts in the ODC position were accommodated by the inclusion of the 
ratio 26.8331Pso in the expression for virtual O2 pressure, where Pso reflects the 50% saturation 
point of the ODe and 26.833 mmHg is the normal operating point. 
Earlier ODC formulations are reviewed by Roughton (1964). 
Carbon Dioxide Dissociation Curves 
Kelman (1967) also formulated an algorithm for the conversion of Peo2 into CO2 content, taking 
into account the effects ofhaematocrit, pH, temperature and Po2. This was based upon the earlier 
nomogram of Singer & Hastings (1948). 
Inverse Dissociation Curves 
Unfortunately the gas exchange and respiratory control models require the calculation of the 
inverse of the dissociation functions. This is normally achieved using an iterative solution-
searching algorithm. Severinghaus (1979) did attempt to derive an explicit inverse function but it 
did not handle corrections required for shifts in pH and temperature. 
3.2.4 Respiratory Control Models 
These models attempt to describe the regulation of respiration via physiological feedback 
mechanisms, which indirectly monitor the amount of O2 and CO2 in the blood and adjust the level 
of alveolar ventilation to maintain homeostasis. This element of the respiratory system describes 
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the respiratory "controller" (respiratory centre) and has usually been developed alongside models 
of the controlled process, i.e. respiratory plant (lung apparatus and body tissues). 
In 1954 Grodins et af presented one of the earliest chemo-stat models of respiratory control. It 
described changes in ventilation in response to partial pressures of CO2 (Pe02)' The process 
model was based upon the laws of mass transfer and the respiratory centre was described by an 
empirical "black-box" model, that of a simple proportional controller; 
(3.1) 
where KJ and K2 are constants and Pve~ is the mixed venous Pe~. However, basing feedback on 
Pve~ was incorrect and later studies used arterial Pe~. The alveolar Pe~ was provided as a model 
output, enabling experimental confirmation of responses to the input stimulus of inspired gas Pe~. 
Significant improvements in descriptions of the gas transport models were made and in 1960 Defares 
et af added a brain tissue compartment with cerebral blood flow varying with Pe~. Further details of 
earlier models relating to the control of breathing in general and the relation of chemical and non-
chemical factors are reviewed by Defares (1964) and Yamamoto and Raub (1967). 
In 1965, Milhorn et af published a model that included elements of the chemical control of 
respiration previously ignored. These included the role of O2 and circulatory time delays in the 
feedback loop. They considered the regulation of respiration to be a function of brain tissue Peo2 
(Pbeo2, central component), aortic-carotid body P02 (Paeo2, peripheral component) and hydrogen 
ion concentration ([W]). Making use of the relationship between [J.f] and Peo2 the alveolar 
ventilation was reduced to a function of two variables; 
(3.2) 
The mechanical status of the lung was also included in the controller. The controlled process 
was represented using lung, brain and tissue compartments with gas storage and transport 
equations derived from mass balance relationships. Cerebral blood flow depended upon arterial 
peo2 and Po2. The ventilation was continuous with no breath-by-breath modelling. 
Grodins et af (1967) extended the process model further and the controller described the 
ventilation as a function of brain Peo2, the fractional concentration of alveolar O2 and the H+ 
concentration in the cerebral spinal fluid. This model represented a major advance towards a 
comprehensive model that could be used to test a wide variety of forcing inputs. 
Milhorn and Brown (1971) published a comparison of two older models of the controller 
subsystem connected to an updated process model. They compared the classical controller 
equation of Gray (1950) against the more recent work of Lloyd and Cunningham (1963). Both 
equations were developed using curve-fitting methods, the former incorporating an additive 
combination of CO2 and O2 whereas the Lloyd model contained multiplicative as well as 
additive CO2 terms. Milhorn and Brown concluded that the Lloyd-Cunningham version was 
more accurate over the range for which it was intended, although t~e equation would need to be 
extended if the entire control range was to be covered, i.e. the low O2 and CO2 range. 
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The next significant advance was the inclusion of the response to perfusion of the medulla 
resulting in high cerebrospinal fluid PC02 [Milhorn and Reynolds, 1973]. This increased the 
range of stimulus to which the model could successfully be subjected and therefore significantly 
increased its validity. 
In 1980 Saunders et al produced a comprehensive model of the human respiratory system, 
incorporating effects within the respiratory cycle. This extended what had previously only been a 
continuous ventilation model into one that described control on a breath-by-breath basis. This 
model was based upon that developed by Grodins et al (1967) and was adapted to include cyclic 
ventilation, dead space, blood shunt and a separate muscle compartment. Sarhan (1983) in his 
Ph.D. thesis modified this cyclical model to explore the relationships between the elements of the 
breathing pattern. 
More recent work has modified earlier respiratory control models to examine apnea response and 
unstable breathing [Longobardo et ai, 1989] and more dynamically the maturation of chemo-
reflex loops in new-born infants [Revow et ai, 1989]. 
3.2.5 Integrated Models 
Early attempts at integrated models were often only theoretical since the relationships between 
system elements required numerical methods only possible using a computer. These were either 
not invented or were inadequate for the complexities of the task. Perhaps one of the most 
significant breakthroughs occurred in 1973 with the model proposed by Farrel and Siegel. At the 
time it represented one of the most complete descriptions of a respiratory system and contained 
10-compartment alveolar-pulmonary gas exchange [West, 1969], lung mechanics [Wald et ai, 
1969; Mead, 1961], lumped arterial, venous and tissue pools, non-linear gas dissociation 
relationships for O2 and CO2 [Kelman, 1966 and 1967], the interaction of cardiac function and 
tissue metabolism, and respiratory control in response to pH, PaC02 and Pa02 [Lloyd and 
Cunningham, 1963]. More importantly, it attempted to address the problem of matching model 
inputs and outputs to quantifiable physiological parameters that could be measured in man or 
animals to facilitate thorough testing of the simulations. 
The benefits of such a system for self-instruction were highlighted by Modell et al (1974) who 
created a collection of 15 programs written in BASIC for teaching the principles of lung 
mechanics, general gas exchange, ventilation-perfusion relationships and acid-base balance. Their 
approach was to split the system into separate modules, providing assumptions about the 
boundary conditions. 
Dickinson (1979) took the next logical step and integrated all of these aspects of respiration into a 
comprehensive computer model called MacPuf, specifically for the purposes of teaching and self-
instruction. It was a difficult model to interpret, due to its constant use of computational 
approximations and the explanation of the physiology in FORTRAN statements rather than using 
mathematical conventions. It was based strongly on the work of Farrel and Siegel, although the 
alveolar-pulmonary gas exchange was described using a much simpler 3-compartment model 
[Riley and Cournard, 1949], with ideal alveolus, dead space and shunt compartments. No attempt 
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was made to model the respiratory dynamics, and although ventilation was divided into 
inspiratory, gas exchange and expiratory phases, the net result approximated to a continuous 
ventilation model with average gas tensions in the ideal alveolus. Whilst it did contain a 
respiratory control model, this could be bi-passed to allow the simulation of assisted ventilation. 
This appears to be the first attempt to provide modelling of both spontaneously ventilated and 
mechanically ventilated subjects. It allowed respiratory rate, tidal volume and inspired O2 fraction 
to be specified with allowances for the addition of positive end-expiratory pressure (PEEP) and its 
effect on both venous admixture and cardiac output were modelled. The usefulness of the model 
for the purposes of teaching was evaluated by Hinds et al (1982) at in-service training courses 
for anaesthetists and specialists in intensive care, and for the undergraduate teaching of 
anaesthesia [Skinner et ai, 1983]. 
The ultimate extension of a teaching model is one that encompasses all aspects of human 
physiology [Coleman and Randall, 1983] and these have been developed to aid anaesthesiology 
training [Schwid 1987; Schwid and O'Donnell, 1992]. However models of this complexity and 
depth are not required for the testing of the advisor developed in this thesis. Of particular interest 
are models developed specifically to simulate patients on artificial ventilation in leu. Dickinson's 
MacPuf model has been used by other researchers as a basis for such development. 
Whilst comprehensive, integrated models can exhibit a high level of realism, matching the number of 
. system parameters to available data becomes more difficult with increased complexity. So although 
physiological model development will continue to increase in complexity as further understanding is 
gained, the true usefulness of a model is its applicability to the problem in hand. Selecting the right 
level of complexity is often a matter of trial and error. One might start with simple models, moving on 
to more complex ones if inadequacies are identified, or a complex model can be reduced in a principled 
manner to arrive at a model that can be matched to the data available. 
3.2.6 Models of Respiration During Artificial Ventilation 
Using Dickinson's model with the respiratory control stimulus disengaged, attempts were made to 
match the parameters of the model to clinically available data [Hinds et ai, 1980]. This was done 
in an attempt to predict the steady-state arterial and venous blood-gases and hence check the 
physiological meaning of the model. Twelve patients ventilated after uncomplicated cardiac 
surgery were studied. The basic information required to simulate an individual patient was 
measured or derived and then the model unknowns adjusted iteratively to match the model 
predictions to the clinical measurements. The variables computed were then compared with those 
measured or derived clinically. Correlation between predicted and measured variables was 
generally good (r > 0.9) although PV02 correlated less well (r = 0.85). 
This study was extended [Hinds et ai, 1984] by tuning the steady-state model to individual 
patient data (as above) and then assessing its ability to predict changes caused by adjustments to 
the ventilator settings. The predictions were deemed acceptable given clinical variability and 
routine measurement inaccuracies. 
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A much simpler model, describing the mass transport of O2 and CO2 through a 3-compartmcnt 
alveolus [Riley & Cournard, 1949] and lumped arterial, tissue, venous and pulmonary pools was 
used as an integral part of a system combining qualitative and quantitative data for mechanical-
ventilator management, known as VentPlan [Thomsen & Sheiner, 1989]. The paper only 
described the O2 transport equations fully, inferring that the CO2 transport equations were 
analogous. Two alternative O2 gas dissociation functions (GDF) were used depending upon the 
complexity of the problem. If corrections for temperature and pH were required then Kelman's 
(1966) function was used, and its inverse derived using a solution-searching algorithm. When 
these corrections were not needed an explicit inverse function was employed [Severinghaus, 
1979], greatly reducing computational overheads. 
More recently this model was extended to include better ventilator modelling, airway mechanics, and 
representation of ventilation-perfusion (V /Q) mismatch [Rutledge, 1994, 1995]. The ventilator model 
explicitly simulates volwne-<:yclcd, constant-flow ventilation. During inspiration the default setting 
represents a plunger moving at constant velocity to deliver the desired tidal volwne. The simulator then 
leaves a short inspiratory hold time after the plunger stops, to allow remaining pressure to equilibrate 
with the airway. Then during expiration the pressure drops to the value of PEEP, and the outflow of air 
from the patient is limited by a variable outflow resistor (retard setting). The default configuration is 
for constant mandatory volwne (CMY) mode of ventilation, but adjustable parameters allow it to 
simulate many volume-cycled constant-flow ventilators. 
Instead of the Riley 3-compartmcnt alveolar-pulmonary diffusion model there are 5-
compartments: a series anatomical dead space, a parallel physiological dead space, a shunt and 
two alveolar compartments. The alveolar compartments can have different V /Q ratios to 
represent asymmetric ventilation perfusion distributions. Each alveolar compartment can also 
have different resistance and compliance values meaning that the distribution of ventilation will 
vary as a function of frequency of ventilation. Kelman's O2 gas dissociation function was 
replaced by that of Hill et al (1973). 
All of these models have used continuous rather than breath-by-breath models of the ventilation 
process, since the time scale of interest is in the order of 10 seconds rather than milliseconds. 
What matters is the change in average blood-gases, and not fluctuations during the breath-cycle. 
3.2.7 Model-based Nomograms 
These are really a sub-category of the models described previously, developed with the specific purpose 
of producing curves of practical use to clinical staff. We have already come across one example in the 
CO2 dissociation models, that of the Singer-Hastings nomogram (1948). Severinghaus (1966) 
developed a similar tool for O2 dissociation in the form of the "blood gas calculator". 
Many other such nomograms have been developed to aid the understanding of respiratory 
physiology and assist clinical decision making. However, the iso-shunt diagrams of Benetar et al 
(1983) is of particular interest, since it enables the prescription of changes to inspired O2 fraction 
(FI02) to achieve a desired Pa02 (see Figure 3.2). This can be thought of as a crude therapy 
advisor tool. In Chapter 6 the relationships behind the iso-shunt lines are used to construct simple 
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rules pertaining to the maintenance of Pa02 via adjustment of FI02. Because of this a detailed 
description of the equations behind the nomogram is given below. 
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Figure 3.2: Iso-shunt diagram (redrawn from Benatar, Hewlett and Nunn (1973». Iso-shunt 
bands have been drawn to include all values of Hb, PaC02 and arterial-venous oxygen content 
difference shown above. 
Iso-Shunt Lines 
The calculations used to construct the iso-shunt lines are as follows; 
Calculate PAD) (alveolar oXYgen tension) 
(kPa) (3.3) 
where PBdry is the dry barometric pressure (assumed to be PB - PH20, where PB is standard 
barometric pressure (101.325 kPa) and PU20 is the saturated water vapour pressure at body 
temperature (6.27 kPa)), R is the respiratory exchange ratio (assumed 0.8) and PaC02 IS 
assumed to be 5.33 kPa. 
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Calculate Sc '02 (pulmonary end-capillary saturation) 
(3.4) 
This assumes there is negligible alveolar/pulmonary end-capillary P02 gradient. It is the 
Severinghaus et al (1978) equation, a modified and more convenient alternative to the Kelman 
(1966) ODC. 
Calculate Cc '02 (pulmonary end-capillary oD'gen content) 
(mUdl) (3.5) 
where Hb is the haemoglobin concentration, Ph is the Hb O2 carrying capacity (assumed 1.31 
mUg) and ab is the solubility of O2 in blood (assumed 0.024 ml/dl/kPa). 
Calculate CaOz (arterial omen content) fOr a given shunt 
(mUdl) (3.6) 
where Qs /Qt is the shunt and C(a-v)02 is the arterial-mixed venous O2 content difference 
(assume 5 mUdl). 
Calculate Pa02 (arterial o~en tension) 
(mUdl) 
where Sa02 is the arterial O2 saturation as given by the Severinghaus equation; 
Sa0
2 
= p~o/ +2.667 xPa02 
Pa02 + 2.667 x Pa02 + 55.4 7 
(3.7) 
(3.8) 
Pa02 is calculated by substituting equation 3.8 for Sa02 into equation 3.7 and obtaining the 
positive, real root of the following quadratic equation; 
ab .Pa024 +(Hb· Ph -Ca02)-PaO/ +(2.667 .ab)·PaO/ + 
(55.47·ab +2.667·Hb·Ph -2.667·Ca02)·Pa02 -55.47·Ca02 =0 
• 
using an iterative programme capable of solving such equations. 
(3.9) 
The iso-shunt lines produced by these equations were found to give satisfactory prediction of 
Pa02 for Fr02 in the range 35 to 100 %. Petros et al (1993) extended the model behind the iso-
shunt lines so that it would behave correctly for FI02 below 35 %, as found during O2 delivery 
via a ventimask. This required the inclusion of a 2-compartment representation of mismatch of 
ventilation-perfusion ratios in addition to shunt. 
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3.3 Black-Box Models 
An altogether different approach to the prediction of alveolar oxygen and carbon dioxide tensions 
from those previously mentioned has been proposed by Rudowski et al [1991]. They have used 
linear multiple regression techniques with Pa02 and PaC02 as the dependent variables to construct 
statistical models for individual patients, specific diagnostic groups and general patients. The 
usefulness of the approach is that such analysis may bring about a better understanding of the 
factors influencing arterial gas tensions in ventilated patients with acute respiratory failure. This 
can be thought of as clinically-based sensitivity analysis. 
Twenty patients were assessed falling into three patients groups; those with pneumonia, chronic 
obstructive pulmonary disease (COPD) and left ventricular failure (L VF). The equations used for 
regression analysis were of the form; 
Pa02 =Yl =allx1+ .. ·+a1nxn +alO 
PaC02 = Y2 = a21xl + ... +a2nxn + a20 
(3.10) 
where yare the predicted values, Xi are the independent variables (i.e. the settings and measured 
variables) and aij are the regression coefficients, determining the significance of each variable. 
The variables initially included in the regression for PaC02 models were as follows; VT (tidal 
volume), RR (respiratory rate), slope-C02 (phase III capnogram slope), Cetco2 (end-tidal CO2 
concentration), VC02 (C02 production), HR (heart rate), BPsys (systolic blood pressure), and 
BPDIAS (diastolic blood pressure). For the Pa02 models; VT, RR, HR, BPSYS, BPDIAS, slope-
CO2, VD (dead space volume) and PEEP (end expiratory pressure) were considered. 
The pertinent variables were selected after regression using the full variable set, using the F-
statistic set at a certain threshold. The regression coefficients were then re-calculated. 
Correlation coefficients for the models obtained were highly variable, ranging from 0.22 to 0.98. 
This variability is unacceptable and highlights the major problem with linear regression analysis 
applied to what is after all a non-linear system. Also, any models arrived at do not readily imply 
information about the various physiological states, since parameters such as dead space are not 
always included in the final equation. 
3.4 Summary & Conclusions 
This chapter has described the classification of respiratory models according to process and 
implementation. Models of lung mechanics, gas exchange, gas dissociation and respiratory 
control have been described, as well as integrated models combining aspects of the 
aforementioned elements. Particular attention has been drawn to integrated models describing 
respiration during mechanical ventilation of patients performing no breathing for themselves, 
since such a model is required to test the ventilator advisor developed in this thesis. The next 
chapter describes the development of just such a patient model, followed in Chapter 5 by its 
clinical validation. 
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Chapter 4: SOPA Vent - Patient Model Development 
4.1 Introduction 
This chapter describes the development of SOP AVent (Simulation Of Patient under Artificial 
Ventilation), a patient model suitable for the validation of the ventilator therapy advisor. The model 
equations are presented first. However these do not constitute the final model, since improvements 
were required in order to provide patient observations not initially fore seen. These modifications are 
discussed in Chapter 7. The prototype model equations fall into five broad categories; 
1). Oxygen transport equations. 
2). Oxygen dissociation function and the calculation of its inverse. 
3). Carbon dioxide transport equations. 
4). Carbon dioxide dissociation function, again with the calculation of its inverse. 
5). Airway mechanics and ventilator equations. 
The model elements were implemented using MArLAB and SIMULINK, with the O2 and CO2 
systems developed independently since cross coupling only occurs within the gas dissociation 
functions. In this way each model subsystem could be tested for functional validity before 
finally integrating them. The O2 gas dissociation function was developed first and tested against 
available data. Since the transport equations require the inverse of this function a suitable 
solution-searching algorithm is discussed. This was then incorporated into the O2 transport 
equations. In order to derive confidence in the O2 subsystem, a normal healthy patient scenario 
was constructed using available empirical formulae to set the parameters of the system. This 
was found to give reasonable arterial P02 figures and using known physical relationships the 
functional validity of the system is shown. 
This was then repeated for the CO2 subsystem, starting first with the development of the CO2 
dissociation function and its 'inverse. Again this was tested against published data. The CO2 
transport dynamics were tested using the normal patient scenario and gave realistic values for 
arterial Peo2. The two subsystems were then integrated and tested to see if normal patient 
values were maintained. 
4.2 Patient Model Architecture 
4.2.1 Overview 
Model complexity can soon escalate, as deeper physiological concepts are included, consequently 
a balance needs to be made between model complexity and functionality. A model with over 
simplifications will become unrealistic, providing little in the way of patient specificity. 
Conversely a complex model incorporating all known physiology becomes unusable, since model 
parameters cannot be matched to real patient data for the simple reason that they cannot be easily 
measured. Statistical models could be used but these cannot be physically interpreted. 
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Figure 4.1: Schematic overview of patient model. 
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Consequently the chosen model needed to be physiologically based but simple enough so that the 
majority of its parameters could be routinely measured within ICU. In this way the model could be 
matched to real patient data and would therefore be clinically meaningful. 
Based on these trade-offs, models describing the respiratory process on a breath-by-breath basis 
were rejected in preference for a continuous ventilation model describing the transport of gas 
volumes around the body using compartmental models. Also the modelling of the neurogenic 
drive was abandoned since the patients were assumed to be fully sedated and therefore unable to 
perform normal respiratory drive. The model constructed needed to respond to changes in the 
following ventilator settings; RR, Vr, F102, PEEP and I:E. It then needed to provide output of 
arterial and venous P02 and Pe02. Later this would be extended to include arterial and venous 
pH and PIP since they were required by the advisor (information that was not available during 
initial model development). 
The transport of O2 within the patient is described by a set of five linked differential equations 
and the CO2 transport by a set of five similar equations [Thomsen el al , 1989]. These represent 
a seven-compartment model that can be divided into two main groups, the lung system and the 
circulatory system, see Figure 4.1. 
The lung system is sub-divided into three functional areas (or compartments); the ideal alveolus 
where all gas exchange takes place (ideal perfusion-diffusion, V /0. = 1), dead space 
representing lungs that are ventilated but not perfused (V /0. = 00 ) and shunt representing those 
area that are perfused but not diffused as well as the anatomical shunts (V /0 = 0). This three-
compartment model of the lung was devised by Riley (1949) and is now well accepted, although 
it does not enable the modelling of V /0. mismatch. 
The circulatory system is made up of four compartments representing the arterial pool, venous 
pool, pulmonary capillary bed and systemic tissue capillary bed. The venous pool behaves as a 
first order exponential time lag, emulating venous return. The arterial pool provides mixing of the 
shunted venous blood with the oxygenated blood from the lungs. The tissue capillary bed allows 
for the consumption of O2 and the production of CO2 as a result of the metabolic processes. The 
pulmonary capillary bed provides diffusion of the respiratory gases to and from the alveolar space. 
Embedded in the model are two inverse gas dissociation functions (GDFs) that convert O2 and 
CO2 contents to partial pressures. This facilitates the calculation of diffusion rates across the 
alveolar membrane since diffusion is driven by pressure gradient, whereas gas transport in the 
blood is described in terms of concentrations. These functions turn what is apparently a linear 
model into a non-linear one. 
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4.2.2 Oxygen Transport Equations 
The O2 transport dynamics are described by the following set of five linked differential 
equations, each describing the transport process of one circulatory compartment. 
(4.1) 
(4.2) 
(4.3) 
(4.4) 
(4.5) 
[ml O:zll blood] (4.6) 
(4.7) 
where 
Vx Where x = A, a, t, v, P - Volumes of alveolar, arterial, tissue, venous, and pulmonary 
compartments, respectively (litres) 
Qt Cardiac output (ml blood/min) 
X Fraction of blood shunted past lungs 
V0 2 Oxygen consumption by tissues (ml O/min, BTPS) 
VD Alveolar dead-space volume (ml, BTPS) 
VT Tidal volume (ml, BTPS) 
RR Respiratory rate (breath / min) 
CA02 Alveolar O2 content (ml O:zll alveolar gas) 
Cx02 Where x = a, t, v, p - Arterial, tissue, venous and pulmonary O2 content, respectively 
(ml O:zll blood) 
Pp02 Pulmonary partial pressure of O2 (kPa) 
t Time (min) 
F102 Inspired O2 gas fraction 
PB Barometric pressure (kPa) 
B02 Diffusion constant (ml 02lkPa/l blood) 
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Equation 4.1 describes the rate of change of arterial O2 content (Ca02) and can be thought of as a 
fixed volume compartment (Va), with two inputs and a single output, see Figure 4.2. Oxygenated 
blood from the pulmonary capillaries mixes with shunted blood from the venous pool to form the 
arterial blood. Blood flow rate through the arterial pool is determined by the cardiac output. 
The size of the arterial volume affects the transient response of the compartment, with larger Va giving 
a slower response. Dickinson [1977] used a pool volume of I litre, but this is a purely notional volume, 
since systemic blood volumes are well distributed and not easily separable. Estimates of compartment 
blood volumes taking into account a patient's mass are discussed in Section 4.4.2 
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Figure 4.2: Schematic of gas transport in the arterial compartment 
The rate of change of O2 content within the tissue capillary bed is described by equation 4.2. It 
represents a single input, dual output compartment with a fixed volume Vt. Mixed arterial blood 
(Ca02) enters the compartment and loses O2 as it diffuses into the neighbouring tissue, resulting 
in de-oxygenated blood flowing out of the tissue capillary bed, see Figure 4.3. The diffusion 
occurs because of a positive pressure gradient across the capillary membrane, and the rate of 
transfer is determined by Vo2 • 
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Figure 4.3: Schematic of gas transport in the tissue compartment 
31 
Equation 4.3 describes the rate of change of venous O2 content (CV02) within the venous pool. It 
represents a simple compartment of volume Vv, with tissue O2 content (Ct02) as the input and venous 
02 content (Cv02) as the output, see Figure 4.4. This simply behaves as an exponential time lag. 
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Blood Venous Pool 
Vv 
Blood Flow Rate Qt 
Venous Blood 
Figure 4.4: Schematic of gas transport in the venous compartment 
Equation 4.4 corresponds to the pulmonary capillary bed and describes a compartment of 
volume Vp, with two inputs and a single output. The inputs are; (1) non-shunted venous O2 
content (CV02), and (2) the O2 diffusing across the lung membrane (02Diff). The compartment 
output is the mixed and oxygenated pulmonary O2 content (Cp02). The blood flow rate through 
the compartment is (1- X)· Ot (Vmin), i.e. only non-shunted blood, see Figure 4.5. 
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Figure 4.5: Schematic of gas transport in the pulmonary compartment 
Equation 4.5 represents the change of alveolar O2 content (CA02) within the alveolar space, where 
the input is the inspired O2 fraction (FI02) and two outputs are; (I) the alveolar O2 content and (2) 
the O2 diffusing across the lung membrane (02Diff). It IS apparent from 
Figure 4.6 that this does not represent the bi-directional nature of the lung (i.e. the same input and 
output path), but describes the lung in terms of a fixed volume compartment (VA) with continuous 
input and output. Consequently the lung ventilation rate does not vary for each breath but remains 
constant so long as the tidal volume (VI) and the respiratory rate (RR) remain constant. 
32 
InSPjred~ 
Fractions 
~ 
RR,VD ~ 
RR.(Vr-VD~ 
Dead Space 
VD 
Alveolar Volume 
VA 
Alveolar Gas 
Fractions 
CAOilOOO 
CAC02/1000 
Q, . (I - X)· C02DifJ Q, . (I - X) .°2 DifJ 
__ -"~ c:::::> c:> c::=:> c-'-"" Oxygenated Blood 
_---., c::=:::> <:::> c::::> oc::=:> 0 c=:> ... ~~~9~~ 
Pulmonary Capillary Bed 
Figure 4.6: Schematic of gas transport in alveolar compartment 
The alveolar ventilation (VA) depends upon the size of the dead space (VD), corresponding to 
the anatomical dead space lumped together with other physiological dead space components, 
and is given in the first part of the equation 4.5 as; 
VA =RR·(Vr-VD) (ml/min) (4.8) 
Equation 4.6 calculates the rate of O2 diffusing into the capillary bed per litre of blood flowing 
through it and is derived from Fick's first law of diffusion. This law states that the volume of 
gas that diffuses per unit time (V) across a membrane, is directly proportional to the surface 
area of the membrane (A), the partial pressure difference of gas on either side of the membrane 
(PI - P2) and the diffusion coefficient for a particular gas (D), and is inversely proportional to 
the thickness of the membrane (~X); 
V = _D_._A_. _( R....:.I_-_P...:2_) 
LU'" 
(ml/min) (4.9) 
However, A and ~x remain unknown since the thickness and surface area of the alveolar-
capillary membrane cannot be measured in a living subject. By rearranging equation 4.9 we 
arrive at an expression for the diffusion capacity as uptake of gas per minute (V) per kPa 
pressure difference (PA - Pp) with units of conductance (ml/minlkPa); 
D·A V DL =--=----LU'" ( P A - Pp) [ml/minlkPa] (4.10) 
where 
PA Alveolar partial pressure of gas (kPa) 
Pp Pulmonary capillary partial pressure of gas (kPa) 
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Dividing the diffusion coefficient for O2 (D02) by the pulmonary blood flow gives the rate of O2 
diffusion per kPa difference per litre of blood; 
Eo = . D02 
2 Qdl-X) [ml 02lkPaJi blood] (4.11 ) 
Since de-oxygenated blood that flows into the pulmonary capillaries is at a lower partial 
pressure of O2 than in the alveolar space, the resulting negative pressure differential causes O2 
to diffuse into the pulmonary capillaries. Conversely the pulmonary blood contains lower Pe02 
than the alveolar space, causing a positive differential with the consequent diffusion of CO2 
from the blood into the alveolar space. 
The pressure gradient across the lung membrane is the difference between the alveolar O2 
partial pressure (PA02) and the pulmonary compartment O2 partial pressure (Pp02)' The alveolar 
POz is simply the alveolar Oz fraction multiplied by the airway pressure, which is assumed to be 
atmospheric pressure (PB); 
[kPa] (4.12) 
However, calculation of the Pp02 is not a straightforward matter. It is derived by calculating the 
inverse of the O2 gas dissociation function (02 GDF), adding non-linearity into a system, which 
has so far only been described in terms of linear first order differential equations. The O2 GDF 
derives Oz content from O2 partial pressure. However no explicit solution exists for the 
calculation of partial pressures from contents. Consequently an iterative procedure is required to 
calculate the inverse function. The next section describes the explicit O2 dissociation function 
and the method used to compute it's inverse. 
4.2.3 Oxygen Dissociation Function 
The O2 content of blood consists predominantly of oxygen in combination with haemoglobin 
plus a smaller component dissolved in the blood plasma; 
C (02) = Ph . Hb . S02 + a b . P02 [mIll blood] (4.13) 
The O2 combined with the haemoglobin is the product of the haemoglobin concentration (Hb), 
the O2 saturation fraction (S02) and the haemoglobin O2 combining capacity ( Ph)' The O2 
dissolved in the plasma is the product of the O2 carrying capacity of blood plasma (a b) and the 
partial pressure of O2 (P02). 
Values for ab are normally quoted as 0.225 m1lllkPa [Nunn, 1993; Taylor et ai, 1989 and others] and 
its effect is small, accounting for approximately 2% of the total ~ content. Typically haemoglobin 
content is 148 gil for men and 135 gil for women [Dickinson, 1977, p.l23]. Values for Ph vary 
considerably and the following levels have been quoted; 1.34 [Dickinson, 1977; Severinghaus, 1979; 
Nunn, 1993], 1.38 [Taylor, 1989], 1.39 [Alwan, 1992; Nunn, 1993] and 1.306 ml/g [Nunn, 1993; 
Gregory, 1974]. Of these 1.34 ml/g is the most widely accepted and has been used within the patient 
model developed here; where as 1.39 mllg is the theoretical maximum. 
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The saturation fraction is a function of O2 partial pressure. Several attempts to formulate this 
curve have been made [Severinghaus, 1979; Sharan, 1989; Alwan, 1992] but the most widely 
accepted formulation is the empirical set of equations derived by Kelman (1966) as used in the 
works of Dickinson (1977); Thomsen et al (1989) and Hinds et al (1984). His equation 
generates a curve indistinguishable from the true curve above a P02 of about 1 kPa (7.5 mmHg), 
and is given as; 
where 
al = -8.5322289 x 103 
a2 =21214010xl03 
a3 = -6.7073989 
and x is the virtual P~ as given by; 
x ~ 10 mmHg [fraction] 
a4 = 9.3596087 x lOS 
as = -3.1346258 x 104 
a6 = 2.3961674 x 103 
a7 = -6.7104406 
(4.14) 
Virtual P0 2 =[3.5774 ,Po2 XIO(A+B+C)]x[ 760 ] [mmHg] (4.15) Pso 101.325 
A = 0.024(37 - T) (4.16) 
B = 0.40( pH -7.4) (4.17) 
C = 0.06· log (5. 3329/Pco2 ) (4.18) 
Shifts in the dissociation curve due to abnormal pH, Pc~ and temperature (known as the Bohr 
effect) are accounted for by the modifiers A, B and C. A normal curve is produced when the 
temperature is 37°C, pH is 7.4, and Pc~ is 5.3329 kPa (40 mmHg). An increase in temperature or 
Pc~ right shifts the curve where as a reduction shifts the curve to the left. Conversely an increase in 
pH shifts the curve to the left and a reduction in pH shifts it to the right, see Figure 4.7 (b) to (c). 
Also included within the virtual P~ equation, and not originally included by Kelman is an 
effect due to shifts in the Pso point [Ingram & Bloch, 1986]. This is the 50% saturation normal 
operating point of the curve and can be offset by various pathological conditions. It is normally 
3.5774 kPa but can have higher values in haemoglobin abnormalities such as San Diego and 
Chesapeake, or lower values in sickle and Kansas. The presence of the organic phosphate 2,3-
diphosphoglycerate in the erythrocyte can also have a pronounced effect on Pso , with higher 
levels increasing the Pso point. 
Finally, the ratio 760/101.325 converts the virtual P02 from kPa to mmHg since equation 4.14 
expects the partial pressures in rnrnHg. 
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However, Kelman's original polynomial expression produces negative values for virtual p~ 
below 1 kPa (see Figure 4.7a). He suggested an improved formulation of saturation for virtual 
p~ below 1.33 kPa (10 mmHg), [Sharan etal, 1989]; 
S02 = 0.003683x + 0.000584x2 x < 10 mmHg [fraction] (4.19) 
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Figure 4.7: (a) Errors associated with Kelman's GDF and their correction using the improved 
formulae below 10 mmHg; (b) Shifts in the GDF curve associated with changes in Pc~ from 
the normal of 5.333 kPa; (c) Shifts in the GDF curve associated with changes in pH from 7.4; 
(d) Shifts in the GDF curve associated with changes in temperature from 37 °e. 
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4.2.4 Inverse O2 Dissociation Function. 
However, the inverse of the O2 GDF is required, since diffusion across the pulmonary-alveolar 
membrane is driven by the pressure gradient across it and O2 in the pulmonary compartment is 
modelled as content (ml 0711 blood). Explicit solutions do not exist and therefore an iterative 
approximation method must be employed. For the sake of simplicity a simple secant gradient 
approach method was used [Atkinson et ai, 1989]. This uses an estimate of the curve's gradient to 
derive a new approximation ofPo2 (Pest), given a target value of O2 content (Cr), see Figure 4.8. 
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Figure 4.8: Secant approximation ofPo2 from C(02). 
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The gradient estimate is established from starting values of P~ (Po and PI) and their 
corresponding O2 contents (Co and CI), calculated using the O2 GDF. A new estimate ofP~ is 
then given by; 
(4.20) 
The initial estimates of Po and PI are then updated; 
(4.21) 
This procedure is then repeated until; 
Ipest - Po I::; err (4.22) 
where err is the convergence error tolerance (kPa). For each calculation of O2 content the other 
blood parameters must be specified; i.e. temperature, pH, Peo2 and Hb. 
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4.2.5 Carbon Dioxide Transport Equations 
The CO2 transport equations are analogous to those of the O2 system and are given as; 
_o_Ct_C_O.::..2 • Vt = Qt . [CaC02 - CtCo2 ] + Veo2 
ot 
_O_CV_C_O.=..2 . Vv = Q, . [CtC02 - CvC02 ] 
ot 
where all parameters are as before except for; 
[ml CO~ blood] 
Veo2 Carbon dioxide production by tissues (ml COimin, BTPS) 
CAC02 Alveolar CO2 content (rnl COil alveolar gas) 
(4.23) 
(4.24) 
(4.25) 
(4.26) 
(4.27) 
(4.28) 
(4.29) 
CxC02 Where x = a, t, v, P - Arterial, tissue, venous and pulmonary CO2 content, 
respectively (ml COil blood) 
PpC02 Pulmonary partial pressure of CO2 (kPa) 
HC02 Inspired CO2 gas fraction (BTPS) 
Bco2 Diffusion constant (ml COz/kPa/1 blood) 
Within the pulmonary compartment the pressure gradient is reversed with PC~ higher in the 
pulmonary capillaries than in the alveolar space, since inspired air contains effectively zero CO2 
(FIC02 = 0.04% [Martini, 1992]). As a consequence, CO2 diffuses out of the blood into the 
lungs, see Figure 4.5. This is expressed via the sign changes in the C02Diff components of 
Equations 4.26 and 4.27. 
Similarly within the tissue compartment (equation 4.24) the pressure gradient is reversed since 
CO2 is produced by the metabolised tissue at a rate of Veo2 (mllmin) and diffuses into the 
tissue capillaries, see Figure 4.3. 
As with 02Diff, the calculation of C02Diff requires the inverse calculation of the CO2 gas 
dissociation function. The explicit dissociation function for computation of C(c~) from Pc~ is 
described in the next section. 
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4.2.6 Carbon Dioxide Dissociation Function 
The CO2 gas dissociation function was based upon Kelman's algorithm [1967]. This first 
derives the total CO2 content of the plasma (square brackets indicate total CO2 concentration, 
i.e. dissolved plus combined CO2 within this algorithm description) from its pH and PCCh, using 
the Henderson-Hasselbalch equation; 
[mVlitre] (4.30) 
where a is the solubility of CO2 in plasma. Both a and pK are temperature dependent, and in 
addition pK varies with pH. The temperature dependence of a is expressed as; 
a = (0.0307 + 0.00057· (37 - T) + 0.00002· (37 - T i). ( 760 ) 
101.325 
[mM/litre/kPa] (4.31) 
where T is blood temperature and the fraction (7601101.325) converts the units from 
mMlL/mmHg to mMlLlkPa. The expression for pK is given by; 
pK = 6.086 + 0.042· (7.4 - pH) +(38 - T) ·(0.0047 + 0.0014· (7.4 - pH)) (4.32) 
The ratio of [C02] in the cells to [C02] in plasma is thcn computed by linearly interpolating 
bctween experimentally derived quadratic expressions of the ratio for fully oxygenated and 
reduced blood; 
Re duced Ratio=0.664+0.2275(7.4 - pH) - 0.0938(7.4 - pH) 1 (4.33) 
Oxygenated Ratio = 0.590 + 0.2913(7.4 - pH) - 0.0844(7.4 - pHi (4.34) 
The ratio is then determined using the observed oxyhaemoglobin saturation fraction (S02), as 
calculated within the O2 GDF; 
d = {(Oxygenated -Reduced) xSo1 } +Reduced (4.35) 
Finally the whole blood CO2 content is then calculated from the expression; 
(4.36) 
Substituting d and re-arranging, gives; 
[C01]BLOOD = 22.2·[C0 2]PLASMA· {d,pcv+(l-pcv) [mIlL] (4.37) 
where pcv is the packed cell volume fraction (or haematocrit), and the factor 22.2 converts 
final units from mMllitre to mIlL. 
A typical dissociation curve produced using these formulae is given in Figure 4.9. The blood 
temperature was assumed to be 37 °C, the O2 saturation 90 % and the haematocrit 40%. 
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Figure 4.9: The CO2 dissociation curve with pH derived using the modified Henderson-
Hasselbalch equation [Taylor et ai, 1989, p244] (see Section 6.7.3); since increased PC~ will 
reduce the effective pH 
4.2.7 Ventilator Model 
In the gas transport equations 4.6 and 4.28, the partial pressures of O2 and CO2 within the 
alveolar space are calculated using barometric pressure (PB) as given by; 
(kPa) (4.38) 
where PAx and CAx are the partial pressures and contents of gas x respectively. This is used to 
detennine the pressure gradient across the lung membrane. A better solution is to use the mean 
airway pressure (PMEAN) instead of PB, since during inspiration and expiration the pressure in the 
alveoli will vary, but the transport dynamics model does not operate on a breath-by-breath basis. 
Since the patient model will only represent ventilated patients (and of these only the subset 
under volume controlled ventilation) the pressure wavefonn can be described by a square wave. 
This represents intennittent positive pressure ventilation (IPPV) and will deliver a fixed volume 
(VT) within time tl, see Figure 4.10. 
PMEAN is therefore given by; 
PMEAN == {(PIP - PEEP) x t I } + PEEP + PB 
tl + tE 
(kPa) (4.39) 
tl I: E 
and --"-- = ---
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where; 
PEEP is positive end-expiratory pressure (kPa) 
PIP is peak-inspiratory pressure (kPa) 
I:E is inspiratory-expiratory ratio 
tl inspiratory time (sec) 
tE expiratory time (sec) 
tr 
I ta tl I iii iI,_ IIi 
Pip 1--' 
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Figure 4.10: Pressure waveform of mechanical ventilator 
In a fixed volume delivery system PIP will depend upon the resistance of the airway (RAW) and the 
compliance of the lung (CAW). This influences ventilator strategy since high ventilation pressures 
can lead to clinical complications. In spontaneously breathing patients this would lead to reduced 
tidal volumes and increased respiratory frequency due to the increased work of breathing. 
This ventilator model assumes that PIP can be measured. However, if the model is to be useful 
for advisor validation then it must be able to model changes in PIP due to changes in ventilator 
strategy. This and other model improvements are dealt with in Section 7.3. 
4.2.8 Unit Conversion 
Many of the observations made in ICU are recorded using units and observation conditions that 
do not match those assumed within the patient model equations. The patient model assumes that 
all measures of gas volume, fraction and flow-rate are expressed at BTPS (body temperature 
pressure saturated) in standard international (S.I.) units, and that all other model parameters are 
in S.I. units. For example inspired O2 fraction is routinely expressed as percentage of inspired 
gas at STPD (standard temperature pressure dry), but the model assumes it to be fraction of 
inspired gas at BTPS. Therefore conversion is required from one unit to another and from one 
set of observation conditions to another. 
In order to keep track of what units and conditions an observation is expressed in, a three-valued 
representation for each patient parameter was employed, thus [value, unit, conditions J . The 
first term represents the value of the parameter, the second term an index corresponding to the 
units of the value (e.g. CMH20=1, MMHG=2, KPA=3, etc) and the third term an index 
referring to the observation conditions (STPD=l, BTPS=2, etc). 
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Gas Volumes & Flow Rates 
Three factors affect the actual volume of a gas (I) the temperature of the sample, (2) the water 
vapour pressure of the sample and (3) the atmospheric pressure at which the sample was made. 
If a volume of gas is measured at STPD then the temperature is 0 °C, the water vapour pressure 
is 0 kPa and the atmospheric pressure is 101.325 kPa. 
At increased temperature the volume of the gas increases. If the gas sample is saturated with 
water vapour (i.e. 100 % relative humidity) then any increase in temperature, will increases the 
water vapour pressure, which will reduce the gas volume. The level of water vapour pressure 
(PH20) is dependent upon temperature, because the warmer the air the more water it can retain. 
This is the reason why it rains when a cold air front meets warm air since the cooling air is less 
able to retain the water vapour. 
Using these relationships it is possible to derive an expression that converts a volume of gas 
from one set of observation conditions to another; 
(
273.15+T(NEW))(PB(OW)- PH20(OW) ) 
volume (NEW) = volume (OW) 
273.15 + T(oW) PB(NEW) - PI!20(NEW) 
(4.40) 
where volume(ow;. T(ow) and PB(ow) are the observed volume and conditions under which it was 
measured, and PH~(ow) is the water vapour pressure at the observation temperature and relative 
humidity (RH). Similarly, T(ow), PB(ow) and PH~(ow) are the new conditions under which the volume 
needs to be expressed. Temperature is given in units ofoC and PB and PH20 are given in kPa. 
PH20 is calculated using the polynomial expression of equation 4.41, derived from the empirical 
relationship between temperature (1) and PI-hO (see Figure 4.11). The additional term RHllOO 
accounts for the relative humidity of the sample. 
PH20 = (683.67 x 10-3 T3 -12985 x 10-3 T2 + 673.55T + 49.269)x (RH) (kPa) (4.41) 
100 
7.0 -r-------------------, 
'2 6.0 
~~ ~ 0 5.0 
~ 51 
'i ~ 4.0 j ~ 3.0 
~ 2.0 
10 
PH20 = 6.27 kPa @ T = 37°C 
15 20 25 30 35 40 
Ambient Temperature eC) 
Figure 4.11: Relationship between air temperature and saturated water vapour pressure. 
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m STPD to BTPS Conversion 
If a volume is to be converted from STPD to BTPS equation 4.40 reduces to; 
volume( BTPS) = volume(sTPD) (
273.15+T(BODY)J( PB ) 
273.15 PB-PH20(BODY) (4.42) 
where T (BODY) is the patient's temperature and PH}O(BODY) is the saturated water vapour pressure at 
body temperature (approximately 6.27 kPa). O2 consumption and CO2 production are normally 
given in STPD and therefore require this conversion before being used by the model equations. 
OJ) ATPS to BTPS Conversion 
If a volume is converted from ATPS (atmospheric temperature pressure dry) to BTPS then 
equation 4.40 becomes; 
(
273.15+T(BODY)) ( PB-PH20(AIR) ) 
volume( BTPS) = volume(STPD) 
273.15+T(AIR) PB- PH20(BODY) 
where T(A/II) is the ambient temperature (0C) and PH}O(A//I) is the PH20 at T(AJI?). 
Parameter Typical Observation Model 
Units & Conditions Units & Conditions 
F102 percent, STPD fraction, BTPS 
FIC02 percent, STPD fraction, BTPS 
PEEP cmH20 kPa 
VT ml, ATPS ml, BTPS 
BPsys mmHg kPa 
17°2 ml/min, STPD ml/min, BTPS 
Ve02 ml/min, STPD ml/min, BTPS 
QJQ, percent fraction 
RAW cmH20llitre/s kPailitre/s 
CAW Iitre/cmH20 IitrelkPa 
PIP cmH20 kPa 
PB mmHg kPa 
PCV percent fraction 
(4.43) 
Table 4.1: Summary of observation units and conditions of various parameters used within the 
patient model, together with the units and conditions required by the model equations. 
43 
Gas Fractions 
With gas volumes expressed as percentages (or fractions) of total volume then assuming that all 
the atmospheric gases obey an ideal gas law, the fraction of gas will remain constant with 
increase in temperature. However, increased water vapour pressure will reduce the effective gas 
fraction as given by; 
. . (PB-PH 20(OW) J jraCtion( NEW) = jractlOn(OW) 
PB-PH 20(NEW) 
(4.44) 
Table 4.1 summanses those parameters used within the patient model that are routinely 
measured using different units and/or conditions. 
That concludes the descriptions of the equations behind the original model architecture and the next 
sections 4.3 through 4.7 describe the implementation of the equations and there functional validation. 
4.3 O2 Dissociation Function Developmen t 
4.3.1 Functional Validity 
The O2 gas dissociation equations described in Section 4.2.3 were implemented as a MA1LAB 
function with the input-output structure as shown in Figure 4.12 and tested for functional 
validity. The results obtained using the MATI..AB function matched published results of the 
Kelman algorithm [Sharan et ai, 1989], indicating correct functional implementation. 
Primary Input Oxygen GDF 
Pe02 pH Temp Hb PSG 
Secondary Inputs 
Primary Output 
Secondary Outputs 
S02 
Figure 4.12: Schematic representation of the O2 GDF showing inputs and output parameters. 
4.3.2 Clinical Validity 
No papers could be located in which the O2 dissociation function was validated against clinical 
data. Instead those that were found continued to compare new curves against a series of older and 
assumed GDFs. The one source of clinical data that was found (Sharan et ai, 1989) used assumed 
or calculated values of pH rather then directly measured values, neither of which was wholly 
satisfactory. However, in order to gain a 'feel' of the GDF's validity, two tests were made. 
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Validation against Severinghaus Data 
The first of these used the data of Roughton & Severinghaus (1973) which they termed the 
Standard Human Blood O2 Dissociation Curve (SHBODC), see Table 4.2. The difference 
between the computed saturation using the MATLAB GDF and that of the SHBODC were 
calculated, see Figure 4.13. Peo2 was assumed to be 5.333 kPa (the normal position of the 
dissociation curve), pH to be 7.4 and blood temperature to be 37 °C, as per the SHBODC. Also 
compared against the SHBODC were saturations estimated using the modified Hill equation 
described by Severinghaus, as expressed by the following equation; 
Sat=~--_____ l ______ ~_ 
( 3 1 x 23.400) + 1 (POz +IS0POz ) 
(4.45) 
P~ Saturation POl Saturation P~ Saturation 
(mmHg) (%) (mmHg) (%) (mmHg) (%) 
1 0.60 34 65.16 80 95.84 
2 1.19 36 68.63 85 96.42 
4 2.56 38 71.94 90 96.88 
6 4.37 40 74.69 95 97.25 
8 6.68 42 77.29 100 97.49 
10 9.58 44 79.55 110 97.91 
12 12.96 46 81.71 120 98.21 
14 16.89 48 83.52 130 98.44 
16 21.40 50 85.08 140 98.62 
18 26.50 52 86.59 150 98.77 
20 32.12 54 87.70 175 99.03 
22 37.60 56 88.93 200 99.20 
24 43.14 58 89.95 225 99.32 
26 48.27 60 90.85 250 99.41 
28 53.16 65 92.73 300 99.53 
30 57.54 70 94.06 400 99.65 
32 61.69 75 95.10 500 '99.72 
Table 4.2: Values for the Standard Blood O2 Dissociation Curve @ 37 °C, pH = 7.4 
[Severinghaus, 1979] 
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Figure 4.13: Errors between Standard Human Blood O2 Dissociation Curve and computed 
values using Kelman equations (1966) and Hill equations [Severinghaus, 1979] 
% Saturation 
No P(Ol) P(COl) pH Measured Calculated Error % Error 
. (mmHg) (mmHg) (Sharan et af) (Kelman) 
1 96.0 43.0 7.40 98.00 97.23 0.77 0.78 
2 66.0 36.5 7.40 91.00 93.22 -2.22 -2.43 
3 52.0 34.8 7.40 84.90 86.97 -2.07 -2.43 
4 41.0 33.8 7.40 76.20 76.07 0.13 0.17 
5 36.0 31.8 7.40 71.20 68.73 2.47 3.46 
6 35.0 29.4 7.40 70.80 67.30 3.50 4.94 
7 74.0 40.6 7.40 94.00 94.90 -0.90 -0.95 
8 57.0 39.4 7.40 88.70 89.70 -1.00 -1.13 
9 55.0 35.0 7.40 88.10 88.84 -0.74 -0.84 
10 49.0 40.0 7.40 83.00 84.31 -1.31 -1.58 
11 36.0 33.2 7.40 72.20 68.57 3.63 5.03 
12 94.0 41.0 7.39 98.00 97.05 0.95 0.97 
13 60.0 33.9 7.44 91.00 92.14 -1.14 -1.25 
14 51.7 28.8 7.49 86.70 89.82 -3.12 -3.60 
15 47.6 29.5 7.48 84.50 86.79 -2.29 -2.93 
16 44.6 27.1 7.51 78.00 85.56 -7.56 -9.69 
Table 4.3: Comparison of experimental and calculated saturation using data ofSharan (1989) 
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It would appear from these graphs that the Modified Hill equation performed better than the 
Kelman algorithm, having a maximum error of 0.546 % saturation, compared to 2.229 % 
saturation using the Kelman algorithm. However, this merely indicates that the Modified Hill 
equation fits the Standard Human Blood data more accurately. Since the SHBODC was of 
unknown source and validity, it does not tell us much. Also the Hill equation does not provide 
correction for pH, temperature and Peo2 and therefore the Kelman algorithm provides a more 
comprehensive interpretation of the dissociation curve. 
Validation against Sharan Data 
The second pseudo-clinical validation was performed against the data of Sharan et al (1989). 
These data were taken from Environmental Biology (1966, Ed. Altman P.L. & Dittmer D.S., 
Pub. Federation of American Societies for Experimental Biology, Bethesda, Maryland, pp.362-
364). The first eleven values correspond to simulated altitude, where they have assumed pH is 
equal to 7.4. The remaining values correspond to incomplete acclimation, where pH was 
calculated from the Peo2, using the procedure described by Kelman (1968), see Table 4.3. 
Excluding entry 16, which appears to indicate experimental error, the largest observed 
saturation error was 3.63 % saturation (entry 11), compared to 2.32 % using the Sharan data. 
The mean absolute error was 1.75 % ± 0.84 (confidence interval 99 %), compared to 1.03 % ± 
0.56 (confidence interval 99 %) using the Sharan O2 GDF equation. Given possible inaccuracies 
in the experimental data, the Kelman function has performed with a similar degree of accuracy. 
Whilst these assessments do not provide a complete picture of the dissociation function's 
clinical validity, they do show that its behaviour matches expected dissociation curve 
characteristics. 
4.3.3 Inverse O2 GDF Validity 
The inverse of the explicit dissociation function was implemented as a MAlLAB function with 
the input-output structure as shown in Figure 4.14. 
In order to assess the validity, accuracy and performance of its implementation, a range of O2 
contents were calculated from known O2 partial pressures using the previously validated O2 
GDF. These were then applied to the IGDF. Any differences between the known and estimated 
P02 were recorded, along with the number of iterations taken to reach the solution and the final 
pressure error. The original P02 values used for this test were 1 to 50 kPa in 1 kPa steps. 
As expected the resulting P02 errors fell below the iteration error tolerance (err), see 
Figure 4.15, which in this case was 0.01 kPa. This was repeated for convergence error 
tolerances of 0.001, 0.1 and 0.5 kPa. The function call times and number of iterations required 
to converge were recorded for each P02 step. These were then averaged to give a measure of 
function performance. In this way the effect of increasing err could be assessed, see Table 4.4 
(test 1 to 4). Improvements in iteration performance were not large, even with an err of 0.5 kPa. 
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Figure 4.14: Schematic representation of the inverse O2 GOP showing inputs and outputs. 
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Figure 4.15: Observed errors in P02 across the P02 space generated using the IGDF. 
Test err Po PI Run Time Ave. No. 
(mill) (kPa) (kPa) (sec) Iteration 
1 0.001 4 6 12.69 8.28 
1 0.01 4 6 12.57 8.10 
3 0.1 4 6 11.26 7.20 
4 0.5 4 6 9.72 6.38 
5 0.01 ± 1O%t S.28 3.22 
6 0.1 ± 10%t 3.95 2.34 
t Po and PI updated using bounded tracking 
Table 4.4: Comparison of average computation times and number of iterations for various 
convergence error tolerances. Performed using normal (1 to 4) and bounded P02 tracking (5-6). 
[Hb = 140 gil, pH = 7.4, T = 37°C, PC02 = 5.333 kPa, Pso = 3.577 kPa]. Run times are based 
upon a 4860X 33 MHz computer. 
48 
Improved Algorithm: (Bounded POz Tracking) 
During simulation C(~) values are unlikely to make rapid changes as they are restricted by a 
first order differential law. Consequently the last P02 estimate may be utilised to give improved 
convergence times. 
New values for Po and PI are obtained by subtracting and adding respectively, a fraction of the 
last P~ estimate, thus encapsulating the last P02 estimate and providing a good initial estimate 
of the function gradient near to the expected solution, see Figure 4.16; 
Po = (1- fraction) x last P02 
PI = (1 + fraction) x last P02 
Possible Position of Ne>.t Solution 
Last Estimate ofPo2 
-10%:+10% • 
I 1 
:-----1 
I 
I 1 
I 
I 
~: 
O2 Partial Pressure 
(4.46) 
Figure 4.16: Diagram showing how bounded P02 tracking improves solution targeting by 
bracketing the next theoretical P02 estimate. 
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Figure 4.17: Graphs comparing the number of iterations required to arrive at P~ solution 
across the P02 space with an iteration error tolerance of 0.0 1 kPa;. (a), with normal iteration and 
(b). with 10 % bounded P~ tracking. 
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With a bracketing fraction of ± 1 0 % the average number of iterations reduced from 8.1 0 to 3.22 
for an error tolerances of 0.0 1 kPa and from 7.20 to 2.34 for an error tolerance of 0.1 kPa. 
Examination of the iteration performance across the P~ space for normal and bounded iteration 
(see Figure 4.17) indicated a broad band improvement in performance by utilising bounded P~ 
tracking. Normal iteration provides optimal performance between 2 and 8 kPa. However, typical 
p02 values in ventilated patients tend to be higher, between 8 and 20 kPa. This would lead to 
poor function performance. A more uniform iteration distribution was achieved with bounded 
P02 tracking, giving less than 5 iterations in the range 2 to 50 kPa, hence a greater likelihood of 
reduced call times. 
4.4 O2 Transport Dynamics Development 
4.4.1 Model Implementation 
The equations describing the O2 transport were implemented using the MATLAB and SIMULINK 
environment described in Appendix A. Each transport equation was converted into a state space 
form where the compartment output is expressed in terms of the integral of the partial 
derivative. This is best explained by way of an example. Consider the equation for O2 transport 
in the venous compartment (see equation 4.3); this can be rearranged to give; 
(mlllitre) (4.47) 
Using this equation an analogue computer of the compartmcnt can be constructed, see 
Figure 4.18. It is then a simple matter to build such a model using SIMULINK (see Figure 4.19) 
which can be solved using numerical integration tcchniques. 
+ 
Figure 4.18: Analogue computer representation of venous compartment equation. 
Of the methods provided by SIMULINK the Adams/Gear [The Math Works Inc, 1991] approach 
was used, being well suited to systems with both fast and slow dynamics. It is a variable step-
length method switching between Adams and Gear algorithms depending upon the rate of 
change of the state variables. This gives good accuracy during periods of rapid change (e.g. after 
a step change in input) and fast simulation times once the transients of a system have settled. 
Using the block diagram approach it was possible to rapidly construct state space models for 
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each of the model equations, see Appendix A (note these are the final model diagrams and not 
the prototype model). Since SIMULINK enables the construction of sub-systems the 
compartmental models can be linked to form a complete patient model. 
Figure 4.19: Venous compartment modelled using SIMULINK (see Appendix A) for explanation 
of model components. 
The SIMULINK model (BROPUS - Block Representation of Patient Under Simulation) is 
controlled from the MAlLAB workspace via program scripts. These scripts declare the patient 
parameters appertaining to a given patient scenario and are passed into the SIMULINK 
environment via variable declarations within the SIMULINK blocks. For example in the venous 
compartment there is a block that defines the cardiac output (labelled sCQ). This is a gain block 
and by double clicking on the block a dialogue box appears enabling the value of the gain block 
to be defined. Instead of it containing a value, it contains a pointer (seO) to a value in a globally 
declared patient scenario array. In this way a value for cardiac output can be declared within 
MAlLAB and passed into BROPUS before simulation commences. 
4.4.2 Derivation & Source of System Parameters 
There were a lot of parameters to be defined within the O2 dynamics model. Some of these 
would be provided by patient measurements and some would be derived from other parameters. 
In order to clarify this the following section describes each system parameter according to its 
classification (e.g. Blood, Patient, Ventilator paramcter) and to what clinical sources it can be 
attributed. This was done so that a 'normal' patient could be constructed in order to assess the 
'ball park' accuracy of the model. Some of the paramcters are based on quoted values, whilst 
others are obtained using empirical formulae. 
Blood Parameters 
{iJ Temperature & pH 
Normal values for these parameters are widely accepted to be 37°C and 7.4 respectively. These 
are the values that cause no left or right shifting of the gas dissociation curves [Kelman, 1967]. 
00 Haemoglobin 
Values for the standard average haemoglobin (Hb) contents are given as 148 gIL for males and 
135 gIL for females [Dickinson, 1977, p.l23]. 
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OW p50: 50 % Saturation Point 
This is simply the 50 % saturation operating point of the 02 GDF curve. It is calculated empirically 
from the normal blood GDF curve, produced using the Kelman equations [Kelman, 1967]. The 
normal curve is produced when pH = 7.4, temperature = 37°C and P(C02) = 5.333 kPa. The default 
value for P50 is 3.5774 kPa, and this is the value assumed for a normal healthy patient. 
Patient Parameters 
0) Oxygen Consumption 
Early tendencies have been to assume that patients consume approx. 250 ml of O2 per minute 
(V02 ) [Nunn, 1993, p.259], but many factors co-exist that often lift it above this basal level in a 
patient supposedly at rest. It is not possible to deal with these here, but the empirical 
relationship between V02 and weight is dealt with by Dickinson (1977, p.122), and is given by; 
V0 2REST = 10.33xWTo.7s (mllmin, STPD)(4.48) 
where V0 2REST is the O2 consumption at rest and WT is the patient's weight in kg. 
(iO Cardiac Output 
Typical values for cardiac output, Ot, are quoted at 5 lImin [Selvakumar el ai, 1992], but a more 
useful formula exists [Dickinson, 1977, p.l22] using the previously described term, V0 2REST; 
Ot(nom) = 0.0195 x Vo 2 REST 
where Qt(nom) is the nominal resting cardiac output. 
(iii) Dead Space 
(11m in) (4.49) 
Typical values for dead space (VD) are quoted as between 150 and 170 ml [Dickinson, 1977]. 
A more useful empirical solution is provided by Taylor el al [1989, p.33]; 
Vo = 2.205 x WT 
where WT is body weight in kilograms. 
(iv) Shunt or Venous Admixture 
(ml) (4.50) 
Estimates of normal shunt (Os/Ot) vary from source to source; Dickinson (1977, p.51) gives < 
3 %; Taylor el al (1989, p.130) gives < 2-3 %; and Nunn (1993, p.l80) gives ~ 1-2 %. A 
Osl Qt of 3 % of cardiac output has been assumed for the purposes of 'ball park' validation. 
~ Diffusion Rate 
A formula to estimate O2 diffusion capacity (D02) using estimates of the functional residual 
capacity (FRC) and age (AGE), is given by Dickinson (1977, p.l23); 
002 = (7.6XFRC+5)X(100-~AGE) 
100 
~AGE = 120 - AGEl 
52 
(mllminlmmHg) (4.51) 
where MGE is the difference in age from 20 years old and FRC is calculated using 
equation 4.56. A 6' 0" tall (183-cm), 20-year-old male will have an FRC of3.81Iitres, giving a 
D02 of34 mVminlmmHg (or 255 mVminlkPa). This is lower than the normal D02 values quoted 
by Selvakumar et al (1992) of 60 mVminlmmHg (450 mVminlkPa) and Piiper & Scheid (1981, 
p.204) of 54 mlIminlmmHg (405 mVminlkPa). 
(vi) Age. Height. Weight & Sex 
These are self-explanatory and for the purposes of 'ball park' validation a 20 year old male, 
weighing 75 kg and of height 183 cm (6' Oil) was assumed. 
(vii) Compartmental Volumes 
Venous Blood Volume: is typically quoted as 3 litres, which is given as approximately 60 % of 
the whole blood volume (VWB) [Dickinson, 1977, p.44]. VWB (in litres) can be estimated by 
taking 7 % of body weight (WT) in kilograms [Martini, 1992, p.607]~ 
VWB = 0.07xWT (litre) (4.52) 
Alternatively, VWB can be considered equal to the resting nominal cardiac output, Qt(nom), in 
normal healthy patients [Dickinson, 1977, p.122] as given by equation (4.49). 
Then if we know VWB' the venous blood volume (VV) is simply; 
Vv = O.6xVWB (litre) (4.53) 
Given a patient of weight 75-kg, VWB is 5.25 litres using equation (4.52), which gives a Vv of 
3.15 litres. This compares to a VWB of 5.13 litres using Qt(nom), which gives a Vv of 3.08 
litres; a difference of 2.2 %. This indicates that the equations are comparable and can be 
substituted in place of one another. Both results agree well with the V v rule of thumb value of 3 
litres. 
Figure 4.20 shows the relative distribution of blood in the circulatory system [Martini, 1992]. 
The venous blood volume includes the venous reservoirs (21 %), the large veins (18 %) and the 
venules (25 %), giving a total systemic venous volume of 64 %. This agrees closely with 
Dickinson's approximation of 60 %. 
Arterial Blood Volume: By referring again to Figure 4.20, we can consider the heart, aorta, 
elastic arteries, muscular arteries and arterioles to constitute the arterial blood volume (Va) , 
giving a percentage of whole blood of 20 %. Again by taking 20 % of 5.25 litres we arrive at a 
Va of 1.08 litres, which correlates well with Dickinson's [1977, p.22] approximation of 1 litre. 
The heart was included as part of the systemic arterial system since its volume is not modelled 
anywhere else in the O2 dynamics model. 
Tissue Blood Volume: This includes all the blood in the capillaries, excluding those of the 
pulmonary circuit and approximates to about 7 % of the total blood volume. Based on a VWB of 
5.25 litres this gives a tissue blood volume (Vt) of 0.368 litres. 
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Figure 4.20: Distribution of blood in the circulatory system [Martini, 1992, p.672] 
Pulmonary Blood Volume: Approximately 9 % of the total blood volume is contained within the 
pulmonary circuit (or 10 % according to Nunn et ai, 1993), giving a pulmonary blood volume (Vp) 
of 0.473 Iitres, based on a VWB of 5.25 Iitres. Table 4.5 summarises the percentages of total blood 
volume for each compartment and gives expected volumes based on a V WB of 5.25 litres. 
Alveolar Volume: can be derived from functional residual capacity (FRC), which can be 
predicted using one of the following pairs of empirical formulae. The first of these calculates 
total lung capacity (TLC) [Taylor et ai, 1989, p.162]. The equations below are divided by a 
factor of two since FRC is widely considered to be 50 % of the TLC; 
Male FRC = (O.076H - 6.69)/2 
Female FRC = (O.0646H - 5.44)/2 (Iitres, BTPS) (4.54) 
where H is height in centimetres. The second formula calculates the functional residual capacity 
(FRC) or resting lung volume directly [Dickinson, 1977, p.122 and p.204]; 
Male FRC = 0.047H - 0.0075A - 4.583 
Female FRC = 0.026H - 0.0090A - 2.180 
where A is age in years. 
(\itres, BTPS) (4.55) 
Figure 4.21 shows the resultant TLCs (results multiplied by 2) computed using these equations 
for a 40 year-old over a range of heights. Curves are shown for both males and females. It can 
be seen that there were some disparities between the curves for each equation. In males, 
equation 4.55 produced a higher gradient, leading to larger TLC values for taller subjects 
(a difference of -12.8 % at H = 200 cm). In females there was a negative bias using equation 
4.55 of24.7 % at H = 200 em). 
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Compartment %ofVWB Effective Volume (I) VWB = S.2S I 
VENOUS 64 3.360 
ARTERIAL 20 1.050 
TISSUE 7 0.368 
PULMONARY 9 0.473 
Table 4.5: Summary of estimated compartment blood volumes based on percentage ofVWB. 
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Figure 4.21: Computed total lung capacity for a 40 year-old (a) male and (b) female at various 
heights, using Dickinson's, Taylor's and average empirical formulae. 
Since no clinical validity was provided for either of these equations, it was decided to average 
the two functions for each sex. The effect of age on predicted TLC using Dickinson's equation, 
is approximately 2.6 % from 20 to 100 years. When one considers the differences between the 
Dickinson and Taylor curves, this age effect is small and can be ignored. It was therefore 
possible to think of both sets of equations as simply functions of height. The average functions 
were calculated by taking the mean results from each function over a range of heights, and 
applying simple first order least squares polynomial fitting, resulting in; 
Male FRC = O.0425H - 3.968 
Female FRC = O.0292H - 2.455 
(litres, BTPS) (4.56) 
The TLC curves produced using these equations are also shown in Figure 4.21. In order to 
derive the alveolar volume (V A), dead space (VD) has to be subtracted from TLC; 
Alveolar Volume (V A)= FRC - VD (litres) (4.57) 
Ventilator Parameters 
m Inspired 0, Fraction 
Table 4.6 shows the composition of the earth's atmosphere. Only the primary gases are shown 
and are quoted in percentage by volume in dry gas (STPD - standard temperature pressure dry). 
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Since under normal conditions (i.e. not half way up a mountain) a person will breath this 
composition of air, the inspired 02 fraction (FI02) is assumed to be 0.20946 (or 20.946 %). For 
this to be of use in the blood-gas dynamics model it needs to be converted to BTPS (body 
temperature pressure saturated). This is because inspired air is warmed as it travels through the 
nasal cavities and humidified by the mucus linings. The equations for this conversion are given 
in Section 4.2.8. Expressed at BTPS the atmospheric inspired O2 fraction is 0.1964. 
GAS NAME PERCENTAGE (%) 
Nitrogen 78.084 
Oxygen 20.946 
Argon 0.934 
Carbon Dioxide 0.035 
Table 4.6: Composition of the atmosphere of earth (by volume in dry gas) [Nunn, 1993, p.4] 
OJ) Respiratory Rate 
Typically the respiratory rate (RR) is assumed to be 15 breaths/min [West, 1979, p.13; Nunn, 
1993, p.127]. Variations from this value depend upon many factors, such as CO2 neurogenic 
drive, patient size, etc., which is too complicated to model for these purposes, and since the 
patients will be artificially ventilated can be ignored. 
Oii) Tidal Volume 
Normal values for tidal volume (VI) are quoted at 500 ml [West, 1979, p.13, etc.] or 1I6th of 
the functional residual capacity (FRC). By implementing tidal volume as; 
FRe VT=--xIOOO 
6 
(ml) (4.58) 
where the 1000 multiplier converts FRC in litres to ml, the expected increase in alveolar 
ventilation (ml/min) with height is modelled. 
Ov) PEEP. PIP & I:E 
These are not normally used for a spontaneously breathing subject, but are available during 
artificial ventilation and are set by the ventilator. However, a peak inspiratory pressure (PIP) is 
generated by the lifting action of the rib cage and there is also a normal inspiratory/expiratory 
ratio (I:E) of approx. 0.66 (i.e. the inspiratory time is two thirds of the expiratory time) 
[Dickinson, 1977, p.61). During inspiration PIP is approximately equal to the transmural l 
pressure gradient; normally between 6 and 7 cmH20 (or 0.6 to 0.7 kPa). 
1 transmural. between the intrapleuml space and the upper airway tract. 
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4.4.3 Ball Park Validation 
A typical healthy 20-year-old male subject, 183 cm tall and weighing 75-kg was constructed using 
the empirical formulae and normal values outlined in the previous section, see Table 4.7. Since the 
CO2 transport was not yet modelled PaC~ was assumed to be 5.333 kPa when using the O2 GDF to 
calculate Cp02 from Pp~. This represents the normal CO2 position of the dissociation curve. 
The PaOz was calculated by using the inverse O2 dissociation function with Ca02 as the input. 
The other blood parameters required by this calculation were assumed to be the same as for the 
pulmonary compartment. This is not entirely valid since the mixing of shunted blood will 
reduce the pH slightly from the pulmonary end-capillary value. 
BREATHING PARAMETERS (VENTILATOR SETTINGS) 
FI02 = 0.2095 STPD Tv (ml) = 634.9 
RR (rpm) = 15 PEEP (cmH20) = 0 
PIP (cmH20) = 6 I:E ratio = 0.6667 
BLOOD PARAMETERS 
Temp. eC) = 37 
Hb (g/ell) = 148 
Pac02 (kPa) = 5.333 
~h (gil) = 1.34 
PATIENT PARAMETERS 
Height (cm) = 183 
Age (years) = 20 
dV02 (ml/min) = 263.3 
Vo (ml) = 165.4 
Daz (mllminIkPa) = 254.7 
ATMOSPHERIC CONSTANTS 
Air Temp (DC) = 20 
PMEAN (kPa) = 10l.56 
COMPARTMENT VOLUMES 
pH = 7.4 
P50 (kPa) = 3.577 
<X.b (mllllkPa) = 0.225 
Weight (kg) = 75 
Sex = male 
C.O. (I/rnin) = 5.134 
Shunt (%) = 3 
B02 (mVllkPa) = 51.14 
PB (kPa) = 101.325 
FRC (I) = 3.81 VWB (I) = 5.25 
VA (1) = 3.644 Vp (1) = 0.4725 
Va (I) = l.05 Vt (I) = 0.3675 
Vv (I) = 3.36 
Table 4.7: Patient parameters used in the ballpark assessment of the O2 transport dynamics model 
4.4.4 Results & Analysis 
Using the patient described above, the simulated steady state PaOz was 13.318 kPa. This falls 
nicely into the expected range of Pa02 values for a 20 year old subject derived using the 
relationship suggested by Marshall and Wyche (1972) [Nunn 1993, p.269]; 
Mean Pa02 = 13.6 - 0.044 x AGE (kPa) (4.59) 
where AGE is in years. About this line there are 95 % confidence limits (2 S.D.) of ±1.33 kPa. 
Using this equation the expected range of PaOz values for a 20-year-old is 11.39 to 14.05 kPa 
(12.72 ± 1.33 kPa). 
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The steady state compartment O2 contents for the 'normal' subject were; CpOz = 197.31 mVL, 
CaOz = 196.33 mIlL, CtOz = 145.05 mIlL, CvOz = 145.05 mIlL and CAOz = 159.09 mVL. 
By using well accepted simple physiological relationships some of the parameters defined using 
the empirical formulae can be derived, thus confirming the functional validity of the Oz model. 
Oxygen Consumption 
Oxygen consumption can be derived from the classic Fick equation [Taylor et aI, 1989, p.55]. This is 
simply the product of the arterial-venous content difference, (Ca~-C~) and the cardiac output, Qt; 
(mVmin) (4.60) 
Using the steady-state values for arterial and venous Oz content; 
V02=(Ca02-Cv02) x QI 
=(196.33-145.05) x 5.134 = 263.3 mIl min 
which matches the calculated value. 
Qz Diffusion Constant 
The rate of Oz uptake from the lungs can be calculated from the pulmonary-venous content 
difference, (Cp~-Cvoz) and the pulmonary blood flow, Ot.( 1- Os/Ot); 
(mVmin) (4.61) 
Where (1- Qs/Qt) is the non-shunted blood fraction, i.e. that which flows through the 
pulmonary circuit. Again using the steady state values for CpOz and CvOz; 
V021ung=(Cp02-CV02) x Qt. (1- QsIQt) 
= (197.91-145.05)x5.134(1-0.03) = 263.24mVmin 
Dividing V0 21ung by the alveolar-pulmonary pressure difference, (PAOz-PpOz) will give us the 
Oz diffusion constant. The pulmonary O2 tension, ppoz. was measured from the model using the 
inverse Oz GDF module and gave a value of 15.123 kPa. The alveolar Oz tension, PAOz can be 
calculated from the alveolar Oz content, CAOz and the mean inspiratory pressure, PMEAN; 
CAO 159.09 PA02 = __ 2 XPMEAN= xlO1.56=16.157 1000 1000 
(kPa) (4.62) 
Therefore the alveolar-pulmonary pressure difference is; 
PA02 - Ppo2 = 16.157 -15.123 = 1.034 (kPa) (4.63) 
from which DOz can be calculated; 
(mVminlkPa) (4.64) 
The predicted Doz was 254.7 mVminlkPa, indicating correct functioning of the diffusion mechanics. 
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Shunt Fraction 
The arterial O2 content, Ca02 can be calculated from the sum of the non-shunted pulmonary 
blood content, Cp02 and the shunted venous blood content, CV02 as follows~ 
Ca02 = (1- Qs/Qt).Cp0 2 +Qs/Qt. CV02 (mIlL) (4.65) 
By expanding the Cp02 term, collecting together the Qs/Qt terms and rearranging we arrive at 
the following expression for shunt; 
QS/Qf = Ca02 -Cp02 = 196.33-197.91 0.0299 
Cv02 -Cp02 145.05-197.91 
(4.66) 
This correlates with the set value of 0.3, indicating that the shunt modelling is performing correctly. 
4.5 CO2 Dissociation Function Development 
4.5.1 Functional Validity 
The CO2 gas dissociation algorithm (see Section 4.2.6), as with the O2 gas dissociation was 
implemented as a MA1LAB function with the input-output structure as shown in Figure 4.22 and 
was tested for functional validity. 
Kelman's paper (1967) included a comparison of C(C02) results obtained using this algorithm 
with the nomograms of Singer & Hastings (1948). For comparison purposes the dissociation 
constant, pK was fixed at 6.11 ~ rather than making use of the algebraic expression given in 
equation 4.32, since this was the value used in the construction of the original Singer-Hastings 
nomogram. Table 4.8 shows the results of Kelman's comparison together with results obtained 
using the MA1LAB GDF. It can be seen that the MA1LAB implementation matched Kelman's 
data exactly (allowing for rounding errors) and gave good correlation with the Singer-Hastings 
nomogram (R=O.999), see Figure 4.23. As expected this correlation fell slightly when using 
algebraically derived pK (R=O.998), although its inclusion is likely to produce more accurate 
results in real patients since there is an inter-dependence between pK and pH (Dickinson, 1977; 
Kelman, 1967~ Nunn, 1993). 
Primary Output 
Primary Input Carbon ~ 
CO2 Content 
Dioxide GDF 
Pe02 
S02 pH Temp PCV 
Secondary Inputs 
Figure 4.22: Schematic representation of the carbon dioxide GDF showing inputs and output. 
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Pc~ pH SOl PCV Singer- Kelman MAT LAB MATLAB 
(mmHg) (0/0) (0/0) Hastings (mUdl) pK=6.11 Algebraic pK 
(mild!) (mlldl) (mlldl) 
14.5 7.01 60 40 67.0 78.0 78.1 78.5 
11.8 7.59 80 59 188.0 184.0 184.1 195.8 
26.0 7.43 66 55 320.0 304.0 304.1 318.2 
44.2 7.25 97 42 384.0 377.0 377.3 387.9 
28.5 7.53 60 40 460.0 442.0 442.0 467.2 
27.7 7.64 95 51 508.0 497.0 497.2 531.4 
132.0 6.89 99 50 546.0 543.0 542.6 539.6 
66.0 7.25 97 48 564.0 559.0 548.8 564.1 
48.0 7.48 97 48 643.0 634.0 634.0 666.7 
55.8 7.41 60 40 696.0 675.0 674.7 704.6 
62.3 7.41 89 59 700.0 677.0 677.2 707.2 
45.5 7.54 60 40 718.0 720.0 720.5 762.3 
Table 4.8: Comparison between whole blood [C02] derived using the Singer-Hastings nomogram. 
the Kelman algorithm and the MATLAB implemented GDF (with both fixed and algebraic pK). 
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Figure 4.23: Graph showing the correlation between CO2 contents calculated using the Singer-
Hastings nomogram and the Kelman algorithm implemented using a fixed pK of 6.11 (as used 
by Singer) and an algebraic pK. 
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4.5.2 Inverse CO2 Dissociation Function (IGDF) 
The CO2 IGDF was implemented in much the same way as its O2 counter part (see Section 4.3.3). 
The shell of the secant iteration function was maintained, with the differences being internal calls 
to the CO2 GDF and fewer parameters passed into the iteration shell (7 instead of 10), as shown in 
Figure 4.24. The function was shown to perform correctly and gave convergence to solution in 
only 2 iterations, due to the almost linear nature of the CO2 GDF curve. 
Primal)' Input 
CO2 Content 
Iteration Controls 
Entol pO pI 
, ___ ....1.-__ -"-;;==========;, Primal)' Output 
Pe02 Carbon 
Dioxide 
Inverse GDF Secondal)' Outputs 
L---...,----r~::;:==::::::;=====~ [No.lterations, Error] 
S02 pH Temp rcv 
Secondal)' Inputs 
Figure 4.24: Schematic representation of the inverse carbon dioxide GDF showing its 
inputs and outputs. 
4.6 CO2 Transport Dynamics Development 
The general structure of the CO2 equations is identical to that of the O2 equations and was 
duplicated to form the CO2 transport model. Some of the O2 system specific parameters were 
replaced with their CO2 counterparts as follows; 
CO2 production, Veo2 replaces 
CO2 diffusion constant, Deo2 replaces 
Inspired CO2 fraction, FIC02 replaces 
O2 consumption, V02 
O2 diffusion constant, D02 
inspired O2 fraction, FI02 
This made the SIMULINK implementation simply a matter of duplicating the basic model 
structure and inserting the relevant parameter or module differences. Again the subsystem was 
validated using a normal patient scenario. This required the derivation of additional parameters, 
which are given below. 
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(i) Packed Cell Volume 
Packed cell volume (PCV) or haematocrit is related to haemoglobin by the following simple 
formula [NOVA SP2 mobile blood analyser, User's handbook]; 
PCV =HbxO.3 
where Hb is in gIL. This is required by the CO2 dissociation function. 
00 Inspired C02 Fraction 
(%) (4.67) 
The inspired CO2 is negligible and can be assumed to be zero. It is actually 0.035 % [Nunn 
1993, pAl, which is the value used for the purposes of the model validation. 
ou) C02 Production 
The respiratory quotient (RQ) describes the ratio of CO2 production to O2 consumption and has 
a normal value of 0.8 [West 1979, p.164; Petros et a11993; Taylor et al 1989, p.133, etc.]. 
Therefore having established V0 2 from Dickinson's empirical formula (see equation 4.48), we 
can derive Ve02 at rest; 
Ve02 = RQ x V02rest 
= RQ x 10.33.WTo.7s 
(ml/min) (4.68) 
RQ has been shown to correlate to the type of substrate that is being oxidised by the metabolic 
process. An RQ of 0.8 corresponds to the oxidation of protein. A slightly higher value than this 
might be expected, to reflect the addition of carbohydrate oxidation in the metabolic process (an 
RQ of 1.0 indicates that only carbohydrates are being burnt). A value of 0.9 would reflect a 
mixed substrate oxidation. 
Typical values for Ve02 are given as approximately 200 ml/min [Taylor et ai, 1989, p.60]. 
This is based on a V0 2 of250 ml/min and an RQ of 0.8 
Ov) CO2 Diffusion Constant 
Quoted values for the CO2 diffusion constant vary. In McPuf [Dickinson 1977] De02 is assumed 
equal to D~, which when calculated for a typical male (183 cm, 75 kg, 20 yr.) is 254.7 mVminlkPa. 
Selvakumar et al (1992) gives a much larger value of 1500 ml/minlkPa. The theoretical diffusion 
constant of CO2 across an aqueous membrane is approximately 20.5 times greater than that for O2, 
giving a De02 of approx. 5220 mVmin/kPa (based on a ~ of 254.7 mVminlkPa). There is not a lot 
of agreement between these estimates, so for the ballpark validation De02 was assumed equal to 
Do2• However, it will be seen that the final choice of ~ and De~ had to be altered due to model 
sensitivity issues during tuning to clinical data (see Section 5.4.4). 
fJi.QJ Saturation 
A typical O2 saturation, S02 was hard to come by, as it is dependent upon many factors. Since at a 
later stage the O2 and CO2 sub-systems would be integrated some relationship with the former would 
be necessary. As a consequence it was decided to use the S02 derived from the standard patient 
scenario used in the assessment of the O2 sub-system. This was calculated to be 98.08 %. 
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4.6.1 Ball Park Validity 
The patient simulation was set up as in Table 4.7 with the inclusion of the parameters mentioned 
above and run until steady state was reached. Since the S(02) value was derived from a fixed 
PacC02) value of 5.333 kPa this becomes the target arterial pressure for the sub-system. In the 
first test Dco2 was assumed equal to 002. 
The resulting steady state arterial PC02 was 4.396 kPa. This was 0.953 kPa (17.9 %) below the 
target pressure. This was deemed unacceptable. Now, since only four parameter changes had 
been made in the CO2 sub-system equations; S02, Dco2, FIC02 and Vco2 ; this error could only 
be due to one of these parameters or the CO2 dissociation function. 
Under normal blood conditions (which is true for this test) a change of S02 from 100 % to 90 % 
only causes a change in PC02 of 0.021 kPa (approx. 0.4 % error). This does not account for the 
large observed error of 17.9 % 
The sensitivity of the model to changes in FIC02 was also small. A doubling of FIC02 from its 
atmospheric value gave rise to an increase in PaC02 of only 0.034 kPa (approx. 0.8 % error). 
Again this error is small and does not account for the large error observed. 
The level of C02 production may give rise to this error since this was dependent upon the 
respiratory quotient (RQ). An increase of RQ from 0.9 to 1.0, giving an effective increase in 
Vco 2 from 237 to 263 mVmin (an 11 % increase), gave an increase of 0.485 kPa in PaCo2 (an 
11 % increase). This would account for more than half of the observed error but since RQ cannot 
be increased beyond 1.0 in normal patient scenarios, this leaves approx. 8 % unaccounted for. It 
could equally be argued that an RQ of more than 0.9 is unrealistic in an intensive care setting. 
This leaves one of two possible hypotheses; 
1). Dco2 is too high, giving rise to increased CO2 elimination. 
2). Alveolar ventilation is too high, leading to the same effect. 
The first of these seems improbable since other sources have quoted larger Dc02 than used here. 
The latter is plausible when one considers that a reduction in alveolar ventilation can be 
achieved by reducing the respiratory rate (RR). 
By reducing RR to 11 b.p.m., the Pac02 is increased to 5.64 kPa and Pa02 is reduced to 12.32 kPa. 
The PaC02 error is now acceptable at 5.8 %, and Pa~ has not fallen outside of its normal range. 
4.7 O2 and CO2 Model Integration 
Having constructed and assessed the gas sub-systems the next obvious step was to integrate them. 
Rather than have two large block diagrams strapped together to form the model, it was decided to 
exploit the symmetry of the problem. Both gases travel through the same physiological structures of 
the model and therefore a vector can represent the state of the gases at any point in the model; 
(4.69) 
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Any subsequent computations within the SIMULINK block diagram are applied to each vector 
element. If there are different parameters associated with each gas, as in the case of diffusion at 
the lung membrane, then these are implemented within the given block as vectors, see Figure 4.25 
Block with parameters implemented vectorally 
Figure 4.25: SIMULINK gain block showing implementation of parameters as vectors 
In this way the gas models function independently whilst making use of the same process structure. 
Cross coupling betwcen the two gas systems occurs within the dissociation functions, where P(h is 
affected by PC<h, which is in tum affected by S(h (being a function of P<h). pH is also affected by 
PC(hwhich will modify Po2, however this was not represented in the prototype model. 
The parameters of the two sub-systems were combined and a standard 20-year-old male subject 
generated as before. This was then run to steady state resulting in a Pao20f 12.33 kPa and PaC02 
of 5.33 kPa. These results are promising with Pa02 within its normal range and PaC(h matching 
the target of5.33 kPa. 
4.8 Summary & Conclusions 
!b Dissociation Function 
The O2 GDF based on Kelman's algorithm (1966) was found to be functionally valid, matching 
published function results exactly. 
It performed moderately well against the SHBODC of Severinghaus (1979), with an observed 
maximum saturation error of 2.23 % compared to 0.55 % for the Hill equation. The larger errors 
occurred below 40 % saturation which is well below the normal operating point for either 
arterial or venous blood, except in cases of critical blood loss. Both of these equations were 
tested against Severinghaus' data, however, no indication of how the Hill equation should be 
modified to account for shifts in pH, temperature and PC02 were given. 
The GDF performed well against the experimcntal data of Sharan et al with a mean absolute 
saturation error of 1.75 % ± 0.84 (confidence interval 99 %) compared to 1.03 % ± 0.56 
(confidence interval 99 %) using the Sharan O2 GDF equation. The maximum observed 
saturation error was 3.63 % compared to 2.32 % using the Sharan equation. 
The Kelman algorithm was deemed suitable for incorporation into the O2 transport model. 
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Inverse 02 GDF 
The inverse O2 GDF was resolved using an iterative secant based method and proved 
functionally valid. It arrived at a target solution in an average of 8.1 iterations, when tested 
across a PCh test space of between 1 and 50 kPa. This was with an iteration error tolerance of 
0.01 kPa and initial pressure estimates of 4 and 6 kPa for pO and pI respectively. 
An improved secant algorithm using bounded P~ tracking was proposed and gave improved 
iteration performance. The average number of iterations reduced to 3.22 with little change in 
P~ accuracy. 
21 Transport Dynamics 
Normal patient-values and appropriate formulae to calculate them were elicited from the 
available literature, for each parameter used within the O2 transport model. 
The O2 transport model was successfully implcmentcd using SIMULINK and gave an artcrial P~ of 
13.32 kPa for a pre-defincd 20-year-old male subjcct, weighing 75 kg and of height 183 cm. This 
fell within the range of typical values for a 20 to 29 year old age group, quotcd by Nunn (1993). 
It would appear from this assessmcnt that the O2 transport model has been constructed correctly 
and was functioning in a reasonably predictive manner. The assessment was of course mainly 
qualitative and the CO2 transport was not included, but the indications of a useful working 
patient model were promising. 
C02 Dissociation Function 
The implemented CO2 GDF, based on Kelman's algorithm (1967) was found to be functionally 
correct matching the published results exactly. Comparison with the results obtained using the 
Singer-Hastings nomogram showed excellent correlation with both fixed pK (R=0.999) and 
algebraically derived pK (R=O.998). 
Inverse C02 GDF 
The inverse function was implemented using the same shell as the O2 IGDF and was proven to 
be functionally correct, giving convergence to solution in 2 iterations, due to the near-linear 
properties of the function. 
CO2 Transport Dynamics 
All parameter values were identical to those for the O2 sub-system with the exception of FIC02, 
Deo2, and S02. Suitable values or derivation formulae were located for all of these, although 
there was some uncertainty regarding Deo2. 
With Dc02 equal to 002 (255 mVminlkPa) and an RQ of 0.9 the model gave a PaCCh of 4.396 
kPa, 17.9 % below the target value of 5.333 kPa. This was with a pre-defined 20-year-old male 
subject as used for the O2 sub-system ballpark assessmcnt. 
Reasons for this were considered and the main source pinpointed to a high RR. This was 
reduced from 15 b.p.m. to 11 b.p.m. and gave a PaC02 of 5.64 kPa, reducing the error to 5.8 %. 
In normal patients such compensation is performed via neurogenic drive, with the alveolar 
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ventilation changing in response to the level of PC02 in the brain. Therefore the discrepancies 
observed could be ignored and the CO2 sub-system deemed to be functioning correctly. 
System Integration 
The O2 and CO2 sub-systems were combined into the same model shell by representing the 
gases through out the system in a vector form. This negated the need for replicated model block 
diagrams and greatly simplified interaction with the model inputs and outputs. 
Using the standard healthy patient scenario the resultant Pa02 was 12.32 kPa and the PaC02 was 
5.33 kPa, both being within normal ranges. 
SOPAVent was now ready for validation using real clinical data and this is discussed in the next 
chapter, together with an investigation of the parameter sensitivity of the model. 
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Chapter 5: Clinical Validation of Patient Model 
5.1 Introduction 
So far it has been shown that the patient model produces normal blood-gases when simulated 
using parameters representing a healthy male patient breathing atmospheric air. However, if it is 
to be useful for advisor development and validation, it must be able to correctly predict blood-
gases when changes are made to the ventilator settings. This must be possible for the types of 
patient routinely found in ICU. This chapter presents the clinical validation of the model's 
predictive performance using data collected from patients in leu at the Hull Royal Infirmary. 
Before attempting any clinical validation the parameter sensitivity of the model was investigated 
(see Section 5.2), in order to identify those parameters within the model that required accurate 
measurement, or indeed parameters that because of measurement inaccuracies might contribute 
to poor predictive performance. 
In Section 5.3, the data collection methods and protocol are presented, and the problems 
encountered in trying to meet them discussed. This is followed by a brief summary of the 
patient data collected (full details are given in Appendix B). These data were processed to 
generate the parameters required by the patient model, see Section 5.4. This involved the 
calculation of prior and post patient parameters to facilitate tuning of the model unknowns, i.e. 
Qs/Q/ , Vo and Pso• The model-tuning algorithm is described and the estimated unknowns for 
each patient presented. 
The model-predicted and actual blood-gases produced in response to ventilator changes are 
compared, see Section 5.S. These comparisons are made using qualitative trend analysis and 
conventional statistical analysis. Finally the possible causes of response mismatch are explored. 
5.2 Model Sensitivity Analysis 
Before commencing clinical validation of the model, attention was given to the behaviour of the 
patient model in response to control and parameter disturbances. This is known as sensitivity 
analysis and is used to identify those parameters that have greatest influence over the model 
outputs. If a model is to reflect a patient's state realistically, parameters identified as sensitive 
will need to be measured accurately for good patient-model matching. However, this may not 
always be possible, and the combination of measurement errors coupled with parameter 
sensitivity may lead to poor blood gas prediction. This reflects problems with the data quality 
rather than the inability of the model to represent true physiology. 
Sensitivity analysis can be complex and therefore a simple methodology was employed. Even so, 
it was still able to provide useful information about the model. The following section describes the 
analysis used and presents the limitations associated with it, when applied to larger models. 
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5.2.1 Theory 
There are many approaches to sensitivity analysis. The simplest is known as c1assieal sensitivity 
analysis and looks at the changes in the state variable Xi with respect to a parameter Pj 
[Tomovic, 1963], and can be expressed thus; 
(5.1) 
Where S ij (t) is the sensitivity ofthe state variable i to parameter j, and is time dependant. Since at this 
stage of model development we are only concerned with steady state sensitivity (i.e. the influence of a 
parameter when there is no change in model inputs), the sensitivity can be rewritten as; 
s .. = oX; 
IJ oP. 
J t=co 
(5.2) 
The simplest implementation of this approach is to vary each parameter by a fixed percentage, 
say 10 % and compare the effects on a given state output. However, it will be seen that this 
leads to problems when interpreting the results. 
Within the blood-gas model the state variables (X,) are the arterial and venous blood-gas 
tensions, Pao2, Paco2, PV02 and PVC02; and the disturbance parameters are (listed by category); 
I). Patient Parameters: cardiac output, haemoglobin content, body temperature, pH, 
O2 consumption, CO2 production, peak inspiratory pressure, O2 diffusion constant, 
CO2 diffusion constant. 
2). Atmm.pheric Constants: barometric pressure, air temperature. 
3). Ventilator Parameters: inspired O2 and CO2 fraction, respiratory rate, tidal 
volume, inspiratory-expiratory ratio, and positive end-expiratory pressure. 
4). Unknown (taned) Parameters: shunt and dead-space. 
Not included in this list are the patient's age, weight, height, sex, O2 haemoglobin binding 
capacity (Ph), plasma O2 absorption constant (Ub) and 50 % saturation point (Pso); since these 
were assumed constant for a given patient during data collection. In retrospect there may be a 
good argument to have included Ph, and Pso since inaccurate values may skew the patients 
physiology. However, these are not routinely measured and their values are often theoretical. 
Also not included in this analysis were the compartment volumes since these are concerned with 
the time constants of the compartments and do not affect steady-state gases. However, short 
time intervals between blood-gas samples could lead to insufficient settling of the CO2 
dynamics (since they are slower than the O2 dynamics) leading to model-patient mismatch. 
In total, 19 parameters were considered. The model was therefore large and the following 
problems can arise when sensitivity analysis is attempted on such a model [Rose, 1987]. 
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Excessive computation requirements 
The computational cost of repeated simulation runs of a large model can become excessive, due 
to the large number of possible permutations required. 
Strong parameter interaction effects 
In some models there is a strong interaction between parameter influences, such that the scnsitivity 
of a given state to paramctcr changc, dcpcnds upon the value of some othcr paramctcr. Lct us 
considcr a simple two-parameter example (see Figure 5.1). The output of a model state X is 
observed under two conditions for a fixed parameter P l. One with P2 = K, and the other with P2 = 
K'. Whcn observed under the condition P2 = K the scnsitivity of X to param(.,'tcr P I is low and 
therefore "unimportant", but when P2 = K' then its sensitivity becomes "significant". 
P2=K' 
:>< 
v 
-~ V; 
-= ~ 
0 
'0 P2=K 
v 
= ~ 
Value of parameter PI 
Figure 5.1: Hypothetical responses depicting an interactive effect between paranleters PI and 
P2, upon the output X. 
Size and shape of the parameter space for valid sensitivity conclusions 
The size and shape of the paramcter space will dramatically affcct the rcsults of a sensitivity 
analysis. For example a 10 % change in all parameters, irrespective of their nominal values and 
standard deviation estimates will give very different results to changes based on the average 
amount each parameter is normally varied. Figure 5.2, illustrates this point by considering the 
variability distributions PDFI and PDF2 for two parameters PI and P2, with nominal values NI 
and N2. If each parameter is changed by ± 10 % of their nominal values then PI is being 
searched across considerably more of its probable values than P2, since its nominal (average) 
value is positively offset. This will result in a lower sensitivity score for PI than if a similar 
proportion of the PDF was tested. 
It might seem reasonable, on the basis of these problems to employ a more rigorous sensitivity 
technique than provided by the classical sensitivity analysis, and this may well be the case for a 
truly quantitative analysis. However, the time and effort required for this would be prohibitive 
and we were forced to settle for a qualitative picture of the respective parameter sensitivities. 
69 
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N1 
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nominal value 
30 40 
PI Parameter Range 
(a) 
! N2 
+/-10%of 
100 110 120 130 140 
P2 Parameter Range 
(b) 
Figure 5.2: Hypothetical parameter space variability showing how this can lead to inaccurate 
sensitivity conclusions, when the parameter disturbance is much smaller than the normal 
parameter distribution. 
5.2.2 Sensitivity Analysis Method 
The model sensitivity analysis (SA) was performed as follows~ 
1). A single real patient data set was used for the test, in this case Patient 1 Record 1 
(obtained during the clinical data collection). This provided the initial parameter 
values and blood gas levels before any parameters were disturbed. 
2). Only one parameter was varied at a time with all other parameters remaining at 
their initial value. Each parameter was varied by ± 10 % of its original value, 
irrespective of its normal range and initial value. 
3). The effect of each parameter disturbance on the blood gases Pa02. PaC02, PV02 and 
PVC02 was recorded, giving a positive and negative response for each. 
4). The magnitudes of the output responses were then averaged to give a sensitivity 
measure for each parameter on each output. This was expressed in terms of 
percentage change from original blood gas levels. 
Figure 5.3 compares the output sensitivities for each blood gas to each parameter disturbance. 
The responses are grouped according to the parameter type (i.e. patient, atmospheric, input and 
unknown). Blood pH was expressed in terms of hydrogen ion concentration [ttl, since pH is 
logarithmic and would otherwise result in non-linear disturbance behaviour. 
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Figure 5.3: Comparison of Pa02 and PaC02 (top chart) and Pvo2and PVC02 (lower chart) output 
sensitivities to 10 % changes in model parameters. Parameters are grouped by type and 
sensitivities are expressed as a percentage change from initial blood gases. Initial parameter and 
gases are based upon patient 1 record 1 (see Appendix B). 
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5.2.3 Analysis 
Over Sensitivity to Barometric Pressure 
Initial inspection of the results indicated a larger than expected sensitivity to changes in Pn. 
However the applied change of ±I 0.26 kPa is equivalent to changes in altitude of approximately 
±3000 feet (914 m). An individual breathing atmospheric air at sea level would experience a 
drop in Pa02 of approximately 2 kPa when elevated to 3000 feet (interpolated from the data of 
West et al (1938) [Nunn, 1993, p340]), a reduction of about 15 %. This is in line with the 
observed change of 18.11%. Since the sensitivity scores for Pn are exaggerated they have been 
ignored for all of the subsequent comparisons. 
Under Sensitivity to PEEP 
Conversely PEEP exhibited a very low score, which does not support expected therapeutic effects. 
This may simply be due to its small disturbance size. However, PEEP also increases Pa02 by 
increasing the resting volume of the lung. Reduced lung volumes are often due to the closure of 
small airways, which are then not ventilated and thus leads to arterial hypoxaemia (Nunn, 1993, 
p.451). PEEP can hold the airways open throughout the entire respiratory cycle and may therefore 
restore ventilation to previously perfused but unventilated regions, improving oxygenation. Since 
the model at this stage does not account for this behaviour, PEEP has no net effect. This effect 
needs to be included in the model before it can be used for advisor development (see Model 
Improvements - Section 7.3). Consequently PEEP has been omitted from any subsequent analysis. 
Comparison of Parameter Sensitivity Scores 
In order to compare the relative sensitivity of the O2 and CO2 systems the parameter sensitivity 
scores (PSS) for the arterial and venous blood gases were averaged; 
(5.3) 
where i is the parameter under consideration and S,(x) is the sensitivity of output x to parameter i. 
Having calculated the PSS for each parameter, they were then ranked according to size and 
grouped using semantic classifiers (e.g. 'very sensitive', 'sensitive', etc.). By doing this it was 
then possible to construct a visual representation of the sensitivity groupings, see Table 5.1. 
The boundaries for the classification were as follows; 
• Very Sensitive PSSi(x) > 10 
• Sensitive 5 < PSSi(x) ~ 10 
• Slightly Sensitive 0.5 < P5:S'i(X) ~ 5 
• Insensitive PSSi(x) ~ 0.5 
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OXYGEN SYSTEM CARBON DIOXIDE SYSTEM 
INSENSITIVE 
FIC02 (0.000) 002 (0.000) 
De02 (0.015) FIC02 (0.000) 
PIP (0.120) FI02 (0.020) 
002(0.140) Hb (0.085) 
TAlR (0.320) ~;'a2 (0.090) 
Vea 2 (0.410) PIP (0.100) 
Shunt (0.120) 
TBODY (0.225) 
De02 (0.415) 
Qt (0.490) 
SLIGHTLY SENSITIVE 
RR (0.860) [W] (0.575) 
VD (1.110) TAlR (3.270) 
VT (2.010) 
[W] (2.770) 
Hb (4.120) 
SENSITIVE 
Shunt (7.140) RR (8.960) 
Qt (9.500) Vea 2 (9.890) 
FI02 (9.550) 
VERY SENSITIVE 
V0 2 (10.510) VD (11.605) 
TBODY (11.580) VT (21.420) 
Table 5.1: Comparison of the parameter sensitivity ranking for the O2 and CO2 systems. 
As expected gas specific parameters were more sensitive in their native system than in the 
opposite system. For example Vea 2 was sensitive in the CO2 system but insensitive in the O2 
system. Similarly, V0 2 was very sensitive in the O2 systcm but insensitive in the CO2 system. 
This pattern was repeated for the diffusion constants 002, De02 and Fr02. However FrC02 was 
also insensitive in the CO2 system. This can be attributed to poor parameter disturbance, since 
FIC02 was effectively zero to begin with. 
Alveolar Ventilation 
Respiratory rate, tidal volume and dead space changes influenced O2 tensions less than CO2 
tcnsions by about a factor of 10. All of these parameters affect alveolar ventilation, which will 
increase the rate of O2 flowing into the lung and CO2 flowing out of it. This has the effect of 
raising the alveolar O2 content and reducing the alveolar CO2 content. The diffusion gradient 
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across the lung membrane is higher for CO2 than for O2 and therefore the effect is greatest in the 
CO2 system. This is in keeping with the therapeutic benefits of changing the ventilation rate to 
bring CO2 tensions to normal. 
The O2 system was sensitive to shunt changes, where as the CO2 system was insensitive. 
Qualitatively, venous shunt reduces the overall efficiency of gas exchange and results in arterial 
blood gases closer to venous levels, depending on the level of shunt involved. Considering the 
gases in terms of content the mixing is easily explained by the mass transport equations; 
Cao2 = Qs /Qt .CV02 + (1- Qs /Qt ).Cp02 
Caco2 = Qs / Qt .CVC02 + (1- Qs / Qt ).CpC02 
(mill) (5.4) 
As (JjQt increases, the arterial O2 content will be reduced by mixing with the lower venous O2 
content level. Conversely the arterial CO2 content will be increased slightly by the higher venous 
level. This effect is linear, so does not explain the difference in sensitivities. However, due to the 
steep gradient of the CO2 dissociation curve ncar the arterial point, the effect on the CO2 tension is 
small. The O2 dissociation curve is almost flat at the arterial point (assuming good saturations) and 
therefore small changes in content produce large differences in O2 tension. If the blood is poorly 
oxygenated then the effects of changes in shunt are reduced and Pa02 remains relatively 
unaffected since the arterial point now lies on a steeper part of the O2 dissociation curve. 
Air Temperature 
Changes in air temperature had little effect on the O2 system but a more marked effect on the 
CO2 system. This is because tidal volumes are expressed at ATPS and require conversion to 
BTPS. Since tidal volume exerts a greater influence on the CO2 system then the increased CO2 
sensitivity was expected. 
Acid I Base System 
Changes in pH (reflected here as changes in hydrogen ion concentration) exert their effect 
through the gas dissociation functions. The effect on each system depends very much on the 
position of the content-pressure point on the curves. Again because the CO2 GDF tends to be 
steeper than the O2 GDF the shifting of the curves produces a larger effect in the O2 system than 
the CO2 system 
Body Temperature 
This affects both of the gas dissociation functions, but was more marked in the O2 system. 
Again the relative position of the content-pressure point on the gas dissociation curves explains 
this difference. 
74 
----
Haemoglobin Concentration 
Haemoglobin concentration determines the carriage of O2 in the blood as given by equation 4.13 
and therefore its greater sensitivity in the O2 system would be expected. The small effect it does 
exert on the CO2 system, is through the CO2 dissociation function, since changes to O2 
saturation affect the CO2 cell to plasma content ratio (see equation 4.35). 
Cardiac Output 
O2 system sensitivity to Qt makes problems for patient-model matching since Q, is very 
difficult to measure reliably. It is probably this single factor alone that will negate the possibility 
of patient matching. The reason being that an erroneous Qt measurement, say 10 % below true 
Q, , would give rise to a reduced shunt estimate when the model was tuned. This would increase 
the model's sensitivity to step changes in Fr02 and impair its predictive performance. 
Cardiac output measurements are normally made using thermo dilution and at the time of data 
collection, was only made on a need to know basis. Almost continuous Q, measurement is now 
possible enabling sample precision to be improved. However, measurement accuracy is still 
uncertain and anaesthetists tend to use changes in Qt as an indication of changing cardiac 
performance rather than rely on the values themselves. 
This does not however mean the model is unsuitable, just that validation against patient data is 
difficult using current measurement technologies. 
Peak Airway Pressure 
Neither system is very sensitive to changes in PIP. In truth this parameter should not be viewed 
as a model-input, since it is really a product of the airway dynamics and the ventilator driving 
waveform. Later improvements to the model derive PIP as a model output (see Section 7.3.2). 
5.2.4 Conclusions of Sensitivity Analysis 
So what can be concluded from all of this? Firstly, the greater sensitivity of the O2 system to 
shunt and the CO2 system to dead space meant that shunt could be adjusted to match Pa02 with 
little disturbance of PaC02, and VD could be adjusted to match PaCQz, with only a slight 
disturbance of Pa02. This made model tuning a lot simpler to implement. 
Secondly, the high P02 sensitivity to cardiac output changes posed the biggest obstacle to 
patient matching, since this measurement suffers from the largest measurement errors. Similarly 
the high sensitivity of the model to O2 consumption and CO2 production meant they required 
accurate measurement. Unfortunately at the time of the data collection, metabolic performance 
was not routinely monitored at the target ICUs and therefore a metabolic computer needed to be 
borrowed. This provided accurate measurement abilities, but unfortunately could only be loaned 
for a limited period. Forearmed with this knowledge of the model's sensitivity, the patient data 
were collected. 
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5.3 Data Collection 
The primary objective of the data collection period (and consequently its major restricting factor) 
was to collect enough patient measurements such that the number of unknowns in the patient 
model was kept to a minimum. Most of the patient parameters could be obtained from routine 
measurements made within the ICU. However cardiac output (Qt), O2 consumption (Vo2 ) and 
CO2 production (Veo 2 ) were also required by the model and these were not as readily available. 
Arterial blood samples were taken via a radial artery catheter (RAC) which is routinely inserted 
into most patients. However, patients with circulatory problems such as those suffering from 
shock may require a femoral artery catheter (F AC) instead. The use of radial catheters is 
preferable to femoral ones both in terms of accessibility and associated risks, since the femoral 
artery has an increased risk of catastrophic bleeding, being more central to the heart. All patients 
in this study were catheterised at the radial artery. 
Venous blood samples were taken from either a central venous catheter (CVC) inserted into the right 
atrium or from a pulmonary artery catheter (PAC). Samples taken via a PAC will give true mixed 
venous blood readings, whereas CVC samples may not, since there is no guarantee that they have 
mixed fully. Both pulmonary artery and central venous catheters carry a degree of risk with their use, 
but this level is not unacceptable. Figure 5.4 indicates the positions of the radial artery, central venous 
and pulmonary artery catheters within the patient when viewed from a model-based perspective. 
Blood samples taken were analysed using an IL System 1302 pHIBlood Gas Analyser, which 
gives direct measurement of pH, P02 and Peo2. This system also measures haemoglobin content 
and calculates standard bicarbonate, base excess and O2 saturation amongst other variables. 
The radial artery catheter was also used to carry a pressure transducer from the M I006A 
Pressure Module (part of the HP Component Monitoring System) to measure systolic, diastolic 
and mean arterial blood pressure as well as pulse rate. A similar module was used to measure 
mean pulmonary blood pressure and wedge pressure via a transducer inserted down the 
pulmonary artery catheter. Wedge pressure measurement required the COl module option with 
an intra-aortic balloon pump. If a central venous catheter was connected then a third similar 
module was used to measure the central venous blood pressure. 
Cardiac output was measured using the MIOl2A C.O. Module (HP Component Monitoring 
System - HPCMS). This measures Qt using the thermal dilution method and requires the use of 
a Swan-Ganz catheter inserted down the PAC. However, this measurement technique is usually 
only reserved for unstable patients. 
This posed a dilemma since the patients needed to be stable but catheterised. This was overcome 
by opting for patients in the period prior to removal of the PAC when they had stabilised; a 
window of between 1-3 days. In reality this was not always practicable and all catheterised 
patients were recorded. Also on occasions during the data collection period there were no 
suitable patients available. In order to maximise the available time with the metabolic computer, 
patients without a PAC were recorded and Qt was estimated using O2 consumption and the 
arterial-venous O2 content difference. 
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Figure 5.4: Schematic of Model Circulation Showing Patient Measurement Points. 
Blood temperature was measured using the temperature probe that forms part of a Swan-Ganz 
catheter. In the absence of a Swan-Ganz catheter, rectal or skin temperature was recorded. 
These provide good estimates of actual blood temperature in stable patients. However, collapse 
of periphery circulation in a post-operative patient may cause a blood-rectal temperature 
differential of as much as 6°C. 
O2 consumption and CO2 production were measured using a metabolic computer (MC). Since 
neither of the ICU's involved in the study possessed one, a DeItatrac-II had to be loaned from 
Datex for a limited period of 3 weeks. This was the largest restricting factor on the data 
collection study and explains why the data set was so small. V0 2 and Vco 2 can be calculated 
indirectly from the arterial-venous blood-gas difference and Qt, but this can lead to large errors 
due to the inaccuracies associated with Qt measurement. 
The M1020A Sa021Plcthysmography Module (HPCMS) was uscd to give a continuous non-
invasive measurement of Sa02, using pulseoximetry techniques. It actually measures end 
capillary O2 saturation and gives poor accuracy ifthcre is peripheral shut down. 
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As mentioned previously there still remained a number of unknowns of which some had to be 
asswned, namely haemoglobin O2 binding capacity, O2 dissolved in plasma coefficient and 
haematocrit, since their measurement would be impractical in such a study. This left QslQ, , VD 
and Pso, which were estimated using an iterative solution searching method. 
5.3.1 Data Collection Protocol 
1) Identify suitable patients for data collection purposes and record where possible two sets of 
measurements prior to and after a ventilator change, see Figure 5.5. The prior 
measurements should be approximately 30 minutes apart in order to establish the steady 
state of the patient. The second measurement should directly precede the ventilator change. 
The first post measurement should occur 30 minutes after the ventilator change and be 
followed 30 minutes later by a second measurement. 
Patient State X Sample Point 
30 mins 
3 
30 mins 
30 mins 
2 t Step Change in Ventilator Setting 
Time 
SAMPLING PROTOCOL: FOUR SAMPLE POINTS 
[1] 30 min before ventilator change. 
[2] Just before ventilator change. 
[3] 30 min after ventilator change 
[4] 60 min after ventilator change. 
Figure 5.5: Steady state sampling protocol. 
2) A suitable patient should ideally have a PAC inserted and be beyond any period of 
instability, but prior to removal of the PAC. This constitutes a window of approximately 1-3 
days when the patient should be stable and cardiac output can be measured, see Figure 5.6. 
Rapid change in S hI . d ~ r bl_::~oW 1 
Surgery or 
Admission 
PAC removed 
Figure 5.6: Stable period during which measurements can be made. 
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3) A set of measurements comprises the following (those measurements required by the 
patient model are indicated by"', all others to be recorded for completeness); 
General Patient Details 
Height"', Weight"', Age'" 
Patient diagnosis, supporting therapies (drugs, dialysis, etc.)'" 
From Radial Artery Catheter 
PaCh"', PaC02"', arterial pH"', Hb"', Sa02, standard bicarbonate (SBC), base excess (BE) 
Systolic, diastolic and mean arterial pressure. 
From Central Venous Catheter 
PV02, PVC02"', venous pH, SBC, BE and SV02 
From Pulmonary Artery Catheter 
PV02 "', Pvco 2 "', mixed-venous pH"', SBC, BE, S v Ch. ToLOoo"', Qt '" 
Mean pulmonary blood pressure and wedge pressure. 
Using Metabolic Computer 
O2 consumption"', CO2 production"', respiratory quotient (RQ) and metabolic rate (MR). 
Air temperature"', ambient pressure'" and ambient CO2''' 
Basal metabolic rate, non-protein RQ, energy substrate utilisation, body surface area 
Ventilator Settings / Measurements 
FI02"', RR"', VT"', PEEP"', PIP"', PMEAN, I:E ratio'" 
Driving waveform characteristics, ventilator type, ventilation modc. 
Tubing and filter arrangement. 
Miscellaneous 
Pulseoximeter O2 saturation, heart rate, rectal temperature, skin temperature 
4) A ventilator change comprises a step changes in one of the 5 primary ventilator settings; 
FI02, RR, VT, PEEP and I:E ratio. These changes are to be madc within the ethical 
committee guidelines, see Appendix B. An optimal test regime will be to make at least two 
changes in a ventilator setting, idealIy in opposite directions and not returning to its 
original value. Figure 5.7 gives an optimal regime, with Fr02 increased to 45 % but then 
reduced to 30 % rather than its original value. 
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It was found through interaction with ICU staff and observation of the patient management 
methodologies that trying to restrict the collection of the data to this protocol would be very 
limiting. Consequently; 
• Sometimes only one PRIOR and POST measurement were made, where the 
protocol stipulated two, in order to establish the steady state condition of the patient 
before and after therapy change. 
• Sometimes not all of the measurements required were recorded due to the time 
constraints on the anaesthetists making the measurements. 
• Sometimes the patients were very unstable and not really suitable for validation 
purposes, but were recorded anyway. 
• Sometimes the patients were not connected to a PAC, thus negating the possibility 
of cardiac output measurements. 
• Sometimes drug maintenance or physiotherapy interfered with a study, introducing 
a further unknown artefact into the data. 
5.3.2 Summary of Collected Data 
Four patients were identified as suitable for study during the 3-week data collection window, 
and from these 9 ventilator changes were recorded. These are detailed in full in Appendix B, 
with a synopsis of each patient, a description of the ventilator arrangement used, atmospheric 
conditions derived from the metabolic computer and full records of the patient measurements 
and ventilator settings. 
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5.4 Data Processing & Model Tuning 
In order to produce parameter values usable by the patient model, the measurements prior to the 
ventilator change needed to be averaged to give a single snapshot of the patient, which could be 
entered into the model. Similarly the post measurements needed to be averaged to give a 
snapshot of what happened after the ventilator change. However before this could be done the 
metabolic computer results for O2 consumption and CO2 production rates needed to be 
processed to produce a single value at each measurement time. In addition to this certain 
patients did not have a Swan-Ganz cathcter inserted. This prevented the measurement of cardiac 
output and it therefore had to be derived using other patient measurements. 
Once the data sets were complete and had been averaged to produce the prior and post paticnt 
snapshots, it was then possible to tune the prior duta to match the measured gases. This was 
done by iteratively adjusting shunt, dead space and P50. It was only after this that the 
performance of the model could be assessed. 
5.4.1 Metabolic Computer Results 
The O2 consumption rate (Vo2 ) and CO2 production rate (Vco2 ) of the patient at the sample 
time (i.e. when the venous and arterial blood gas samples were taken) were obtained by taking a 
lO-point average of the metabolic computer (MC) data centred on the sample time. Since the 
metabolic computer takes measurements once every minute, this gave an average based upon 5 
minutes prior to and 5 minutes after the sample point. During the measurement period the MC 
would sometimes generate artefact flags indicating that V0 2 and Vco 2 measurements were 
unstable and therefore to be treated with caution, see Figure 5.8. If these caused deviations of 
greater than 5 % from mean when calculating the sample average, then the next nearest non-
artefact data were used. 
5.4.2 Calculation of Cardiac Output 
In records Pl-3, Pl-4 and P2-1 the patients were not fitted with a pulmonary artery catheter 
(PAC) and therefore it was not possible to measure cardiac output using thermo-dilution 
techniques. However, Qt can be estimated using O2 consumption (Vo 2 ) and the arterial-venous 
O2 content difference (Ca02 - CV02) via the following equation; 
(5.5) 
This is only possible because of the use of the metabolic computer to measure Vo 2 . The 
arterial-venous content difference was calculated from the blood gas tensions using the O2 gas 
dissociation function together with the other blood measurements (haemoglobin, blood 
temperature, etc). The haemoglobin binding capacity was assumed to be 1.34 gil, the plasma O2 
carrying coefficient to be 0.225 ml/llkPa and the P50 point to be 3.5774 kPa. Table 5.2 shows the 
results of these calculations. 
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Figure 5.8: Example of output generated by Dcltatrac II Metabolic Computer for O2 
consumption and CO2 production in Patient 1-2. The computer indicates regions of artefact (x) 
when the measurements cannot be relied upon since they vary well beyond expected ranges. 
Averages taken around the sample points (0) need to avoid these artefacts. 
Reference CaOz CvOz C(a-v)Oz V02 Q/ (mIll) (mVI) (mM) (mVrnin) (I/min) 
PI-Ill 123.21 101.55 2l.66 289.4 13.36 
2 123.04 1Ol.64 2l.40 282.1 13.l8 
3 127.36 106.51 20.85 279.1 13.38 
4 131.25 109.64 2l.61 284.4 13.16 
Pl-2/1 127.36 106.51 20.85 279.1 13.38 
2 131.25 109.64 21.61 284.4 13.16 
3 132.30 11l.99 20.31 266.2 13.11 
P2-1/1 148.06 100.18 47.88 368.5 7.70 
2 148.07 94.98 53.09 314.2 5.91 
3 15l.69 106.46 45.23 309.7 6.85 
4 143.18 104.98 38.20 308.4 8.07 
Table 5.2: Estimated cardiac output for patients without pulmonary artery catheters. Arterial-
venous content difference calculated using O2 gas dissociation function and arterial/venous 
measurements. O2 consumption measured using metabolic computer. 
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Figure 5.9: Correlation between measured cardiac output (using thermo-dilution) and calculated 
cardiac output using O2 consumption and arterial-venous O2 content difference. 
However, deriving Ot in this manner is very approximate as illustrated when measured Ot 
(using thermo-dilution) was compared with that calculated using equation 5.5, for those patient 
records where Ot was measured, see Figure 5.9. 
Indeed, the values derived for P 1-3 and P 1-4 appear to be a lot higher than previous measurements 
would suggest. However, the absence of any other measure for Ot meant that these values had to 
be used. By implication this will lead to larger estimates of shunt than might be expected, reducing 
the sensitivity of the model and therefore perhaps the accuracy of the model. 
5.4.3 Generation of PRIOR and POST Data 
In order to apply the data to the patient model, measurements made prior to a ventilator change were 
averaged to give a starting patient scenario. This was repeated for measurements made after the 
ventilator change. Two prior and two post measurements were not always available and in these 
instances a single measurement had to suffice. No consideration was taken of the data quality and all 
points were considered. The data resulting from this averaging is given in Table 5.3 and Table 5.4. 
This generated most of the parameters required to run a patient simulation with the exception of 
those which were not easily measured (because they are not routinely monitored or because of 
the physical difficulties in measuring them). This includes shunt, dead space and Pso, which 
were adjusted to match the simulated blood gases to the measured values. The parameters 
obtained form the data collection, were as follows; 
• F102, RR, VI, PEEP, I:E and PIP 
• pH(art), pH(ven), Hb, blood temperature, Ot, V0 2 and Veo 2 
• PB, air temperature and FIC02 (ambient CO2) 
• Height, weight, age and sex. 
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P1-1 P1-2 P1-3 P1-4 P2-1 P3-1 P3-2 P3-3 P4-1 
VENTILATOR SETTINGS 
FI02(%) 55 50 55 60 40 65 70 75 50 
Respiratory Rate (rpm) 24 20 18 18 17 16 16 16 14 
Tidal Volume (ml) 680 670 870 870 700 618 615 590 693 
PEEP (cmH20) 10 5 7.5 7.5 2 10 10 10.3 5 
I:E Ratio (liE) 0.8 1.1 1 1 0.333 2 2 1.43 1.56 
PIP (cmH20) 30.2* 22.6* 24* 24* 36* 35* 33.8* 39.6* 31 
ARTERIAL 
Pa02 (kPa) 17.55 12.35 8.65 9.25 20.9 8.1* 7.8* 11.7 11.5 
PaC02 (kPa) 4.3 5.48 4.795 4.735 5.255 5.12* 5.31* 5.245 3.79 
pH 7.535 7.4725 7.4635 7.487 7.376 7.349* 7.356* 7.3655 7.3535 
Hb (g/100ml) 11.6* 10.6* 9.6* 9.95 10.8* 10.4* 10.1* 10.4* 13.6 
VENOUS 
Pv02 (kPa) 4.5 4.9 5.3 5.5 4.85 4.5* 4.6* 4.6 5.95 
PvC02 (kPa) 4.95 5.905 5.465 5.315 6.405 5.61* 5.48* 5.67 4.125 
pH 7.49 7.4595 7.468 7.467 7.3225 7.359* 7.351* 7.3565 7.3515 
OTHER MEASUREMENTS 
Blood Temperature (OC) 36.45 36.45 36.7 36.6* 36.25 38.8* 38.8* 37.2 37.95 
Cardiac Output (llmin) 5.35 7.75 13.27 13.27 6.805 7.5* 7.2* 5.8 11.15 
02 Consumption (mllmin) 276 286.35 285.75 281.75 341.35 218.6* 202.1* 214.7 237.9 
C02 Production (mllmin) 239 249 252.9 242.8 273.55 179.6* 162.1* 190.2 203.55 
ATMOSPHERIC CONSTANTS 
Air Temperature (OC) 28.4* 28.4* 29.2* 29.2* 29.1* 29.6* 29.3* 29.3* 25.4 
Ambient Pressure (kPa) 102.525* 100.391* 100.791* 100.791* 100.658* 100.658* 100.658' 100.658' 100.395 
Ambient C02 (%) 0.05* 0.06' 0.04* 0.04* 0.05* 0.05* 0.06' 0.06' 0.04 
Table 5.3: Averaged PRIOR patient data (* indicates only a single measurement was available). 
P1-1 P1-2 P1-3 P1-4 P2-1 P3-1 P3-2 P3-3 P4-1 
VENTILATOR SETTINGS 
FI02(%) 55 45 60 65 35 70 75 70 50 
Respiratory Rate (rpm) 26 20 18 18 16 16 16 16 12 
Tidal Volume (ml) 680 670 870 880 700 615 615 590 689 
PEEP (cmH20) 10 5 7.5 7.5 3 10 10 10.2 5 
I:E Ratio (liE) 0.6 1.1 1 1 0.333 2 2 1.43 1.85 
PIP (cmH20) 36.2* 22.7* 24* 24* 32* 33.8* 33.8* 38.8' 35 
ARTERIAL 
Pa02 (kPa) 16.9 10.45 9.25 9.7* 17.8 7.8* 10* 11.5 11.7 
PaC02 (kPa) 3.95 4.9 4.735 4.79* 4.685 5.31" 5.28* 5.345 4.095 
pH 7.56 7.501 7.487 7.503* 7.4175 7.356" 7.348* 7.3685 7.3735 
Hb (gIl OOml) 11.6" 10.6* 9.95 10.1" 10.85 10.1" 9.9* 10.6* 11.75 
VENOUS 
Pv02 (kPa) 4.2 5.47 5.5 5.6* 5.35 4.6* 4.8* 4.7 5.9 
PvC02 (kPa) 4.65 4.7 5.315 5.29* 5.675 5.48" 5.15* 5.835 4.42 
pH 7.52 7.482 7.467 7.476" 7.3695 7.351" 7.346* 7.3615 7.361 
OTHER MEASUREMENTS 
Blood Temperature (OC) 36.55 36.5 36.6* 36.5* 37.05 38.8* 38.8* 37.2 37.9 
Cardiac Output (llmin) 5.05 8.15 13.27 13.11 * 7.46 7.2* 5.9* 6.2 10.6 
02 Consumption (mllmin) 281.65 289.7 281.75 266.2* 309.05 202.1" 210.5* 216.8 265.6 
C02 Production (mllmin) 240.5 245.25 242.8 235.6* 267.55 162.1* 173.3* 186.75 203.9 
ATMOSPHERIC CONSTANTS 
Air Temperature (OC) 28.4* 28.4* 29.2* 29.2* 29.1* 29.6* 29.3* 29.3* 25.4 
Ambient Pressure (kPa) 102.525* 100.391* 100.791* 100.791* 100.658* 100.658* 100.658* 100.658* 100.395 
Ambient C02 (%) 0.05* 0.06* 0.04* 0.04* 0.05* 0.05* 0.06* 0.06* 0.04 
Table 5.4: Averaged POST patient data (* indicates only a single measurement was available). 
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From these the patient model calculated the following additional parameters; 
• Haematocrit (or PCY) from Hb (see equation 4.67). 
• Mean airway pressure from ventilator settings (see equation 4.39). 
• Compartment volumes from weight (see equation 4.52). 
• Functional residual capacity (FRC) from height (see equation 4.56). 
• Gas diffusion coefficients from FRC and age (these were latcr replaced by fixed 
coefficients). 
This left the model unknowns; 
• PSQ, Qs /Qt and VD to be derived during model tuning. 
• Hb O2 combining capacity, assume to be 1.34 mVg (see Section 4.2.3). 
• Plasma O2 solubility coefficient, assumed to be 0.225 mVl/kPa 
Applying these measured, calculated and tuned parameters for each patient to the model, it can 
then be used to predict the effects of ventilator changes on the blood gases. However, before this 
can be done the PRIOR model snapshot needs to be tuned, such that the arterial and venous 
blood gases match with those measured. 
5.4.4 Model Tuning 
The tuning of the model's steady-state blood-gases to match those measurcd was performed in 
an iterative manner as shown in Figure 5.10. Shunt was adjusted to match Pa02, dead space to 
match PaC02 and P50 to match PV02. The parameter tuning was performed using a secant-
searching algorithm similar to that used in Section 4.2.4. Due to parameter interaction the 
matching procedure had to be repeated until the error between the model and measured blood-
gases was less than 0.01 kPa. Tuning of Pvc02 was not possible and the value arrived at by 
tuning the other variables was accepted. 
Convergence was possible because shunt primarily affects Pa02 and dead space primarily 
affects PaC02. The tuning of P50 to match PV02 accommodates errors in the position of the 
saturation curve. This is similar to the approach used by Hinds et al (1983). 
Problems were encountered during the initial attempts to tune the model. In some cases VD 
estimates were unrealistically high, in others the search algorithm was unable to find a positive 
solution for shunt. Investigation of possible causes showed that the empirical formula used to 
calculate the gas diffusion constant (see equation 4.51) was giving very low values for some of the 
patients. This resulted in higher PaC02 levels requiring larger VD estimates and lower Pa02 levels 
requiring lower or negative shunts. It was decided to remove this variable factor and use a fixed 
D02 of 450 mVkPalmin and Dc02 of 1500 mVkPalmin as quoted by Selvakumar et al (1992). 
Examination of the effects of changing D02 and Dc~ supported this assumption and also 
showed that the new fixed values sat within an less sensitive region of the curves, see Figure 
5.11. In some cases the model was arriving at D02 and Dc02 values of less than 
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200 ml/minlkPa, which according to the graphs would give deviations in the predicted O2 and 
CO2 of greater than 5 %. The results of the model tuning, using fixed D02 and De02 values, are 
shown in Table 5.5. 
All known patient parameters 
entered into model 
Calculation of PC V, 002, DC02, 
PRe and compartment volumes 
.... 
.. 
Shunt tuned to match Pa02 
.. 
Dead space tuned to match PaC02 
.. 
P50 tuned to match Pv02 
Repeated until 
error < 0.01 kPa 
.. 
Matched steady state representation 
of patient 
.. 
Model prediction of effect of 
proposed venti lator changes 
Figure 5.10: Flow diagram of the model tuning algorithm. 
PI-I PI-2 Pl-3 Pl-4 P2-l P3-1 P3-2 P3-3 P4-1 
Iso shunt (%) 14.76 19.38 31.47 30.22 6.42 36.02 38.38 27.47 21.13 
Shunt (%) 12.84 18.90 40.63 39.55 4.96 36.92 41.12 26.91 31.17 
Vn (ml) 405.22 404.16 516.40 528.45 331.31 352.35 389.73 311.77 219.37 
Pso (kPa) 4.2242 4.0577 3.9315 3.9066 3.9934 2.9473 3.0729 3.3773 3.2383 
Table 5.5: Shunt, VD and P50 estimates obtained by matching the model to the measured PRIOR 
blood-gases. Also sho\\'n for comparative purposes are the shunt estimates arrived at using the 
iso-shunt diagram of Benetar et af (1973). 
86 
2 
VI 
CI.) 
~ 
VI 0 VI 
CI.) 
.... 
~ 
ta § 
0 
Z 
e 
0 
<l::: 
CI.) 
~ 
..c: 
U 
?ft. 
-2 
-4 
-6 
Normal D02 = 450 mllminlkPa 
--Pa02 
_. _. PaC02 
100 200 300 400 500 600 700 800 900 1000 
O2 Diffusion Constant (mJ/minlkPa) 
(a) 
40 ,-~.----------------------------------. 
VI 35 
~ 30 CIl CIl 
J: 25 
-tIS E 20 0 
Z 
S 15 
0 ~ 10 § 
5 
..c: 
U 
~ 0 
-5 
100 
_. _. Pa02 
--PaC02 
Nonnal DCO, ~ 1500 m,\:pa 
• -. -. - -. _. _. _. -_. - .:-=-:":-.:. =--j-a..:.. . .:.;-.~-~. 
300 500 700 900 1100 1300 1500 1700 1900 
CO2 Diffusion Constant (ml/minIkPa) 
(b) 
Figure 5.11: (a) The effect of changes in D02 on the arterial gases. As D02 falls below 200 
mllminIkPa the Pa02 is more affected. A low D02 would create lower model Pa02 and therefore 
the possibility of negative venous shunt if the simulated and measured Pa02 are to match. DC02 
was fixed at 1500 ml/minlkPa; (b) the effect of changes in Dc~ on the arterial blood gases. As 
DC02 falls below 1000 mllminlkPa the PaC02 becomes more affected. A low DC02 would create 
higher model PaC02 and therefore the possibility of excessively large dead space estimates. D~ 
was fixed at 450 mllminlkPa and all other parameters were taken from patient PI-I. 
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5.5 Clinical Validity 
So far we have; (1) examined the model's sensitivity to parameter disturbances enabling the 
identification of those parameters that may contribute to poor predictive performance; 
(2) defined a data collection protocol and used this to collect 4 patient records (containing 9 
ventilator changes); (3) processed the collected data to form snap-shots of the patient's state, 
prior to and after a ventilator change; and (4) tuned the model unknowns for each prior data set 
to match the measured blood gases. 
It was now possible to assess the model's predictive performance by changing the ventilator 
settings of the model, as per the changes made on the real patients. The simulated patient 
responses can then be compared with those measured. The measured and model-predicted 
responses are shown in Figure 5.13, with the actual response values given in Table 5.7. 
There are clearly some instances when the model-predicted responses match the measured 
responses, some when the direction is the same but the magnitudes are different and others 
when the changes are in opposite directions. There also appears to be a greater disturbance of 
the O2 system than the CO2 system as shown by the overall difference in magnitude of the Pa02 
and PaC02 changes. 
Two methods of analysis were employed to assess the accuracy of these model predictions. The 
first of these, qualitative trend analysis looks at the direction of the responses rather than their 
magnitude [Leaning, 1980; Leaning et aI, 1983]. This gives an indication of whether the patient 
and/or model are responding to ventilator changes as expected. 
The second method uses statistical measures such as standard error and correlation coefficient to 
quantify the model's predictive performance. A similar (though not identical model) was 
assessed by Hinds et al (1983), and the results of their analysis are used as a yard stick against 
which to gauge the model's performance. 
5.5.1 Qualitative Trend Analysis 
Three qualitative trend comparisons were made. The first of these compared the measured 
trends with the expected trends. The expected trends (or intuitive trends) were derived from the 
simple rules used by an anaesthetist to achieve blood-gas management, see Table 5.6. By 
comparing these intuitive trends with the measured trends it was possible to assess the quality 
of the measured responses. This was not an indicator of measurement error, more a means of 
distinguishing between well behaved and poorly behaved patient responses. 
Note that the effects of ventilator changes on PV02 and PVC02 were not considered. However, 
PV02 changes will normally match the Pao2 changes in terms of direction but with much smaller 
magnitude (lower sensitivity) and PVC02 will change in a similar manner to PaCo2. 
This can be explained by the relative positions of the dissociation curves. Because the O2 
dissociation curve is non-linear, the arterial points lie on a flatter portion of the curve than the 
venous points. Therefore when the haemoglobin saturation changes by a small amount at the 
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arterial point, it results in large shift in Po2, where as at the venous point, where the curve is 
much steeper the effect is greatly reduced (see Figure 5.l2). The CO2 dissociation curve on the 
other hand is fairly linear and therefore changes in CO2 content cause similar changes in CO2 
tension at the arterial and venous points. 
This behaviour is confirmed in Figure 5.l3, where the model-predicted PV02 responses match 
the Pa02 responses in terms of direction but are considerably smaller in magnitude. The PVC02 
and PaC02 responses on the other hand are almost identical. 
Direct Therapy Trends Cross-coupled Therapy Trends 
An increase in Fr02 will increase Pa02 An increase in RR will increase Pa02 
A decrease in FI02 will decrease Pa02 A decrease in RR will decrease PaOz 
An increase in PEEP will increase Pa02 An increase in VT will increase PaOz 
A decrease in PEEP will decrease Pa02 A decrease in VT will decrease Pa02 
An increase in RR will decrease PaCOz An increase in FI02 gives no change in PaC02 
A decrease in RR will increase PaC02 A decrease in Fr02 gives no change in PaC02 
An increase in VT will decrease PaC02 An increase in PEEP gives no change in PaCo2 
A decrease in VI will increase PaC02 A decrease in PEEP gives no change in PaC02 
Table 5.6: Summary of intuitive responses to ventilator changes. Direct therapy trends 
correspond to the intended therapeutic effects of a ventilator change, and cross-coupled trends 
are the indirect consequences of a ventilator change. 
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Figure 5.12: Sensitivity of the oxygen dissociation curve at typical arterial and venous points, 
illustrating how shifts in the haemoglobin saturation cause larger shifts in O2 tension at the 
arterial point (13.3 kPa) than at the venous point (5 kPa). 
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The second comparison was made between the intuitive trends and the model predictions (or 
predicted trends). Since the patient model should reflect a well-behaved patient, it was 
anticipated that the model predicted trends would match the intuitive trends in all cases. 
By implication therefore patients deemed well behaved from the first trend comparison should 
match the predicted trends. This constitutes the third and final comparison bctween the 
measured trends and the predicted trends. 
Scoring of Intuitive Trends 
Using the following symbolic notation the expected patient trends were scored for each patient 
record based upon the ventilator changes, see Table 5.8~ 
• t Increase in gas tension expected. 
• t Small increase in gas tension expected. 
• ~ No change in gas tension expected. 
• ,j.. Small decrease in gas tension expected. 
• J, Decrease in gas tension expected. 
Scoring of Measured and Model-Predicted Trends 
The measured and predicted responses were scored using the following classification 
boundaries to give the measured trends and predicted trends~ 
• t Increase in gas tension: response ~ 0.1 kPa 
• ~ No change: -0.1 < response < 0.1 kPa 
• J, Decrease in gas tension: response ~ -0.1 kPa 
The choice of classification threshold was somewhat arbitrary but was made such that very small 
changes would be classes as no change whilst retaining information about the direction of smaller 
but not insignificant responses. Setting the threshold too high would lead to a broad classification 
of ~ (no change). The measured and predicted trend classification is also given in Table 5.8. 
Comparison of Measured and Intuitive Trends 
The measured trends were found to match the intuitive trends in; 
6 cases for Pa02 (PI-2, PI-3, PI-4, P2-1, P3-2, P3-3) 
4 cases for PaC~ (PI-I, PI-3, P3-2, P4-I) 
The venous gases were not considered. 
The reasons for mismatch were not always obvious, but each measurement that failed to match 
was assessed and possible reasons identified. 
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Figure 5.13: Comparison of the POST-PRIOR difference between measured and model 
predicted responses to ventilator changes for Pa02, PaCo2, PV02 and PVC02. See Table 5.7 for 
actual values. 
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Pl-l Pl-2 Pl-3 Pl-4 P2-1 P3-1 P3-2 P3-3 P4-1 
PRIOR Measured Gases 
Pa02 (kPa) 17.55 12.35 8.65 9.25 20.90 8.10 7.80 11.70 11.50 
PaC02 (kPa) 4.30 5.48 4.80 4.74 5.26 5.12 5.31 5.25 3.79 
Pv02 (kPa) 4.50 4.90 5.30 5.50 4.85 4.50 4.60 4.60 5.95 
PVC02 (kPa) 4.95 5.91 5.47 5.32 6.41 5.61 5.48 5.67 4.13 
POST Measured Gases 
Pa02 (kPa) 16.90 10.45 9.25 9.70 17.80 7.80 10.00 11.50 11.70 
PaC02 (kPa) 3.95 4.90 4.74 4.79 4.69 5.31 5.28 5.35 4.10 
Pv02 (kPa) 4.20 5.47 5.50 5.60 5.35 4.60 4.80 4.70 5.90 
PvC02 (kPa) 4.65 4.70 5.32 5.29 5.68 5.48 5.15 5.84 4.42 
POST Model-Predicted Gases 
Pa02 (kPa) 17.69 11.38 9.03 9.79 17.66 8.41 8.04 10.77 11.44 
PaC02 (kPa) 4.00 5.48 4.80 4.62 5.56 5.16 5.31 5.24 4.40 
PV02 (kPa) 4.49 4.83 5.38 5.58 4.79 4.56 4.66 4.54 5.98 
PvC02 (kPa) 4.63 5.90 5.47 5.19 6.75 5.66 5.48 5.67 4.74 
POST Model-Predicted (+pH changes) Gases 
Pa02 (kPa) 17.50 11.15 8.86 9.66 17.45 8.36 8.10 10.74 11.27 
PaC02 (kPa) 3.99 5.48 4.79 4.62 5.56 5.16 5.31 5.24 4.39 
PV02 (kPa) 4.36 4.74 5.40 5.54 4.59 4.60 4.68 4.52 5.94 
PVC02 (kPa) 4.54 5.95 5.75 5.26 6.62 5.84 5.46 5.64 4.83 
PRIOR-POST Measured Difference 
Pa02 (kPa) -0.65 -1.90 0.60 0.45 -3.10 -0.30 2.20 -0.20 0.20 
PaC02 (kPa) -0.35 -0.58 -0.06 0.05 -0.57 0.19 -0.03 0.10 0.31 
PV02 (kPa) -0.30 0.57 0.20 0.10 0.50 0.10 0.20 0.10 -0.05 
PvC02 (kPa) -0.30 -1.21 -0.15 -0.02 -0.73 -0.13 -0.33 0.17 0.30 
PRIOR-POST Model-Predicted Difference 
Pa02 (kPa) 0.14 -0.97 0.38 0.54 -3.24 0.31 0.24 -0.93 -0.06 
PaC02 (kPa) -0.30 0.00 0.00 -0.12 0.31 0.04 0.00 0.00 0.61 
PV02 (kPa) -0.01 -0.07 0.08 0.08 -0.06 0.06 0.06 -0.06 0.03 
PvC02 (kPa) -0.32 0.00 0.00 -0.12 0.35 0.05 0.00 0.00 0.62 
PRIOR-POST Model-Predicted (+pH changes) Difference 
Pa02 (kPa) 0.60 0.70 -0.40 -0.04 -0.35 0.56 -1.90 -0.76 -0.43 
PaC02 (kPa) 0.04 0.57 0.05 -0.18 0.88 -0.15 0.03 -0.11 0.29 
Pv02 (kPa) 0.16 -0.73 -0.10 -0.06 -0.77 0.00 -0.12 -0.18 0.04 
PvC02 (kPa) -0.11 1.25 0.43 -0.03 0.94 0.36 0.31 -0.19 0.41 
Table 5.7: Measured and model-predicted responses resulting from the ventilator changes 
(see Table 5.8 for the ventilator changes made) 
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P1-1 P1-2 P1-3 P1-4 P2-1 P3-1 P3-2 P3-3 P4-1 
red. Fi02 red. RR 
inc. RR inc. Fi02 sm. red. RR sm. red. Vt I 
Ventilator Change sm. red. I:E red. Fi02 inc. Fi02 sm. inc. Vt sm. inc. Peep inc. Fi02 inc. Fi02 red. Fi02 sm. inc. I:E J 
Pa02 I 
Intuitive t .!- t t .!- t t .!- .j. I 
Measured .!- .!- t t .!- .!- t .!- t 
I 
Model Predicted t .!- t t .!- t t .!- ++ 
PaC02 
I Intuitive .!- ~ ++ .j. t ++ ++ ++ t 
Measured .!- .!- ++ ++ .!- t ++ t t I 
Model Predicted .!- ~ ++ .!- t ++ ~ ~ t 
PV02 
Intuitive t .j. t t .j. t t .j. .j. 
Measured .!- t t ~ t ++ t t ++ 
Model Predicted ~ ~ ++ ++ ~ ++ ++ ~ ++ 
PvC02 
Intuitive .!- ~ ++ .j. t ++ ++ ~ t 
Measured .!- .!- .!- ~ .!- .!- .!- t t 
Model Predicted .!- ~ ~ .!- t ++ ++ ~ t 
--
Key: t increase .!- reduction ++ no change t sm. increase .j. sm. reduction 
Table 5.8: Comparison of measured and model predicted response trends to therapy changes. 
PaD] mismatch in PI-I: the post measurements for Pa02 varied by 2.2 kPa indicating either a 
measurement error in one of the measurements or patient instability. Ignoring point 3 (the most 
likely candidate for measurement error) the measured response would be t, matching the 
intuitive trend. Additionally V02 increased from 276 mVmin to 281.6 mVmin, contributing 
further to the negative trend in Pa02. 
PaD] mismatch in P3-1: only a single sample was available for this measurement and therefore 
may be subject to patient instability. The dip in O2 saturation (recorded using a pulse-oxymeter) 
from 96% to 94% seems to support this hypothesis. Since the FI02 was increased it follows that 
the O2 saturation should increase, but it does not. 
PaD] mismatch in P4-1: the increase in Pa02 was very small (0.2 kPa) and since the intuitive 
trend was J, (a small reduction). Such a discrepancy is well within possible measurement errors, 
especially when it is observed that there was a 12.5% variation in prior Ot measurements and a 
9.9% in post Qt measurements. 
PoCO] mismatch in Pl-2: the main cause of this mismatch seems to be a general instability in 
the acid-base balance as indicated by the spread of pH and standard HCO; values. Since only 
F102 was adjusted these should remain constant across the whole test. The pH range was 7.452 
to 7.507 (a difference of 0.055) and the standard HCO; range was 28.4 to 30.7 mmoVl (a 
difference of 2.3 mmoVI). Since this patient was known to be clinically unstable and did 
eventually die (after withdrawal of treatment) the instability observed and resulting trend 
mismatch were expected. 
PoCO] mismatch in Pl-4: the measured response was zero (actually +0.055 kPa), and was 
based upon a single post measurement. The intuitive trend was a small Paco2 reduction, which 
given possible measurement errors, means that the trends are similar. 
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Figure 5.14: Improvement in patient P2-1, caused by re-inflation of collapsed alveoli through 
the application of PEEP. The increased alveolar ventilation gives rise to increased Pa02 and 
reduced PaC02. The drop in Pa02 occurring after 15:40 is due to a reduction in F102. 
PoCO] mismatch in P2-1: this patient was improving after an emergency operation and 
therefore it seems likely that airways will have collapsed during anaesthesia. This explains the 
application of a small amount of PEEP. Since the collapsed alveoli will begin to re-inflate, 
alveolar ventilation will improve and consequently CO2 elimination will improve. This is 
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confirmed if we plot the PaC02 data, see Figure 5.14. Supporting this theory is the general 
increase in O2 tension, which would be expected as the physiological shunt reduces. The 
intuitive trend should be modified to -1-, to reflect this more complex and dynamic physiology. 
PaC02 mismatch in P3-1: the intuitive trend was ~, but the measured trend was t. However 
the increase in PaC02 was only 0.19 kPa. Given possible measurement errors and only one 
prior/post data point this can be considered reasonable trend matching. 
PaC02 mismatch in P3-3: the measured increase was small (0.305 kPa) and appears to be an 
artefact of gradually rising PaC02 levels, see Figure 5.15. Reasons for this are unclear. 
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Figure 5.15: Arterial PaC02 measurements for patient P3-3 showing gradually increasing trend. 
Comparison of Model Predicted and Intuitive Trends 
The predicted trends were found to match the intuitive trends in all cases with the exception of 
the Pa02 trend in patient P4-1, where because of the classification boundary used, the model 
trend was classed as ~, instead of -1-. 
Comparison of Model Predicted and Measured Trends 
As anticipated, it was found that those measured trends, which matched the intuitive trends, also 
matched the model-predicted trends. 
To summarise then~ the model was able to match the intuitive rules in all cases, although some 
of the responses were small, due to low model stimulation. The model matched the measured 
trends in all cases when the measured trends behaved intuitively. This is encouraging as a first 
indicator of model performance. However, a measured response may be in the same direction as 
a model response yet of such varying sizes to consider the match poor. 
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5.5.2 Statistical Analysis 
Before attempting any statistical analysis of the model's performance it has to be noted that the 
data set was very small and therefore likely to be statistically unrepresentative. The accumulated 
effect of measurement errors on the model means that large numbers of patient observations 
would be required to make the analysis meaningful. This proviso aside it was important to 
obtain a quantitative indication of the model's performance using the limited data collected. 
The accuracy of the model predictions was assessed using correlation analysis. Figure 5.16 shows 
the comparison between the model predicted and measured blood gas tensions for the arterial and 
venous gases. Predictions for Pa02 showed a good correlation (r = 0.97), which was slightly better 
than the correlation obtained by Hinds et al (1983), see Table 5.9. However PaC02 predictions 
gave much poorer correlation (r = 0.76) than Pa02 and was worse than Hinds et a/. 
Two possible explanations for this reduced performance in PaC02 correlation are; 
1) At this point in the model development the pH was assumed constant and was set at 
the prior value, even after changes in the ventilator settings. This does not reflect 
what actually happens, especially after changes to minute volume which directly 
affect the pH. 
2) Changes made to minute volume were small and therefore the CO2 system was 
under stimulated. This is evident when we compare the size of changes observed in 
the Pao2 and PaCo2 systems (see Figure 5.13) This coupled with possible patient 
instability masks any underlying changes. 
The first of these was simple enough to confirm by including the post pH values with the 
ventilator changes before simulating. However this gave no improvement in Pa02 correlation (r = 
0.97) or PaC02 correlation (r = 0.76), see Table 5.9. Therefore, it can be concluded that patient 
instability coupled with under stimulation was the major contributing factor to response mismatch. 
The situation was much the same for the venous gases. The predicted PV02 correlation 
(r = 0.86) whilst not as good as the arterial case was much better than that observed by Hinds et 
al. The PVC02 correlation (r = 0.65) was the worst of all four gases, comparing unfavourably 
with Hinds et al. Inclusion of post pH values slightly degraded the PV02 correlation (r = 0.83) 
and made no difference to PVC02 correlation (r = 0.65). 
PaOl PaCOl PVOl PVCOl 
r CJE r CJE r CJE r CJE 
Hinds et al 0.94 2.31 0.89 0.27 0.61 0.51 0.88 0.29 
Model Predicted 0.97 0.89 0.76 0.36 0.86 0.29 0.65 0.39 
Model Predicted 0.97 2.l0 0.76 0.63 0.83 0.58 0.65 0.89 
(with updated pH) 
Table 5.9: Comparison between correlation coefficients (r) and standard deviation of the mean 
response error (CJE) for the predicted model responses. 
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Figure 5.16: Regression analysis of predicted model responses against measured responses for 
arterial and venous O2 and CO2• The dashed line indicates the ideal correlation and the dark line 
the calculated regression line. 
5.5.3 Causes of Response Errors 
There are many reasons why the measured and predicted responses do not match and obviously 
poor representation of patient physiology within the model may be one of those reasons. 
However, other sources of error exist and need to be considered. The purpose of this section is 
not to quantify such errors but simply to identify them. Four possible sources of response errors 
have been identified; 
1). Patient instability: 
The patient state may be changing erratically over relatively short time periods. In such cases 
the measured data may be accurate but the patient is pathologically unsuited to this type of 
validation. The model will be unable to predict such behaviour, even if its complexity is 
increased. 
2). Physiological glitches at measurement time: 
The overall trend of the patient response may be in the correct direction or of the correct 
magnitude but momentary fluctuations in the patients physiological states (such as a cardiac 
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surge) give the appearance of incorrect response. Problems such as these are removed with rapid 
data sampling and response filtering. 
3). Drift in underlying patient state: 
Patient parameters such as Qt or V0 2 may have changed over the period of the patient test. 
However, these changes are not caused by patient instability, but by slow trends in one or more 
of the patient parameters. Maybe Qt was stabilising after the infusion of a stimulant, or there 
was lessening of internal bleeding in response to a drug. Pe02 has a much slower time constant 
than P0:2 and may not have stabilised by the time POST blood-gases are taken. 
4). Measurement errors: 
Differences caused by human error, clinical error or instrumental error may all conspire to 
obscure the underlying patient response and therefore cause poor response behaviour. 
Of these hypotheses the first three can be classified as physiological, since they are due to 
changes in the patient state. A clearer separation of these effects would be established with an 
increased measurement rate and longer test length. However, close involvement with the data 
collection process has indicated that there would be many problems in trying to establish a more 
rigorous collection regime. 
The measurement errors can be classified as one of three primary types; 
1). Clinical measurement errors: 
Even if the patient state was assumed to be stable throughout the period of the test, there will 
always be errors due to the nature of the physiological processes and how they can be measured. 
For example, blood sample lines cannot be inserted at any location, and consequently their 
position may cause errors associated with blood mixing. This is certainly true with samples taken 
using a central venous line where venous return will not always have mixed properly. Other 
examples of this error include breath-by-breath fluctuations observed in the arterial Pae~. The 
contribution of these effects is unknown. 
2). Experimental measurement errors. 
This probably accounts for the largest contribution to the overall error since they are caused by 
the human factor. Intensive care patient management is such that many people will be involved 
in the patient blood sampling and measurement acquisition. Therefore problems are likely to 
occur due to poor or inconsistent blood sampling techniques, inconstant thermo-dilution 
injections, incorrect instrument calibration, etc. 
For example Gosling (1995) described the following errors associated with blood-gas sampling; 
• The incomplete withdrawal of hepar ani sed saline solution (anticoagulant) from line 
before sampling of the blood may cause dilution errors. However about 0.05 ml 
will always remain in the syringe dead space, which for a 1 ml blood sample will 
give an overall dilution of 5%. Plasma constituents that can easily pass into the red 
blood cells such as CO2 will be reduced by about 5%. Blood pH is less effected 
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since it is dependent upon the ratio between dissolved CO2 and plasma bicarbonate, 
which dilution does not greatly disturb. 
• Bubbles introduced into the syringe during sampling, which is usually unavoidable, 
will if allowed to equilibrate with the blood increase Pa02. For example, 1 % of 
introduced air (0.01 ml in a 1 ml sample) can increase Pa02 by up to 15 % if 
allowed to equilibrate. 
• The delay between sample and analysis time, should be less than 10 min's. For 
example, a measured Pa02 of 13.3 kPa after 10 min's, will be approx. 0.7 kPa lower 
than at sample time, the Pe02 approx. 0.08 kPa higher and pH 0.006 lower (0.98 
increase in [tt]), [Nunn 1993, p.570). 
• Red cells settle out of the plasma rapidly, especially in critically ill patients. If the 
sample is not shaken thoroughly before introduction into the analyser, 
measurements will be made on a red cell rich or red cell deficient sample, leading 
to inaccurate Hb, pH, Pe02 and P02 results. 
• Violent injection into the analyser can cause haemolysis increasing potassium and 
in some instruments p02 results. 
Similar analysis could be applied to the other measurement procedures and potential errors 
identified. However, their likelihood and degree of influence of each error source for each 
measurement are a matter of speculation. We can merely identify their potential and hope that 
reasonable precautions are taken by clinical staff to minimise their effects. 
3). Instrumental measurement errors. 
Assuming correct calibration these will tend to be the smaller of the error contributions. Typical 
machine accuracy is given below; 
IL System 1302 pH/Blood Gas Analyser 
pH 
Accuracy 
Precision 
-0.007 ± 0.007 
0.0046 ± 0.0026 
([tt) -0.984 ± 0.984) 
([In -0.989 ± 0.994) 
Pe02 
@ 4.666 kPa (35 mmHg) Accuracy +0.067 ± 0.047 
Precision 0.093 ± 0.027 
@ 6.666 kPa (50 mmHg) Accuracy -0.067 ± 0.053 
Precision 0.080 ± 0.040 
@ 12.666 kPa (95 mmHg) Accuracy o ± 0.240 
Precision 0.107 ± 0.040 
P02 
@ 6.666 kPa (50 mmHg) Accuracy -0.133 ± 0.067 
Precision 0.093 ± 0.067 
@ 12.666 kPa (95 mmHg) Accuracy +0.160 ± 0.133 
Precision 0.080 ± 0.040 
@ 18.665 kPa (140 mmHg) Accuracy 
-0.133 ± 0.040 
Precision 0.080 ± 0.053 
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C.O. Module: HP Component Monitoring System 
Cardiac Output Accuracy 
2 % standard deviation @ blood / injectate temp. diff. > 10 °C 
Temperature Accuracy 
±0.1 °C (0.2 OF) 
The interaction of the above physiological and measurement errors (and others not considered) 
is complex. It would be a large undertaking to establish the approximate effects of most of them 
and then to arrive at an estimate of their combined effect. However, as a crude rule of thumb, a 
physiological measurement is deemed to have changed if it increases or decreases by at least 
10%. Turning the argument around, we can say that physiological measurements might have 
combined errors of up to 10 %. With careful measurement procedures, errors should be much 
less than this, but they do remain the overriding factor in being able to accurately assess the 
performance of the model. 
5.6 Summary & Conclusions 
Sensitivity Analysis of the Model 
A simple sensitivity analysis methodology was used in preference to more involved methods. 
This provided a preliminary indication of the relative parameter sensitivities of the model. The 
method used is known as 'Classical Sensitivity Analysis' and ignores parameter interaction and 
variability in the size of the parameter's disturbance space. 
Direct comparison between sensitivities of the state outputs was possible since they were 
expressed in the same units (i.e. all measures of partial pressure and in kPa), and it was 
observed that Pa02 was more sensitive than the other state outputs by a factor of 5:1. Since this 
is one of the primary therapy decision variables, it has important considerations in terms of 
model-patient matching. 
The O2 system was found to be most sensitive to FI02, with much smaller sensitivities to VT 
and RR. Conversely, the CO2 system was most sensitive to VT and RR, with little response to 
Fr02 changes. This matched the changes in blood-gases predicted by the intuitive therapy rules. 
The O2 system was found to be very sensitive to Qs/Qt' but insensitive to VD, whilst the CO2 
system was sensitive to VD and insensitive to Q s / Qt . The tuning of the patient model used this 
difference to arrive at unique solutions of Qs /Qt and VD that produced blood-gases to match 
those observed clinically. 
Sensitivity to PEEP and I:E was extremely low which does not correlate with their known 
therapeutic effects. This was because the model did not simulate the effect of PEEP and I:E on 
the physiology of the lung. The inclusion of PEEP, opens up more airways and has the result of 
reducing the dead space to alveolar volume ratio (an effective increase in ventilation rate), and 
reduces the effective physiological shunt. 
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Cardiac output was found to be very sensitive in the O2 system, and since this parameter is 
subject to large measurement uncertainties, poses the likeliest cause of model-patient mismatch. 
Quality of Measured Data 
Not all of the patients responded in an intuitive manner to changes in ventilator therapy; only 69 
% of cases for the Pa02 and PaC02 trends. This indicates either underlying measurement 
problems or instability in the patient. 
The amount of data collected was very small and highlights the problems associated with 
clinical data collection. The following restrictions to successful data collection were identified; 
1). The lack of suitable patients. 
2). The need to use a PAC to measure Qt in the absence of non-invasive methods. 
This set up a contradiction between the need to measure many parameters, which 
are only routinely monitored in highly critical patients, and the need for 'stable' 
patients. Consequently many of the records obtained were unsuitable due to their 
unstable nature. 
3). Lack of equipment to measure metabolic function (namely O2 consumption and 
CO2 production), hence the need to hire a metabolic computer. 
4). Restrictions imposed by ethical considerations; 
5). Number of measurements on any given patient restricted, especially with reference 
to Qt measurements. 
6). Limitation on size of ventilator therapy change causing under stimulation of both 
the patient and the model. 
7). Interference during a patient record by priority treatments such as physiotherapy 
and drug changes, which could dramatically alter patient state. 
8). The difficulty of asking clinical staff to perform extra work, albeit small. 
9). The time consuming nature of the data collection itself, waiting for the therapy 
changes to be made and for suitable patients to become available. Since overseeing 
the collection itself is not always practicable, there is a need to stimulate enough 
interest and understanding of the data collection objectives to maintain collection 
over long periods. 
The problem of Qt measurement should improve as alternatives to thermal dilution begin to 
emerge, such as partial CO2 re breathing [Mahutte et ai, 1991; Vidal Melo et ai, 1992; Gedeon 
et ai, 1980; Capek et ai, 1988]; thoracic electrical bioimpedance [Young & McQuillan, 1993]; 
and doppler ultrasound. Such methods would increase the pool of available patients, and might 
be considered in a more extended study. 
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Clinical Validity 
Given the limitations of the patient data and the unsuitability of the available patients the model 
was shown to predict the therapy responses well. The model responded intuitively to all therapy 
changes, although some responses were small due to the small therapy step sizes, or large 
Qa/Qt and VD estimates. Consequently the model trends matched the measured trends in all 
cases when the measured trends behaved intuitively (69 % of cases). 
The overall impression of this analysis is that the model behaves well to therapy changes, with 
the exception of PEEP and I:E which require the inclusion of additional model elements. 
However, its ability to match real patient data is limited, primarily because of the errors 
attributable to physiological measurement. To validate the model more rigorously would require 
either accurate data from a lung function lab on healthy patients that are known to be stable; or 
observation of ICU patients using continuous and where possible non-invasive measurement 
techniques. This is especially necessary with respect to cardiac output. By having continuous 
data, local instabilities in the data can be rejected or averaged out. The use of non-invasive 
techniques eliminates the problem associated with say PACs, which are usually only used on 
very unstable patients. Since unstable patients are not likely to behave predictably, they can 
hardly be used for model validation purposes. 
The introduction of automated data collection techniques within the ICU and the non-invasive 
measurement of certain critical parameters will facilitate a more rigorous statistical analysis of 
the model in the future. 
The model still needs some improvement for it to be truly useful for advisor validation, and 
these modifications are presented in Chapter 7. The next chapter presents the prototype 
development of the ventilator advisor itself. 
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Chapter 6: FAVeM - Advisor Development 
6.1 Introduction 
Thus far development and testing of a patient model suitable for the simulation of patients on 
volume control (VC) and pressure regulated volume control (PRVC) modes of ventilation has 
been presented. This model has been shown to provide a reasonable level of patient realism, and 
together with the improvements discussed in Section 7.3, can be used to validate and improve 
the fuzzy advisor via simulated closed-loop control. 
This chapter provides a comprehensive account of the fuzzy advisor's prototype development. It 
includes an overview of the advisor architecture (see Section 6.2) followed by a discussion of the 
reasons behind the choice of membership functions, inference algorithm and defuzzification method 
employed (see Section 6.3). 
In Section 6.4 the methods used to implement the advisor rules are presented. This includes 
reasons for the avoidance of rule-holes and approaches taken to avoid them, the method of 
representation of the rule-consequents and a description ofa rule-reduction algorithm. 
Sections 6.5 to 6.8 present the initial attempts to encapsulate the anaesthetist's decision process 
for the FI02, PEEP, VT and RR controls when ventilating patients using ve and PRve. FI02 
and PEEP are described first, representing the controls used for Pa02 maintenance. The FI02 rule 
development shows how the iso-shunt diagrams were used to produce the first rule-map, and 
then how this was modified according to feedback from an anaesthetist. Next the PEEP rule 
development is presented, introducing the benefits and disadvantages of PEEP and how these 
might be encapsulated. 
The Mv and RR-Vt control rules provided Paco2 and PIP maintenance. The elicitation of the Mv 
control rules with particular reference to PaC02 and pH imbalance is described, followed by their 
improvement via the introduction of rules pertaining to high levels of PIP. Finally the balancing of 
RR and VT settings through the use of rules derived from normalised iso-MY lines is described. 
6.2 Advisor Architectu re 
6.2.1 Overview 
The advisor comprises four primary maintenance pathways; 
1). Safe control of Pa02. 
2). Normalisation ofPaco2 and to a lesser degree arterial pH. 
3). Prevention of harmful PIP levels. 
4). Establishing of ideal VT and RR settings. 
These maintenance objectives are accomplished via the manipulation of five ventilator controls 
FI02, PEEP, RR, VT and TIN, and are associated with volume-cycled modes of ventilation, such as 
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volume control (VC) and pressure-regulated volume control (PRVC). The fuzzy knowledge-based 
controller (FKBC) advises changes to these settings based upon the following information; 
1). Current Ventilator Settings; F102, PEEP, RR, VT and TIN. 
2). Patient Observations; Pa02, PaC02, pH, PIP and weight. 
3). Patient Goals; PaCo2 and pH set points. 
4). Patient Alarms; high PIP. 
These inputs are processed by the observation processing module (OPM) to produce the crisp 
values used in the rule-antecedents of the advisor sub-systems, see Figure 6.1. In the prototype 
version of FA VeM, there were four advisor sub-systems, each with its own set of control rules. 
The FI02 and PEEP sub-systems combine to provide Pa~ maintenance. The Mv and VT-RR 
sub-systems combine to provide PaC02, pH and PIP maintenance with consideration to 
normalisation of VT and RR settings. These sub-systems operate independently of one another, 
with the exception of the VT-RR sub-system, which relies upon the output of the Mv sub-
system to calculate the new observed RR (one of the VT-RR sub-system antecedents). The 
reasoning being that changes in Mv affects how changes to VT and RR are distributed. 
After analysing the close-loop performance of the FAVeM (see Section 7.5) it was deemed 
necessary to introduce a fifth advisor subsystem for the control of TIN. 
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Figure 6.1: Overview ofFAVeM's architecture. Note that the TIN subsystem was not present in 
the prototype version ofFAVeM. 
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Each sub-system generates the required change in ventilator setting (i.e. ~FI02' ~PEEP, ~RR, 
~VT and ~TIN). This is quantised and added to the current ventilator settings to give the new 
settings. The quantisation or rounding of the advice enables the changes to be expressed in steps 
that match the ventilator resolution or the smallest changes likely to be made by a clinician. 
6.2.2 Observation Processing Module (OPM) 
This uses the patient observations, ventilator settings and patient goals/alarms to derive the 
inputs required by the advisor subsystems. This process was abstracted from the subsystem 
modules themselves, since some antecedents are used by more than one module (see Table 6.]). 
It also meant that the modules themselves could be based upon the same code structure, 
simplifying and speeding up system development. 
Two processes are performed by the OPM; (i) the calculation of normal ventilator settings and 
(ii) the calculation of observation errors. 
Advisor Inputs required by Inputs required by 
Sub-system Prototype Advisor Modified Advisor 
FI02 Pa02, FI02 Pao2, FI02 
PEEP Pa02, FI02, PEEP Pa02, FI02, PEEP 
Mv ePaC020, epH 0, ePIP § ePaC02 0, PIP, eVTNORM § 
VT-RR eVTNORM 0, RR, ePIP § eVTNORM 0, RR, PIP 
TIN N/A PIP, TIN 
§ Calculated by Observation Processing Module 
Table 6.]: Rule-antecedents required by each sub-system, for the prototype and modified advisor 
Calculation of Normal Ventilation Settings 
For the majority of patients (approx. 80%) their prescribed normal tidal volume (VTNORM) is 
proportional to their weight, being about 10 - 15 ml/kg body weight [Anderson, 1988, pI2]. 
FA VeM assumes VT NORM to be 10 ml/kg. The use of VT NORM enables an optimal VT to be 
defined for any given patient irrespective of their weight. 
Calculation of Observation Errors 
Of the 9 fuzzy variables used by the advisor sub-systems (see Table 6.1); 2 represent errors 
from set point level (ePaco2 and epH); 1 represents error from alarm level (ePIP); and 1 
represents distance from normal ventilation levels (eVTNORM). 
These are all measures of distance from some pre-defined norm and are calculated as follows; 
pH Error (epH): this represents how far the observed pH is from the normal pH of 7.4; 
epH = Observed pH - 7.4 (6.1) 
PIP Error (ePIP): this represents the distance from the maximum PIP threshold or alarm; 
ePIP = Observed PIP - PIP Alarm (6.2) 
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PaC02 Error (ePaCOJ: this represents the distance from the target PaC02 and is expressed as a 
percentage error, rather than an absolute error since there is a roughly inverse proportional 
relationship between PaC02 and Mv (see Section 6.7.1)~ 
P Observed Paco2 - Paco2 Set Po int 100 e aco2 = x 
Set Point 
(%) (6.3) 
For example if the PaC02 set point is 5 kPa and the observed PaC02 is 6 kPa this gives an ePaC~ 
of 20 %. If the Mv is raised by 20 %, the new PaC02 should be approximately 5 kPa, i.e. a 20 % 
increase in Mv produces a 20 % reduction in PaC02. If PaC~ error were expressed in kPa the 
change required in Mv for different PaC02 set points would vary for the same PaC02 error. 
VT Error (eVTNomd: represents distance of observed VI from normal VI. This is expressed as 
a percentage error, since a 100 ml discrepancy in a large patient with a high VINORM would be of 
less significance than in a smaller patient with low VINORM. By using a percentage error the 
relative significance of such a volume difference can be inferred~ 
v; _ Observed VT - VTNORM 100 
eyTNoRM - x 
VTNORM 
(%) (6.4) 
6.2.3 Subsystems Architecture 
Each advisor sub-system follows the same basic structure, see Figure 6.2. The crisp inputs 
required by each module are passed to the inference module, which uses individual rule-based 
inference with Larsen's implication and the arithmetic product liaison operator. The fuzzy 
consequent generated by this inference is then defuzzified using the Centre-of-Sums method to 
produce the crisp controller output. The choice of inference method, liaison operator and 
defuzzification strategy is discussed in detail in Section 6.3. 
~ ~ Crisp Inputs 
Rule Base 
Fuzzy Inference 
Engine 
LARSEN (S up-Prod) 
MAX-DOT 
Fuzzy 
Output 
Crisp 
Output 
Centre of Sums 
Figure 6.2: Ventilator control sub-system architecture. 
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6.2.4 Output Quantisation 
Once the advice has been de-fuzzified it is then quantised. Three quantisation options were 
defined; raw, ventilator and clinician, see Table 6.2. The first of these raw, returns the 
unprocessed output of the inference engine, although a small amount of quantisation is applied 
to prevent very small changes that result from the defuzzification process. The second option 
ventilator, sets the quantisation to the expected resolution of the ventilator, thus preventing 
advice that cannot be implemented because the step change is too small. The final option 
clinician sets the quantisation to the minimum step change routinely made by an anaesthetist. 
Advisor Output raw ventilator clinician 
F10z (%) 0.1 1 5 
PEEP (cmH2O) 0.01 0.5 1 
RR(r.p.m.) 0.01 0.5 1 
VI (ml) 0.1 10 50 
TIN (%) 10 10 10 
Table 6.2: Advice quantisation levels provided by FAVeM. The fixed quantisation level for TIN 
reflects the winner-takes-all strategy employed when computing the generated advice (see 
Section 7.5.5). 
6.3 Inference Methodology 
Early advisor development was more concerned with rule construction and little focus was 
given to the choice of inference method. It was felt that this over sight needed to be addressed, 
and the influence of differing methodology on advisor behaviour investigated. In this way 
subsequent rule construction would correctly reflect the implementation chosen. Seven elements 
of the inference process were identified that might impact controller behaviour; 
1). Choice of membership function. 
2). Membership function geometry. 
3). Choice of inference algorithm. 
4). Choice of implication operator. 
5). Choice of liaison operator. 
6). Choice of defuzzification method. 
7). Choice of output quantisation level. 
A more detailed description of membership function geometry and the mechanics of fuzzy 
inference are given in Chapter 2. This section will only give a brief outline of the options 
available to each process element, together with justification of the selcction madc. 
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6.3.1 Choice of Membership Function 
Six main types of fuzzy membership function are referred to throughout the literature; 
1). sigmoid or S-functions 
2). bell-shaped or 1t-functions 
3). triangular form or T-functions I A-functions 
4). trapezoid form or n-functions 
5). exponential forms; includes variants of 1t-functions and S-functions 
6). crisp sets and singletons 
Crisp sets and singletons are used for binary logic, i.e. true or false; and with the exception of 
fuzzy singletons, which are used to represent crisp inputs upon a fuzzy domain, are not useful 
for fuzzy control. Sigmoid and bell-shaped sets (and their exponential variants) provide 
membership functions that gradually reduce to zero. These may have advantages in strongly 
linguistic operators such as dilation and concentration and are frequently used in fuzzy logic, 
but seldom in fuzzy control. 
Triangular and trapezoid membership functions have become the norm in fuzzy control 
applications, since they are functionally simple to represent and are computationally efficient. 
Due to this convention in fuzzy control and in the absence of strong evidence for the use of 
alternative representations; n-functions and T -functions were chosen as the method of set 
representation for the antecedent and consequent terms in FA VeM. 
6.3.2 Membership Function Geometry 
The way in which linguistic terms of a fuzzy variable are mapped onto its domain (or universe 
of discourse, UoD) can affect the performance of the controller in a number of ways. Three 
characteristics of membership function geometry were identified as having greatest impact upon 
the inference process. These were (1) cross point; (2) symmetry and (3) condition width. 
Influence of Cross-Point Level and Ratio 
The cross-point level (as defined in Section 2.2.1) for any two neighbouring membership 
functions must be greater than zero, such that a crisp observation upon that domain will belong 
to at least one membership function. If this condition is not met, input values will exist that do 
not match a rule-antecedent, leading to incompleteness in the control space. This can cause 
discontinuities in the controller output. Furthermore if the cross-point ratio (i.e. the number of 
cross-points between neighbouring membership functions) is zero then only one rule at a time 
will fire, since a crisp observation will only have membership in at most one set. In a rule-base 
with only a single antecedent, this behaves as though the observation universe is defined using 
crisp linguistic sets. 
Boverie et al (1991) has shown that for linear systems up to 3rd order with symmetrical 
membership functions there exists "optimal" values for the cross-point level and ratio, although 
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this evidence was only empirical. A cross-point level of 0.5 and a ratio of 1 provide for 
significantly less overshoot, undershoot and faster rise times. The shape does not play an 
important role, although trapezoid functions are responsible for slower rise times. This choice of 
values matches those reported elsewhere in the literature. 
The choice of cross-point parameters has greatest influence over system behaviour when applied 
to antecedent set definitions. Consequent sets are able to have a cross-point ratio of zero, so long 
as the sets have equal area and are symmetrical. However, this may affect the plausibility of the 
crisp control output (see Section 6.3.5). 
J.l 
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0.=0.7 
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Figure 6.3: The membership function of NM and its clipped version caused by a firing weight 
of 0.7 (shaded area). 
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Figure 6.4: When the degree of membership is 1 the clipped consequent and the original 
consequent are the same. In the case of asymmetric membership functions the peak value is 
different from the Centre-of-Gravity. 
Influence of Symmetry and Width 
Inference performed using single rule firing, may produce as a result of some crisp observation 
xo, a "clipped" control output. Consider the rule "if x is Z then u is NM", and Xo has a degree of 
membership a in J.lz of 0.7. If the membership function describing the consequent NM is 
asymmetrical then the meaning represented by f.JNM is given in Figure 6.3 and the certainty of 
the rule (a) results in the clipped version of the consequent J1cNM. 
Calculation of the crisp control output u* requires the application of a defuzzification method, 
for example the Centre-of Gravity (CoG) method. This obtains a single control output by 
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averaging across every element of the output domain U. Ifwe consider the case when the degree 
of match in the rule antecedent is 1 (i.e. ex. = 1) then the fuzzy consequent jlCNM is a triangular 
shape. Only one element of U satisfies to a degree of 1, namely Jlpeak. Thus it makes 
interpretative sense to take jlpeak to be the actual value of u*. However, if we take the CoG of 
jlCNM then jlpeak '* jlcoG as shown in Figure 6.4. 
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Different defuzzification methods such as Centre-of-Maxima (CoM) are able to resolve this conflict 
but as discussed in Section 6.3.5, these can themselves have a disadvantageous effect on the control 
output. The simplest way to resolve this problem is by making the consequent f.JNM symmetrical about 
jtpe;,k. Symmetry is not important in the rule antecedent, however condition width must be satisfied. 
Condition Width 
Two neighbouring membership functions on the same universe of discourse must have left 
width equal to right width in the interval between the two peak values. Also, the widths must 
equal the interval between the peak values. 
To illustrate how contravention of condition width can affect control behaviour, consider the 
following example. A proportional FKBC has two rules; 
1). If e is PM then u is PB 
2). If e is PS then U is PM 
Let the meaning of the linguistic terms PM and PS in the rule-antecedent be denoted by jlpM and 
jlPS. These are mapped onto the observation universe E in two different manners, see antecedent 
universe in Figure 6.5 and Figure 6.6. In version 1, the condition width is met. In version 2 jlPs 
has a left width less than the interval between epeakl and epeak2 and the condition width is not met. 
In version 1 when e changes smoothly from epeakl to e pcak2, and after inference and CoG 
defuzzification, one observes that u* also changes smoothly from Upeakl to upeak2 as illustrated in 
Figure 6.5. However in version 2, u* changes step wise from Upeakl to upeak2, see Figure 6.6. It is 
therefore preferable that condition width be met by two adjacent membership functions 
describing the meaning of the linguistic values in the rule-antecedent. 
6.3.3 Choice of Inference Algorithm & Implication Operator 
The inference-engine or rule-firing algorithm can be of two basic types; 
1). Compositional Rule oflnference (CRI) 
2). Individual-Rule based Inference (IRI) 
IRI is preferred as the method of reasoning since it is computationally very efficient and saves 
on the memory required to express the fuzzy relation of a large rule-base using CRI. It can also 
be shown that compositional based inference is equivalent to individual rule-based inference for 
crisp observations [Driankov et aI, 1993, p 129] and therefore there is no loss of meaning using 
IRI. Although the FISMA T toolbox provides both compositional and individual rule-based 
inference, the latter was chosen for its simplicity and computational efficiency. 
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Of the various fuzzy-inference methods available, the most commonly used in today's industrial 
fuzzy logic controllers are; 
1). Mamdani's implication operation: Also known as sup-min inference, 'clipped' 
inference and MAX-MIN inference. 
2). Larsen's implication operation: Also known as sup-product inference, 'scaled' 
inference and MAX-DOT inference. 
It will be shown in Section 6.3.6 that the choice of inference method has very little impact upon 
the resulting crisp consequent. A far greater impact on controller output is caused by the choice 
of defuzzification strategy and the antecedent liaison operator. 
6.3.4 Choice of Liaison Operator 
Conventionally the firing weight of a rule using individual rule inference is defined as; 
ex = min ( .... A(XO), .... B(yO) ) or 
ex = .... A(XO) 1\ .... B(yO) (6.5) 
However, any number of alternative liaison operators could be used, namely algebraic product, 
bounded sum, bounded product, and drastic-product. Of these only algebraic product is 
routinely used and is defined as; 
(6.6) 
Remember that XO and Yo are crisp and therefore equations 6.5 and 6.6 resolve to scalar 
operations. The algebraic product liaison operator was chosen since it avoided the exaggeration 
of rule importance observed using the min operator. 
6.3.5 Choice of Defuzzification Method 
The six most often-used defuzzification methods are; 
1). Centre of Area or Centre of Gravity (CoG) 
2). Centre of Sums (CoS) 
3). Centre of Largest Area (CoLA) 
4). First of Maxima (FoM) I Last of Maxima (LoM) 
5). Middle of Maxima (MID oM) 
6). Height or Mean of Maxima (MoM) 
The choice of method depends on whether it meets certain 'ideal' criteria for the application it is 
intended. Driankov et at [1993] describes the most important of these criteria, and for fuzzy 
control in general and FAVeM in particular, these criteria should have the following properties; 
Continuity:- a small change in the input should not result in a large change in output, since such 
behaviour may cause instability in the system being controlled (i.e. the patient). 
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Disambiguity:- defuzzification must be able to arrive at a single crisp value. 
Plausibility:- the crisp defuzzified output should lie approximately in the middle of the support of 
the fuzzy output and have a high degree of membership within it. This is not always possible if the 
consequent sets are to remain symmetrical in a system with non-uniformly spaced control actions. 
Computational Complexity:- the method must be suited to the time constraints of the problem. 
Advice will be required approximately every 30 minutes so this is not really of any significance. 
Weight Counting:- all fired rules are reflected in the aggregated control output. This is thought 
to provide a more intuitive control profile. 
The CoS method was chosen since it met all of the above criteria. Although this assumes the use 
of symmetrical and uniformly spaced consequent set declarations. 
6.3.6 Analysis of Inference Methods 
The effect of the various methods of reasoning upon the advisor output was investigated by 
examining a subset of the PEEP control space. The crisp output dPEEP was plotted for Pa02 
between 5 and 12 kPa, with values for the other observations as specified in Table 6.3. These 
values were chosen such that multiple rule firing occurred, thus enabling the comparison of 
weight and non-weight counting methods. 
Decision plots (see Figure 6.7) were generated for the following combinations of inference method; 
1). Mamdani's implication (sup-min). 
2). Larsen's implication (sup-prod). 
and with the following combinations of defuzzification method and liaison operator; 
I). Centre of sums, product liaison (CoS-prod). 
2). Centre of sums, min liaison (CoS-min). 
3). Centre of gravity, product liaison (CoG-prod). 
4). Centre of gravity, min liaison (CoG-min). 
Observation Value Set Membership 
PaOl 5 -12 kPa VLOWtoNORM 
eBPsys -10 mmHg LOW (0.5), OKAY (0.5) 
Fi01 60% MEDIUM (1) 
PEEP 6 em H20 LOW (0,5), MEDIUM (0.5) 
Table 6.3: Observation settings for a subset of the dPEEP control space, indicating grade of 
membership within the appropriate linguistic sets. 
There was little observed difference between the sup-min and sup-prod inference 
methodologies. This would result in a negligible difference in any advice given. Consequently 
the remainder of this analysis only focuses on the plots generated using Larsen's implication. 
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Figure 6.7: Comparison of control output for various combinations of inference method, 
defuzzification method and liaison operator. 
Fire Weigbt for Eacb Rule 
Rule No. COG-min COS-min COG-prod COS-prod Rule CSQ Label 
27 0.5 0.5 0.125 0.125 PM27 ) 
29 0.5 0.5 0.125 0.125 PS(29) 
32 0.5 0.5 0.25 0.25 NS(32) 
42 0.5 0.5 0.125 0.125 Z(42) 
44 0.5 0.5 0.125 0.125 PS(44) 
48 0.5 0.5 0.25 0.25 NS(48) 
Total Consequent Weight 
PM 0.5 0.5 0.125 0.125 
PS 0.5 1 0.125 0.25 
Z 0.5 0.5 0.125 0.125 
NS 0.5 1 0.25 0.5 
Crisp Output 
u· 1.25 0.833 0.4 -0.125 
Table 6.4: Comparison of rule-firing weight, aggregated consequent weight and crisp output 
using different combinations of defuzzification method and liaison operator. These are based 
upon observations made at Paco2 = 6 kPa. 
In order to compare each method, the rule firing weights for each were generated for an 
observed Pa02 of 6 kPa (membership VLOW = 0.5, LOW = 0.5). This point was chosen since it 
corresponds to the point of largest difference between the curves. 
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Min Liaison, Centre-of-Gravity 
This method generates the most positive output relative to the other methods. It can be seen that 
in this example, the min-operator results in equal plausibility for all of the rules (Table 6.4, col. 
2). It is felt that this does not meaningfully reflect the certainty of the rule, since more than one 
observation has a certainty less than one and therefore the evidence to support the rule is further 
diminished. Using the min-operator only the smallest evidence is considered, which means the 
observations could have values ranging from this minima up to one (certainty) without affecting 
the rules credibility. 
Using CoG defuzzification, contributions made by rules PS(44) and NS(48) are lost, since this is a 
non-weight counting method. The loss of these rule-consequents coupled with exaggeration of 
PM(27) caused by the min liaison operator, lead to a crisp output (u *) of 1.25 cmH20. 
Min Liaison, Centre-of-Sums 
The exaggeration of rule plausibility imparted by the min-operator leads to regions of increased 
control. However, this is offset against the fact that CoS defuzzification, being a weight 
counting method, re-introduces the effects ofPS(44) and NS(48). Now since these consequents are 
themselves exaggerated by the min-operator, it leads to oscillations in the control space not 
consistent with changes to the input. 
Product Liaison, Centre-of-Gravity 
The measure of rule certainty is now reflected through the product of the antecedent 
memberships. However, using CoG the influences of PS(44) and NS(48) are again no longer felt. 
This accounts for the rise in dPEEP as Pa02 increases towards 8 kPa, since PM(27) is provided 
proportionally greater significance. 
Product Liaison, Centre-of-Sums 
This approach appears to have the balance between scaling of the rule significance and inclusion 
of lesser rule-consequents. The result is a smooth fuzzy control space, consistent with input 
changes and without apparent bias. This combination of liaison operator and defuzzifieation 
method matches those finally chosen for use in the advisor. 
6.3.7 Choice of Output Quantisation 
Once the advice has been generated and the proposed changes to the ventilator settings 
computed from it, they then need to be quantised. It was found that changes derived using the 
raw quantisation levels would occasionally produce decision creep. This was caused by very 
small firing weights in rules with non-zero consequents. The advised change was not enough to 
prevent the rule from firing at the next decision point but large enough to cause gradual increase 
or decrease in the controller output. This behaviour is symptomatic of systems using only 
proportional control. Creep does eventually stop, once the rule-antecedents fall wholly within a 
region of zero consequent. However, the anaesthetist's decision process is discrete and therefore 
a method of preventing unnecessarily small changes from being made is required. 
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The solution was to use larger quantisation levels, which only allow changes to the controller 
output when the advised change is at least as large as the quantisation level. However, make the 
quantisation interval too large and the control can become crude, with the possibility of limit-
cycle behaviour. The ventilator quantisation levels were felt to be the best compromise between 
decision creep and crude control that also allowed the true behaviour of the rules to be observed. 
6.4 Rule Development Methodology 
6.4.1 Rule Prototyping and Completeness 
In safety critical systems there should never exist a combination of input values that result in no 
rule being fired. This is especially true with patients in the intensive care environment, when acute 
events can occur that give unexpected controller inputs. Incomplete rule definition in such 
circumstances may prove fatal. 
Linguistic rule statements of the form 'If A is x and B is y then C is z' provide a rapid method 
for rule-base construction, especially when elicited from a knowledge expert (i.e. an 
anaesthetist), and are simple to interpret. However, construction of a rule-base using only rule-
statements can be susceptible to rule holes or incompleteness, see Figure 6.8. 
Rules 
If(X. is N) and (X2 is Z) then (Y is PS) 
If(X. is N) and (X2 is P) then (Y is Z) 
If (X. is Z) and (X2 is Z) then (Y is Z) 
If(X. is Z) and (X2 is P) then (Y is NS) 
If (X. is P) and (X2 is N) then (Y is PB) 
If(X. is P) and (X2 is Z) then (Y is PS) 
If (X. is P) and (X2 is P) then (Y is NS) 
Rule Map 
... 
~ 
P 
Z 
N 
Xl 
P Z N 
NS PS PB 
NS Z 
Z PS 
Figure 6.8: Using the above rule-statements the resulting rule-map is incomplete. Whilst it 
would be a simple matter to spot such occurrences in a small knowledge-base like this, in a 
large n-dimensional system it is easy to see how rule-holes might be missed. 
These rule-holes were avoided by declaring the rule-base using a matrix rather than via rule-
statements. In this way every possible observation event will have a consequent action defined 
for it. For example, consider the subset of the minute volume control rules, see Figure 6.22, this 
is declared in the MATLAB environment using a 5-by-5 matrix~ 
-60 -30 -15 0 0 
-45 -30 -5 0 0 
R= -30 -15 0 +25 +50 (6.7) 
0 0 0 +50 +75 
0 0 +15 +50 +100 
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This does not mean that elicitation of rule-statements from an expert was negated. Merely that these 
statements were mapped onto the rule-matrix and then all empty elements given a consequent action, 
in order to complete it. The choice of consequent action at these hole-regions was estimated from the 
values in neighbouring cells by either (I) averaging the values at neighbouring regions or (2) by 
making intuitive guesses. This prevented decision space discontinuity. 
Rule prototyping was also made using known physiological relationships and nomograms 
regularly referred to in the literature. This resulted in fewer if any holes, but did require 
modification of the consequents at the observation extremes. This was done via discussion with 
an anaesthetist. 
6.4.2 Fuzzy Consequent Construction 
The values defined for the consequent actions in equation 6.7, represent the peak value of the 
fuzzy consequent sets. The sets themselves were defined with a support twice the smallest 
interval between neighbouring peaks and were made to be symmetrical about the peak value. So 
in the above example the fuzzy sets will have a support of 10 (twice the distance bctween N 1 
and Z). The result is narrow fuzzy sets, distributed across the output domain with only NI and Z 
having intersection, see Figure 6.9b. 
This approach could be criticised in that the dcfuzzified output may be implausible, falling at a 
point in the output domain with no set membership. However, if the cross-points are fixed at 0.5 
and the peak values are non-uniformly distributed, then the resulting membership functions 
become asymmetrical, see Figure 6.9a. Using the centre-of-gravity or centre-of-sums 
defuzzification methods, this approach skews the crisp output in favour of the heavier side of 
the sct's support. This gives rise to biased controller output and is best avoided rather than 
adhering strictly to the notion of plausibility. 
In the worst case scenario, that of very narrow consequent support with a cross-point ratio of zero, 
the defuzzification behaves as though it were a mean-of-maxima (or height) method. When the 
cross-point is 0.5 the defuzzification behaves as a centre-of-sums method. Both of these methods 
provide a smooth control space and therefore the approach taken was considered appropriate. 
6.4.3 Rule Reduction Algorithm 
In order for the rule-matrices to be used by the inference engine they have to be converted back 
into rule statements of the form; 
If [x/ is A] and [X2 is B] and [xJ is C] then [y is D] 
This appears to be reverting back to the original expert rule-statements. However, it is more a 
symptom of the FISMAT toolbox than part of the rule design process. The design of the rule-map 
using the matrix defmition is by far the most practical method of declaring the rules, but the 
rules are more easily processed by the fuzzy toolbox when declared as rule-statements. 
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Figure 6.9: Comparison of consequent set declaration methods using (a) asymmetrical sets with 
a cross-point of 0.5 and (b) symmetrical sets with a support of twice the smallest distance 
between consequent neighbours. 
It would be possible to generate a rule-statement for every observation co-ordinate. However, in 
large rule-maps this would result in nIx n] x , .. x nj rule-statements, where i is the number of 
fuzzy input variables and n is the number of fuzzy sets for each input i. Whilst theoretically not 
a problem, computationally it would be excessive, since every rule must be checked to 
determine its firing weight. Therefore a rule reduction algorithm was written enabling regions of 
neighbouring and identical consequent action to be described via a single rule-statement. 
The algorithm works by taking a 2-dimensional slice (or hyper-plane) of the n-dimensional 
decision space (see Figure 6.10) and searches for blocks of identical neighbours within it. So 
returning again to the example of equation 6.7. This represents a hyper-plane obtained from the 
3-dimensional rule-map for the condition when ePlP is OKAY. The reduction algorithm will 
identify 16 regions, of which 5 contain more than one identical neighbour, see Figure 6.11. 
These regions are then coded using a co-ordinate system. So for example region 'c' will be 
coded as [2,2,4,5, 1, 1, -30]. The first two elements are the start and stop co-ordinates in the X 
direction (ePaco2) and correspond to the observation class NS. The second value pair is the start 
and stop co-ordinates in the Y direction (epH) and corresponds to the observation classes ALK 
to VALK. The third pair is the start and stop co-ordinates in the Z direction (ePlP) which 
corresponds to the hyper-plane axis and an observation class of OKAY. The last value is the 
consequent action attributed to this region. 
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The codes resulting from the rule-reduction were then used to generate the rule statements. So 
considering region c again, this is described by the rule "If [ePaC02 is NS] and [epH is ALK to 
VALK] and [ePIP is OKAy] then [dMv is N3 (-30 %)]" 
L./:////1 
/// ///// 
I I I I 
/7//// ./ 
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/' / 
y / V 
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V 
x 
Figure 6.10: A 2-dimensional hyper-plane taken from the 3-dimensional rule-map along the Z-
axis. Hyper-plane slices can be taken along any of the observation axes. 
-60 a -30 -15 f 0 0 
-45 b -30 c -5 g 0 0 j 
-30 d -15 e 0 25 I 50 n 
0 0 0 i 50 75 0 
0 0 h 15 k 50 m lOOp 
Figure 6.11: Regions of identical and neighbouring consequent action identified by the rule-
reduction algorithm. 
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Phrase Construction 
The phrase [epH is ALK to V ALK] is expressed as a bounded sum of the fuzzy sets ALK and V ALK; 
(6.8) 
This gives an augmented membership functions (see Figure 6.12) that will return a membership 
weight of 1 for all epH observation in the range alkaline to very alkaline. 
1.0 
:a 
~ 
~ 
~ 0.5 
""' 0 QJ ] 
0.0 
0.00 0.10 0.20 0.30 0.40 0.50 
Universe of Discource for epH 
Figure 6.12: Representation of the phrase "epH is ALK to VALK" using bounded sum. 
Algorithm Improvements 
This rule-reduction algorithm was optimised by the inclusion of hyper-cube searching. This 
enabled large regions with identical consequents spanning n-dimensions to be described by a 
single rule. This greatly reduces the number of rules required to describe more complex rule-
maps and therefore improves computation times. Typically a 60 % reduction in the number of 
rules required to describe the rule-map was achieved. 
6.5 FI02 Rule Development 
6.5.1 Elicitation ofPa02 Membership Functions 
Inspired O2 fraction is the main mechanism for the maintenance of blood gas oxygenation and 
the normal indicator of this is arterial O2 tension (Pa~). In order to construct rules for the 
control of Pa02 it was first necessary to identify and elicit the fuzzy set membership functions 
for it. This was achieved via discussion with a consultant anaesthetist. 
They were asked to assign values to the linguistic classes very low (VL), low (L), slightly low 
(SL), normal (N), slightly high (SH), high (H) and very high (VH). This was performed with 
reference to the iso-shunt diagrams since they were to be used to prototype the control rules. 
The fuzzy sets arrived at are shown in Figure 6.13. The cross-points were fixed at 0.5 and the cross-
point ratio at 1. It can be seen that VH lies at some distance from the other sets and reflects the level of 
Pa~ that might be observed when a patient has little or no effective shunt and a FI02 of between 50 
and 70 %. The remaining sets are very similar to those derived in a later study [Kwok et ai, 2000]. 
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Figure 6.13: Fuzzy set defmition for Pa02. 
6.5.2 Rule Prototyping Using Iso-Shunt Diagram 
The iso-shunt diagram (see Figure 3.2) of Benetar et al (1973) and Pedros et al (1993) is used 
by some anacsthetists to adjust inspired O2 concentration to obtain a required level of Pa02 that 
prevents hypoxia while avoiding the administration of unnecessarily high O2 concentrations. 
This follows a goal-orientated approach similar to that required by FA VeM. 
Using the equations behind the iso-shunt curves, it was possible to estimate the changes required 
in Fr02 needed to bring Pa02 towards the set point for a range of initial Pa02 and FI02 levels. The 
set point was assumed to be 12 kPa, corresponding to expected normal values defined previously. 
Ifwe take the iso-shunt equation for arterial O2 content (Ca02), see Section 3.2.7; 
where Cc '02 is the end pulmonary capillary O2 content (mIldl) 
C(a-v)02 is the arterial-venous O2 difference (mIld I) 
Q)Qt is the shunt fraction 
This can be re-arranged to calculate the shunt fraction; 
. /. R Qs Qt =--xlOO 
R-l 
h R Ca02 -CC'02 w ere = ---=-----=-
C(a-v)02 
(ml/l) (6.9) 
(%) (6.10) 
Assuming C(a-v)02 to be 50 ml/l and using the equations given by Pedros et al for Ca02 and 
Cc '02 (see equations 3.7 and 3.5), it is possible to estimate a patient's shunt, based upon 
observations of PaOz and B02. For example, given an observed PaOz of 19 kPa and a Fr02 of 
0.9, the calculated shunt would be 24.3 %. The Pao2-Fi02 relationship for this shunt can then be 
computed using the original iso-shunt equations and interpolated to estimate the new Fr02 
required to achieve a given Pa02 set point, see Figure 6.14. Subtracting this from the observed 
FI02 gives the change required in F102. 
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Figure 6.14: Iso-shunt curve calculated for an observed Pa02 of 19 kPa and F102 of 0.9, showing 
how the Fi02 change can be estimated for a given Pa02 target. 
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Figure 6.15: Fuzzy set defmition for FI02. 
By repeating this process for every peak value of the Pa02 and F102 fuzzy variables, an array of 
consequent actions was produced. The choice of fuzzy membership functions for FI02 are shown 
in Figure 6.15. The classes MIN and MAX reflect the lower and upper limits of deliverable FI02, 
since an FI02 below 30 % will be almost atmospheric air and an FI02 of 100 % is a pure oxygen. 
The class MED reflects the default level of O2 support for healthy post-operative patients and the 
remaining classes HI and VHI were chosen to have increments of 20 % above MED. 
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The calculated consequent actions were rounded to the nearest 5 % in order to reduce the number 
of consequent classes required to specify the rule-map. Any derived dFI02 estimates that would 
cause the new Fi02 levei to exceed the upper or lower limits (l00 % and 30 % respectively) were 
reduced accordingly. The resulting 7-by-5, prototype rule map is shown in Figure 6.16. 
Fi01 
MIN MED HI VHI MAX 
VH 0 -20 -40 -50 -50 
H 0 -20 -35 -35 -35 
SH 0 -15 -20 -20 -20 
.... 
0 N 0 0 0 0 0 CIS 
~ 
SL +30 +35 +30 +10 0 
L +70 +50 +30 +10 0 
VL +70 +50 +30 +10 0 
Figure 6.16: Prototype Fi02 rule map derived from iso-shunt diagram. 
6.5.3 Evaluation of Iso-Shunt Rules 
The main criticism of the rule-map derived using the iso-shunt equations, was that it attempted 
to drive Pa(h towards the target regardless of other therapeutic considerations, such as the need 
to balance Pa02 against undesirable levels of FI02. In an attempt to identify these weaknesses in 
the rule-map, an anaesthetist was presented with random observations of Pa(h and FI02 together 
with the changes proposed by the advisor, and asked the following; 
1). Whether they agreed with the advice? 
2). What action they would take? 
3). What additional therapy might they consider? 
However, in order to cover as much of the observation space as possible without resorting to large 
numbers of observations, the random selection of observation data was regionalised, by defining 
three target regions for F102; 30-50 %, 55-75 % and 80-100 %. Each peak value of Pa02 (see 
Figure 6.13) was then given an observed F102 falling randomly within each of these three ranges, 
resulting in 21 observations. The observation data, iso-shunt responses and the clinician's 
comments are shown in Table 6.5. 
Since the primary objective of the advisor was to mimic clinical decision making, the differences 
outlined by the anaesthetist were incorporated into a modified set of rules, see Figure 6.17. 
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Obsen'ed Obsen'ed Proposed Anaesthetist's Comments 
PaOl Fi01 Fi01 
(kPa) (%) (%) 
12 30 30 No action - adequate oxygenation 
9 35 65 Increase Fr02 to 50%. 65% appears rather excessive 
7 40 100 Increase FIOz to 70% and increase PEEP unless 
contraindicated. FrOz greater than 70% are used cautiously 
and only if absolutely required to maintain oxygenation 
because of the risk of oxygen toxicity 
16 45 30 Decrease O2 to 35% The proposed step seems a bit large as 
the Pao2 is only slightly above nonnal 
25 50 30 Agree 
5 50 100 Agree and increase PEEP if not contraindicated 
40 50 30 Agree 
9 55 90 Increase to 70% The proposed increase seems large 
considering that the Paaz is not too far below nonnal 
40 55 30 Agree 
12 65 65 Agree 
16 65 45 Decrease to 50% The proposed reduction seems a little 
generous. It is better when reducing FI02 to err on the side 
of caution to avoid inadvertent hypoxia 
25 75 40 Reduce to 50% for the same reason as above 
5 75 100 Agree and increase PEEP if not contraindicated 
7 75 100 Agree and increase PEEP if not contraindicated 
40 80 30 Reduce to 40% to be cautious 
9 85 100 Agree and increase PEEP if possible 
25 90 55 Agree 
12 95 95 Agree. Increase PEEP if not contraindicated 
5 95 100 Agree. Increase PEEP if not contraindicated 
16 95 75 Agree 
7 95 100 Agree. Increase PEEP if not contraindicated 
Table 6.5: Comments made by anaesthetist to prescribed FI02 changes derived from iso-shunt 
diagram using randomly generated Pao2-FIOz obsen'ations (see text). 
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Fi01 
MIN MED HI VHI MAX 
VH 0 -20 !:;i~i~?±i -50 -50 
H 0 -20 . -2°i, -35 -35 
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Figure 6.17: Modified FiOz rule map based upon knowledge derived from anaesthetist. The 
shaded regions indicate those regions that have been modified from the original rule-map of 
Figure 6.16. 
6.6 PEEP Rule Development 
Whilst FI02 provides the principal mechanism for O2 maintenance, PEEP also plays an important 
role in certain patient conditions. In order to construct sensible control rules it was necessary to 
understand the clinical benefits and disadvantages of PEEP. 
6.6.1 Clinical Benefits of PEEP 
The clinical benefits of PEEP can be summarised as follows; 
1). Opens up closed alveoli improving arterial oxygenation. This allows lower levels 
ofFI02 to be used, reducing the risks of O2 toxicity. 
2). Increases functional residual capacity (FRC), preventing air trapping and lowering 
airway resistance caused by alveolar collapse. This has the overall effect of reducing 
peak inspiratory pressure (PIP). 
3). Increases lung compliance as collapsed alveoli are recruited, again lowering PIP 
From these benefits it is possible to identify three potential observation variables; PaOz, PIP and 
F102. PEEP can be increased in response to low Pa02 levels to prevent excessively high F102 or 
reduced as Pa02 levels improve. However the degree to which PEEP is modified will also 
depend upon the current level of PEEP applied. As PEEP approaches 15 - 20 cmH20 the 
suitability of PEEP reduces as the risks associated with PEEP increase. 
The possible reduction in PIP associated with PEEP (see benefits 2 and 3) will depend upon the 
nature of the patient condition. However a single observation of PIP imparts no knowledge about the 
effect that additional PEEP will have on subsequent airway pressures. This makes construction of 
rules pertaining to PIP optimisation via PEEP adjustment difficult to realise, since the calculation of 
'mechanical-best PEEP' requires the step-wise increase of PEEP without adjusting other ventilator 
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settings. Such a manoeuvre whilst occasionally necessary does not fit within the initial objectives of 
FA VeM and would require a hierarchical decision process, see Chapter 9: Future Work. 
Using Pa02, FI02 and PEEP as the observation variables, it was possible to construct a simple set 
of guidelines for PEEP change. 
1). IfPa02 is low then increase level of Peep. 
2). IfPa02 is high then reduce level of Peep. 
3). IfFi02 is high then increase level of Peep. 
4). If Fi02 is low then reduce level of Peep. 
5). If Peep is high then limit any Peep increases. 
6). If Peep is high then increase any Peep reductions. 
7). If Peep is low then limit any Peep reductions. 
8). If Peep is low then increase any Peep increases. 
The membership functions for Pa02 and Fi02 observations were kept as for the Fr02 control 
rules (see Figure 6.13 and Figure 6.15 respectively) and the membership functions for PEEP was 
defined as in Figure 6.18. 
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Figure 6.18: Fuzzy set definition for PEEP 
Using these fuzzy set definitions and the simple guidelines outlined above, a draught sct of rule-
consequents was constructed, see Figure 6.19. This includes modifications made to the consequents 
based upon discussions with an anaesthetist. However, most of these were limited to the regions 
PEEP is OFF and LOW. 
6.6.2 Disadvantages of PEEP 
The benefits of PEEP are often contraindicated by other patient observations or it does not 
impart any benefit to the patient at all. Such instances can be summarised as follows; 
1). Alveolar recruitment does not occur in healthy lungs, therefore little improvement 
to Pa02 will be seen. 
2). PEEP is additive to airway pressure and at high levels can increase risk of barotrauma. 
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3). Hyperinflation of open alveoli can lead to impaired perfusion, increasing the 
effective dead space. However, this only usually occurs in lungs with regions of 
differing compliance. 
4). Increases intrathoracic pressure, which impedes venous return, increasing 
pulmonary vascular resistance and thus reducing cardiac output. This effect is least 
when the lungs are stiff, and therefore more of a problem in healthy lungs. 
Consequently low systolic blood pressure (BPsys) contraindicates the use of PEEP. 
F10z 
MIN MED HI VHI MAX 
VHI 0 0 0 0 0 
HI 0 0 0 0 0 
SHI 0 0 0 0 0 
N 0 0 0 4 4 
SLO 0 4 4 4 4 
LO 4 4 4 4 8 
VLO 4 4 4 8 8 
(a) PEEP = OFF 
F10z 
MIN MED HI VHI MAX 
VHI 
-4 -3 -3 -2 -2 
HI 
-3 -2 -1 0 0 
SHI 
-3 0 0 0 0 
N 
-2 0 0 0 0 
SLO 0 0 0 2 4 
LO 0 2 2 4 4 
VLO 2 2 4 4 4 
(b) PEEP = LOW 
F10z 
MIN MED HI VHI MAX 
VHf 
-6 -6 -6 -6 -6 
HI 
-4 -4 -4 -4 -2 
SHI 
-4 -4 -2 -2 2 
N -4 -4 -2 0 2 
SLO 
-2 0 0 2 4 
LO 
-2 0 0 2 4 
VLO 0 2 2 4 4 
(c) PEEP=MED 
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F10z 
MIN MED HI VHI MAX 
VHI 
-8 -8 -8 -8 -8 
HI 
-6 -6 -6 -4 -4 
SHI 
-6 -4 -4 -4 -2 
~ N -4 -4 -4 -2 0 
~ 
SLO 
-2 -2 0 0 2 
LO 
-2 -2 0 0 2 
VLO 0 0 2 2 4 
(d) PEEP = HIGH 
F10z 
MIN MED HI VHI MAX 
VHI 
-16 -12 -12 -12 -12 
HI 
-12 -8 -8 -8 -8 
SHI 
-12 -8 -8 -8 -8 
0 N 
-8 -6 
-4 -4 -4 ~ 
~ 
SLO 
-4 -4 0 0 0 
LO 
-4 -4 0 0 0 
VLO 
-2 0 0 0 0 
(e) PEEP = MAX 
Figure 6.19: Prototype rule-map for PEEP 
changes based upon observations of Pa02, 
F102 and current PEEP. 
The disadvantages of PEEP are less easily converted into a set of rules. The first statement is not 
so much a disadvantage, more a reason for not increasing PEEP, since patients with no collapsed 
alveoli will not benefit from it. Therefore increasing PEEP will only serve to raise PIP, although 
some reduction in airway pressure may result due to dilation of the bronchioles. The risk of 
barotrauma is more likely with high PIP (statement 2) and there is some argument for limiting 
PEEP in such circumstances. 
At this stage in the advisor development it was felt best to forgo the inclusion of PEEP rules 
pertaining to BPsys and/or PIP, since the rule set was already quite large and hand-crafting of 
larger sets is very time consuming. It was considered best to optimised the current rules adding 
the new observation variables afterwards, time permitting. 
6.7 Mv Rule Development 
6.7.l Ventilation-Paco2 Relationship 
It is known that Paco2 follows an approximately inverse-proportional relationship with alveolar 
ventilation ( VA ) [Mushin et aI, 1980, p39]. Hence if VA is doubled then PaC02 will be halved. 
Alveolar ventilation can be expressed as the total ventilation or minute volume (MV) minus the 
dead space ventilation (Vo ); 
VA=Mv-VD 
or VA = ( RR . Vr) - ( RR . VD) (ml/min) (6.11) 
where RR is the respiratory rate (r.p.m.), Vr is the tidal volume (ml) and VD is the dead space 
volume (mI). Consequently a doubling of Vr will not result in a doubling of VA (unless VD is 
very small), but a doubling of RR will. If we assume that Mv is adjusted using RR only, then 
we can say that VA is proportional to Mv. For example, a 50% increase in Mv will result in a 
50% reduction in PaC02. 
Clinical practice requires that Paco2 maintenance be goal driven, since conditions exist when it 
needs to held artificially above or below its normal level (e.g. during the care of head injury 
patients). Consequently FAVeM expresses the observed PaC02 as error from the PaC02 set point 
(ePaCQz). However, expressing ePaC02 in kPa will not allow the implementation of the above 
inverse relationship since the size of Mv depends upon the PaC02 set point. Therefore ePaC02 is 
expressed as a percentage error from set point (see equation 6.3). 
During mechanical ventilation the primary objective is to normalise Paco2 levels. Consideration 
can then be given to acid-base imbalances indicated by abnormal pH values. It is therefore 
possible to construct a simple set of rules using the above inverse PaCo2-Mv relationship, which 
will normalise PaC02 (see Table 6.6). 
The choice of fuzzy classes was made to reflect the range of normally observed PaC02 values. 
Based upon a target of 5.3 kPa, the minimum observed Paco2 error (NB) corresponds to an 
observed PaCQz of approximately 2 kPa. Levels below this are rarely seen. The maximum PaC02 
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error (PB) was set to + 1 00% corresponding to an observed Pac02 of approximately 10 kPa. 
Whilst PaC02 levels greater than this are common in ventilatory failure, it was fclt appropriate to 
restrict Mv changes to + 100% (effectively a doubling of the lung ventilation) so as to prevent 
possible problems with high inspiratory pressures. The intermediate classes PS and NS were sct 
to lie halfway between PB and zero (Z) and NB and Z respectively (see Figure 6.20). 
However, it is unlikely that these simple rules would give good control behaviour since a trade-
off often has to be made between ideal PaC02 levels and the type of acid-base imbalance 
present. In the next section the various types of imbalance are discussed and how they were 
used to extend the simple Paco2 correction rules. 
:E! 1.0 
~ 
-S 
~ 0.5 
-75 
-60 -30 o +50 +100 
PB 
-50 -25 0 25 50 75 100 125 
Universe ofDiscource for ePaC02 (%) 
Figure 6.20: Fuzzy set definition for ePaC02. 
ePacO] 
NB NS Z PS PB 
-60% -30% 0% +50% +100% 
Table 6.6: Simple rule map for PaC02 correction using inverse MV-Pac~ relationship 
6.7.2 Acid-Base Balance 
Several causes of acid-base imbalance can occur and are categorised as either respiratory or 
metabolic in nature. Respiratory acid-base disturbances are related to CO2 elimination, where 
elevated Pac02 causes reduced pH (acidaemia) and low PaC02 causes high pH (alkalaemia). 
These are known respectively as respiratory acidosis and respiratory alkalosis. Metabolic acid-
base disturbances involve either gain or loss of fixed acid It or buffer (predominantly HCO;-) 
in the extra-cellular fluid. The causes are varied but the net result is either acidaemia or 
alkalaemia, known as metabolic acidosis and metabolic alkalosis respectively. A single type of 
acid-base disturbance is rarely seen, being normally of mixed origin. 
Usually changes in pH are compensated for by either metabolic or respiratory mechanisms 
depending upon the type and duration of the disturbance. Respiratory mechanisms involve the 
increase or decrease of alveolar ventilation via the influence of plasma pH on the central 
chemoreceptors. Metabolic mechanisms involve HCO;- salvage and excretion of excess acid or 
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base into the urine. Patients under mandatory mechanical ventilation will not perform any 
respiratory compensation, since this is controlled by the ventilator and is at the discretion of the 
attending anaesthetist. 
Figure 6.21 attempts to summarise the physiological compensation mechanisms and therapeutic 
correction methods of acid-base and PaC02 disturbances. A more detailed explanation of each of 
these regions is given below. 
1). Normal pH I Paco2 (Region E) 
Both respiratory and metabolic components are in balance, resulting in normal pH and normal 
PaC02. Under normal circumstances such a patient would require no intervention. However, 
preservation of the airway in obstructive airway disease may require permissive hypocapnia in 
order to prevent excessive inflation pressures. Also, patients coming off of sedation post-
operatively sometimes require their ventilatory drive kick started by increasing the brain PC02. 
This is often the case in patients that have suffered from chronic hypoventilation. 
2). Respiratory Acidosis (Region I) 
This is indicated by high PaC~ (hypercapnia) and plasma pH below 7.4 caused by hypoventilation. 
In mechanically ventilated patients this may simply be the result of under ventilation and is corrected 
very easily by increasing the minute volume (patient moves from region I to E). 
Prolonged under ventilation, perhaps as a consequence of obstructive lung disease, will be 
compensated for by the kidneys. Bicarbonate is conserved and I-t secretion into the urine is 
increased. These renal effects cause the pH to approach normal (patient moves from region I to 
F) resulting in respiratory acidosis with renal compensation. Chronic respiratory disorders such 
as chronic bronchitis will exhibit hypercapnia with normal pH. It might also arise from 
prolonged prescriptive under ventilation. In this case the patient can be returned to normal by 
gradually increasing the ventilation. This has to be done in small steps since the metabolic 
compensation changes slowly compared to the respiratory effects and rapid respiratory 
correction would give rise to sudden temporary alkalosis. 
3). Respiratory Alkalosis (Region A) 
This is indicated by low PaC02 (hypocapnia) and plasma pH above 7.4 caused by 
hyperventilation. In mandatory ventilation, correction is made by reduction of Mv (patient 
moves from region A to E). Chronic hyperventilation produces reduced HCO:; absorption and 
less I-t secretion into the urine by the kidneys, both of which cause the pH to become more 
acidic (patient moves from region A to D). This condition is defined as respiratory alkalosis 
with renal compensation. 
4). Metabolic Acidosis (Region H) 
This is indicated by normal PaC02 together with acidaemia caused by abnormal accumulation of 
fixed acids in the plasma. The central chemoreceptors are activated and the alveolar ventilation 
increases (patient moves from region H to D). This increases CO2 elimination and raises plasma 
pH, known as metabolic acidosis with respiratory compensation. 
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Obviously in mechanically ventilated patients the respiratory compensation will remain at the 
discretion of the anaesthetist. Mild acidosis will be tolerated and may be preferable to elevated 
airway pressures associated with increased ventilation. 
5). Metabolic Alkalosis (Region B) 
This is indicated by normal Paco2 with alkalaemia and results from the loss of It due to 
nasogastric suction. The high pH depresses the central chemoreceptors and alveolar ventilation 
decreases, causing pH to fall as PaC02 builds up in the plasma (patient moves from region B to 
F). This defines metabolic alkalosis with respiratory compensation. 
6). Acute Metabolic Acidosis + Hyperventilation (Region G) 
This occurs when acute metabolic acidosis produces a compensatory hyperventilation (air 
hunger), as described for normal levels of metabolic acidosis (region H), but is not sufficient to 
normalise pH. Treatment requires correction of the underlying metabolic acidosis first, since 
respiratory correction of PaC02 would only further antagonise the acidaemia. 
7). Acute Metabolic Alkalosis + Hypoventilation (Region C) 
This time the patient is chronically under ventilating with metabolic alkalosis. Again normal 
compensatory mechanisms are insufficient and the underlying metabolic alkalosis must be 
treated first before normalising PaC02. 
When the normal compensatory mechanisms fail, clinical intervention is necessary. However 
not all pH I PaC02 abnormalities can be controlled via changes to the ventilator regime. Others 
require intervention at a metabolic level with the introduction of buffers or acids. Table 6.7 
summarises the clinical actions required for the conditions detailed above in terms of ventilator 
and/or intravenous correction. This forms a framework around which pH aspects of the Mv rule 
construction were made. 
6.7.3 Calculation of pH Fuzzy Sets 
In order to implement the Mv rules sensible values for the pH fuzzy classes had to be chosen. These 
were expressed as error from normal pH (epH). As with the F102 rule development there are 
physiological relationships that can be utilised to provide meaningful fuzzy sets and rule constructs. 
It is possible to derive approximations of pH using the logarithmic form of the modified 
Henderson-Hasselbalch equation [Nunn, 1993, p222]; 
{HCO- J 
pH=pK + log 3 
a·Peo2 
(6.12) 
where PC02 is in kPa, [HeOl ] is in mmolll and pK is the logarithm of the inverse of the 
apparent first dissociation constant of carbonic acid, and has an experimentally derived value of 
approximately 6.1. However, it is variable with both pH and blood-temperature (T) and can be 
derived using equation 4.32 (see Section 4.2.6). 
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Figure 6.21: Physiological 
compensation and therapeutic 
correction of acid-base and 
PaC(h disturbances 
Region Imbalance & Clinical Action 
A Respiratory Alkalosis 
Reduce My to increase PaCo2 and normalise pH 
B Metabolic Alkalosis 
Reduce My slightly in short term and treat alkalosis with intravenous saline and 
potassium or as appropriate for pathology. 
C Acute Metabolic Alkalosis + Hypoventilation 
Treat underlying metabolic alkalosis first with intravenous saline/potassium, 
which will reduce pH and move patient into region F where small increases in 
ventilation can be made whilst continuing to treat the alkalosis. 
D Respiratory Alkalosis with Renal Compensation or 
Metabolic Acidosis with Respiratory Compensation 
Difficult to identify cause of condition and compensatory mechanism in 
operation. Consequently a cautious reduction of My is required. In compensated 
respiratory alkalosis a temporary acidosis will occur until renal compensation 
normalises pH (see curve (i), Figure 6.21). In metabolic acidosis with respiratory 
compensation the pH will not normalise and may require bicarbonate therapy or 
other therapy of the underlying cause of the metabolic acidosis. 
E Normal pH I Pacoz 
No changes normally required 
F Respiratory Acidosis with Renal Compensation or 
Metabolic Alkalosis with Respiratory Compensation 
As with region D it is difficult to identify the cause, therefore tentative increases 
in My will be required, only treating the resultant alkalaemia ifrenal 
compensation not evident. Respiratory acidosis with renal compensation will 
return pH to normal via counter renal compensation (see curve (ii), Figure 6.21). 
G Acute Metabolic Acidosis + Hyperventilation 
Treat the underlying acidosis first by treating the cause and administering 
bicarbonate if appropriate, so increasing pH and moving the patient into region 
D. 
H Metabolic Acidosis 
Increase My slightly and treat the acidaemia by treating the cause of the 
metabolic acidosis and administering bicarbonate if appropriate. 
I Respiratory Acidosis 
Increase My to reduce Paco2 and normalise pH 
Table 6.7: Summary of ventilator therapy decisions associated with pH / PaC02 observations. 
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The solubility of CO2 in plasma (a) has an experimentally derived value of 0.231 mmollllkPa 
but is variable with blood temperature as given by equation 4.31. Since pK is itself dependent 
upon pH we have to substitute equation 4.32 into equation 6.12 and solve for pH; 
6.3968 + 0.01506· (38 - T) + log [HCO:;] 
H- a.Peo2 
p - 1.042+0.0014·(38-T) (6.13) 
This equation enables the calculation of pH for observed PaC02 and [HCO:;]. This makes it 
possible to estimate a patient's pH at the observed ePaC~ points defined earlier (see Table 6.6). 
However before this can be done, the [HCOi] at the nonnal pH-PaC02 point must be calculated 
by using the rearranged form of equation 6.12; 
rHCO:; J = a· Peo2 .10( pH-pK) (mmolll) (6.14) 
At a normal pH of 7.4 and PaC02 of 5.3 kPa, the bicarbonate concentration will be 24.878 
mmoill. We can now use this value to estimate the pH at the ePaC02 point. For example let us 
assume the observed PaC02 is 60% below the nominal target of 5.3 kPa (i.e. ePaC02 = -60 %) . 
Therefore the actual observed PaC02 is calculated as; 
( epac0
2 ) (-60») Paco2 =5.3· 1+ =5.3· 1+-- =2.12kPa 100 100 (kPa) (6.15) 
Using equation 6.13 with an assumed blood temperature of 37 °C, the pH will be 7.781. 
Subtracting this from the normal pH of 7.4, we arrive at a value of 0.381 for epH. 
This process was repeated for each peak value of the ePaC02 fuzzy sets. The epH values obtained 
were assigned to the linguistic classes V.ALK, ALK, NORM, ACID, and V.ACID (see Figure 
6.23), and were found not to be symmetrical about zero due to the logarithmic nature of pH. 
The ePaco2-epH observation points [NB, V.ALK], [NS, ALK], [Z, NORM], [PS, ACID] and [PB, 
V.ACID] describe the line of normal pH-Paco2 relationship and have consequents as per the 
initial PaC02 correction rules. These fonn the diagonal of the ePaCorepH rule map (see Figure 
6.22 shaded area). The remaining rules were inferred from the principles outlined in Table 6.7. 
ePaC02 (%) -60 -30 0 50 100 
PaC02 (kPa) 2.12 3.71 5.30 7.95 10.60 
pH 7.781 7.549 7.400 7.231 7.112 
epH 0.38 0.15 0.00 -0.17 -0.29 
Table 6.8: Estimated epH values at the ePaCo2 points using equation 6.13. Assumes a nominal 
PaC~ of5.3 kPa, nominal pH of 7.4, [HCOi] of24.878 mmolll and blood temp. of37 °C. 
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ePaco2 
NB NS Z PS PB 
V.ALK ~O··' -30 -15 0 0 
ALK -45 ·~30 .. -5 0 0 
== 
NORM -30 -15 ':0 25 50 c. 
~ 
ACID 0 0 0 ',50'i 75 
V.ACID 0 0 15 50 100 
Figure 6.22: Mv rule map for observed epH and ePaC02. Shaded region indicates normal 
respiratory correction as per inverse Mv-Paco2 relationship. The ePaC02 fuzzy sets are as per 
Figure 6.20 and the epH fuzzy sets as per 
-0.29 -0.17 0 +0.15 +0.38 
;.a 1.0 
~ 
~ 
~ 
'e1 
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'I:j 
8 0.0 
-0.4 -0.3 -0.2 -0.1 0.1 0.2 0.3 0.4 0.5 
Universe ofDiscource for epH 
Figure 6.23: Fuzzy set definition for epH. 
6.7.4 Volume Constraints 
The acid-base / PaC02 rules thus far do not account for limitations that might be imposed on 
upper and lower ventilation volumes. It is important not to under ventilate a patient as this may 
cause hypoxia, especially in patients with high shunt andlor dead space volumes. Conversely 
over ventilation can lead to high inspiratory pressures with the possibility of airway damage. 
PIP Alarm 
There are times when a need to increase Mv (normally due to high Paco2) is precluded by high 
peak inspiratory pressures (PIP). In such cases anaesthetists allow permissive hypercapnia in order 
to reduce the risks of barotrauma. The level of PIP that can be toleratcd very much dcpends upon 
the pathology or trauma present. It was therefore necessary to introduce a PIP alarm. If this PIP 
threshold is approached or exceeded then the original Mv rules can be modified to prevent further 
increases in Mv. The proximity to the alarm threshold was expressed as an error (ePIP) such that 
PIP values below the alarm are negative and above it they are positive. 
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Five decision regions were identified, corresponding to five fuzzy classes of observed PIP error; 
1). Pip is well below the given alarm threshold and therefore the Mv rules can remain 
unchanged. Typically the alarm threshold will be 35-40 cmH20. 
2). Pip is below but approaching the alarm threshold and any increases in Mv must be 
moderated. 
3). Pip is at the alarm threshold and all Mv increases must be drastically reduced. 
Some increase may still be necessary, especially in cases of acute hypercapnia. 
4). Pip is just above the alarm threshold and Mv should be reduced in all but extreme 
cases of hypercapnia. 
5). Pip is well above the alarm threshold and Mv must be reduced regardless of the 
current Pac02 to reduce the chance of barotrauma. 
Using the original epH-ePaC02 rule map as a template the regions 2 to 5 were created by 
modifying the appropriate rules (see shaded areas Figure 6.24). This resulted in a 5-by-5-by-5 
set of rules for Mv control. The choice of peak values for the membership functions of ePIP (see 
Figure 6.25) were estimated from observations made during clinical data collection for the 
validation of the patient model. 
ePaco2 ePaco2 
NB NS Z PS PB NB NS Z PS PB 
V.ALK -60 -30 -15 0 0 V.ALK -60 -30 -15 -10 -10 
ALK -45 -30 -5 0 0 ALK -45 -30 -10 -10 -10 
== NORM -30 -15 0 25 '25 Q,. == NORM -30 -15 -10 0 0 =-401 401 
ACID 0 0 0 25 25 ACID -10 -10 -10 0 ,0 
V.ACID 0 0 15 :25 50 V.ACID -10 -10 -10 0 0 
(a) ePip = NR_ALARM (c) ePIP = mGH 
ePaco2 ePaco2 
NB NS Z PS PB NB NS Z PS PB 
V.AU< -60 -30 -15 0 0 V.AU< -60 -30 -15 -15 -15 
ALK -45 -30 -5 0 0 ALK -45 -30 -15 -15 -15 
== 
NORM -30 -15 0 0 ,:,IS' 
-401 == 
NORM -30 -15 -15 0 15 
-401 
ACID 0 0 0 15 15 ACID -15 -15 -15 ·10 -10 
V.ACID 0 0 0 f/15' ,25 V.ACID -15 -15 -15 ·10 .. 10 
(b) ePip = ALARM 
Figure 6.24: Extensions to the Mv rule map to include proximity to PIP alarm. Shaded regions 
indicate areas of rule map that have been altered from the original map of Figure 6.22. 
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Figure 6.25: Fuzzy set defmition for ePIP. 
Mv Constraints 
As mentioned in Section 6.2.2 the majority of patients (approx. 80%) have a prescribed normal 
tidal volume (VTNORM) that is proportional to their weight, being about 10 - 15 mIlkg body 
weight [Anderson, 1988, p12]. Similarly approximately 80% of all patients will have a 
prescribed RR of 12 to 16 r.p.m. Since My is the product of VT and RR, this corresponds to a 
prescribed normal Mv range of 120 - 240 mVminlkg body weight. 
Situations will require ventilation outside of this range and therefore the safe upper and lower 
limits of My were set to +/- 50 % of normal My. This gives a minimum of 60 mVminlkg and a 
maximum of 360 ml/minlkg. By expressing these limits in units per kilo of body weight the 
upper and lower limits will reflect differences in patient size such that a minimum My for a 
heavy male patient will be appropriate for a smaller female patient. This limit was not 
incorporated as a rule-antecedent, since it was a simple matter to limit any advice generated by 
the MY rules so that these limits were not exceeded. The advisor reports the limiting of Mv 
advice, so that rule behaviour can be properly understood. 
As explained previously the product of RR and Vt determines Mv, and therefore any changes to My 
must be met by changes to one or both of these ventilator controls. Choosing in which way they are 
adjusted is a complex matter and required careful rule construction. This is discussed in the next section. 
6.8 Vr-RR Rule Development 
Having established a new minute volume using the MY advisor rules, this has to be translated 
into changes in one or both of the ventilator settings RR and VT. It has already been seen that 
RR is the best parameter for adjusting My since it ignores any losses in ventilation attributable 
to dead space volumes (be they physiological or apparatus based). However, adjustments to 
patient ventilation based solely on RR changes do not reflect the actions made in practice. At 
small My it is also necessary to reduce VT in order to prevent periods of prolonged expiration 
and at higher Mv the increased volume load is better met by increases in both RR and VT. 
For any given MY there exist a large number of possible RR-VT combinations that will generate the 
same ventilation, as illustrated in Figure 6.26. However certain combinations are unsuitable. For 
example very small VT should be avoided, due to dead space effects, and very high VT may generate 
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excessive inflation pressures. Therefore for any given Mv there will exist preferred RR and Vr values. 
By establishing this ideal VI -RR relationship the best settings can be calculated for any observed Mv. 
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Figure 6.26: Iso-MV lines showing how for any given Mv there exist a wide range of theoretical 
respiratory rate and tidal volume combinations. 
6.8.1 Normalised VT 
In normal clinical practise tidal volume is maintained at approximately 10 ml/kg body weight 
and therefore varies form patient to patient. Unfortunately this would affect any Vr-RR 
relationship since what might be prescriptively normal for one patient will not be appropriate for 
another. Similarly classification of the observed Vr will differ. For example, a Vr of 600 ml for 
a 60 kg patient would be classed as normal, but for an 80 kg patient this would best be classed 
as small. This was resolved by representing observed VI as percentage error from normal 
prescriptive Vr (eVINORM); 
V - VT-VTNORM 100 e TNORM - x 
VTNORM 
(%) (6.16) 
where VTNORM = 10 x Weight (ml) (6.17) 
A similar approach to normalisation of Vr was implemented by Schaublin et al (1996), see 
Section 2.3.3. 
6.8.2 Normalised Iso-Mv Lines 
The iso-MY lines of Figure 6.26 assume an explicit value for Vr and RR. However, by using 
eVrNORM to represent any vr, it is possible to generate normalised iso-MY lines (iso-MvNoRM) 
that hold true for all patients independent of weight. Normalised Mv is given by; 
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(
eVTNORM ) MVNORM =RRx +1 100 
(6.18) 
The eVINORM is normalised about 1 to avoid zero iso-MYNoRM points. By rearranging this 
equation it is possible to calculate eVINORM for any RR on a given iso-MYNoRM line; 
TJ: 100 x Mv NORM 1 
eyTNoRM = -RR 
(%) (6.19) 
Using these normalised iso-MY lines and the normalised VI error it was possible to construct an 
ideal VI -RR relationship curve applicable to any patient. 
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Figure 6.27: Anticipated normal RR-VI relationship as My increases. 
6.8.3 Ideal VT-RR Relationship 
Based upon dialogue with a consultant anaesthetist, through preliminary observations made in 
ICU and some personal assumptions, the ideal VI-RR relationship was constructed 
(see Figure 6.27). It comprises four regions as detailed below 
1). Approximately 80 % of all patients have a prescribed RR of 12 to 16 r.p.m. Under 
normal circumstances this would be accompanied by a normal tidal volume. 
Clinical observations confirmed that this relationship often extended to RR as low 
as 10 r.p.m. This defines region B of the ideal Vt-RR curve and implies that 
changes in MV falling between 100 - 160 mllmin/kg will be met by increases or 
decreases in RR only. 
2). At MV above 160 mllmin/kg, increases are met by proportional increases in RR 
and VI up to a maximum VI of 1.5 times VINORM (or 15 ml/kg). It was assumed 
that the ratio between VI and RR should remain constant as Mv increases. At the 
beginning of region B the ratio is; 
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r= VT = lO·W =0.625.W 
RR 16 
(6.20) 
where W is weight (kg). Therefore at the upper VT limit RR can be calculated as~ 
RR = 1.5· VTNORM = 15· W = 24 
r 0.625·W 
(r.p.m.) (6.21) 
3). Beyond this further My increase is met by increases in RR only, to avoid 
excessive tidal volumes (see region C). 
4). Below 100 mVminlkg (the lower extent of region B), further reductions in My 
again require a proportional reduction in RR and VT (see region A) 
The e VT NORM obtained using the ideal VT -RR relationship is a function of observed RR, and can 
be described mathematically as~ 
e VTNORM = 6.25 . RR - 62.5 
=0 
= 6.25 ·RR-IOO 
=50 
RR<lO 
10 ~ RR ~ 16 
16 <RR~24 
RR>24 
(%) (6.22) 
Let us call this functional relationship f(RR}. Now by substituting it into equation 6.18 the 
normalised My for any observed RR can be calculated; 
(
f(RR) ) 
MVNORM =RRx +1 
100 
(6.23) 
However, the original problem was to derive the ideal VT and RR settings given an observed 
Mv. It was therefore necessary to calculate the inverse relationship between MYNoRM and RR. 
This was done by calculating the cubic spline polynomial of this inverse relationship~ 
pp = spline(MYNoRM, RR)t (6.24) 
It is then possible to calculate the ideal RR for any observed MYNORM using the function; 
RR = f(MVNoRM ) = ppval (pp, MYNORM) tt (r.p.m.) (6.25) 
t pp = spline(x,y) - MATLAB function that calculates a piece-wise cubic polynomial expression of the 
relationship between x and y, where x must be monotonically increasing and x and y are equal size 
vectors. 
tt Y = ppva/(pp,x) - MATLAB function that uses the polynomial expression pp derived using splineO to 
derive an estimate of y based upon observation x. 
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RR 
MIN LO MED HI VHI MAX 
PVB -38 -38 -26 -16 -7 -6 
PB -35 -31 -22 -12 -3 3 
~ PM -30 -23 -18 -7 3 12 
~ PS -24 -13 -13 -1 9 19 ~ Z -17 0 0 6 17 27 
NS -8 11 18 18 27 38 
NM 5 25 42 43 43 52 
Figure 6.28: Rule map describing percentage change required in VT to normalise RR-VT 
relationship. Consequent values were derived using the rule estimation algorithm given in 
section 0, and based upon observations of respiratory rate (RR) and percentage error, from 
normal tidal volume (eVTNORM). 
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Figure 6.29: Fuzzy set definition for eVTNORM. 
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Figure 6.30: Fuzzy set defmition for RR 
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6.8.4 Rule Estimation 
Using the above polynomial expression of f(MVNoRMJ it was possible to calculate for any 
observed RR and VT the change required in VT to bring the VT-RR relationship in line with the 
VT -RR curve. The estimation algorithm is as follows; 
1). Calculate VT NORM from patient's weight using equation 6.17. 
2). Calculate eVTNORM from VTNORM using equation 6.16. 
3). Calculate MVNORM from observed RR and eVTNORM using equation 6.18. 
4). Estimate ideal RR (RRi) form MVNORM using f(MvNoRM), see equation 6.25. 
5). Calculate VT change required from RRi, original Mv (Mvo) and original VT (VTo); 
Mvo ~VT=---Vr. RR. 0 
I 
(ml) (6.26) 
6). Expressing this as a percentage change from VTo, means that the consequent 
action holds true for all VT irrespective of patient weight; 
ilVT= 
Mvo -Vr. 
RR. 0 
I xl00 (%) 
7). The result is then rounded to the nearest percent. 
(6.27) 
By applying this algorithm to every combination of peak values for the RR and eVTNORM fuzzy 
sets, a rule map of changes required in VT to achieve optimal VT-RR settings was produced (see 
Figure 6.28). Initially, seven equal-spaced fuzzy classes were defined for eVTNORM, ranging 
from -30% to +60% in 15% steps (see Figure 6.29). These were the expected limits of VT 
settings. Therefore a 60 kg-patient will have a VT rage of 420 - 960 mt. Similarly the initial RR 
fuzzy classes ranged from 6 to 26 r.p.m. in 4 r.p.m. steps (see Figure 6.30), giving six sets. 
From this preliminary rule map, attempts were made to reduce the number of sets without 
adversely affecting the advisor performance. It was found that; 
I). The number of eVTNORM sets could be reduced from 7 to 5 with little perceptible 
difference in advisor subsystem outcomes. This involved the removal of the fuzzy 
sets PS and PB. 
2). The number of RR sets could not be reduced. In fact the addition of RR = 8 (VLO) 
was required to give better curve matching, see Figure 6.31. 
3). The number of consequent sets could be reduced from 26 to 15 by rounding the 
advice to the nearest 5 % change where possible. This was performed judiciously 
in an attempt to prevent estimate overshoot. Consequently if the original advise 
was to increase VT, the consequent was rounded down. Conversely reductions 
were rounded up, to give smaller VT changes. 
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~ 
The revised rule-map is shown in Figure 6.32. 
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Figure 6.31: Modified fuzzy set definition for RR. 
RR 
MIN VLO LO MED HI VHI MAX 
PVB -35 -35 -35 -25 -15 -5 -5 
~ PM -30 -20 -20 -15 -5 2 10 
0 
-15 -5 0 0 5 15 25 z Z ~ 
> QoI NS -5 2 10 15 15 25 35 
NM 5 15 25 40 40 40 50 
Figure 6.32: Modified VT rule map after set reduction and consequent rounding. 
6.8.5 Handling My Changes 
The rule-map described thus far has assumed fixed observations of initial RR-VT. However, a 
prescribed change in My (as derived using the Mv advisor sub-system) will result in a different 
set of observation conditions. However, we only have knowledge of the original RR-VT 
observations. In order to provide the VT advisor with sufficient information, it was assumed that 
any changes in My are implemented as changes in RR. This new RR estimate (RRnew) and the 
original VT observation (VTo) are used to stimulate the VT-RR rules. 
The advantages of this approach are; 
1). The rules are applicable for initial patient observations as well as for when Mv 
changes. 
2). Unnecessary refinements to VT are avoided by first changing RR and then using 
the rules to ascertain if the new observations require VT to be modified. 
143 
RR 
MIN VLO LO MED HI VHI MAX 
PVB -35 -35 -35 -25 -15 -5 -5 
~ PM -30 Z -15 ~ 
~ NS -5 
NM 5 
(a). ePIP = NR_ALARM 
RR 
MIN VLO LO MED HI VHI MAX 
PVB -35 -35 -35 -25 -15 -5 -5 
~ PM 
0 
~ Z ~ NS 
NM 
(b). ePIP = ALARM 
RR 
MIN VLO LO MED HI VHI MAX 
PVB -35 -35 -35 -25 -15 -5 -5 
~ PM Z 
> ~ NS 
NM 
(c). ePIP = HIGH 
RR 
MIN VLO LO MED HI VHI MAX 
PVB 
~ PM Z ~ ~ NS 
NM 
(d). ePIP = V_HIGH 
Figure 6.33: Extensions made to the VT rule-map of Figure 6.32. The shaded regions indicate 
areas of the rule-map that have been altered. 
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6.8.6 Volume Constraints 
As identified during the My rule construction, there are occasions when prescribed increases in 
delivered volume cannot be realised due to the risks associated with high airway pressures. 
When the observed PIP was high, increases to My were moderated or restricted. A similar 
restriction has to be applied to any proposed increases in VI. Whilst the Mv rules will prevent 
inappropriate increases in MY, there will exist situations when a lower VI with higher RR will 
produce a reduced airway pressure (assumes a fixed volume cycle ventilation regime). 
It was therefore possible to modify the original rules of Figure 6.32 to account for observations 
of PIP. Observed PIP was expressed as error from a prescribed alarm threshold (ePIP), as per the 
Mv rules and the same fuzzy classes were used (see Figure 6.25), describing ePIP as OKAY, 
NR_ALARM, ALARM, HIGH and Y _HIGH. 
When observed PIP is well below the alarm threshold (ePIP is OKAY) the normal VI rule-map of 
Figure 6.32 applies. However, as observed PIP approaches and then exceeds the alarm threshold 
the rules pertaining to VI increases are moderated and eventually stopped. The extended rule-
maps (see Figure 6.33) were derived using intuitive guess work, since rapid rule refinement 
would be made during the closed loop simulation of the advisor. 
6.9 Summary & Conclusions 
This chapter has described the development of the prototype advisor. 
Inference Methodology 
By comparing the pros and cons of different methods it was proposed to use individual rule-based 
inference with Larsen's implication. Rule significance will be imparted using the product 
antecedent liaison operator and the crisp control output will be derived using the Centre of Sums 
defuzzification method, a weight counting approach. Membership functions in the rule-antecedent 
are to be constructed using triangular and trapezoid functions. They must meet condition width 
criteria, have cross-point levels of 0.5 and a cross-point ratio of 1. Membership functions in the 
rule-consequent must be symmetrical, have equal area but do not necessarily require a cross-point 
ratio of 1. With non-uniformly spaced control actions (as observed within elements of FA VeM) 
plausibility is negated. However this approach will still produce smooth decision surfaces. 
Rule Development Methodology 
The importance of rule completeness was highlighted, and rule-holes were avoided by declaring 
the rule-base using a matrix rather than rule-statements. This rule-matrix was converted into 
rule-statements using a rule-reduction algorithm in order to minimise the number of rules 
required. This greatly reduced the amount of memory required to code the rule-matrix and also 
minimised the computational overheads of calculating the advice. 
FIOz Rule Development 
Suitable membership functions for the Pa02 observations were elicited from an anaesthetist, and 
these were found to be similar to those reported by Kwok et al (2000). These classifications 
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were then used in a modified form of the iso-shunt diagram to derive an initial prototype version 
of the FI02 control rules. When assessed by an anaesthetist these preliminary rules were found 
to advise excessive FI02 changes, and were modified accordingly. 
PEEP Rule Development 
The clinical benefits and disadvantages of PEEP were identified and from these a preliminary set 
of rules drafted. Areas of improvement were proposed but these required the addition of new 
antecedents. It was considered best to establish some validity in the prototype rules before 
attempting any rule-base modifications. 
Mv Rule Development 
MY was used to adjust PaC02 since there is an inverse proportional relationship between them. 
PaC02 was represented in the rule-antecedent as error from PaC02 set point (ePaco2) enabling 
goal-orientated control. This allowed different therapeutic needs to be met; for example in head 
injury patients when PaC(h must be kept low to help reduce brain swelling. 
The causes of respiratory and metabolic pH imbalance were discussed and possible therapeutic 
actions identified. Suitable peak values for the pH membership function were derived using the 
Henderson-Hasselbalch equation and represented in the rule-antecedent as error from normal 
pH. An initial rule-map was generated using the ePaC02 and epH fuzzy classes, coupled with the 
inverse MY-PaC02 relationship and the therapeutic actions previously identified. 
This preliminary rule-base was extended to include consideration of PIP, preventing increases in 
My as the risk of barotrauma increases. Volume constraints were also applied to the maximum 
and minimum aIlowable My that can be suggested. 
VT-RR Rule Development 
Having established a new level of MY, this was converted by the Vr-RR rules into the best 
combination ofRR and Vr setting. However any given My can be generated using a wide range 
of possible RR and Vr combinations as explained by the concept of iso-MY lines. This idea was 
extended using the representation of Vr as error from normal (e Vr NORM) to produce normal iso-
MY lines, applicable to any patient irrespective of weight. Normal Vr was derived as 10 mllkg. 
Using the normal iso-MY lines an ideal eVrNORM-RR relationship was proposed. This was used 
to calculate the changes required in Vr based upon observations of eVrNORM and RR. Fuzzy 
classes for eVrNORM and RR were chosen to give a good approximation of the ideal eVrNO~ 
RR curve. Changes in My were handled by expressing all of the change via RR only and then 
using this new RR together with the old Vr to drive the Vr -RR rules. 
The Vr-RR rule-base was extended to include consideration of PIP, with Vr reduced and RR 
increased preferentially when PIP was high. 
The prototype advisor now required validating and refming. This was best achieved using the 
patient model to facilitate simulated closed-loop control, and is the subject of the next chapter. 
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Chapter 7: Closed Loop Advisor Validation 
7.1 Introduction 
Having established a prototype set of rules for the advisor, their validity needed to be tested. It 
has already been demonstrated in the F102 control rules that what might appear a good control 
strategy (in this case based upon the iso-shunt models), falls short of what is actually practised. 
Predominantly this is exhibited as greater caution on the part of the anaesthetist. It is likely 
therefore that rule refinement will be required as a consequence of advisor testing. Identifying 
the reasons for any rule modifications requires a clear understanding of the context within which 
the observations were made. After all, a given set of observations may lead to ventilator changes 
in one class of patient that would be inappropriate for another, based upon the same 
observations. Isolating these differences helps to identify insufficiency in the rule-base and may 
highlight new observations required to better separate the decision space. 
This chapter describes the closed-loop validation of the prototype advisor using the patient 
model described earlier (see Chapter 4). The next section discusses the rationale behind the 
choice of validation methodology, together with an overview of the validation process itself. 
However, before model-based validation could be performed, improvements needed to be made 
to the patient model (see Section 7.3). Using this improved patient model, virtual scenarios were 
constructed via dialogue with an anaesthetist (see Section 7.4), and employed to test the closed-
loop performance of the prototype advisor. Decision histories generated by the advisor were 
compared with those produced by an anaesthetist (see Section 7.5) and modifications made to 
the rules where necessary. The new rule-base was then re-evaluated using the same patient 
scenarios in simulated closed-loop. 
7.2 Rationale & Overview 
The simplest method to test rule validity would be to generate random observations, apply these 
to the advisor and then test the response generated against that of an anaesthetist. However, this 
method has two major disadvantages. Firstly, and perhaps most importantly, all therapeutic 
decisions are based not only upon the key observations, but also upon the context within which 
they occur. This includes factors such as patient pathology or trauma, their treatment history and 
recent response characteristics, all of which may contribute to an anaesthetist's prescribed 
course of action. This information would be absent using randomly generated observations and 
therefore the clinician's response would be ill informed. Secondly, the number of possible 
permutations required to exhaustively test the rule-base is large and not all combinations would 
be meaningful. 
A preferable approach would be to use real clinical data that can be carefully recorded so as to 
preserve as much contextual information as possible. This provides not only observation context 
but also information regarding the actual course of action taken. Records thus obtained can be 
used not only to compare actual and advised responses, but also provide a means for third party 
appraisal. An independent anaesthetist can be recruited to give the decisions they would have 
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made, based upon the observations recorded. This would not be intended to assess the 
credibility of the observed anaesthetist (highly unethical without prior consent), but rather to 
highlight that differing approaches are equally valid. One anaesthetist's decision may better 
match the computed advice. This would say more about the variability of anaesthetist practice 
within ICU, than of weaknesses in the advisor. 
Whilst clinical validation is an important stage in the assessment of the advisor, it does have 
distinct disadvantages. Most significantly are the difficulties associated with data collection. 
These problems have been highlighted previously during the clinical validation of SOPAVent 
and focused principally on the time involved to accurately record all relevant information. The 
type of patient available for study is very much luck of the draw, although there will be different 
potential groups depending on the ICU site. Of the two JCUs used in this research, one focused 
predominantly on post-operative cardio-thoracic care and the other dealt with all possible 
scenarios including post-operative care, accident and emergency and acute pathology. 
Approximately 90% of the data were collected from the latter. 
Even if the data collection issues could be overcome and a large sample set was available, it still 
would not provide a flexible framework for advisor testing and validation. This arises because 
differences between actual and advised decisions cannot be explored beyond the fact that they 
differ. Ideally we would want to apply the computer-advised changes as well as the actual 
changes to the patient, in order to compare patient outcomes. Ethically this would not be 
possible and it would still not enable comparison of patient outcomes beyond a single decision, 
since we cannot repeat the patient's history. More importantly, small differences between actual 
and computed advice (which might be considered as a good decision match) may mask any 
divergent instability or limit cycle behaviour within the rules. This has very real safety 
implications and can only be investigated using a simulated closed loop methodology. 
By using a computer-based patient model, scenarios can be constructed that are both repeatable 
and unaffected by measurement errors. An anaesthetist can then attempt to ventilate these virtual 
patients to produce benchmark decision profiles that can then be compared against computer-
generated advice. If the advisor and patient model are connected together to simulate closed-loop 
control then patient outcomes can be compared in a manner not possible using real patients. 
The patient model also provides the flexibility to incorporate measurement errors and process 
disturbances that would aid the understanding of the clinician's response to poor observations as 
well as the robustness of the advisor. Also, because every element of the patient's behaviour is 
repeatable, any rule modifications can be tested to see if the expected improvements have occurred. 
However, in order to provide simulated closed loop behaviour the patient model must generate 
all of the observations required by the advisor, and they must respond to ventilator changes in a 
manner appropriate to the pathology or trauma being considered. Throughout the rule 
prototyping certain inadequacies and omissions in the patient model became apparent. These 
can be summarised as follows~ 
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pH Modelling: The prototype minute volume (Mv) control rules required observation of pH. In 
the early SOP AVent model, pH was assumed fixed which clearly does not model changes in pH 
caused by respiratory acidosis and alkalosis, as well as changes due to metabolic dysfunction. 
PIP Modelling: PIP was required by both the Mvand RR-VT control rules as a measure of the 
possible risk of barotrauma. As the ventilation is adjusted the airway pressures changes 
according to the mechanics of the lung. No mechanical modelling had been included in the 
original patient model. 
PEEP Effects: PEEP is applied to open up previously closed airways, but can also have 
disadvantageous effects on cardiac output and arterial blood pressure. These require the 
inclusion of modifiers to shunt and cardiac output respectively. 
BPSYS Index: Low systolic blood pressure contraindicates the use of PEEP and therefore any 
relationships governing its behaviour needed to be considered. 
Miscellaneous Improvements: Empirical relationships governing O2 consumption, CO2 
production and cardiac output may improve model behaviour. These include the effects of body 
temperature, metabolic activity, weight and hypoxia. 
These improvements together with the introduction of a graphical user interface (GUJ) to 
improve the usability of the model and event profiling to facilitate time variations in certain 
model parameters are discussed in detail in the next section. 
The updated SOP AVent model was then used to construct patients with a variety of trauma and 
pathology (e.g. head injury, lobar pneumonia, etc). This was done with direct input from an 
anaesthetist in order to generate as much clinical realism in the scenarios as possible. They were 
then asked to ventilate these virtual patients to produce 'ideal' decision histories. At each 
decision point they were asked to state when they would next take a blood-gas sample. The 
patient would then be simulated to this point and the process repeated until weaning from the 
ventilator was proposed or the patient was stable and no further action was possible, e.g. waiting 
for a patient to regain consciousness. For each patient simulated, the anaesthetist was also asked 
to identify their therapeutic objectives and define set-point goals. 
The prototype advisor was then connected to these patient scenarios and allowed to run in 
simulated closed-loop control, see Figure 7.1. New advice was generated at the blood-gas 
sample times established by the anaesthetist when they ventilated the virtual patients. At each 
advice cycle a report was generated, stating the antecedent set membership and rules fired, with 
their respective weightings to help identify the causes of any decision mismatch. 
The performance of the prototype advisor in simulated closed-loop control was analysed and 
refinements made to the rules accordingly. In some instances this only required changes to be 
made to the rule-consequent, in others new fuzzy classes were required and occasionally a new 
observation variable was identified. The modification process was performed in an iterative 
manner with each change or group of changes being evaluated by re-running the closed-loop 
simulation and comparing the patient outcomes. In most cases the rules were modified so that 
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they matched the anaesthetists, but sometimes advised decisions were deemed preferable to 
those of the clinician and no further rule-modification was made. 
Modifications made in response to a scenario sometimes caused errors in other scenarios that 
were previously giving good decision matching. In such circumstances either a compromise was 
made in the consequent action or a new fuzzy class or variable was introduced to better separate 
the decision space. The modified rule-base was then re-evaluated using closed-loop simulation 
and the performance of the advice analysed. 
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Figure 7.1: Closed loop simulation of advisor performance using a process model of a ventilated 
patient (SOPAVent). The dashed connections from the anaesthetist indicate input prior to the 
closed-loop simulation (Le. definition of the patient scenario, blood-gas sample times and set-
point goals). 
7.3 Model Improvements 
7.3.1 pH Modelling 
Perhaps the single most significant omission from SOPAVent was the ability to model changes 
in pH. This shortfall affected not only its ability to match real patient behaviour, but also its 
usefulness for advisor rule testing. The prototype Mv advisor rules (see Section 6.7) use the 
observed error from normal pH as one of the controller's antecedents. Without pH modelling 
there is no feedback from the process model in response to advised ventilator changes. 
Consequently, the controller will continue to generate advice based upon the initial pH 
observation. It is not difficult to see how this will lead to erroneous and possibly dangerous 
ventilator changes (albeit simulated). 
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Modelling of pH behaviour was achieved using the modified Henderson-Hasselbalch equation; 
6.3968+ 0.01506·(38 -T )+log [HC03'] 
H- dW2 
P - 1.042+0.0014.(38-T) (7.1) 
where peo] is partial pressure of CO2 (kPa), a is the solubility of CO2 in plasma (mmolll/kPa), 
T is blood temperature eC) and [HC03'] is bicarbonate concentration (mmolll). This equation 
is identical to that used in the Mv rule prototyping, see Section 6.7.3 for details. 
The pH calculation was performed within the gas dissociation function (GDF) prior to the 
calculation of O2 and CO2 contents, since both algorithms have a pH dependent component. In 
the O2 GDF this is in the equation for virtual P02 (see Section 4.2.3) and in the CO2 GDF this is 
in the Henderson-Hasselbalch equation, the pK formula and the equations deriving the reduced 
and oxygenated cell to plasma [C02] ratio (see Section 4.2.6). 
A similar approach has been taken by Dickinson (1977) in his McPufpatient model, although in 
this case he used a much simpler form of the Henderson-Hassclbalch equation with no 
adjustments made to pK and a. based upon pH and temperature. 
SOPAVent requires the inverse of the GDF (i.e. calculation of gas tensions from contents) which 
was implemented using a simple secant-searching algorithm (see Section 4.7). Unfortunately the 
inclusion of the pH modification meant that it was possible for the inverse GDF to get stuck 
within an iterative loop. This occurred when changes in PC02 estimate generated changes in pH 
that itself produced changes in the P02 and PC02 estimates that would not converge. 
This was overcome by adopting the 2-dimensional secant-searching algorithm as employed in the 
tuning of shunt and dead space. In this case the PC~ was estimated first (being the more sensitive 
variable to pH) and then Po2. This was repeated until the estimation error fell below a predetermined 
level in both P~ and Pc~. 
Clinical Validation 
The predictive performance of equation 7.1 was tested by using 151 observations of PaC02, pH, 
bicarbonate and temperature taken as part of a second data collection phase (see Chapter 8). 
Allowing for measurement and recording errors, the equation performed well with a correlation 
coefficient ofr = 0.967 (standard error of estimate 0.0281), see Figure 7.2. 
Pulmonary Bicarbonate Approximation 
The inverse GDFs are used not only to calculate arterial and venous P02 and PC02, but also to 
derive the pulmonary gas tensions that drive diffusion across the lung membrane. However, the 
calculation of pH requires knowledge of [HCO;] which is easily measured in the arterial and 
venous circulation but is not available in the pulmonary compartment. It was therefore 
necessary to assume pulmonary [HCO;] to be equal to arterial [HCO;]. 
151 
7.7 
7.6 R2 = 0.9347 
7.5 
= Coo 7.4 Ie 
"CI 
~ 7.3 
-
y 
... 
"CI 
~ 7.2 ~ 
7.1 Ie • . 
;' 
7.0 
6.9 
6.9 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 
Obscn'cd pH 
Figure 7.2: Correlation bctween observed pH and predictcd pH, using data collected during the 
clinical validation of the advisor (see Appendix H). 
7.3.2 Airway Modelling 
Prescriptive changes in mechanical ventilation (e.g. Vr, RR, driving waveform, etc) impact on 
the pressure at the mouth and the pressure in the alveoli. The relationship between these 
ventilator settings and observed pressures is dctermined by the respiratory mechanics of the 
patient and ventilator. The two main properties that characterise breathing mechanics are total 
compliance (C) being a measure of lung and chest-wall elasticity, and total flow resistance (R), 
which reflects properties of both the tissue and the peripheral airways. Compliance is measurcd 
in litres/cmH20 or litreslkPa and flow resistance in cmH20llitre/sec or kPaIlitre/scc. 
This can be represented using a simple two-element rcsistance-compliance linear model. 
However, in such a model it has to be remembered that the lumpcd paramctcrs R and C includc 
any resistance and compliance between the ventilator and the patient as well as bctwecn the 
mouth and the alveoli. A first order approximation of this nature is sufficicnt for pscudo-
realistic simulation of various mechanical abnormalities (e.g. stiff lungs associated with ARDS 
and high flow resistance associated with chronic obstructive airway disease), However there is 
good evidence that a three-element model with additional parallel compliance will give bettcr 
matching to observed pressure and flow data in routine post-operative ICU [Barbini et ai, 1994]. 
Making physical sense of a three-element model in physiological or mechanical terms is 
difficult even if it does give better frequency and time domain response characteristics, whcreas 
the two-element model is readily understood by clinicians. 
PIP Modellin! 
The prototype MY and Vr-RR rules require that consideration be made of PIP. In theory this 
should be measured at the mouth, but in practice the manometer is almost invariably situated on 
the ventilator. However, resistance between the ventilator and the patient's mouth, and hence 
the pressure difference between the two is usually negligible. Therefore for all practical 
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purposes, the pressure at the ventilator can usually be taken to be the same as the mouth. In 
order to determine the simulated PIP we have to derive the equations describing the pressure at 
the mouth (Pm) during the inspiratory phase of the respiratory cycle. 
R 
c 
Figure 7.3: Electrical analogue of the respiratory mechanics during the inspiratory phase of the 
respiratory cycle. 
The ventilator is assumed to be in volume control mode and delivers a certain pre-set volume 
during a pre-set time with a constant flow. This is analogous to a constant current generator in 
electrical terms. Similarly the flow resistance is analogous to electrical resistance and lung 
compliance to capacitance, see Figure 7.3. 
The pressure at the mouth will be the sum of pressure drop across the flow resistance and the 
lung compliance; 
. 1 J . Pm(t) =PR(t)+PC(t) =VR+ C V.dt 
where the flow V is given by; 
. Vr 
V=-
t[ 
Substituting equation 7.3 in equation 7.2 and integrating we arrive at; 
(7.2) 
(Vsec) (7.3) 
(cmfJzO) (7.4) 
The additional term PEEP represents the initial conditions of the system due to applied positive 
end-expiratory pressure. 
The peak: inspiratory pressure is simply this equation calculated at the end of inspiration (t = tJ; 
Vr Vr P[p=-·R+-+PEEP 
t[ C (cmH20) (7.5) 
Using this equation it is then possible to model the effect of changes in ventilator setting and 
patient lung mechanics on the observed PIP. 
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Mean Alveolar Pressure 
Originally, mean alveolar pressure was approximated using equation 4.39 (see section 4.2.7). 
However, this equation is incorrect in three respects. Firstly, it does not actually represent the 
alveolar pressure but the pressure at the mouth; secondly the ventilator is a constant flow source, 
which does not result in a square pressure waveform; and finally it takes no account whatsoever 
of the respiratory mechanics. 
The mean alveolar pressure is calculated by integrating the alveolar pressure across the whole 
ventilation cycle. However, this requires definitions of the equations describing the alveolar 
pressure wave. This ventilation cycle can be divided into three distinct regions; the inspiratory 
phase, the pause phase and the expiratory phase. 
1}. Inspiratory Phase 
During the inspiratory phase the respiratory mechanics behave as in Figure 7.3 with a constant 
flow source connected to a lumped compliance and flow resistance network. The alveolar 
pressure (PA) is equal to the pressure drop across the lung compliance; 
1 f' Vr PArt} = Pc(t} =- V.dt =--'I+PEEP 
C C·tl 
(7.6) 
The mouth pressure during inspiration is as described previously in equation 7.4. 
2}. Pause phase 
During the pause phase (which is optional) the constant flow generator stops, but a non-return 
valve prevents gas from leaving the system. This is provided to allow the alveolar pressure to 
equilibrate with the mouth pressure and gives better gas mixing in the alveolar space. The model 
now behaves as though the mouth is effectively a fixed volume at pressure Pm(tj) discharging 
via the R-C network into the alveolar space which is already at pressure P A(tj). 
The relationship between Pm and PA is described by a pair of simultaneous differential equations, 
since the pressure difference driving the equilibration decays as the pressures equalise.; 
(7.7) 
Using Laplace transforms these equations resolve to; 
(7.8) 
where Ip is the length of the pause phase in seconds and PAO and PmO are the alveolar and mouth 
pressures at the end of inspiration as given by; 
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VT PAO =-+PEEP C 
VT VT PmO =-·R+-+PEEP 
II C 
3). Expiratory phase 
(7.9) 
(cmH20) (7.10) 
Assuming that the internal resistance of the ventilator (r) during expiration is low (typically 2 
cmH20) the alveolar pressure during the expiratory phase is given by; 
-(t-(t[Hp )) 
PA(t) = (PAl -PEEP)'e (R+r)C +PEEP (cmH20) (7.11) 
where PAl is the alveolar pressure at the end of the pause phase as given by; 
(7.12) 
The pressure at the mouth is only restricted by the intcrnal resistance of the ventilator and 
therefore falls much more rapidly; 
-(t-(t[+tp )) 
Pm(f)=(Pml-PEEP)'e rC +PEEP (7.13) 
where P ml is the pressure at the mouth at the end of the pause phase. A typical pressure 
waveform generated by these equations is shown in Figure 7.4. 
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Figure 7.4: Typical pressure waveforms generated at the mouth and in the alveolar space using 
the airway mechanics model. The ventilator settings used were VT = 0.71itres, RR = 12 r.p.m., 
PEEP = 5 cmH20 (0.49 kPa), tl = 33 %, tp = 10 %, and the ventilator-airway mechanics were 
defined by R = 5 cmH20/l/sec (0.49 kPalVsec), C = 0.1 VcmH20 (1.02 VkPa), r = 2 cmH20/Vscc 
(0.2 kPalVsec). 
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Calculation of the mean alveolar pressure PA (I ) (or PMEAN) requires integrating the equations 
for PArt) in the three respiratory phases and averaging over a single respiratory cycle; 
1 foT PMEAN = - PA(I).dt+PB 
IT 0 
1 {for J,tr+tP fT } =- PA(insp).dt+ PA(pause).dt+ PA(exp)dt +PB 
~ 0 ~ ~~ 
(7.14) 
It should be noted that the units ofPMEAN are in kPa and therefore the average PA(t) value must 
first be converted from cmH20 to kPa to be meaningful in this expression. The difference b<.:twecn 
the original and new estimates of mean alveolar pressure depends upon what the ventilator and airway 
mechanical parameters are set to. When the airway resistance is high (e.g. 120 cmtl20IVscc as secn in 
patients with acute asthma) the difference in estimates can be as much as 50 %. 
7.3.3 Modelling Benefits and Disadvantages of PEEP 
Since FAVeM will be advising changes to PEEP, some attempt needs to be made to model the 
advantages and disadvantages that it can impart upon the patient. The two most significant effects 
of PEEP are known to be: (1) the improvement in arterial oxygenation probably attributable to the 
opening up of collapsed alveoli - this can be modelled by a reduction in the effective shunt; and 
(2) a reduction in cardiac output known as cardiac tamponade. The latter is brought about by a 
reduction in venous return because of an increase in mean right atrial pressure. 
Reduction in Shunt 
The physiological shunt fraction is reduced from its nominal value (Xphys) as PEEP is applied. 
The amount of PEEP required to reduce Xphys to zero is determined by a notional threshold term 
(THpEEP), see equation 7.15. So for example with THpEEP set to 40 cmH20 (3.92 kPa) the 
application of 15 cmH20 (1.47 kPa) of PEEP has the effect of reducing the physiological shunt 
to 25/40 of its nominal value. Any fixed or anatomical shunt (Xjixed) remains unaffected by PEEP. 
( TH
pEEP -PEEP) X elf = X nom • + X fixed 
THpEEP 
(7.15) 
Cardiac Tamponade 
The reduction of cardiac output due to PEEP depends upon the compliance of the lungs. If the 
compliance is low (i.e. stiff lungs) then there is little effect. If they are compliant then cardiac 
pumping is brought virtually to zero at maximum PEEP. Dickinson used the following equation 
to modify the resting cardiac output estimate (this forms part of a more involved formula to 
estimate changes in cardiac output, see equation 7.23); 
P CO AI dill 30- (PEEP x5 x C) EEP JV10 l.!.er=---"----..:... 
30 
(7.16) 
where C is the lumped compliance of the airway and lungs (lIcmH20). In the conscious subject 
compliance is approximately 0.2 litre/cmH20, which with 15 cmH20 of PEEP would reduce the 
resting cardiac output by almost half. 
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This effect will underestimate the disadvantage of PEEP on cardiac output if filling of the right 
atrium is already inadequate and overestimate it if cardiac filling is adequate. Dickinson made 
no attempt to model this influence merely stating; 
"The user of the artificial ventilation option has a choice: either he accepts the empirical 
formulation of the effects of PEEP as a reasonably realistic package correct for average 
conditions; or he fixes PEEP at zero, and uses the manually-changeable controls to make his 
own more appropriate changes in dead space, venous admixture, and cardiac output . .. 
As mentioned in Section 6.6.2, systolic blood pressure (BPSYS) is used as an indicator of 
cardiovascular suppression (i.e. inadequate right atrium filling), and when it is low contra-indicates 
the use of PEEP. Since the model wants to be used for simulated closed-loop control, the application 
of PEEP should produce an increased cardiac tamponade effect when BPsys is low. Conversely, 
adequate filling (as indicated by a good level ofBPsys) should reduce the tamponade effect. 
The problem is further complicated by the fact that arterial blood pressure also declines with 
increasing PEEP in a manner which closely follows the change in cardiac output [Jardin et aI, 
1981]. This further compromises filling, increasing the sensitivity of the tamponade effect to 
further increases in PEEP. The relationship between PEEP and BPsys and their effect on cardiac 
output is the parameter feedback required by FA VeM to stimulate and test the PEEP advisor 
rules. Unfortunately, equations tying together PEEP, cardiac tamponade and arterial blood 
pressure could not be found. 
The solution therefore was to include a sensitivity term (Stamp) within the PEEP modifier expression; 
30-(PEEP x5 x C x Stamp) 
PEEP CO Modifier = -----------!.-
30 
(7.17) 
The user then has the option of modifying the tamponade effect as required. Similarly any further 
reduction in arterial pressure as a consequence of increased PEEP will have to be adjusted 
manually. This wasn't a satisfactory solution but will have to be accepted until a better tamponade 
model can be found. By setting Stamp to 0, the tamponade model is turned off. 
Miscellaneous Effects of PEEP 
Whilst the above effects constitute the primary influences of PEEP, other effects should perhaps 
be mentioned, although they are not modelled here. These include amongst others; 
1). Lung Volume. PEEP increases functional residual capacity (FRC), which in tum 
reduces the airway resistance (R) according to the inverse relationship between lung 
volume and airway resistance as reported by Mead and Agostoni (1964) and Zamel et 
al (1974). This will reduce the calculated PIP although little net increase will be 
observed since PEEP itself raises the inspiratory pressure. 
2). Dead Space. There is indirect evidence that prolonged application of PEEP may cause 
a very large increase in the dead space, probably because of bronchiolar dilation 
[Slavin, 1982]. 
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7.3.4 Cardiac Output & Metabolic Function 
Oxygen Consumption 
In the earlier SOPAVent model cardiac output, O2 consumption and CO2 production were defined 
explicitly by the user. Dickinson used a different approach whereby nominal values were derived 
using simple empirical formulae, which could then be adjusted using modifiers that related to 
other physiological aspects of the patient. So for example the nominal O2 consumption at rest is 
dependent upon patient weight in kg (WT), and is given by [Dickinson, 1977, p122]~ 
V02 REST = 10.33 X WTO.7S (mllmin, STPD) (7.18) 
This is the same formula as used to create a standard-normal patient for ballpark testing of the 
model (see Section 4.4.2). However, patient measurements may indicate a wholly different level 
of O2 consumption. Dickinson dealt with this by adding two modifiers to account for increases 
in patient temperature (leading to increased metabolic activity), and a manual control for 
adjusting metabolic rate (MR). The modified O2 consumption is then represented by the 
following expression [Dickinson, 1977, P 11 0]; 
. . (T -26 )1.05 MR V0 2 = V0 2REST X x-37 -26 100 (ml/min, STPD) (7.19) 
where Tis temperature (0C) andMR is the percentage from normal metabolic activity. Using the 
above two equations the user can specify the patient weight and temperature to derive an 
estimate of O2 consumption. If this value does not match the desired rate of O2 consumption, or 
if the model is being tuned to some observed clinical data, then MR can be reduced or increased 
as required. If the user specifies a target V0 2 thenMR is calculated automatically. 
Carbon Dioxide Production 
The modified O2 consumption can then be used to calculate the CO2 production using the tissue 
respiratory quotient (normally 0.8)~ 
(mllmin, STPD) 
Again if a certain CO2 production is required then RQ can be adjusted accordingly. 
Cardiac Output 
(7.20) 
As with the estimation of O2 consumption, Dickinson gives an expression for the resting cardiac 
output. However this is itself dependent upon the resting O2 consumption; 
QtREST = 0.0195 X V0 2REST (llmin) (7.21) 
If the patient is female then this estimate is reduced by a factor of 0.9. 
The effective cardiac output is influenced by various factors and Dickinson included the effects 
of exercise, temperature, cardiac tamponade and hypoxia in his McPuf model [Dickinson. 1997, 
pl00-l03]. Cardiac tamponade has been dealt with previously (see above). 
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His equation for effective cardiac output was given as; 
Q =(A+~)XCP 
t Y y2 100 (litres/min) (7.22) 
This comprises two primary components; one pertaining to resting cardiac output - modified 
according to temperature and tamponade (AN), and the other to the effects of exercise as 
represented by the difference between the O2 consumption at rest and during exercise (BN2). 
These are additive and can be tuned to give the desired cardiac output using the percentage 
modifier CP. This can be taken to represent 'percentage normal cardiac function' and setting it 
to 200 % will give twice the normal average value for those conditions. 
Tamponade and Temperature Effects 
The modified cardiac output component is given by equation 7.23; 
A = (30 -PEEP x 5 XC)x( T -12.2 )x 1.1904 . Qt REST 
30 37 -12.2 
(7.23) 
where the first bracketed element is the tamponade model as presented in equation 7.16; the 
second element is the effect of body temperature on resting cardiac output; and the additional 
coefficient 1.1904 was not clearly identified in Dickinson's work. 
Exercise E(fect 
The exercise component of equation 7.22 is given by; 
B = ('°2 - V02REST 
100 
(7.24) 
Whilst it may seem unnecessary to include a factor that accounts for exercise, the increase in 
metabolic function and body temperature associated with infection exhibit an increase in O2 
consumption and cardiac output. This can be thought of as increased work and therefore in 
nature very similar to exercise. Relating changes in cardiac output to increased O2 consumption 
in this way enables the changes to apply not only to normal subjects but also to those of 
different age, sex and size. 
Hypoxia Effect 
Both the cardiac component (A) and the O2 consumption component (B) are modified by the 
divisor Y; 
y = max{0.35,Ca02 x 0.0056) (7.25) 
This models the increase in cardiac output when arterial oxygen content falls, up to a realistic 
limit. The effect on the exercise component is smaller as indicated by squaring of the devisor. 
Figure 7.5 shows the effective cardiac output with changing arterial O2 content at various body 
temperatures. 
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Figure 7.5: Effective cardiac output for varying artcrial O2 content and body temperature based 
on a resting cardiac output of 5 IImin. 
It was dccided to omit modelling of the hypoxia effcct since its implcmcntation would be 
problematic. Arterial O2 content is constantly changing in response to ventilator adjustmcnts and 
therefore cardiac output would constantly nced recalculating .The model structure would not easily 
accommodate dynamic cardiac output without large scale rcdesign, although such an improvemcnt 
may well need to be considered in the future. This feature was switched off by setting Y equal to 1. 
7.3.5 Event Profiling 
When constructing patient scenarios there are physiological parameters, which will vary over 
time. For example a patient suffering from pneumonia will initially begin with a high level of 
physiological shunt. Over a period of 24 hours this would reduce as the infcction subsidcs. In 
addition there will be episodes of suddcn shunt improvement, as plugs of consolidatcd sputum 
are removed during physiotherapy. 
These changes are modelled in SOPAVent using a table of parameter events. The initial 
condition of the patient represents the first event, with each subsequent event bcing described by 
the following five term structure; 
[Value, Unit, Condition, Time, Function] 
where; 
Value is the new setting that the parameter will have at the event time. 
Unit is the observation unit for the parameter value (e.g. kPa, cmH20, %, etc) and enables event 
values to be declared in units other than those required by the patient model. A conversion 
program ensures that these event values are in the correct units before commencing simulation. 
Condition is the observation conditions for the parameter value (e.g. STPD, BTPS, etc). Again this 
is because the model requires all parameters to be in BTPS, but events may be declared otherwise. 
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Time is the point in the simulation in minutes at which the event value takes effect. 
Function is the manner in which the new event value is arrived at from the previous one. This 
can be either step or ramp. Step provides discrete level changes and ramp gives a linear increase 
or decrease in the parameter value. 
So considering the pneumonia example given above, the changes in physiological shunt could 
be described by the event profile of Table 7.1, producing the parameter history of Figure 7.6. 
This is converted into a lookup matrix with time values in the first column and parameter values 
in the second column. In our example this would look like; 
o 40 
120 30 
P.PhysShunt = 
120 25 
360 21 
(7.26) 
This matrix is then placed in a SIMULINK block called 'From Workspace' which interpolates 
between rows to derive the physiological shunt value at any given simulation time. Whilst only 
ramp and step functions have been implemented here, it would obviously be possible to extend 
this to include any number of alternative functions, e.g. exponential, random, etc. 
Value Unit Condition Time Function 
40 % nla 0 initial value 
30 % nla 120 ramp 
25 % nJa 120 step 
21 % nJa 360 ramp 
Continued as necessary ... 
Table 7.1: Example of an event profile to describe changes in physiological shunt for a patient 
with pneumonia undergoing physiotherapy. 
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Figure 7.6: Time history of physiological shunt produced using the event profile of Table 7.1. 
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7.3.6 Graphical User Interface 
In order to aid the usability of the patient model a graphical user interface (GUI) was designed 
using the GUI construction modules provided by MATLAB. This front-end to the model enabled 
rapid definition and modification of patient scenarios, as well as access to graphical reports and 
text summaries of simulations performed, see Figure 7.7. 
File SmJote Repotl3 Tools 01Xiom 
Se. 9 Raw 
We/thl Caw 
Height CII Pip 
Age 
Body Te.p. 
C.llliacOIP HC03(ven) 
02 Con • . PCV 
C02 Prod. p50 
Call1iae EfflC. Plasaa 02 
Wet.b_ Rate Hb 02 Binet 
AQ 
Ta.p Senlil. Fi02 
BP S1.lolic Peep 
RR 
Oea~ VI 
~ •• 51)unt Tin 
Fixed Shunl rpause 
Ell. Shunt 35 % 1:£ Ratio 
Poep Thro.h. .60 
Pb 
002 IIIlkp .. /noin A;' 'efIIP 
Oe02 IIIlkP./noin FiC02 
gil 
I1IflIOIJI 
nooIII 
kPa 
IIIl1lkPa 
1.34 illig 
50 
0 
I 101.325 kPa 
J. 20 dege 
I o.~ 
Progress 
• Idle . 
...J 
• Generati-lo SIMULINK pafMletefs. .. 
. 
:I 
... ... c, .;J 
Blood GII.o.1 pH 
P .. 0 2: 9.541 kP.. Pv02: 4.834 kP" 
PIlC02: 8.510 kPII PVC02: 10.911 "PII 
pHlart): 7.019 pH[ven): G.9G1 
S .. 0 2: 8O.~ % Sv02: 37.2 % 
Patient Synopsis 
Figure 7.7: Patient defmition screen used to create and modify patient scenarios. From here 
scenarios can be saved and loaded; simulations run; and reports generated. Links are available 
for closed loop simulation; patient tuning; airway calcu lator and simulation control options. 
7.4 Patient Scenario Development 
In order to test the simulated closed-loop performance of the advisor and hence facilitate rule 
refinement it was necessary to construct scenarios that would represent specific classes of 
patient. The range of possible pathologies, their severity and the nature of any complicating 
factors provide an almost endless number of potential scenarios. However, it was decided to 
limit thjs to five frequently encountered patient groups so that major rule-anomalies could be 
identified and corrected rapidly without the need for exhaustive scenario development. 
The five patient classes modelled were; 
Normal lungs - this describes a post-operative elective ventilation following abdominal 
surgery. The patient's lungs are healthy and there are no major complications to consider. This 
should be the simplest of the scenarios to control. 
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Lobar pneumonia - a long-term infection has weakened the patient and they require ventilatory 
support whilst antibiotics and physiotherapy can be administered. They are hypoxic due to large 
physiological shunts, resulting from the infection. The lungs are stiff with slightly elevated 
airway resistance, leading to raised PIP and a possible risk of barotrauma. Such patients provide 
a good balance of therapeutic needs but are normally fairly straightforward to ventilate. 
Acute asthmatic - an acute episode induced by severe allergy. The predominant feature is high 
flow resistance culminating in dangerously high levels of PIP. The primary challenge here is to 
give adequate ventilation whilst avoiding barotrauma. 
Head injury - this describes a motorcyclist admitted to leu following a road traffic accident 
(RTA). They have received severe head injuries and are unconscious. Apart from the injuries 
sustained they can be thought of as healthy. They are being ventilated to control brain PC02 in 
order to reduce cerebral oedema (brain swelling) and to give good brain oxygenation to reduce the 
risk of possible brain damage. Ventilation is continued until the patient regains consciousness. 
Adult respiratory distress syndrome (ARDS) - the patient has developed lung shock resulting 
from the inhalation of smoke and chemicals. This represents the most difficult scenario since the 
lungs are very stiff, the patient is hypoxic and hypercapnic. It is difficult to provide adequate 
ventilation due to very high inspiratory pressures and excessive FI02 can exacerbate the lung 
shock due to O2 toxicity. The condition improves only very slowly. 
These patient scenarios were developed with the help of a consultant anaesthetist and were 
constructed to be as realistic as possible. The initial conditions and event profiles for each 
patient are given in Appendix C. 
7.4.1 Anaesthetist Decision Histories 
Having developed the patient scenarios, an anaesthetist was then asked to ventilate them, basing 
their decisions upon the current simulated patient state and ventilator settings. The changes that 
they proposed were then entered into the patient model and the simulation continued until the 
next blood-gas sample time (for example 30 minutes or 3 hours) as agreed by the anaesthetist. 
In this way a decision history for each patient was created against which any computer 
generated advice could be compared. Of course these decision histories do not represent a 
definitive solution to the patient ventilation problem and other clinicians may arrive at different 
but equally valid ventilation strategies. However, they do enable glaring errors in the advisor 
rules to be identified and provide a standard against which subsequent advisor versions can be 
judged. 
Throughout this process, the anaesthetist involved felt that the patient model behaved in a 
convincing manner to the ventilator changes made. The simulated anaesthetist's decision 
histories are shown in Figure 7.29 to Figure 7.33 (see pages 187 to 201) and the actual response 
values are given in Appendix D. 
163 
7.5 Closed-Loop Validation & Rule Refinement 
The virtual patient scenarios were then connected to the prototype rules and allowed to run in 
simulated closed-loop control, see Figure 7.8. New advice was generated at the predetermined 
blood-gas sample times that were established by the anaesthetist during their simulated 
ventilation of the virtual patients. At each decision point the advisor produced a report similar to 
that of Figure 7.10, enabling the rule-firing behaviour to be inspected and the causes of decision 
differences to be understood and if possible corrected. 
Patient & Ventilator Observations 
r------..... Anaesthetist's 
Anaesthetist 
Ventilalor Changes 
: Blood-Gas 
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Histories and Patient 
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Figure 7.8: Block diagram showing how the simulated closed-loop behaviour of the advisor and that 
of the anaesthetist were compared. 
The performance of the prototype rules was measured by calculating (i) the mean absolute error 
1 E 1 between the ventilator settings made by the anaesthetist and those made by the advisor; (ii) 
the standard error of this mean aiEl; and (iii) the maximum absolute error 1 E I. The maximum 
error helps to highlight any extreme decision differences that may be dangerous to the patient. 
These three measures were made for each patient individually, as well as across the entire data 
set, enabling patient specific errors to be identified. 
Careful inspection of the anaesthetist's decision histories identified occasions when they prescribed 
new ventilator settings outside of normally expected ranges. These were omitted from the statistical 
analysis, since they caused decision errors inconsistent with the advisor's performance. The 
following points were dropped from the Mv, RR, VI and PaC~ error calculations; 
1). Normal lung patient at 2.5 hours:- the anaesthetist made an Mv change from 5.6 to 
7 litres causing the Paco2 to drop to 4.73 kPa. This change was too large and was 
corrected by the anaesthetist at the next blood-gas sample time. 
2). Acute asthmatic patient at 8.5 hours:- again the anaesthetist increased Mv by too 
much, reducing PaC02 0.62 kPa below the set-point goal. 
3). Head injury patient at 2.5 hours:- again the Mv was increased by too much 
reducing PaC02 0.6 kPa below set-point goal. A decision that was corrected by the 
anaesthetist at the next blood-gas sample time. 
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4). ARDS patient at 26.5 and 34.5 hours:- the Mv reduction caused an increase in the 
level of hypercapnia with only marginal improvement in PIP. Since PIP is already 
reducing and the patient is acidotic the decision appears inconsistent with previous 
behaviour. 
Modifications were made to the advisor rules based upon the errors observed. The ventilator 
controls were considered in tum, starting with the FI02 subsystem. Each patient was dealt with 
separately and modifications were made to the rules in an attempt to reduce I E I, aiEl and I E I 
where possible. The effect of each change on the remaining virtual patients was checked to 
ensure that the modification would not adversely affect their decision performance. Any 
changes that resulted in an overall improvement in decision matching were implemented. Those 
that didn't required either~ 
1). Better separation of the of the observation space via the inclusion of (i) new fuzzy 
classes or (ii) new observation variables. 
2). OR a compromise in the final value of the rule-consequent to minimise the overall 
decision error. 
The performance of the modified rule-base was then assessed and the causes of any remaining 
decision mismatch explored. The I E I, aiEl and I E I of the prototype and modified advisor are 
given in Table 7.2. 
The correlation between the anaesthetist and advisor's decisions was also assessed. This 
required the observation data produced by the anaesthetist during simulated closed-loop 
ventilation, to be applied to the advisor. By using the same observation data a direct comparison 
of decision difference could be made, see Figure 7.9. This was not possible using the data that 
resulted from the advisor's closed-loop ventilation, because the observations were different 
(resulting from slight variations in the decision histories). 
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Figure 7.9: Block diagram showing how the data generated during the anaesthetist's closed-loop 
control was applied to the advisor in order to directly compare ventilator decisions. 
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Rule Versions: 1.2 1.1 2.1 3.1 
Inference Methodology: 
Larsen (Sup-Prod), Prod-Liaison 
Centre of Sums Defuzzification, Ventilator-Quantisation 
F~ Rules Fired 
13 [0.56) IF (Pa0:2 = SLO) AND (F102 = MIN-HI) THEN [dFI~ = P2 (20») 
12 [0.25) IF (Pa0:2 = VLO-SLO) AND (FI02 = VHI) THEN [dFI~ = P1 (10») 
14 [0.19) IF (Pa0:2 = LO) AND (FI~ = MED-HI) THEN [dFI~ = P3 (30») 
PEEP Rules Fired 
38 [0.56) IF (Pa0:2 = SLO) AND (FI~ = MED-HI) AND (PEEP = LOW-MED) THEN [dPEEP = Z (0») 
50 [0.19) IF (Pa0:2 = LO) AND (FI~ = MED-HI) AND (PEEP = LOW) THEN [dPEEP = P1 (2») 
51 [0.19) IF (Pa0:2 = SLO) AND (FI~ = VHI) AND (PEEP = LOW-MED) THEN [dPEEP = P1 (2») 
59 [0.06) IF (Pa0:2 = LO) AND (FI~ = VHI) AND (PEEP = OFF-LOW) THEN [DPEEP = P2 (4») 
Mv Rules Fired 
20 [0.64) IF (ePaC0:2 = PS-PB) AND (epH = VACID-ACID) AND (ePIP = HIGH) THEN [dMv = Z (0») 
10 [0.19) IF (ePaC0:2 = NB-Z) AND (epH = VACID-ACID) AND (ePIP = HIGH) THEN [dMv = N2 (-10») 
19 [0.09) IF (ePaC0:2 = PS) AND (epH = NORM) AND (ePIP = ALARM-HIGH) THEN [dMv = Z (0») 
23 [0.04) IF (ePaC0:2 = PS) AND (epH = VACID-ACID) AND (ePip = ALARM) THEN [dMv = P1 (15») 
11 [0.03) IF (ePac0:2 = Z) AND (epH = NORM-AU<) AND (ePIP = HIGH) THEN [dMv = N2 (-10») 
16 [0.01) IF (ePac0:2 = Z) AND (epH = ACID-NORM) AND (ePIP = OKAY-ALARM) THEN [dMv = Z (0») 
VT Rules Fired 
21 [0.63) IF (RR = MED-VHIGH) AND (eVTnorm = NS) AND (ePIP = HIGH) THEN [dVT = N1 (-5») 
10 [0.28) IF (RR = LOW-MED) AND (eVTnorm = Z) AND (ePIP = HIGH) THEN [dVT = N2 (-10») 
29 [0.04) IF (RR = MED-MAX) AND (eVTnorm = NS) AND (ePIP = ALARM) THEN [eNT = Z (0») 
18 [0.03) IF (RR = VLOW-LOW) AND (eVTnorm = NS) AND (ePIP = ALARM-HIGH) THEN [dVT = N1 (-5») 
19 [0.02) IF (RR = LOW-HIGH) AND (eVTnorm = Z) AND (ePIP = ALARM) THEN [dVT = N1 (-5») 
Advice old ~ change Goals 
FI02 (%) 75.0 94.0 19.0 Paco2 (kPa) 5.3 
PEEP (emH2O) 4.00 5.00 1.00 pH 7.4 
RR (rpm) 14.0 14.5 0.5 
VT (ml) 670.0 640.0 -30.0 
Mv (ml) 9380 9235 -145 
Antecedent Observations Patient Observations Ventilator Observations 
Pao2 8.49 kPa Pao2 8.49 kPa FI02 75.0 % 
FI02 75.0 % Paco2 7.34 kPa PEEP 4.0 em H20 
PEEP 4.0 em H20 pH 7.252 RR 14.0 rpm 
ePaco2 38.6 % PIP 54.7 emH20 VT 670 ml 
epH -0.148 Weight 75.0 kg Normal VT 750 ml 
ePIP 4.7 em H20 
RR1 13.8 rpm 
eVTnorm -10.7 % 
Membership for FI02 Observations 
Pa~ = 8.49 kPa: LO (0.25) SLO(0.75) 
FI02 = 75.0 %: HI (0.75) VHI(0.25) 
Membership for PEEP Control Observations 
Pa~ = 8.49 kPa: LO (0.25) SLO(0.75) 
FI02 = 75.0 %: HI (0.75) VHI(0.25) 
PEEP = 4.0 cmH20: LOW (1) 
Membership for Mv Control Observations 
ePaco2 = 38.56 %: Z (0.23) PS(0.77) 
epH = -0.148 : ACID (0.88) NORM (0.12) 
ePIP = 4.7 cmH20: ALARM (0.06) HIGH (0.94) 
Membership for Vt Control Observations 
RR = 13.8 rpm: LOW (0.05) MED (0.95) 
eVTnorm = -10.7 %: NS(O.7) Z (0.3) 
ePIP = 4.7 cmH20: ALARM (0.06) HIGH (0.94) 
Figure 7.10: Typical report generated by the advisor at each blood-gas sample time during the 
closed-loop validation of the advisor rules. The report includes (i) the rule-base version 
numbers, (ii) the inference methodology and advice quantisation level used, (iii) the subsystem 
rules fired together with their weights (ordered according to significance), (iv) the crisp 
quantised advice, (v) the therapeutic goals, (vi) the patient observations, (vii) the antecedent 
observations and (viii) the antecedent set membership. 
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Normal Lung Lobar Pneumonia Acute Asthmatic Head Injury ARDS Total 
lEI aiEl lEI lEI aiEl lEI lEI aiEl lEI lEI a!EI lEI lEI aiEl lEI lEI aiEl lEI 
Prototype Advisor 
Pa02 (kPa) 3.68 2.22 5.98 1.94 1.56 4.56 5.30 1.25 6.51 5.66 2.43 8.67 1.57 1.03 3.93 2.88 2.21 8.67 
PaC02(kPa) 0.16 0.19 0.44 0.28 0.18 0.50 0.36 0.07 0.43 0.23 0.09 0.31 1.05 0.88 2.98 0.55 0.66 2.98 
pH 0.013 0.016 0.037 0.025 0.018 0.049 0.028 0.005 0.034 0.020 0.007 0.028 0.053 0.037 0.130 0.033 0.029 0.130 I 
PIP (cmH20) 2.29 0.85 3.77 1.79 0.77 3.41 5.22 1.87 7.10 0.93 0.45 1.50 11.50 2.91 15.64 5.68 5.01 15.64 
FI02 (%) 3.80 2.17 5.00 6.10 3.18 10.00 8.75 2.50 10.00 7.80 2.59 10.00 19.00 9.67 30.00 11.05 8.76 30.00 
PEEP (cmH2O) 2.10 0.55 3.00 0.50 0.62 2.00 0.00 0.00 0.00 0.00 0.00 0.00 2.29 1.35 4.00 1.25 1.34 4.00 I 
MY (litres) 0.165 0.173 0.400 0.388 0.365 1.125 0.128 0.063 0.185 0.620 0.068 0.705 1.643 1.217 3.740 0.822 0.983 3.740 
VT(ml) 20.0 21.6 50.0 44.0 15.8 60.0 120.0 50.0 170.0 85.0 35.1 120.0 126.7 59.9 250.0 83.0 58.6 250.0 
RR(rpm) 0.13 0.25 0.50 0.65 0.58 1.50 3.17 1.53 4.50 2.00 0.58 2.50 6.50 3.39 11.00 3.11 3.42 11.00 
TIN (%) nla nla nla nla nla nla nla nla nla nla nla nla nla nla nla nla nla nla 
Modified Advisor 
Pa02 (kPa) 1.40 1.60 4.06 0.59 0.69 2.04 1.66 1.81 3.40 1.07 1.61 3.93 0.47 0.54 1.97 0.83 1.11 4.06 
PaC02 (kPa) 0.27 0.26 0.66 0.08 0.08 0.27 0.12 0.13 0.26 0.12 0.23 0.47 0.16 0.14 0.48 0.14 0.16 0.66 I 
pH 0.022 0.022 0.055 0.007 0.008 0.026 0.009 O.OlD 0.020 0.011 0.020 0.042 0.009 0.008 0.025 0.010 0.012 0.055 i 
PIP (cmH20) 2.00 0.48 2.74 1.40 0.45 2.00 1.13 0.88 2.11 0.35 0.22 0.50 1.67 0.97 3.85 1.41 0.84 3.85 I 
FI02 (%) 1.00 2.24 5.00 2.10 1.45 4.00 2.50 2.89 5.00 1.00 2.24 5.00 6.79 4.15 12.00 3.58 3.84 12.00 ! 
PEEP (cmH2O) 1.70 0.27 2.00 0.15 0.34 1.00 0.38 0.25 0.50 0.20 0.27 0.50 0.89 0.86 3.00 0.66 0.76 3.00 J 
MY (litres) 0.278 0.278 0.675 0.330 0.406 1.200 0.042 0.052 0.100 0.175 0.350 0.700 0.245 0.252 0.820 0.248 0.306 1.200 I 
VT(ml) 17.5 15.0 40.0 15.0 24.2 50.0 30.0 26.5 50.0 0.0 0.0 0.0 26.7 22.2 70.0 19.1 22.0 70.0 ! 
RR(rpm) 0.25 0.29 0.50 0.85 0.67 2.00 1.00 0.87 1.50 0.25 0.50 1.00 1.13 0.96 2.50 0.82 0.80 2.50 
TIN (%) 0.00 0.00 0.00 4.20 3.61 7.00 2.50 5.00 10.00 0.00 0.00 0.00 3.57 4.97 10.00 2.68 4.09 10.00 
--
Table 7.2: Mean absolute error I E I , standard error of estimate 0' lEI and maximum absolute error I E I for the prototype and modified advisors. Values have been calculated 
for each individual patient as well as across the complete data set. Numbers in italic indicate calculations made with anomalous anaesthetist decisions excluded - see text. 
The next sections describe the prototype closed-loop performance of the advisor for each 
ventilator control. Possible causes of any decision mismatch are discussed and the modifications 
made to the rules presented. The modified advisor closed-loop performance is then re-evaluated 
and the causes of any remaining inaccuracies are discussed. Finally the correlation between the 
advisor and anaesthetist decisions is assessed. 
The closed-loop behaviour of the prototype and modified advisor is shown in Figure 7.29 to 
Figure 7.33 (see pages 187 to 201). The Pao2, PaC02, arterial pH, PIP, FI02, PEEP, RR, VT, Mv 
and TIN responses are compared against those produced by the anaesthetist. Tables of the actual 
decision history values are given in Appendix D. Lists of the prototype and modified rules are 
given in Appendix E, together with plots showing how the shape of the decision space was 
modified by the changes made to the control rules. 
7.5.1 FI02 Advisor Performance Analysis 
Prototype Rule Closed-Loop Performance 
It was found that the F102 control rules repeatedly advised bigger changes than the anaesthetist, 
and accepted F102 levels lower than and higher than those tolerated by the anaesthetist. This 
was evident in the normal lung, acute asthmatic and head injury patients where the anaesthetist 
executed more caution when reducing FI02, whereas the advisor rapidly reduced the FI02 to its 
minimum of 30 % (see Figure 7.2ge, Figure 7.3le and Figure 7.32e). Also in the lobar 
pneumonia and ARDS patients the anaesthetist did not increase FI02 above 80 % despite low 
PaOz levels, whereas the advisor continued to make increases up to 90 % in the pneumonia 
patient and 100 % in the ARDS patient (see Figure 7.30e and Figure 7.33e). This explains the 
large overall decision errors observed (IE I = 11.05 %, (J =8.76 %, 1£1 = 30.0 %)1. A 
difference in prescribed FIOz of 30 % as indicated by I £ I , would be unacceptable. 
Rule Modifications 
However, these errors do not indicate poor Pa02 control. In fact, in every scenario the advisor 
maintained a PaOz closer to the normal level of 12 kPa than the clinician. The difference is that the 
clinician is not always attempting to maintain PaOz at this level. They will be constantly revising 
the Pa02 goal based upon the current state of the patient. Three rules-of-thumb were observed; 
1). A margin of safety should be maintained in the Paoz levels when reducing FI02. 
At Oz levels of 40 % or lower a PaOz of approximately 20 kPa was desired. At 60 
% FrOz the PaOz goal was lower at about 15 kPa, since higher FIOz levels should 
be avoided where possible. These safety margins can be lowered if the patient 
exhibits good stability over several hours, since the likelihood of sudden patient 
de-saturation is reduced. 
1 percentage refers to actual FIOz and not percentage error. 
168 
2). Fr02 should not be increased above 80 % due to the toxic effects of high O2 levels. 
Consequently a degree of hypoxia should be tolerated. In the pneumonia patient a 
Pa02 of 10 kPa was tolerable and in the ARDS patient this was slightly lower at 
between 8 and 9 kPa. The lower value in the ARDS patient reflects the fact that the 
lungs are already shocked and further damage may result from the use of high O2 
levels. 
3). FI02 is not normally reduced below 35 %, except when weaning is likely and the 
patient has produced good Pa02 for several hours . 
These new rules required the addition of 4 new Fr02 fuzzy classes at 35, 40, 60 and 80 % 
giving 9 fuzzy classes in all, see Figure 7.12. The linguistic classes very low (VLO), low (LO), 
medium-high (M_ffi) and very high (VID) are new, and the prototype class v:m was renamed as 
extremely high (Effi). The modified rule-map is shown in Figure 7. 1.1. 
FIOl 
MIN VLO LO MED MID ID VHI Em MAX 
VH 0 -5 -5 -10 -20 -20 .,30 -40 -50 
'!''"-
H 0 0 -5 -10 -15 -20 -25 -35 -35 
SH 0 ,I Ib '!' ' !I!' !S i'11 ,!, -10 0' II -10 ;1 1 .. 16 -10 -20 
0 N 0 0 0 0 0 0 0 -5 -5 CIS 
~ 
SL +20 +20 +20 +20 + 15 +10 0 0 0 
L +40 +35 +20 +20 +20 +10 +5 0 0 
VL +70 +65 +50 +50 +40 +30 + 10 +10 0 
Key: D New consequents Modified consequents 
Figure 7.11: Refinements made to FI02 rule-map based upon closed-loop behaviour of the 
prototype rules. 
30 35 40 50 60 70 80 90 100 
0.. 1.0 
:.E 
Vl 
.... 
~ 
G) 0.5 ~ 
'-0 
G) 
"0 
~ 0.0 
20 30 40 50 60 70 80 90 100 
Universe ofDiscource for FI02 (%) 
Figure 7.12: Modified fuzzy set definition for the Fr02 antecedent in the Fr02 advisor sub-system. 
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Modified Rule Closed-Loop Performance 
The FI02 advice for the normal lung patient now matched the anaesthetist's decision history in 
all but the last change (at 5 Yz hours) when the clinician reduced the FI02 from 35 to 30 % (see 
Figure 7.2ge). The anaesthetist did state that such a reduction was not entirely necessary and 
therefore this small difference can be ignored. The mean decision error was small (I E 1 = 1.00 
%, a =2.24 %), and the maximum decision error (I E 1 = 5.0 %) was well within safe limits. 
In the lobar pneumonia patient, the advisor performance improved and closely matched the 
anaesthetist's decisions (I E 1 = 2.10 %, a =1.45 %, 1 E 1 = 4.00 %). Unlike the prototype rules, 
the 80 % maximum F102 prescribed by the anaesthetist was not exceeded (see Figure 7.30e). 
Good decision matching was also observed in the acute asthmatic paticnt ( 1 E 1 = 2.50 %, (J 
=2.89 %, 1 E 1 = 5.00 %) and the head injury patient (I E 1 = 1.00 %, a =2.24 %, 1 E 1 = 5.00 
%), see Figure 7.31e and Figure 7.32e. 
The ARDS patient produced the worst advisor performance ( 1 E 1 = 6.78 %, a = 4.15 %, 1 E 1 = 
12.00 %), although it was considerably better than that produced by the prototype rules, with the 
advisor only marginally exceeded the 80 % FiOz limit. However, the anaesthetist was more 
reluctant to increase F102 beyond 70 % and preferred to reduce it again sooner than the advisor. 
The anaesthetist appears to be waiting to see if the patient condition improves before increasing 
FI02, and the reduction was made as soon as the Pa02 had increased to approximately 10 kPa. 
This reduction in Fr02 cannot be incorporated into the rules without conflicting with the lobar 
pneumonia patient decisions, since at 10 kPa the anaesthetist was still suggesting FI02 
increases. These differences in Fr02 decisions appear to be specific to the ARDS patient and 
would require unique rules to give the decision separation required. 
The overall FI02 decision errors (I E 1 = 3.58 %, (J = 3.84 %, 1 E 1 = 12.00 %) showed an 
improvement of approximately 50 % over the prototype rules. 
Comparison between the prototype and modified FI02 decision space plots (see Figure E.l in 
Appendix E), clearly demonstrates that the rule modification process has altered the fuzzy 
control algorithm, adding small regions of non-linearity. It is also reflected in the increase in the 
number of rules required to describe the rule-map, from 18 to 34. Whether this is significant in 
therapeutic terms is unclear. 
Correlation Analysis 
The correlation between the anaesthetist and advisors' decisions for the prototype and modified 
FI02 rules is shown in the scatter diagrams of Figure 7.13. The observation data used to 
stimulate the advisor rules was the same as that presented to the anaesthetist during their 
simulated patient ventilation. As already indicated in the closed-loop performance analysis, the 
modified FI02 control rules gave improved decision matching (r = 0.891) when compared with 
the prototype rules (r = 0.754). This represents a significant improvement. 
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Figure 7.13: Scatter diagrams of the advisor's FI02 changes plotted against the anaesthetist's 
changes for (a) the prototype rules and (b) the modified prototype rules. 
7.5.2 PEEP Advisor Performance Analysis 
Prototype Rule Closed-Loop Performance 
The prototype PEEP control rules correctly maintained zero PEEP in the acute asthmatic and head 
injury patients since its application was contraindicated. In the acute asthmatic this was because of 
high PIP and in the head injury patient it was to avoid raising the intra-cranial pressure. However, the 
advisor was avoiding increases in PEEP because the oxygenation was good and the FI02 1ow, and not 
for the reasons given above. This was why in the normal lung patient the PEEP was rapidly turned 
off and the advice matching was poor (I E 1 = 2.10 cnll-hO, cr = 0.55 cmH20, 1 E l = 3.00 cmH20). 
The lobar pneumonia patient gave good decision matching ( 1 E 1 = 0.50 cmH20, cr = 0.62 
cmH20, 1 E 1 = 2.00 cmH20). However, the anaesthetist reduced the PEEP sooner than the 
advisor, basing their decision upon an observed F102 of 60 % (moderately high) and a Pa02 of 
20 kPa (a good margin of safety above normal levels), see Figure 7.30a and Figure 7.30f. The 
ARDS patient gave the worst decision matching ( 1 E 1 = 2.29 cmH20, cr = 1.36 cmHzO, 1 E I = 
4.00 cmH20). This was caused predominantly by the poor FI02 advice and hence different 
observation data upon which PEEP decisions were based. 
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Rule Modifications 
Only limited changes were made to the PEEP control rules, see Figure 7.14, since indications 
were that the advisor sub-system needed a complete re-think of its structure. The suitability of 
PEEP appears to be very patient specific as does the length of time it is maintained. As 
mentioned in Section 6.6.2, PEEP is also contraindicated by low BPSYs. This therefore needs to 
be included as an antecedent. None of these factors were implemented due to the lack of 
available time and are considerations for future work (see Chapter 9). 
FIOz 
MIN MED HI VHl MAX 
VH 0 0 0 0 0 
H 0 0 0 0 0 
L! I: , 
N SH 0 rl"2 0 0 0 
0 N 0 +2 0 +4 +4 e= ~ 
SL 0 +4 +4 +4 +4 
L +4 +4 +4 +4 +8 
VL +4 +4 +4 +8 +8 
(a) PEEP = OFF (0 cmH20) 
FIOz 
MIN MED HI VHI MAX 
I 
VH -4 -2 -2 0 0 
H ,.4 -2 l'". -2 , 0 0 
N SH "lI' i "'i:;!il! 'ill'_ I 0 0 0 0 
0 N -2 0 0 0 0 e= 
~ 
SL 0 0 0 0 +4 
L 0 +2 liII :+4 if) , +6 11 
VL +2 +2 iltH) ' I '" !1!" ~jll'i'Ii' I +6 I I"':'~ '''' ' -'!L
' 
(b) PEEP = LOW (4 cmH20) 
Figure 7.14: Refinements made to PEEP rule-maps based upon closed-loop behaviour of the 
prototype rules . Shaded regions indicate modified regions of the rule-map , 
Modified Rule Closed-Loop Performance 
The acute asthmatic and head injury patients now incorrectly included a small increase in PEEP 
of 0.5 cmH20 , see Figure 7.3lf and Figure 7.32f. This is not significant, but does refl ect a 
reduction in performance from that of the prototype rules . This was caused by the modifications 
made to the PEEP rules at Pa02 = N/sH, FI02 = MED and PEEP = OFF (see Figure 7.14a), in an 
attempt to correct the excessive PEEP reductions observed in the normal lung patient. It is clear 
that the maintenance of PEEP for post-operative patients cannot be determined solely from 
observations ofPao2, FI02 and PEEP. Therefore the modifications made will need to be reversed 
and a new observation variable defined determining whether PEEP is advantageous or not. 
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The lobar pneumonia patient now gave better matching than with the prototype rules ( 1 E 1 = 0.15 
cmH20, cr = 0.34 cmH20, 1 E 1 = 1.00 cmH20) as did the ARDS patient ( 1 E 1 = 0.89 cmH20, cr = 
0.86 cmH20, 1 E 1 = 3.00 cmH20), although this was still the worst of the five patients assessed, 
see Figure 7.30f and Figure 7.33f. These differences may well result from the errors generated in 
the FI02 control, since the advisor was being presented with slightly different observation data than 
the anaesthetist. Inspection of decision errors generated when using the same observation data as 
the anaesthetist showed that this was not the case, and the decision matching was worse in the 
ARDS patient (I E 1 = l.03 cmH20, cr = 0.75 cmH20, 1 E 1 = 4.00 cmH20). 
Overall the modified PEEP rules gave only slight improvement (I E 1 = 0.66 cmH20, cr = 0.76 
cmH20, 1 E 1 = 3.00 cmH20) over the prototype rules. 
Correlation Analysis 
The correlation between the advised and anaesthetist's PEEP changes was only average, see Figure 
7.15. There was some improvement from the prototype (r = 0.696) to the modified control rules (r 
= 0.781) but the modified rules still contained occasional large errors (I EI = 4.0 cmH20). This 
was to be expected since as already stated the PEEP rules need significant re-structuring. 
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Figure 7.15: Scatter diagrams of the advisor's PEEP changes plotted against the anaesthetist's 
changes for (a) the prototype rules and (b) the modified prototype rules. 
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7.5.3 Mv Advisor Performance Analysis 
Prototype Rule Closed-Loop Performance 
The normal lung and acute asthmatic patients exhibited good PaC~ maintenance (see Figure 
7.29b and Figure 7.31b) via Mv changes, and the decision matching was good (I E 1 = 0.165 
litres, C1 = 0.173 litres, 1 E 1 = O. 400 ljtres~ and 1 E 1 = 0.128 litres, C1 = 0.063 litres, 1 E 1 = 0.185 
litres respectively). 
The head injury patient regularly gave My decisions lower than that of the anaesthetist (see 
Figure 7.32i), resulting in larger decision differences (I E 1 = 0.620 litres, C1 = 0.068 litres, 1 E 1 
= 0.705 litres). This was caused by smaller My increases, triggered by the presence of mild 
alkalosis. The rules responsible for this behaviour were incorrect, since the normalisation of 
PaC02 is made via adjustments to the ventilation with the causes of any underlying acidosis or 
alkalosis treated separately. The correction of acute metabolic imbalance is sometimes 
necessary but is made through the administration of intravenous therapy and not through 
changes to the ventilation. This is contrary to the initial understanding outlined in Section 6.7.2 
The moderation of My changes observed above was repeated in the lobar pneumonia patient. In 
this case the underlying metabolic acidosis caused the My reductions to be smaller than those 
made by the anaesthetist (I E 1 = 0.388 litres, C1 = 0.365 litres, 1 E 1 = l.125 litres). The rules 
were attempting to balance pH and Paco2 around normal values, resulting in normal pH with 
mild hypocapnia. This was clearly not the approach taken by the anaesthetist. They attempted to 
normalise PaC02 using changes in ventilation and letting the metabolic acidosis reduce as the 
infection subsided (treated via antibiotics). 
My decision matching in the ARDS patient was extremely poor (I E 1 = 1.643 litres, C1 = 1.217 
litres, 1 E 1 = 3.740 litres) and was triggered by a combination of factors. The advisor continued 
to reduce My down to below 6 litres in response to the dangerously high levels of PIP being 
generated, see Figure 7.33i and Figure 7.33d. The anaesthetist was achieving much better PIP 
levels and therefore could tolerate higher My settings. 
The elevated PIP produced by the closed-loop behaviour of the advisor was caused by (i) the 
absence of TIN control rules and (ii) the reluctance of the VI -RR rules to reduce VI below 
500 ml (or eVINORM of -30 %). The anaesthetist used a TIN of60 % and VI of 425 ml to keep 
PIP as low as possible and then tolerated permissive hypercapnia. 
Rule Modifications 
There were four major changes made to the My control rules; 
1). The removal of epH as an observation variable since the normalisation of PaC~ appears 
to be the primary maintenance consideration when making changes to ventilation. 
2). The replacement of ePIP, with direct observations of PIP, since the anaesthetist was 
shown to alter the PIP goal as the patient condition changed. The specification of a 
unique PIP alarm led to poor PaCo2 and PIP maintenance. The new fuzzy set 
definition for PIP is shown in Figure 7.16. 
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3). The addition of eVrNORM as an antecedent (Figure 7.17), allowing permissive 
hypercapnia in patients that have low Vr caused by high PIP. This was needed 
because the VT-RR rules would not reduce VT below -45 % of VTNORM and 
therefore any prescribed increase to Mv would cause an inappropriate increase in 
RR. Such behaviour was prevented by reducing the Mv consequents (or setting 
them to zero) when the following observation criteria were met (i) PIP was greater 
than 40 cmH20, (ii) the patient was hypercapnic and (iii) eVrNORM was bclow -35 
%. By defining the peak of eVTNORM = OKAY to be -15 % the use of permissive 
hypercapnia is restricted to those patients with poor respiratory mechanics (and 
consequently high PIP), since only these patients will normally have Vr this low. 
4). The inclusion of three new fuzzy sets at -15 0/0, +15 % and +30 % in the ePaC02 
universe, as well as redefining the peak values of the +50 % and + I 00 % to be +60 
% and +90 % respectively, see Figure 7.18. The set names have been altered to 
accommodate these changes. The new sets NS and PS (±I5 %) were included to 
improve control near to the PaC02 set point. These changes were necessary to 
better describe the Mv decisions made. 
The Mv modifications were made at the same time as the Vr-RR rules and after the inclusion of 
the simple TIN controller (see Section 7.5.5). The consequents were then handcrafted to give the 
best apparent decision matching across the virtual patient scenarios, see Figure 7.19. 
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Figure 7.16: New fuzzy set definition for PIP, replacing ePIP. 
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Figure 7.17: Fuzzy set definition for new antecedent eVrNORM in Mv advisor. 
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-60 -30 -15 o +15 +30 +60 +90 
-75 -50 -25 o 25 50 75 100 
Universe ofDiscource for ePa CO2 (%) 
Figure 7 .18: Modified fuzzy set definition for ePaC02. 
PIP 
LOW MED m VHI Em 
PVB +90 +30 +25 +10 +5 
PB +60 +30 +25 +10 -10 
PM +30 +15 +15 +5 -15 
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Figure 7.19: New rule maps for the modified Mvadvisor. Shade regions indicate the changes 
required, to facilitate permissive hypercapnia when Vr is already low. 
Modified Rule Closed-Loop Performance 
The greatest improvement was made in the ARDS patient ( I E 1 = 0.245 litres, 0' = 0.252 Jitres, 1 E 1 = 
0.820 Jitres), with a perfonnance now better than that observed in the pneumonia patient. The pneumonia 
patient showed a slight improvement in Mv decision matching (I E 1 = 0.330 litres, 0' = 0.406 litres, 
1 E 1 = 1.20 litres) with excellent matching ofPacOz ( I E 1 = 0.08 kPa, 0' = 0.08 kPa, 1 E 1 = 0.27 kPa). 
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The head injury patient no longer underestimated the required My and gave good decision matching 
(I E 1 = 0.175 litres, 0' = 0.350 litres, 1 E 1 = 0.70 litres). However, the advisor did overestimate the 
initial My change with the anaesthetist arriving closer to the PaC~ goal of 4.5 kPa, 
see Figure 7.32b. This suggests that the consequents around ePaC~ = NS and NM might need 
making a little less negative. 
The already good decision matching in the asthmatic patient was improved (I E 1 = 0.042 litres, 
0' = 0.052Iitres, lEI = 0.10 litres), but the normal lung patient gave marginally worse matching 
(I E 1 = 0.278 litres, 0' = 0.278 litres, lEI = 0.675 litres). However, inspections of the closed-
loop PaC02 behaviour (see Figure 7.29b) shows less overshoot and undershoot of the PaC02 goal 
than produced by the anaesthetist. 
Correlation Analysis 
The prototype rules only gave moderate My decision correlation (r = 0.710). This was due 
mainly to the poor ARDS decision matching. The modified My rules gave significantly bcttcr 
correlation (r = 0.937), with the best performance of all the ventilator controls, see Figure 7.20. 
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7.5.4 RR-VT Advisor Performance Analysis 
Prototype Rule Closed-Loop Performance 
The dependence of RR and VT upon the advised Mv means that poor decision in the later will be 
reflected in the VT and/or RR decisions. Consequently in the ARDS patient the large decision 
errors (VT: I E I = 126.7 ml, (J = 59.9 ml, I E I = 250.0 ml; RR: I E I = 6.50 rpm, (J = 3.39 rpm, 
I E I = 11.0 rpm) are to be expected, since the Mv errors were large (see Figure 7.33g and Figure 
7.33h). The situation is made worse by the fact that the VT-RR rules only allow a maximum 
reduction in VT of -30 %, whereas the anaesthetist reduces it by nearly 45 % ofVTNORM. 
In the normal lung patient the Mv decision matching was good and this is reflected in the small 
VT and RR decision errors (VT: I E I = 20.0 ml, (J = 2l.6 ml, I it I = 50.0 ml; RR: I E I = 0.13 
rpm, (J = 0.25 rpm, I E I = 0.50 rpm). There was a tendency for the advisor to increase VT in 
preference to RR, even though RR was on the low side (8 to 8.5 rpm). This preferential increase 
in VT was repeated in the asthmatic, head injury and pneumonia patients. The anaesthetist was 
more inclined to adjust RR in the range 8-14 rpm than to make changes to VT. 
Rule Modifications 
The following changes were made to the VT-RR rules giving the VT-RR rule maps of Figure 7.22; 
1). The fuzzy class PVB (+60 %) was dropped from the eVTNORM universe, since tidal 
volumes this high are seldom required. An eVTNORM of +30 % gives a VT of 975 
ml on a 75-kg patient, which should be more than adequate. 
2). The inclusion of eVTNORM = NB (-45 %), because a greater reduction in VT was required 
than provided by the prototype rules. Also, inclusion of eVTNORM = NS (+ 15 %) to give 
better control near to normal VT. These modifications are shown in Figure 7.21. 
3). The calculation of VTNORM was restricted to a maximum of 750 ml, since in the 
head injury patient VT was incorrectly increased towards a VTNORM of 850 ml. 
What constitutes a normal VT appears to change from the 10 ml/kg rule of thumb 
as the patient size and weight increases. 
4). The fuzzy variable ePIP was replaced by PIP as in the Mv rules. The same 
membership functions were used as given in Figure 7.16. 
5). A broadening of the region that represents normal VT and RR settings when no 
change is required. This is a region defined by RR = 8 to 14 rpm, eVTNORM = -15 
to 0 % and PIP is LOW (20 cmH20). This is better explained by comparing the 
decision behaviour of the prototype and modified VT-RR rules, see Figure 7.23. It 
can be seen that the decision behaviour is much more relaxed than the optimal VT-
RR settings proposed by the prototype rules. However, they do still roughly follow 
the ideal VT -RR relationship. 
6). A greater reduction in VT with increased PIP. This helps to improve the PIP 
maintenance by using smaller volumes to inflate the lungs. 
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Figure 7.2 1: Modified fuzzy set definition for eVTNORM in VT-RR advisor subsystem. 
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Figure 7.22: Modified rule maps for the VI-RR advisor. 
Modified Rule Closed-Loop Performance 
The normal lung patient showed a small improvement in VI decision matching (I E 1 = 17.5 ml, 
cr = 15 .0 ml, 1 E 1 = 40.0 ml), with the tendency to increase VI later in the simulation removed. 
The RR matching was slightly worse than with the prototype rules (I E 1 = 0.25 rpm, cr = 0.29 
rpm, 1 E 1 = 0.50 rpm) but the error was still only small. 
The pneumonia patient had improved VT matching ( I E 1 = 15.0 ml, cr = 24.2 ml, 1 E 1 = 50.0 
ml) although the advisor did not reduce VI at 12 Yz hours as the anaesthetist did, 
see Figure 7.30g. This decision by the anaesthetist appears unnecessary since the PIP had 
already reduced to 20 cmH20 and the RR was almost normal (16 rpm). The advisor' s decisions 
can therefore be considered safe. The RR matching was only slightly worse (I E 1 = 0.85 rpm, cr 
= 0.67 rpm, 1 E 1 = 2.00 rpm) and the differences were still small. 
The asthmatic patient gave significantly improved decision matching in both VI and RR 
(VT: 1 E 1 = 30.0 ml, cr = 26.5 ml, 1 E 1 = 50.0 ml; RR: 1 E 1 = 1.00 rpm, cr = 0.87 rpm, 1 E 1 = 
1.50 rpm) although the anaesthetist preferred to opt for slightly lower VI (by about 50 ml) and 
higher RR (by about 2 rpm). However, the PaC~ and PIP maintenance achieved was very good 
(see Figure 7.3 1b and Figure 7.31d) . 
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Figure 7.23: The decision behaviour of (a) the modified and (b) the prototype VT-RR rules 
when PIP is low (i.e. not affecting VT changes). The graphs were generated by applying every 
combination of eVTNORM in the range -45 to +45 % (in 2.5 % steps) and RR observations in the 
range 6 to 24 rpm (in 1 rpm steps) to the VT-RR advisor subsystem. The advised VT change was 
then used to calculate the new RR and VT (expressed as eVTNO~ values. 
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Figure 7.24: Scatter diagrams of the 
advisor's VI and RR changes plotted 
against the anaesthetist's changes for 
(a) the prototype rules and (b) the 
modified prototype rules. 
The head injury patient exhibited exact VI matching and excellent RR matching (I E I = 0.25 
rpm, cr = 0.50 rpm, I E I = 1.00 rpm). The ARDS patient exhibited greatly improved VI and RR 
matching (VT: I E I = 26.7 ml, cr = 22.2 ml, I E I = 70.0 ml; RR: I E I = 1.13 rpm, a = 0.96 
rpm, I E I = 2.50 rpm), although the anaesthetist was more cautious than the advisor when 
increasing VI and reducing RR in the later stages of the closed-loop simulation (see Figure 
7.33g and Figure 7.33h). 
Correlation Analysis 
Both the VI and RR decisions showed significant improvements in correlation from the 
prototype to the modified rules. For VI this was an improvement from r = 0.542 to r= 0.884, 
and for RR, an improvement from r = 0.688 to r= 0.889, see Figure 7.24. 
7.5.5 TIN Advisor Performance Analysis 
As mentioned in the assessment of the Mv advisor performance some of the differences in Mv 
decisions were attributable to the lack of control rules for TIN. The anaesthetist would increase 
the I:E ratio (by increasing TIN) in patients with high PIP in an attempt to lower airway pressure 
and reduce the risk of barotrauma. A very simple set of rules was constructed to emulate this 
aspect of PIP maintenance, see Figure 7.27. The antecedents for this advisor were PIP (see 
Figure 7.26) and the current level of TIN (see Figure 7.25). 
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Figure 7.25: Prototype fuzzy set definition for TIN in the TIN controller. 
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Figure 7.26: Prototype fuzzy set definition for PIP in the TIN controller. 
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Tin 
NRM MED HI MAX 
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Figure 7.27: Prototype rule map for the TIN advisor subsystem. 
The advice generated was quanti sed at 10 % intervals, producing a winner-takes-all 
defuzzification strategy, avoiding intermediate settings. 
Modified Rules Closed-Loop Performance 
TIN was correctly maintained at 33 % in the normal lung and head injury patients, giving perfect 
decision matching. In the lobar pneumonia patient the advisor incorrectly prescribed an increase in 
TIN to 40 %, whereas the anaesthetist maintained a TIN of 33 %. This explains the large decision 
errors calculated (I E 1 = 4.20 %, (J = 3.61 %, 1 E 1 = 7.00 %)2. It is a simple matter to resolve this 
by changing the consequent of the rule 'If PIP =HI and TIN = NRM'fromPS (10 %) to Z (0 %). 
The asthmatic patient saw a correct increase in TIN to 50 % at the start of the simulation, but 
reduced it back to 40 % at 8.5 hours, whereas the anaesthetist maintained it at 50%. This may be 
an oversight on the part of the anaesthetist since the PIP has reduced below 20 cmH20. Similarly 
with the ARDS patient the advisor matched the TIN increases but made reductions sooner than 
the anaesthetist. This can be corrected by increasing the consequent of the rule 
'lfPIP = HI and TIN =M4X' from NS (-10 %) to Z (0 %). 
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Correlation Analysis 
The correlation between the advisor and anaesthetist's TIN changes was not striking (r = 0.653), 
see Figure 7.28. However, the correlation test is not entirely suitable, since a large proportion of 
the changes are zero which skews the results produced by the correlation coefficient formula. 
7.6 Summary & Conclusions 
Inadequacies in the patient model were identified and the improvements required were 
successfully implemented. The resulting model was then used to construct virtual patient 
scenarios that exhibited physiological behaviour similar to that observed in real patients. It was 
possible to model a wide range of physiological disturbances using event profiling to control 
model parameters such as shunt, airway resistance, etc. 
Five patient scenarios were constructed (via discussion with an anaesthetist) representing 
patients with normal lungs, lobar pneumonia, acute asthma, head injury and ARDS. These 
facilitated simulated closed-loop validation of the advisor, and comparison with the 
anaesthetist's decision behaviour. This enabled rapid identification of possible rule errors and 
the subsequent assessment of the effectiveness of any modifications made. The virtual patient 
scenarios had the advantage over real clinical data of being rcpeatable and free from 
measurement errors. The true flexibility of using a model to test the advisor is that even 
measurement errors can be incorporated if so desired. The behaviour of the virtual patients to 
changes in the ventilation regime was deemed realistic by the anaesthetist. 
Overall, the modified advisor exhibited significant improvement in decision matching and in 
closed-loop control, when compared with the prototype advisor. This was particularly evident 
for the FI02, MV, VT and RR sub-systems. 
The F102 rules only required modification to the size of some of the rule-consequents, in order 
to match the more conservative approach to F102 changes made by the anaesthetist. F102 
decision matching using the modified advisor was good (r = 0.891), with the only noticeable 
exception occurring in the ARDS patient. In this scenario the anaesthetist was reluctant to 
increase F102 above 70 % due to the increased risk of O2 toxicity. Such behaviour could not be 
incorporated into the rules without compromising the decisions required by the other scenarios. 
Therefore the controller's behaviour needs to be modified according to the type of pathology or 
trauma presented. 
The Mv rules were modified quite radically, with the removal of pH as an observation variable 
(although it will be seen in the next chapter that this needs to be reversed). In addition, PIP no 
longer required an upper alarm threshold and was instead handled by the advisor directly as PIP 
rather than ePIP (i.e. distance from alarm). This reflected the trade-off by the anaesthetist 
between acceptable PIP and desired PacQz. The final MV modification was the addition of 
e VT NORM as a rule-antecedent. This was included to prevent Mv increases, in patients requiring 
permissive hypercapnia due to high PIP, and consequently with low prescribed VT. 
The Mv rules were shown to give better Paco2 maintenance than the anaesthetist in the 
pneumonia and normal lung patients, and overall the level of decision matching was excellent 
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(r= 0.937). The improvements in the Mv performance were also influenced by changes made to 
the RR-VT rules and the inclusion of TIN control rules. 
The TIN advisor helped to reduce the problems associated with high PIP and its affect on the Mv 
and RR-VT rules. However, this was only a crude first attempt to define the TIN rules and gave 
only moderate decision matching (r = 0.653). This was due predominantly to the advisor's 
tendency to increase TIN sooner than the anaesthetist, and keep it at an elevated level for longer. 
Modifications required to the RR-VT rules included the limiting of VTNORM to a maximum of 
750 ml to prevent excessive VT and the addition of lower acceptable VT. The representation of 
PIP was also changed as per the Mv rules. Overall the changes made to the rule-consequents and 
set membership produced a broadening in the range of RR and VT values that were deemed 
normal, and therefore not requiring adjustment. The decision matching was good for both RR 
and VT (r= 0.889 and r = 0.884 respectively). 
The PEEP control rules behaved less convincingly, with only a moderate level of decision 
matching (r= 0.781). The advisor did not contain knowledge pertaining to the prophylactic use 
of PEEP in post-operative patients with healthy lungs, and therefore when presented with low 
F102 and normal Pa02 did not prescribe PEEP (or reduced any currently applied). Attempts to 
modify the rule-consequents to prevent this only resulted in the inappropriate application of 
PEEP in the asthmatic and head injury patients. It will therefore be necessary to incorporate rules 
that determine the suitability of PEEP and modify any changes accordingly. 
The closed-loop behaviour of the modified advisor is promising. However, the patients used to 
test it only represent a sub-set of the possible scenarios that can be encountered and 
consequently only a small percentage of the rules were tested. This has important safety 
implications and is best resolved by the construction of patient scenarios, which further explore 
the advisor's behaviour especially at the physiological extremes. 
Whilst simulated closed-loop validation is a good methodology for rule testing, and provides 
rapid insights into patient-advisor interaction, the advisor must also demonstrate good decision 
matching using real patient data. The validation of the advisor using clinical data is presented in 
the next chapter. 
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Figure 7.29 (normal lung) continues overleaf ... 
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Figure 7.29: Comparison of anaesthetist, prototype advisor and refined advisor decision 
histories for the Normal Lung patient scenario. Patient responses are shown for (a) Pa02, 
(b) PaC~, (c) arterial pH and (c) PIP. Ventilator changes are shown for (e) Fr02, (f) PEEP, 
(g) VT, (h) RR. (i) Mvand (j) TIN. 
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Figure 7.30 (lobar pneumonia) continues overleaf. .. 
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Figure 7.30: Comparison of anaesthetist, prototype advisor and refined advisor decision 
histories for the Lobar Pneumonia patient scenario. Patient responses are shown for (a) Pa02, 
(b) PaC{)z, (c) arterial pH and (c) PIP. Ventilator changes are shown for (e) FI02, (f) PEEP, 
(g) VT, (h) RR, (i) Mvand G) TIN. 
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Figure 7.31 (acute asthmatic) continues overleaf ... 
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Figure 7.31: Comparison of anaesthetist, prototype advisor and refined advisor decision 
histories for the Acute Asthmatic patient scenario. Patient responses are shown for (a) Pa02, 
(b) PaC02, (c) arterial pH and (c) PIP. Ventilator changes are shown for (e) FI02, (t) PEEP, 
(g) VT, (h) RR, (i) Mv and G) TIN. 
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Figure 7.32: Comparison of anaesthetist, prototype advisor and refined advisor decision 
histories for the Head Injury patient scenario. Patient responses are shown for (a) Pa02, 
(b) PaC02, (c) arterial pH and (c) PIP. Ventilator changes are shown for (e) FI02, (f) PEEP, 
(g) VT, (h) RR, (i) Mv and G) TIN. 
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Figure 7.33: Comparison of anaesthetist, prototype advisor and refined advisor decision 
histories for the ARDS patient scenario. Patient responses are shown for (a) Pa02. (b) Pac~. 
(c) arterial pH and (c) PIP. Ventilator changes are shown for (e) FI02, (t) PEEP, (g) VT, (h) RR, 
(i) Mv and (j) TIN. 
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Chapter 8: Clinical Validation of Advisor 
8.1 Introduction 
The simulated closed-loop behaviour of the modified advisor was shown to give improved 
decision matching over the prototype rules, and in the majority of cases gave good patient 
maintenance. However, this was only based upon a sub-set of the possible patient scenarios. It 
remains to be seen whether the advisor can match decisions made by an anaesthetist using real 
patient data. 
This chapter describes the clinical validation of the advisor using data collected during routine 
care in ICU. The validation procedure is presented first (see Section 8.2), followed by a 
synopsis of the data collected (see Section 8.3). This data was then applied to the advisor and 
the error between the anaesthetists' decisions and the advised decisions was analysed 
quantitatively using statistical techniques (see Section 8.4) and qualitatively using linguistic 
scoring (see Section 8.5). The reasons for any decision mismatch observed are then discussed 
(see Section 8.6). 
8.2 Procedure 
Ideally clinical validation would be done in an alongside advisory capaeity, with the anaesthetist 
explaining the reasons for each and every change they make, and then commenting on the advice 
given by FA VeM. However such an exercise would be very time consuming and perhaps not 
justifiable with the advisor still in its infancy. 
Instead data were collected over a 3-week period at the Hull Royal Infirmary ICU, with only 
patients on volume control (VC) or pressure regulated volume control (PRVC) being recorded. 
The attending anaesthetists were asked to explain their reasons for the care given and specify 
patient goals. All available details were recorded for the suitable patients, including admission 
details, therapeutic objectives, blood-gases, ventilator changes, drugs administered, 
investigations undertaken and any care events (such as physiotherapy, suctioning, turning, etc). 
Whilst this amount of information was not required by the advisor, it was felt that it may prove 
useful in identifying the causes of any decision mismatch observed. 
The ventilator/patient observations and PaCo2 goal required by the advisor were extracted from 
this data, and the changes advised were then compared with those made by the anaesthetist, see 
Appendix F. The decision differences were assessed using statistical and qualitative analysis. 
In order to provide a yardstick against which the clinical performance could be measured, the 
statistical and qualitative analysis was also performed on the closed-loop advisor responses, see 
Figure 8.1. These were the ventilator changes prescribed by the advisor in response to the 
observations generated by the anaesthetist during their simulated maintenance of the virtual 
patients (this is the same data used in the correlation analysis of the advisor's closed-loop 
performance, see Section 7.5). The possible causes of decision mismatch using the clinical data 
are then discussed. 
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Figure 8.1: Block diagram showing the comparison made between the decision performance of 
the advisor based on data collected in ICU, and using the data generated by the anaesthetist 
when performing simulated closed-loop of the virtual patients (yardstick performance). Ideally 
the clinical performance should be similar to the simulated performance. 
8.3 Synopsis of Collected Data 
Eleven patients were recorded in total. Ten of these were during the 3-week period at HRI and the 
eleventh was recorded at Castle Hill Hospital ICU. A brief description of each patient follows, 
with an indication of the number of usable blood-gas observation and ventilator changes made. 
Patient 1: A 58-year-old, male smoker with known COPD (chronic obstructive pulmonary 
disease) and emphysema electively ventilated following an aorto bi-femoral graft. He required 
warm-up and fluid support and was placed on PRVC mode of ventilation. This constituted a 
fairly straightforward ventilation problem with no major lung complications. However, they 
were haemodynamically challenged. The patient was eventually weaned from the ventilator 
after a brief spell on pressure support (PS) mode of ventilation. 6 sets of observation data; 6 
ventilator changes (2 FIO]. 2 Mv, 2 VT) 
Patient 2: A 27-year-old male admitted to ICU following a motorcycle accident. He had sustained 
multiple head, chest and limb injuries and was intubated at the scene. The head had massive 
contusions (swelling) and the pupils were fixed. The chest was bleeding with broken ribs and a 
pneumothorax (for which 2 chest drains were inserted). He was placed on VC mode of ventilation. 
The head injury and chest damage were the primary considerations, together with oxygen 
management. The head injury required good ventilation in order to reduce PaC02 and help 
minimise inter-cranial pressure. However the presence of the pneumothorax complicated matters. 
The performance of the lung fluctuated depending upon the effectiveness of the drain and also the 
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amount of air that was being directed into usable lung space. The use of too much ventilation just 
blew the pneumothorax open. The lungs were also filling due to internal bleeding. Consequently 
the shunt fraction was increasing, requiring constant suctioning. After suctioning the lung function 
would improve allowing the FI02 to be maintained or reduced as appropriate. Data collection was 
stopped when the patient was transferred onto high-frequency jet ventilation (HFJV). 39 sets of 
observation data; 48 ventilator changes (18 FI02, 3 PEEP, 8 Mv, 2 RR, 7 VT) 
Patient 3: A 57-year-old female with COPD, admitted with ventilatory failure after a chest 
infection. She had also incurred a superior lateral myocardial infarction. Her blood pressure was 
very low and she had an elevated heart rate (120 b.p.m.). She had probably had a central vascular 
stroke. Both the heart and lungs were deficient. The lungs were stiff due to COPD and therefore 
provide a challenge in terms of PIP. She was ventilated using PRVC mode of ventilation. 
Treatment was eventually withdrawn and the patient died. 25 sets of observation data; 12 
ventilator changes (5 FI02, 1 PEEP, 2 Mv, 2 RR, 2 VT) 
Patient 4: A 28-year-old male admitted following a pedestrian road traffic accident, with possible 
drugs/drink involvement. He had sustained multiple head injuries and a chest drain was inserted 
since there was a high risk of pneumothorax. He had no hyperventilation response, and a fixed 
dilated pupil response, the prognosis was poor. He was ventilated using VC mode of ventilation. 
Treatment was eventually withdrawn and the patient died. 13 sets of observation data; 13 
ventilator changes (3 FI02, 4 Mv, 3 RR, 3 VT) 
Patient 5: A 74-year-old female with post-ventricular failure, having arrested at home. Her lung 
condition was good, and she was ventilated using VC mode of ventilation. The patient's 
progress was poor and she became acutely acidotic with Sa02 below 95 %. The relatives agreed 
to withdraw treatment and the patient died. 12 sets of observation data; 13 ventilator changes (4 
FI02, 1 PEEP, 2 MV, 2 RR, 4 VT) 
Patient 6: A 71-year-old female with sepsis in the lung or abdominal region, occurring after 
surgery. The patient was beginning to show evidence of ARDS, with general stiffening of the 
lungs as exhibited by elevated PIP levels. Patient was initially ventilated using VC, which was 
later changed to PRVC. She made steady improvement and were weaned after 3-days. 12 sets of 
observation data; 14 ventilator changes (8 FI02, 3 Mv, 3 RR) 
Patient 7: A 76-year-old male with complications, following hindquarter amputation. This 
amputation was required, after surgery to remove an aneurysm resulted in vascular failure. The 
patient had become slightly sceptic with bilateral chest consolidation. They were ventilated using 
PRVC mode of ventilation. His condition became progressively worse with increased shunt and 
reduced Pa02. The patient died after 10-days of treatment. However only the first two days were 
recorded. 8 sets of observation data; 13 ventilator changes (4 FI02, 2 PEEP, 2 Mv, 2 RR, 1 VT) 
Patient 8: A 71-year-old female requiring ventilation after an operation to repair a perforated 
bowel. Only one ventilator change was usable since the patient soon began triggering breaths 
for themselves. The patient was eventually weaned from ventilator. 1 set of observation data;1 
ventilator change (1 FIOJ.J 
204 
Patient 9: A 59-year-old male being ventilated post-operatively, following a right carotid 
endarterectomy. Patient had a mild stroke during surgery and periods of bradycardia « 40 
b.p.m). They had a myocardial infarction 3-years ago and a history of hypertension. His lungs 
were healthy and he was ventilated initially using VC mode of ventilation then switched to PS 
(pressure support). The patient was weaned after over night observation. 3 sets of observation 
data; 2 ventilator changes (2 FIOJoJ 
Patient 10: A 48-year-old female heavy smoker with hypertension, admitted after arrest at 
home. Lungs stiff requiring PRVC mode of ventilation. Cardio function was initially unstable 
and the patient arrested at the first attempt to wean. Patient successfully weaned after cardiac 
function stabilised. 5 sets of observation data; 3 ventilator changes (1 FI02, 1 Mv, 1 VT) 
Patient 11: A previously healthy 75-year-old male admitted from theatre, following an elective 
aortic aneurysm repair. Initially ventilated using VC, then switched to PC (pressure control). 
Patient was mildly acidotic, with moderate lung stiffness. 2 sets of observation data; 4 
ventilator changes (2 Mv, 2 RR) 
8.4 Statistical Performance Analysis 
The mean error (E ), standard error (a lEI)' mean absolute error (I E I), maximum error (I E I ) 
and correlation coefficient (r) between the changes made by the anaesthetist and those proposed 
by the advisor, were calculated for each ventilator control. The results of this analysis are shown 
in Table 8.1, and was repeated using the simulated closed-loop data, to provide a measure against 
which the clinical performance could be compared, see Table 8.2. A value for the TIN correlation 
coefficient using the clinical data is not given since no changes were made by the anaesthetist, 
causing the sum of the squared deviations to be zero and hence the result of the correlation 
formula to be 00. It should also be noted that in 25 cases the TIN was not recorded and therefore 
no TIN advice could be generated in these instances. 
It is clear from this analysis that the advisor's ability to match the anaesthetist's decisions was 
measurably worse than observed using the closed-loop data. This is not unexpected since the 
virtual patients are well behaved and not subject to the measurement errors that occur in the real 
ICU setting. 
The best performance was observed in the FI02 decisions, with a correlation of r = 0.751. 
However, I E I was almost twice that observed using the closed-loop data and I E I of 21 % was 
unacceptably large. 
In addition to the increased absolute mean and standard deviation of the errors, there was also a 
bias observed in the VT and RR decisions. The advisor was tending to prescribe lower VT and 
higher RR than the anaesthetist did. This is confirmed if we compare the frequency distribution 
of the decision errors produced using the clinical and closed-loop data, see Figure 8.2. In some 
cases this was caused by therapeutic considerations outside of the advisor's knowledge. In 
others it appears to be simply a question of different treatment styles, see Section 8.6. 
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Control - lEI lEI E (jff r 
F10l (%) -0.75 6.37 4.37 21.00 0.751 
PEEP (cmH1O) -0.40 l.93 l.44 7.00 0.176 
Mv (11m in) -0.23 1.58 1.13 5.40 0.430 
RR(rpm) 1.04 1.82 1.70 6.00 0.276 
VT (ml) -77.0 69.9 85.9 270.0 0.258 
TIN (%) 4.72 4.07 4.72 15.00 
-
Table 8.1: Statistical analysis of decision errors between actual ventilator changes and those 
proposed by the advisor using the clinical data. 
Control - lEI lEI E (jI! r 
FIOl (%) 0.89 3.97 2.37 10.00 0.891 
PEEP (cmH1O) -0.24 0.95 0.55 4.00 0.781 
Mv (llmin) -0.10 0.48 0.34 1.37 0.909 
RR(rpm) -0.43 1.07 0.80 2.50 0.860 
VT (ml) 8.68 25.00 15.26 70.00 0.891 
TIN(%) -0.76 4.72 2.39 10.00 0.653 
Table 8.2: Statistical analysis of decision errors between actual ventilator changes and those 
proposed by the advisor, using the simulated closed-loop data (see Figure 8.1 for clarification 
of the difference between clinical and simulated closed-loop data). 
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Figure 8.2: Frequency distribution of the decision errors for (a) tidal volume and (b) respiratory 
rate between the actual and advised changes using the clinical data (grey bars) and simulated 
closed-loop data (black line). 
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8.5 Qualitative Performance Analysis 
Whilst the statistical analysis gives us a measure of the relative performance of the advisor, it 
does not indicate what number of the decisions match the anaesthetists exactly, how many are 
good approximations and how many are just not acceptable. 
Calculating the frequency distribution of the errors does not identify decisions that have 
relatively small errors but represent ventilator changes in different directions. These are more 
likely to be unsafe than changes being made in the same direction. It was therefore proposed to 
use a qualitative scoring approach. The computed advice was classed as either exact, good, 
moderate or poor (Xl, with the classification criteria defined as follows; 
1). exact - when the advised decision (x) exactly matches the anaesthetist's (y); 
x-y=O (8.1) 
2). good - when the error between the advised (x) and anaesthetist decision (y) is less 
than or equal to some threshold (A); 
(8.2) 
The choice of threshold for each ventilator setting is given in Table 8.3. These 
were chosen to be equal to the smallest ventilator changes normally made by an 
anaesthetist. 
3). moderate - when the decision error is less than some higher threshold (B) and the 
change is not in opposing directions; 
1 x - y I:::; B AND (sign( x) = sign( y) OR no change in either x or y ) (8.3) 
The threshold (B) for each ventilator setting was double that for A, see Table 8.3. 
4). poor (X) - the decision error is greater than B, or greater than A and in the 
opposite direction; 
1 x- y 1 > B OR (I x- yl > A AND sign(x) = -sign(y)) (8.4) 
Ventilator A B 
Control 
F10l (%) 5 10 
PEEP (cmH1O) 1 2 
Mv (llmin) 0.5 1 
RR(rpm) 50 100 
VT (ml) 1.5 3 
TIN(%) 5 10 
Table 8.3: Qualitative scoring thresholds good (A) and moderate (B), for each ventilator control. 
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Each decision was scored using these classification criteria and the individual results are shown in 
Appendix F, together with the scoring frequency for each ventilator control across the entire data 
set (see Table F.2). 
Obviously the choice of scoring threshold will greatly affect the frequency distribution. Therefore, 
in order to provide a standard against which the clinical performance can be measured the above 
scoring algorithm was also applied to the closed-loop decisions, see Table F.3. 
Figure 8.3 compares the percentage distribution of the decision scoring for the clinical and 
simulated data. It can be clearly seen that the clinical performance was worse than the simulated 
performance in every ventilator control. Considering all the decisions together, the advisor gave 
exact or good matching in only 48.6 % of cases, compared to 82.5 % using the closed-loop data. 
Of greater concern though is that 23.5 % of the advice given was a poor match. Such a level of 
mismatch is not tolerable. 
8.6 Discussion 
This poor level of performance is perhaps to be expected since examination of the clinical data 
identified several possible causes of decision mismatch. These are as follows~ 
Anomalous Decisions 
This includes changes made by the anaesthetist that seem contrary to all the clinical indications, 
and are often corrected at the next blood-gas sample or sooner. This occurs relatively 
infrequently, although similar decision errors were observed during the simulated closed-loop 
ventilation (see Section 7.4). 
An obvious example occurred in the clinical data at observation 1 in Patient 1, when the 
anaesthetist increased MV from 7.5 up to 8.0 lImin despite the Paco2 being on the low side of 
normal. This was corrected one hour later, at the next blood-gas sample time. 
Advisor Naivety 
This is when the anaesthetist's decisions are based upon information outside of the advisor's 
knowledge paradigm. This often includes reluctance by the anaesthetist to make ventilator 
changes until other treatment possibilities have been considered, even when presented with 
measurements that would suggest otherwise. This probably constitutes the main cause of 
decision mismatch and was highlighted in the motor-cycle accident patient (Patient 2), where 
many of the decisions were delayed or contraindicated by extenuating factors. For example; 
1). A larger Vr was employed to maintain the level of ventilation necessary to keep 
PaC02 at approximately 4 kPa. This was a difficult compromise between the need 
for low PaC02 (because of head injury) and air being lost through the 
pneumothorax and chest drain. 
2). Fr02 was not increased in response to falling Pa02 as this was caused by blood 
filling the lungs. This was suctioned first, with the F102 only being increased if the 
Pa02 did not improve. 
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Differing Therapeutic Styles 
Anaesthetists do not approach patient treatment in the same way. Therefore the advisor's 
decisions may score less favourably against one anaesthetist than another. What is important is 
that the computed advice is safe, and has a variance smaller than the variability in the 
anaesthetists' decisions. This is an important consideration for future work (see Chapter 9). 
For example the advisor always increased TIN from 25 % to 33 %. Some anaesthetists set a 
normal I:E ratio using a TIN of 33 %, ignoring any pause time. Others include TPAUSE (usually 
set at 10 %) and therefore reduce TIN to 25 % accordingly. Which one is correct? The advisor is 
correct using the first case, but wrong with respect to the second. 
Measurement Rejection 
The advisor takes the observation data at face value, where as the anaesthetist may be suspicious 
of sudden changes. For example a sudden fall in Pa02 if not met by a similar drop in Sa02 would 
be rejected as a measurement error and the blood-gases reanalysed. 
Anaesthetist Not Present 
During the night when an anaesthetist is on-call they will only be requested to make changes to 
the ventilator settings if the patient condition worsens. The patient measurements are still 
recorded and may indicate an improvement that the advisor would respond to, but do not require 
intervention by an anaesthetist. Obviously the time at which an observation is made has an 
important bearing on any changes made. This would need including into the advisor rules and 
highlights the need for hierarchical control (see Chapter 9). 
Set-point Ranges 
The advisor uses a single set point for Pac~ whereas the anaesthetist will stop making changes to Mv 
when the PaC~ is within an acceptable range. Consequently the advisor continues to make 
unnecessary refinements to the level ofMv. A similar problem exists for nonnal RR and VT settings. 
Genuine Rule Errors 
Despite the above causes of decision mismatch, there will be occasions when the difference is 
simply a matter of an incorrect rule-consequent or the need of a new observation class I 
variable, to better separate the decision space. Possible examples of these and suggested 
modifications are given below; 
1). In Patient 2, at the beginning of ventilation the clinician was more cautious in 
reducing the F102 than the advisor. This seems to correspond to the margin of 
safety observed during the closed-loop validation. The Pa02 is reasonable at 
approx. 20 kPa but not high enough to warrant the size of changes proposed by the 
advisor. The consequents at PaO] = HI and FlO] = EHIIMAx need reducing from 
-35 % to -10 % and atPaO] = 8HI and flO] = EHlfrom -20 % to -10 %. 
2). The inclusion of a new Pa~ set at 20 kPa, or the peak of HIGH changed from 25 
kPa to 20 kPa, since this seems to be a common Pao2 level giving a margin of 
safety in the patient's oxygenation. 
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3). In Patient 6 the clinician is allowing pennissive hypocapnia to compensate for the 
acute acidosis and keep pH above 7.25, as defined in the therapeutic goals. This 
indicates the need for pH as an observation variable, as originally proposed in the 
prototype Mv control rules. This had been removed in the modified advisor. It 
appears to be the set definitions that were incorrect, requiring instead a much 
wider set membership for nonnal pH. 
8.7 Summary & Conclusions 
The clinical perfonnance of the advisor was disappointing, with only the FI02 control giving a 
reasonable level of decision matching. However, the validation process has highlighted areas 
that need to be addressed before the advisor can be considered safe. It is only when a certain 
level of safety has been achieved, that bedside clinical trial can be commenced. The following 
features need to be incorporated into the advisor if it is to perform safely. 
1). The advisor must be able to detect and ignore possible measurement errors. This is 
a measure of its robustness. 
2). Changes need to be negated when the patient's gases lie within a set-point range. 
This is more critical in patients where unnecessary modification to the ventilation 
can destabilise their condition. As it stands the advisor is too sensitive to input 
changes close to the PaC02 set-point goal. 
3). The ability to wait to see if a patient's condition is making slight improvement 
before adopting a more aggressive ventilation regime. Again this is more critical in 
patients that may be destabilised by changes in their ventilation. 
The best strategy to meet these shortfalls is through the use of carefully constructed patient 
scenarios that match some of the complex clinical behaviour observed. These will be repeatable 
and enable the improvements in advisor performance to be quantified. 
This concludes the description of all work undertaken thus far. The final conclusions are given 
in the next chapter together with considerations for future work. 
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Chapter 9: Conclusions & Future Work 
This thesis has described the development of a fuzzy-based advisor for the maintenance of 
patients on artificial ventilation in ICU. It has been shown that the use of a computer-model of 
the respiratory process provides a rapid methodology for rule-elicitation, validation and 
refinement. Simulated closed-loop assessment of the advisor performance, together with 
feedback from a clinical expert, rapidly highlighted rule errors. It also enabled the identification 
of non-convergent and limit-cycle behaviour in the rules, a function not possible using real 
clinical data. The model allowed the representation of a wide range of patient patho-physiology 
and unlike recorded patient data enabled quantitative evaluation of the efficacy of alternative 
advisor rules. This model-based approach forms a strong platform for future advisor 
development and testing, enabling confidence to be established in the advice generated before 
bedside testing is commenced. 
Patient Model Development & Validation 
About half of the research project involved the selection and development of a suitable patient 
model and its validation against clinical data. The model developed was selected for its ability to 
represent a variety of respiratory pathology and trauma whilst avoiding excessive complexity. The 
majority of its parameters are routinely monitored in a typical ICU environment, therefore 
minimising the number of system unknowns. By keeping these unknowns to a minimum it was 
possible to match the model to real patient data using a solution-searching algorithm. This model 
can be classed as a white-box model since it is physiologically meaningful and interpretable. 
The model selected used a compartmental structure similar to that employed by Dickinson (1977) 
in earlier work and by Thomsen et al (1989) in recent extensive studies. It described pulmonary 
gas exchange in the lungs using three functional areas or compartments (Riley & Cournard, 1949); 
an ideal alveolus, where all gas exchange takes place, a dead space representing lung areas that are 
ventilated but not perfused, and a shunt that is a fraction of cardiac output, representing both 
anatomical shunts and lung areas that are perfused but not ventilated. The circulatory system was 
divided into 4 additional compartments representing the alveolar, tissue, venous and pulmonary 
pools. Only the transport of O2 and CO2 were modelled and these were linked through the inverse 
gas dissociation functions (Kelman 1966 and 1967). These functions were used to derive the 
partial gas pressures that drive diffusion across the lung membrane from gas contents, as well as 
generate the model outputs of arterial and venous P02 and Peo2. 
No attempt was made to model the respiratory control of ventilation since it was assumed that 
the patients were on mandatory ventilation and performing no breathing for themselves. A 
continuos-ventilation model of the lung was chosen over breath-by-breath models since it more 
than adequately described the changes in Pa02 and Paeo2 routinely monitored in ICU. The use 
of a breath-by-breath model would only have added unnecessary complexity. 
Classical sensitivity analysis of the model parameters was performed, and it identified cardiac 
output (0,), O2 consumption (Vo2 ), CO2 production (Veo2 ), shunt (Os /0, ) and dead space 
(VD) to be of particular importance to blood-gas outcomes. Since these parameters are not 
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routinely measured, clinical validation of the model was difficult. Cardiac output is subject to 
large measurement errors and is only monitored in patients with unstable cardiac function making 
them less suitable for study. The measurement of V0 2 and Vco 2 requires the use of a metabolic 
computer and it was therefore necessary to borrow one for the purposes of the study. 
Unfortunately it was only available for a limited period, greatly reducing the amount of clinical 
data that could be collected. Four patients were recorded in all, representing 9 ventilator changes. 
The data collected were used to investigate the model's ability to predict arterial and venous 
blood-gases in response to changes in ventilator settings. This was achieved by applying the 
patient measurements prior to any ventilator change to the model, and then iteratively adjusting 
shunt, dead space and Pso until the simulated steady-state blood-gases matched those measured. 
The ventilator changes made on the real patients were then applied to the tuned model, and the 
simulated and actual responses compared. 
The model was shown to be qualitatively correct. However, establishing whether it can give 
accurate quantitative blood-gas predictions is unlikely without the collection of further clinical 
data that is both well behaved and free from measurement error. Until regular and accurate 
measurement of Ot. V0 2 and Veo 2 become available and data are routinely logged on a 
patient data management system for easy retrieval, true clinical validation will be difficult. Thc 
correlation coefficients and standard deviation of the response errors indicated only modcratc 
predictive performance, but these results were comparable with those obtained by Hinds et al 
(1983) in a similar study. 
However this did not undermine the suitability of the model for advisor rule-validation, since it 
was possible to construct virtual patient scenarios that exhibited behaviour similar to the types of 
patient encountered in ICU. Five virtual patient scenarios were modelled in order to test the 
advisor rules. These represented routinely encountered patient types and included; a patient with 
healthy lungs being ventilated post-operatively, an acute asthmatic, a patient with lobar 
pneumonia, a patient with head injuries and a patient with acute ARDS. The scenarios were 
constructed to be as realistic as possible but also typical of the patient-types they represented. 
When an anaesthetist was asked to ventilate the virtual patients, they felt that the model responded 
as expected to ventilator changes and were representative of the pathologies simulated. 
The model was originally developed to simulate patients on continuous mandatory ventilation 
(CMY); in particular volume control (VC) and pressure regulated volume control (PRVC). 
Obviously this only represents a sub-set of the modes currently in use. Other ventilation modes 
include synchronised intermittent mandatory ventilation (SIMV) where the breaths are 
synchronised to patient effort, and continuous positive airway pressure (CPAP) where the 
patient is breathing for themselves but is given support to maintain lung volume and 
oxygenation. If the advisor is to be valid in all possible scenarios, then the model used for 
simulated closed-loop validation will only be useful if it can represent these modes of 
ventilation and the majority of pathologies encountered in ICU. This will require better 
modelling of the airway dynamics and their interaction with the ventilator, as well as better 
models of the ventilators themselves. It may also require the inclusion of models relating to the 
respiratory control of ventilation, since as the patient moves from CMV (perhaps via SIMV) to 
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CP AP the patient begins to breath unaided. However, the inclusion of greater model complexity 
must be carefully balanced against its ability to be tuned to real patient data. 
Other areas for possible model improvement and investigation include; the addition of alveolar 
compartments representing 11/ Q mismatch and the investigation of the causes of steady-state 
PY02 error and identification of methods to tune it to observed values. Finally, the manner in 
which shunt and dead space respond in different disease states or traumas may best be modelled 
using statistical or neuro-fuzzy sub-systems. In this way the basic model structure will remain 
simple, with more complex behaviour being switched in and out as required. This will create a 
grey-box model of a patient's patho-physiology and provide a balance bctween physically 
describable physiology and more complex variable interactions. 
Advisor Development & Validation 
Initial control rules were handcrafted using known physiological relationships, nomograms and 
via discussion with an anaesthetist. Individual rule-bases were constructed for F102, PEEP, My and 
VT-RR control. This was later extended to include rules for I:E control through changes to TIN. 
The prototype advisor was then connected to the virtual patients described earlicr, and allowed 
to run in simulated closed-loop control. New advice was generated at the blood-gas sample 
times established by the anaesthetist during their simulated ventilation of the virtual patients. In 
this way direct comparison of the patient histories was possible. 
The prototype advisor gave poor decision matching when compared with the ventilator changes 
prescribed by the anaesthetist. In some cases the patient diverged from acceptable levels. 
However the causes of decision error were easily identified via inspection of the rules that were 
contributing to the mismatch. In some instances it was simply a matter of changing the value of 
the rule-consequent, in others new fuzzy classes or even new rule-antecedents were required to 
better separate the decision space. Improvements to the advisor were implemented where 
possible, and its performance re-evaluated using simulated closed-loop control. 
The modified advisor showed significant improvement in decision matching for the FI02, Mv 
and RR-VT sub-systems. There was no longer any divergent behaviour, and Pao2, PaC02 and 
PIP maintenance closely followed that produced by the anaesthetist, although some differences 
in prescribed ventilator setting still existed. In some instances the advisor suggested My 
changes that avoided the PaC02 undershoot or overshoot produced by the anaesthetist. Also of 
note is that the ARDS patient required more cautious ventilation in terms of FI02 increases and 
RR and VI changes. These differences were clearly identified using the simulated closed-loop 
approach. However, encapsulating them in the rules was not possible without compromising the 
decisions required for normal ventilation. This decision dichotomy and others like it 
encountered during the evaluation are pathology specific. They require different rules depending 
upon the presenting condition and are best handled using a hierarchical control structure. Such 
an approach has been successfully implemented in the control of neuro-muscular block [Shieh 
et aI, 1996,1997] and anaesthesia [Link ens 1993; Shieh et aI, 1998]. 
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The closed-loop simulation only provided limited stimulation of the available control rules and 
it will therefore be necessary to construction additional virtual patients that fire different rules, 
including those at the observation extremes. 
Clinical validation of the advisor against ventilator changes made in ICU resulted in a poor 
level of decision matching. This was disappointing, but careful examination showed that 
decision mismatch was caused by one of or a combination of the following; (1) an inability to 
reject measurement errors; (2) the use of broader ranges of acceptable gases that require no 
refinement of the ventilator settings; (3) decisions based on information outside of the advisor 
paradigm and (4) a tendency on the part of an anaesthetist to wait to see if a patient's condition 
improves before making ventilator changes that might destabilise certain patients. These add 
further weight to the need for hierarchical control. 
The ability to create pseudo-realistic patient scenarios may have other advantages for 
knowledge elicitation. One of the biggest problems in producing an advisory system is that 
treatment styles vary between hospital ICUs and even between individual anaesthetists. This 
often reflects the ventilation strategies and accepted norms in vogue at the time they did their 
initial training, as well as the variability in patient types encountered. Using the patient model, a 
library of patient scenarios can be created that represent a wide range of pathology and trauma. 
These can include critical events, untenable scenarios and measurement errors. Different 
anaesthetists could then be asked to care for the patients as they would a real patient and the 
variation in treatment styles recorded. Because the scenarios are repeatable, direct comparison 
between anaesthetist styles would be possible. The consensus or average care profiles can then 
be identified and the data used to train the advisor. It should also help to isolate pathology-
specific strategies that require different control rules from those required for normal control. 
If the model can be successfully tuned to real patient data, then the generation of scenario 
libraries will be much simpler. It will also be possible to use the model on-line to predict the 
outcomes of advice given and therefore assess its suitability. 
Initial advisor development used handcrafting of the rules. However, when there are more than 
3 rule-antecedents this quickly becomes cumbersome, and is bctter achieved using automatcd 
techniques such as self-organising fuzzy-logic control (SOFLC). Using the patient-model and a 
library of virtual patients a SOFLC based advisor can quickly be trained and its performance 
compared directly against other advisor rule-bases. 
A major restricting factor to rule testing and development was the speed at which patient 
simulations could be performed. The model was written using MATLAB and SIMULINK, which 
provides benefits in terms of rapid research and development but are slow to run. This is 
because they are interpretative run-time languages and are by nature much slower than compiler 
languages such as C. Compilers are available for MATIAB and SIMULINK but the improvement 
in performance experienced by other researchers was not significant. Therefore before 
predictive-control or self-learning fuzzy logic can be explored using the patient-model, it will 
require implementing in C or C++. MATLAB supports the integration of C programs and 
therefore advisor development can be continued using this platform. 
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If an advisor is to become truly useful it must form an integral part of any computerised patient 
data management system currently in place. It is not reasonable to expect clinicians or nursing 
staff to enter information into a separate stand-alone system [Standage, 1997]. Therefore any 
future development must consider data transfer protocols between existing management systems. 
In conclusion, model-based advisor validation has demonstrated advantages over decision 
comparisons made using clinical data alone. It provided a method for assessing the closed-loop 
stability of the advisor, and successfully highlighted differences in decision behaviour from that of 
an anaesthetist. This enabled rapid refinement of handcrafted rules and will form a validation 
platform for the development of new rules for future ventilation strategies. However, the advisor is 
not yet in a usable finished form, and will require enhancing before bedside validation can be 
considered. A hierarchical control strategy will be needed, since universal control rules cannot 
adequately encapsulate the entire decision processes of an anaesthetist. 
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Appendix A 
SIMULINK Block Diagrams of the Patient Model 
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Figure A.l: Top level diagram of the SIMULINK model, with FROM blocks passing all of the model 
parameters and output variables to the MA TLAB workspace for inspection and manipulation. The 
Blood Gas Model Subsystem contains the actual model representations and has a global call in its 
input mask to a MAlLAB structure that contains all of the required input parameters. 
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Figure A.2: Blood Gas Model Subsystem - showing the compartments of the patient model. The 
Input Parameters module copies the MATLAB input structure into the local parameter labels 
used within the compartment subsystems. The Steady State Error Check module, stops the 
simulation when the blood-gas content and pressures have reached steady-state, or the 
simulation stop time has been reached. 
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CONSTANT INPUTS ONLY 
P.Weight k WEIGHT 
P.Sex k SEX 
P.Hb02Binding k BETAH 
P.Plasma02 k ALPHAB 
P.Pb k PB 
P .voLPulmonary k Vp 
P .VoLArterial k Va 
P .VoL Tissue k Vt 
P .VoLVenous k Vv 
P.LungVol kLUNGVOLI 
P.02Diffusion k 002 I 
P.C02Diffusion k DC02 I 
BLOOD MATRIX INPUTS 
P.BodyTemp k BTEMP 
P.Haemoglobin k HB 
P.P50 k PSO 
P.BicarbArt k HC03 
P.PackCeliVol k PCV 
P.pHArt k PH 
CALCULATE Valv K Valv J 
I CALCULATE AVENT KAVENTl 
I CALCULATE PEFF K-prn] 
CALCULATE 
Blood Gas Diffusion 
I CALCULATE SHUNTKSHUNT] 
CALCULATE PIP K PIP J 
VENTILATOR MATRIX INPUTS 
P.Fi02 K FI02 
P.FiC02 K FIC02 
P.Tin K TIN 
P.Tpause KTPAUSE 
P.Peep K PEEP 
P.RespRate k RR 
P.TidaiVol K TVOL 
CALCULATE 
CO 
dV02 
dVC02 
* 
MISC MATRIX INPUTS 
P.Caw k CAW 
P.Raw K RAW 
P.Deadspace KDEAoS!J 
P.PhysShunt HHYSHUNj 
P.FixedShunt kIXSHUN~ 
P.CP K-cp~ 
P.MR K MR I 
P.RQ K RQ I 
I P.TamponadeSens ~MPSEN~ 
I P.ShuntPeepThresh K THRESH I 
Figure A.3: Input Parameters -
this subsystem, maps the values in 
the MATLAB input structure (e.g. 
P.FI02) into GOW blocks. These 
enable the parameters to be used 
elsewhere in the system by using a 
corresponding FROM block. This 
module also derives parameter 
values used by the model, from 
various input values (e.g. AVENT 
from TVOL (VT), RR and 
DEADSP (VD). 
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Figure A.4: Alveolar Compartment - representation of the mass transport equations 4.5 and 4.27. 
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Figure A.5: Pulmonary Compartment - representation of the mass transport equations 4.4 and 4.26. 
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Figure A.6: Lung Membrane - representation of model equations 4.6 and 4.28. 
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Figure A7: Subsystem C-to-P - converts the pulmonary gas contents to partial pressures using 
the MATLAB inverse gas dissociation function gasinv.m. 
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Figure A9: DualMem - provides the previous gas pressures used in the bounded tracking. 
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Figure AlO: Arterial Compartmenf- representation of mass transport equations 4.1 and 4.23. 
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Figure All: Tissue Compartment - representation of mass transport equations 4.2 and 4.14. 
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Figure A12: Venous Compartment - representation of mass transport equations 4.3 and 4.25. 
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Figure A.I3: Steady State Error Check - passes all gas content and pressures into the serrstop. m 
MA TLAB function to check for steady state convergence. 
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Appendix B 
Data Collected For Patient-Model Validation 
and Ethical Committee Guidlines 
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B.l Patient Data 
PATIENT 1 RECORD 1 (14/2/94) 
GENERAL INFORMATION 
Status: Cardiogenic shock, Sepsis, Multi-system failure. 
Drugs: Adrenaline, Flolan, Dopamine 
Support: SIMV Ventilation, Dialysis, Fluid balance, Blood infusions 
Measurements: PAC, CVC, SAC, Deltatrac II, Thermo-dilution CO Measurements 
Female, 65 years, 165 cm, 69 kg 
VENTILATOR ARRANGEMENT 
Puritan -Bennett nOOa, Disposable Tubing (2.5m insp., 2m exp.) 
Bennett Cascade Filter (gives good humidification.), SIMV mode with sloping square wave driving 
waveform 
METABOLIC COMPUTER (DELTATRAC II) RESULTS 
Gas Temperature (0C) 28.4 
Ambient Pressure (kPa) 102.525 
Ambient CO2 (% STPD) 0.05 
Non-Protein RQ 0.86 
Body Surface Area (m2): Deltatrac2 l.76 
SAMPLE RESULTS 
TIME 14:18 14:48 15:32 16:17 
VENTILATOR SETTINGS 
FI02 (%) 55 
Respiratory Rate (rpm) 24 26 
Tidal Volume (mI) [set (measured)] 700 (680) 
PEEP (cmH2O) 10 
I:E Ratio (lIE) 0.8 0.6 
PIP (cmH2O) 30.2 36.2 
Mean Airway Pressure (cmH2O) 2l.0 24.5 
SYSTEMIC ARTERY BLOOD (Arterial Catheter) 
Pa02 (kPa) 17.2 17.9 '! 15.8 18.0 
PaC02 (kPa) 4.30 4.30 3.90 4.00 
Co-oximeter O2 Saturation (%) 99.0 99.0 99.0 99.0 
pH 7.540 7.530 7.560 7.560 
Standard Bicarbonate (mmolll) 3l.0 30.0 30.0 3l.0 
Base Excess (mmolll) +7 +6 +6 +7 
Hb (g/lOOml) 11.6 
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PULMONARY ARTERY BLOOD (pulmonary Artery Catheter) 
Pv02 (kPa) 4.4 4.6 4.1 4.3 
PvC02 (kPa) 5.00 4.90 4.70 4.60 
Co-oximeter O2 Saturation (%) 69.0 71.0 65.0 68.0 
Standard Bicarbonate (mmol/l) 29.0 29.0 30.0 30.0 
pH 7.490 7.490 7.520 7.520 
OTHER MEASUREMENTS 
Blood Temperature (OC) 36.5 36.4 36.5 36.6 
O2 Saturation (%) Oximeter 96 97 95 98 
Cardiac Output (Vmin) 4.9 5.8 4.9 5.2 
Cardiac Index 2.75 3.25 2.75 2.92 
Heart Rate (bpm) 106 103 103 105 
O2 Consumption (mVmin) 273.8 278.2 278.6 284.7 
CO2 Production (ml/min) 239.1 238.9 238.2 242.8 
Metabolic Rate (kcaV24hr) 1901 1923 1924 1969 
Respiratory Quotient 0.878 0.860 0.855 0.854 
PRESSURES 
Systolic B.P. (mmHg) 116 138 152 132 
Diastolic B.P. (mmHg) 
- - - -
Mean Arterial B.P. (mmHg) 64 73 81 70 
Central Venous B.P. (mmHg) 12 13 14 12 
Mean Pulmonary B.P. (mmHg) 27 28 31 29 
Wedge Pressure (mmHg) 10 11 12 11 
Notes: 
Measurement 3 for Pa02 appears to be too low, probably a measurement error. 
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PATIENT 1 RECORD 2 (15/2/94) 
GENERAL INFORMATION 
Status: Cardiogenie shock, Sepsis, Multi-system failure. 
Drugs: Adrenaline, Flolan, Dopamine; Reduction of sedation during test but no arousal. 
Support: SIMV Ventilation, Dialysis, Fluid balance, Blood infusions 
Measurements: PAC, SAC, Deltatrac II, Thermo-dilution CO Measurements 
Female, 65 years, 165 em, 69 kg 
VENTILATOR ARRANGEMENT 
Puritan -Bennett nOOa, Disposable Tubing (2.5m insp., 2m exp.) 
Bennett Cascade Filter (gives good humidification.) 
SIMV mode with sloping square wave driving waveform 
METABOLIC COMPUTER (DELTATRAC II) RESULTS 
Gas Temperature (DC) 2S.4 
Ambient Pressure (kPa) 100.391 
Ambient CO2 (% STPD) 0.06 
Non-Protein RQ 0.S6 
Body Surface Area (m2): Deltatrac2 1.76 
SAMPLE RESULTS 
TIME 15:03 15:28 16:03 16:53 
VENTILATOR SETTINGS 
FI02 (%) 50 45 
Respiratory Rate (rpm) 20 
Tidal Volume (ml) [set (measured)] 700 (670) 
PEEP (cmH2O) 5 
I:E Ratio (lIE) 1.I 
PIP (cmH2O) 22.6 22.7 
Mean Airway Pressure (cmH2O) 11.9 13.1 
SYSTEMIC ARTERY BLOOD (Arterial Catheter) 
Pa02 (kPa) 12.4 12.3 10.4 10.5 
PaC02 (kPa) 5.S0 5.16 4.n 5.0S 
Co-oximeter O2 Saturation (%) 95.6 97.S 95.4 95.0 
pH 7.452 7.493 7.507 7.495 
Standard Bicarbonate (mmolll) 30.7 30.1 2S.4 29.7 
Base Excess (mmol/I) +6.7 +7.0 +5.S +6.7 
Hb (g/lOOml) 10.6 
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PULMONARY ARTERY BLOOD (pulmonary Artery Catheter) 
Pv02 (kPa) 4.80 5.00 5.36 5.58 
PvC02 (kPa) 6.06 5.75 4.70 4.70 
Co-oximeter O2 Saturation (%) 71.2 74.2 72.9 70.6 
Standard Bicarbonate (mmol/l) 32.0 31.7 31.0 31.1 
pH 7.450 7.469 7.490 7.474 
OTHER MEASUREMENTS 
Blood Temperature (OC) 36.5 36.4 36.5 36.5 
O2 Saturation (%) Oximeter 98 98 97 97 
Cardiac Output (Vrnin) 7.2 8.3 8.3 8.0 
Cardiac Index 4.04 4.66 4.66 4.49 
Heart Rate (bpm) 97 97 98 98 
O2 Consumption (mVmin) 279.0 293.7 286.9 292.5 
CO2 Production (mVmin) 244.7 253.3 245.7 244.8 
Metabolic Rate (kcal/24hr) 1940 2035 1985 2012 
Respiratory Quotient 0.879 0.865 0.857 0.838 
PRESSURES 
Systolic B.P. (mmHg) III 146 145 127 
Diastolic B.P. (rrunHg) 45 64 53 45 
Mean Arterial B.P. (mmHg) 66 81 77 71 
Central Venous B.P. (mmHg) 14 15 14 12 
Mean Pulmonary B.P. (mmHg) 29 38 31 30 
Wedge Pressure (mmHg) 16 18 17 15 
Instability in PRIOR PaC02 measurements (11.03 % variation), also reflected in arterial 
pH change. Unable to say which point is incorrect therefore the average has to be used. 
This may lead to bad VD estimate and hence poor response matching. 
Instability in PRIOR Qt (15.1 % variation). 
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PATIENT 1 RECORD 3 (21/2/94) 
GENERAL INFORMATION 
Status: Cardiogenic shock, Sepsis, Multi-system failure. 
Drugs: Adrenaline (being reduced), Flolan, Dopamine 
Support: SIMV Ventilation, Dialysis, Fluid balance, Blood infusions 
Measurements: PAC, SAC, Deltatrac II, Cardiac output calculated. 
Female, 65 years, 165 cm, 60 kg (reduced) 
VENTILATOR ARRANGEMENT 
Puritan -Bennett nOOa, Disposable Tubing (2.5m insp., 2m exp.) 
Bennett Cascade Filter (gives good humidification.) 
SIMV mode with sloping square wave driving waveform 
METABOLIC COMPUTER (DELTATRAC II) RESULTS 
Gas Temperature eq 29.2 
Ambient Pressure (kPa) 100.791 
Ambient CO2 (% STPD) 0.04 
Non-Protein RQ 0.89 
Body Surface Area (m2): Deltatrac2 1.65 
SAMPLE RESULTS 
TIME 11:49 12:13 12:39 13:22 
VENTILATOR SETTINGS 
FI02 (%) 55 60 
Respiratory Rate (rpm) 18 
Tidal Volume (mI) [set (measured») 900 (870) 
PEEP (cmH2O) 7.5 
I:E Ratio (lIE) 1.0 
PIP (cmH2O) 24.0 24.0 
Mean Airway Pressure (cmH2O) 13.6 13.7 
SYSTEMIC ARTERY BLOOD (Arterial Catheter) 
Pa02 (kPa) 8.5 8.8 9.2 9.3 
PaC02 (kPa) 4.87 4.72 4.69 4.78 
Co-oximeter O2 Saturation (%) - - - -
pH 7.490 ? 7.437 7.494 7.480 
Standard Bicarbonate (mmol/l) 29 ? 25.5 28.5 28.1 
Base Excess (mmol/l) 5.3 ? 1 4.7 4.2 
Hb (gllOOml) 9.6 
-
9.8 10.1 
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PULMONARY ARTERY BLOOD (pulmonary Artery Catheter) 
Pv02 (kPa) 5.3 5.3 5.5 5.5 
PvC02 (kPa) 5.52 5.41 5.17 5.46 
Co-oximcter O2 Saturation (%) - - - -
Standard Bicarbonate (mmol/l) 29.5 29.1 28.4 29.1 
pH 7.468 7.468 7.469 7.465 
OTHER MEASUREMENTS 
Blood Temperature (OC) 36.7 36.7 
-
36.6 
O2 Saturation (%) Oximeter 100 100 - 100 
Cardiac Output (Vrnin) derived 13.36 13.18 13.38 13.16 
Cardiac Index 
- - - -
Heart Rate (bpm) 100 102 
-
100 
O2 Consumption (mVmin) 289.4 282.1 279.1 284.4 
CO2 Production (mVmin) 253.6 252.2 242.2 243.4 
Metabolic Rate (kcaV24hr) 2012 1970 1934 1966 
Respiratory Quotient 0.879 0.896 0.869 0.860 
PRESSURES 
Systolic B.P. (mmHg) 140 134 
-
114 
Diastolic B.P. (mmHg) 50 49 
-
44 
Mean Arterial B.P. (mmHg) 80 76 
-
65 
Central Venous B.P. (mmHg) 13 13 
-
12 
Mean Pulmonary B.P. (mmHg) 32 31 
-
29 
Wedge Pressure (mmHg) 15 15 
-
16 
Possible measurement error in arterial pH, standard bicarbonate and BE results for point 
2. Drop in pH would normally be due to PaC02 increase over short time periods, but in 
this case PaC02 reduces. 
Cardiac output derived using Ot = V0 2 with Ca02 and CV02 derived from gas 
C(a-v)o2 
tensions using the gas dissociation functions. Estimates seem large, giving rise to large 
shunt estimates. 
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PATIENT 1 RECORD 4 (2112/94) 
GENERAL INFORMATION 
Status: Cardiogenic shock, Sepsis, Multi-system failure. 
Drugs: Adrenaline (being reduced), FIolan, Dopamine 
Support: SIMV Ventilation, Dialysis, Fluid balance, Blood infusions 
Measurements: PAC, SAC, Deltatrac II 
Female, 65 years, 165 cm, 60 kg (reduced) 
VENTILATOR ARRANGEMENT 
Puritan -Bennett nOOa, Disposable Tubing (2.5m insp., 2m exp.) 
Bennett Cascade Filter (gives good humidification.) 
SIMV mode with sloping square wave driving waveform 
METABOLIC COMPUTER (DELTATRAC In RESULTS 
Gas Temperature (DC) 29.2 
Ambient Pressure (kPa) 100.791 
Ambient CO2 (% STPD) 0.04 
Non-Protein RQ 0.89 
Body Surface Area (m2): Deltatrac2 1.65 
SAMPLE RESULTS 
TIME 12:39 13:22 14:13 
-
VENTILATOR SETTINGS 
F10z (%) 60 65 
Respiratory Rate (rpm) 18 
Tidal Volume (ml) [set (measured)] 900 (870) 900 (880) 
PEEP (cmH2O) 7.5 
I:E Ratio (lIE) 1.0 
PIP (cmH2O) 24.0 24.0 
Mean Airway Pressure (cmH2O) 13.7 13.7 
SYSTEMIC ARTERY BLOOD (Arterial Catheter) 
Pa02 (kPa) 9.2 9.3 9.7 
-
PaC02 (kPa) 4.69 4.78 4.79 -
Co-oximeter O2 Saturation (%) - - - -
PH 7.494 7.480 7.503 
-
Standard Bicarbonate (mmol/l) 28.5 28.1 29.4 
-
Base Excess (mmol/l) 4.7 4.2 5.9 
-
Hb (g/100ml) 9.8 10.1 10.l 
-
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PULMONARY ARTERY BLOOD (pulmonary Artery Catheter) 
Pv02 (kPa) 5.5 5.5 5.6 -
PvC02 (kPa) 5.17 5.46 5.29 -
Co-oximeter O2 Saturation (%) - - - -
Standard Bicarbonate (mrnol/l) 28.4 29.1 29.3 
-
pH 7.469 7.465 7.476 
-
OTHER MEASUREMENTS 
Blood Temperature (0C) 
-
36.6 36.5 
-
O2 Saturation (%) Oximeter - 100 100 -
Cardiac Output (Vrnin) derived 13.38 13.16 13.11 
-
Cardiac Index 
- - - -
Heart Rate (bpm) 
-
100 96 
-
O2 Consumption (mVrnin) 279.1 284.4 266.2 -
CO2 Production (mVrnin) 242.2 243.4 235.6 -
Metabolic Rate (kcaV24hr) 1934 1966 1853 
-
Respiratory Quotient 0.869 0.860 0.889 
-
PRESSURES 
Systolic B.P. (rnmHg) 
-
114 129 
-
Diastolic B.P. (mmHg) 
-
44 47 
-
Mean Arterial B.P. (mmHg) 
-
65 72 
-
Central Venous B.P. (rnmHg) , 
-
12 12 
-
Mean Pulmonary B.P. (mmHg) 
-
29 31 
-
Wedge Pressure (mmHg) 
-
16 16 
-
Notes: 
Cardiac output derived using Qt = V0 2 with Ca02 and CV02 derived from gas 
e(a -v)02 
tensions using the gas dissociation functions. Estimates seem large, giving rise to large 
shunt estimates. 
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PATIENT 2 RECORD 1 (22/2/94) 
GENERAL INFORMATION 
Status: Post operative emergency with acute aortic anurism. 
Drugs: Dopamine 200mg/50ml @ 2mllhr. Incresed to 5ml/L at 15:30 
Support: Ventilation, Blood and plasma infusions at 15:35 
Measurements: CVC, SAC, Dcltatrac II. 
Male, 69 years, 180 cm, 82 kg 
VENTILATOR ARRANGEMENT 
Siemens Servo 300, Standard Non-disposable tubing + PALL Filter 
CMV mode with square wave driving waveform 
METABOLIC COMPUTER (DELTATRAC II) RESULTS 
Gas Temperature (0C) 29.1 
Ambient Pressure (kPa) 100.658 
Ambient CO2 (% STPD) 0.05 
Non-Protein RQ 0.82 
Body Surface Area (m2): Deltatrac2 2.01 
SAMPLE RESULTS 
TIME 15:00 15:35 16:05 16:40 
VENTILATOR SETTINGS 
FI02 (%)* 40 35 
Respiratory Rate (rpm) 17 16 
Tidal Volume (ml) [set (measured)] 700 700 
PEEP (cmHzO) 2 3 
I:E Ratio (lIE) 0.333 
PIP (cmH2O) 36.0 32.0 
Mean Airway Pressure (cmH2O) 
- -
SYSTEMIC ARTERY BLOOD (Arterial Catheter) 
Pa02 (kPa) 20.5 21.3 17.1 18.5 
PaC02 (kPa) 5.36 5.15 4.93 4.44 
Co-oximeter O2 Saturation (%) 
- - - -
pH 7.369 7.383 7.400 7.435 
Standard Bicarbonate (mmol/l) 24.1 24.2 24.4 24.6 
Base Excess (mmol/l) 
-1.1 -0.9 -0.7 -0.5 
Hb (g/100ml) 10.8 
-
11.2 10.5 
CENTRAL VENOUS BLOOD (Central Venous Catheter) 
Pv02 (kPa) 4.70 5.00 5.20 5.50 
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PvC02 (kPa) 6.36 6.45 5.95 5.40 
Co-oximeter O2 Saturation (%) - - - -
Standard Bicarbonate (mmol/l) 24.4 24.4 24.4 24.4 
pH 7.325 7.320 7.367 7.372 
OTHER MEASUREMENTS 
Blood Temperature - rectal (0C) 35.9 36.6 36.9 37.2 
O2 Saturation (%) Oximeter 100 100 97 97 
Cardiac Output (Vrnin) derived 7.70 5.91 6.85 8.07 
Cardiac Index 
- - - -
Heart Rate (bpm) 94 96 95 97 
O2 Consumption (mVrnin) 368.5 314.2 309.7 308.4 
CO2 Production (mllmin) 282.3 264.8 267.8 267.3 
Metabolic Rate (kcal/24hr) 2499 2168 2149 2141 
Respiratory Quotient 0.766 0.845 0.865 0.866 
PRESSURES 
Systolic B.P. (mmHg) 115 95 110 130 
Diastolic B.P. (mmHg) 60 50 60 65 
Mean Arterial B.P. (mmHg) 85 65 75 90 
Central Venous B.P. (mmHg) 12 9 10 12 
Mean Pulmonary B.P. (mmHg) 
- - - -
Wedge Pressure (mmHg) 
- - - -
Notes: 
Cardiac output derived using Qt = V02 with Ca02 and CV02 derived from gas 
C(a-v)o2 
tensions using the gas dissociation functions. Estimates seem large, giving rise to large 
shunt estimates. 
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PATIENT 3 RECORD 1 (01/3/94) 
GENERAL INFORMATION 
Status: Paraplegic with post operative complications, septic shock, kidney failure 
Drugs: Paracetarnol, Renal Dopamine 
Support: Ventilation 
Measurements: PAC, SAC, Deltatrac II, Thermodilution C.O. measurements. 
Female, 47 years, 154 crn. 50 kg 
VENTILATOR ARRANGEMENT 
Siemens Servo 900c, Standard disposable tubing (2.5m insp, l.5m exp) + Bennett Cascade II Filter 
SIMV mode + pressure support (inspiratory time 67 %, pause time 10 %). 
METABOLIC COMPUTER (DELTATRAC II) RESULTS 
Gas Temperature eC) 29.6 
Ambient Pressure (kPa) 100.658 
Ambient CO2 (% STPD) 0.05 
Non-Protein RQ 0.82 
Body Surface Area (m2): Deltatrac2 1.46 
SAMPLE RESULTS 
TIME 13:01 
--
13:37 
--
VENTILATOR SETTINGS 
F102 (%) 65 70 
Respiratory Rate (rpm) 16 
Tidal Volume (rnl) [set (measured)] 618 615 
PEEP (crnH2O) 10 
I:E Ratio (lIE) 2.0 
PIP (crnH2O) 35.0 33.8 
Mean Airway Pressure (crnH2O) - 20 
SYSTEMIC ARTERY BLOOD (Arterial Catheter) 
Pa02 (kPa) 8.1 
-
7.8 
-
PaC02 (kPa) 5.12 - 5.31 -
Co-oximeter O2 Saturation (%) 95 
-
90 
-
PH 7.349 
-
7.356 
-
Standard Bicarbonate (mmolll) 22.3 
-
23.2 
-
Base Excess (rnrnolll) -3.2 
-
-2.1 
-
Hb (gllOOrnl) 10.4 
-
10.1 
-
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PULMONARY ARTERY BLOOD (pulmonary Artery Catheter) 
Pv02 (kPa) 4.5 - 4.6 -
PvC02 (kPa) 5.61 - 5.48 -
Co-oximeter O2 Saturation (%) 
- - - -
Standard Bicarbonate (mmol/l) 23.2 
-
22.5 
-
pH 7.359 
-
7.351 
-
OTHER MEASUREMENTS 
Blood Temperature (0C) 38.8 
-
38.8 
· 
O2 Saturation (%) Oximeter 96 - 94 · 
Cardiac Output (Vmin) 7.5 
-
7.2 
-
Cardiac Index 5.1 
-
4.89 
-
Heart Rate (bpm) 130 
-
128 
· 
O2 Consumption (mVmin) 218.6 - 202.1 -
CO2 Production (mVmin) 179.6 - 162.1 -
Metabolic Rate (kcaV24hr) 1491 
-
1372 
-
Respiratory Quotient 0.824 
-
0.802 
-
PRESSURES 
Systolic B.P. (mmHg) 110 . 114 
-
Diastolic B.P. (mmHg) 50 
-
52 
· 
Mean Arterial B.P. (mmHg) 72 
-
70 
-
Central Venous B.P. (mmHg) 8 
-
14 
-
Mean Pulmonary B.P. (mmHg) 20 
-
24 
-
Wedge Pressure (mmHg) 8 
-
8 
· 
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PATIENT 3 RECORD 2 (01/3/94) 
GENERAL INFORMATION 
Status: Paraplegic with post operative complications, septic shock, kidney failure 
Drugs: Paracetamol, Renal Dopamine 
Support: Ventilation, Plasma infusions stopped at 13:42 
Measurements: PAC, SAC, Deltatrac II, Thermodilution C.O. measurements. 
Female, 47 years, 154 em, 50 kg 
VENTILATOR ARRANGEMENT 
Siemens Servo 900c, Standard disposable tubing (25m insp, 105m exp) + Bennett Cascade II Filter 
SIMV mode + pressure support (inspiratory time 67 %, pause time 10 %). 
METABOLIC COMPUTER (DELTATRAC II) RESULTS 
Gas Temperature (OC) 29.6 
Ambient Pressure (kPa) 100.658 
Ambient CO2 (% STPD) 0.05 
Non-Protein RQ 0.82 
Body Surface Area (m2): Deltatrac2 1.46 
SAMPLE RESULTS 
TIME 13:37 
--
14:30 
--
VENTILATOR SETTINGS 
FI02 (%) 70 75 
Respiratory Rate (rpm) 16 
Tidal Volume (ml) [set (measured)] 615 
PEEP (cmH2O) 10 
I:E Ratio (lIE) 2.0 
PIP (cmH2O) 33.8 
Mean Airway Pressure (cmH2O) 20 
SYSTEMIC ARTERY BLOOD (Arterial Catheter) 
Pa0 2 (kPa) 7.8 
-
10.0 
-
PaC02 (kPa) 5.31 - 5.28 -
Co-oximeter O2 Saturation (%) 90 - 93 -
PH 7.356 
-
7.348 
-
Standard Bicarbonate (mmolll) 23.2 
-
22.7 
-
Base Excess (mmolll) -2.1 
-
-2.7 
-
Hb (g/lOOml) 10.1 
-
9.9 
-
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PULMONARY ARTERY BLOOD (pulmonary Artery Catheter) 
PvOz (kPa) 4.6 
· 
4.8 
· 
PvC02 (kPa) 5.48 · 5.15 · 
Co-oximeter O2 Saturation (%) . · . · 
Standard Bicarbonate (mmol/l) 22.5 
· - -
pH 7.351 
· 
7.346 
· 
OTHER MEASUREMENTS 
Blood Temperature (DC) 38.8 
· 
38.8 
· 
Oz Saturation (%) Oximeter 94 
· 
96 
· 
Cardiac Output (Umin) 7.2 
· 
5.9 
· 
Cardiac Index 4.89 4.01 
Heart Rate (bpm) 128 112 
Oz Consumption (mUrnin) 202.1 
· 
210.5 
· 
CO2 Production (mVmin) 162.1 · 173.3 · 
Metabolic Rate (kcaV24hr) 1372 
· 
1437 
· 
Respiratory Quotient 0.802 
· 
0.826 
-
PRESSURES 
Systolic B.P. (mmHg) 114 
· 
100 
· 
Diastolic B.P. (mmHg) 52 
· 
50 
· 
Mean Arterial B.P. (mmHg) 70 
· 
66 
· 
Central Venous B.P. (mmHg) 14 
· 
16 
· 
Mean Pulmonary B.P. (mmHg) 24 
-
26 
· 
Wedge Pressure (mmHg) 8 
· 
11 
· 
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PATIENT 3 RECORD 3 (0213/94) 
GENERAL INFORMATION 
Status: Paraplegic with post operative complications, septic shock, kidney failure 
Drugs: Renal Dopamine, Patient becoming more aware at last measurement. 
Support: Ventilation 
Measurements: PAC, CVC, SAC, DeItatrac II, Thermodilution C.O. measurements. 
Female, 47 years, 154 cm. 50 kg 
VENTILATOR ARRANGEMENT 
Puritan Bennett nOOA, Standard disposable tubing (2.5m insp, 1.5m exp) + Bennett Cascade II 
Filter 
SIMV mode (sloping square wave) 
METABOLIC COMPUTER (DELTATRAC II) RESULTS 
Gas Temperature (0C) 29.3 
Ambient Pressure (kPa) 100.658 
Ambient CO2 (% STPD) 0.06 
Non-Protein RQ 0.88 
Body Surface Area (m2): Deltatrac2 1.46 
SAMPLE RESULTS 
TIME 11:13 11:45 12:54 13:28 
VENTILATOR SETTINGS 
FI02 (%) 75 70 
Respiratory Rate (rpm) 16 
Tidal Volume (ml) [set (measured)] 590 
PEEP (cmH2O) 10.3 10.2 
I:E Ratio (lJE) 1.43 
PIP (cmH2O) 39.6 38.8 
Mean Airway Pressure (cmH2O) - -
SYSTEMIC ARTERY BLOOD (Arterial Catheter) 
Pa02 (kPa) 1l.6 11.8 11.3 11.7 
PaC02 (kPa) 5.22 5.27 5.30 5.39 
Co-oximeter O2 Saturation (%) - - - -
pH 7.363 7.368 7.378 7.359 
Standard Bicarbonate (mmolll) 23.3 23.7 24.3 23.6 
Base Excess (mmolll) -2 -1.5 -0.7 -1.6 
Hb (gl100ml) 10.4 10.6 
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CENTRAL VENOUS BLOOD (Central Venous Catheter) 
Pv02 (kPa) 4.5 5.0 5.0 4.8 
PvC02 (kPa) 5.82 5.79 5.70 5.87 
Co-oximeter O2 Saturation (%) - - - -
Standard Bicarbonate (mmol/l) 23.8 23.2 23.6 23.8 
pH 7.360 7.347 7.360 7.355 
PULMONARY ARTERY BLOOD (pulmonary Artery Catheter) 
Pv02 (kPa) 4.6 4.6 4.7 4.7 
PvC02 (kPa) 5.69 5.65 5.84 5.83 
Co-oximeter O2 Saturation (%) - - - -
Standard Bicarbonate (mmol/l) 
-
23.3 24.0 24.0 
pH 7.354 7.359 7.361 7.362 
OTHER MEASUREMENTS 
Blood Temperature (0C) 37.2 37.2 37.2 37.2 
O2 Saturation (%) Oximeter 98 98 98 98 
Cardiac Output (llmin) 5.6 6.0 5.8 6.6 
Cardiac Index 3.80 4.08 3.94 4.48 
Heart Rate (bpm) 105 108 109 112 
O2 Consumption (mllmin) 217.6 211.8 214.6 219.0 
CO2 Production (mllmin) 193.5 186.9 186.1 187.4 
Metabolic Rate (kcaIl24hr) 1511 1471 1481 1508 
Respiratory Quotient 0.894 0.883 0.869 0.857 
PRESSURES 
Systolic B.P. (mmHg) 145 148 140 149 
Diastolic B.P. (mmHg) 65 67 65 67 
Mean Arterial B.P. (mmHg) 95 100 94 100 
Central Venous B.P. (mmHg) 8 8 6 9 
Mean Pulmonary B.P. (mmHg) 24 23 22 23 
Wedge Pressure (mmHg) ? 18 7 7 7 
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PATIENT 4 RECORD 1 (03/3/94) 
GENERAL INFORMATION 
Status: Septic shock. kidney problems 
Drugs: Unknown 
Support: Ventilation, Fluid balance, PlasmaiColoid infusions 
Measurements: PAC, SAC, Deltatrac II, Thermodilution C.O. measurements. 
Female, 56 years, 157 em, 76 kg 
VENTILATOR ARRANGEMENT 
Siemens Servo 300, Standard disposable tubing (Urn insp, 1.5m exp) + Fisher & Packel MR600 
Filter 
CMV (pressure regulated volume control) 
METABOLIC COMPUTER (DELTATRAC II) RESULTS 
Gas Temperature (0C) 25.4 
Ambient Pressure (kPa) 100.395 
Ambient CO2 (% STPD) 0.04 
Non-Protein RQ 0.79 
Body Surface Area (m2): Deltatrac2 l.77 
SAMPLE RESULTS 
TIME 13:33 14:26 13:07 13:43 
VENTILATOR SETTINGS 
FIOz (%) 50 
Respiratory Rate (rpm) 14 12 
Tidal Volume (mI) [set (measured)] 700 (693) 700 (689) 
PEEP (cmH2O) 5 
I:E Ratio (lIE) 1.56 1.85 
PIP (cmH2O) 31.0 35.0 
Mean Airway Pressure (cmH2O) 14 15 
SYSTEMIC ARTERY BLOOD (Arterial Catheter) 
PaOz (kPa) 11.9 11.1 11.5 11.9 
PaC02 (kPa) 3.9 3.68 4.16 4.03 
Co-oximeter O2 Saturation (%) 96.9 96.6 96.8 97.0 
pH 7.333 7.374 7.363 7.384 
Standard Bicarbonate (mmolll) 18.6 19.5 20.4 21.0 
Base Excess (mmolll) -8.0 -9.1 -5.8 -5.1 
Hb (gilOOml) ? 15.4 11.8 11.6 1l.9 
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PULMONARY ARTERY BLOOD (Pulmonary Artery Catheter) 
Pv02 (kPa) 6.0 5.9 5.9 5.9 
PvC02 (kPa) 4.21 4.04 4.35 4.49 
Co-oximeter O2 Saturation (%) 82.9 83.8 83.2 83.9 
Standard Bicarbonate (mmolll) 19.8 19.2 20.0 21.4 
pH 7.353 7.350 7.350 7.372 
OTHER MEASUREMENTS 
Blood Temperature (DC) 38.0 37.9 37.9 37.9 
O2 Saturation (%) Oximeter 95 96 97 97 
Cardiac Output (Vmin) 10.5 11.8 10.1 11.1 
Cardiac Index 5.76 6.48 5.54 6.09 
Heart Rate (bpm) 150 146 148 148 
O2 Consumption (mVmin) 242.5 233.3 269.0 262.2 
CO2 Production (mVmin) 208.4 198.7 207.5 200.3 
Metabolic Rate (kcaV24hr) 1674 1607 1819 1768 
Respiratory Quotient 0.862 0.852 0.771 0.765 
PRESSURES 
Systolic B.P. (rrunHg) 100 100 101 99 
Diastolic B.P. (rrunHg) 50 51 52 52 
Mean Arterial B.P. (rrunHg) 68 70 69 69 
Central Venous B.P. (mmHg) 14 18 17 17 
Mean Pulmonary B.P. (mmHg) 32 34 34 35 
Wedge Pressure (mmHg) 15 16 17 19 
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B.2 Ethical Committee Guidelines 
Location of Research 
To be carried out at two centres; (I) Intensive Care Unit, Hull Royal Infinnary (2) Intensive Care 
Unit, Castle Hill Hospital 
Subjects 
The clinical investigation will be based on patients who are being mechanically ventilated in the 
above intensive care units. 
Informed Consent 
At the initial stages of the work no changes will be made to patient treatment. The study will be 
based on accurate recording of nonnal therapy. 
At a later stage alterations may be made to ventilator settings. These will be restricted to changes 
within the nonnal range for therapy in the specific clinical situation. Predictions from the system 
as to optimum therapy will be regarded as advisory only. Any change to ventilator therapy will be 
made on the basis of the clinical judgement of the anaesthetist in charge. However during this 
stage of the work, where therapy may be influenced by the trial, infonned consent will be 
obtained from the patient where possible. 
Permission of other Professionals 
The consultant in overall charge of the cases will be asked for permission for their patients to be 
entered into the trial. 
Substances to be Given 
No changes to drugs, etc given will be made for the study. 
Samples 
Blood gases will be measured by the nonnal methods employed for intensive care using nonnal 
sample sizes for the equipment employed. More regular samples, up to 4 time per hour, may be 
taken but no more than might be required in an individual anaesthetist's nonnal practice during 
ventilation. 
It is not considered that there are any special risks to the patients or staff involved in the study. 
Benefits 
There will be no financial benefit to subjects or staff involved. 
Facilities 
There will be no significant affect on nursing or laboratory workload. 
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Appendix C 
Simulated Patient Definitions 
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C.l Normal Lung Patient 
NORMAL LUNGS 
Physiological Shunt (%) 
Time (min) Value 
0 8 
30 2 
300 0 
Body Temperature eC) 
Time (min) Value 
o 35 
120 37 
Function 
init value 
ramp 
ramp 
Functions 
initial 
value 
ramp 
10 I~~ I i i i i i 
0 SO 100 ISO 200 2S0 300 
Time (min) 
o so 100 ISO 200 2S0 300 
Time (min) 
Table C.I: Event profiles for Normal Lung patient scenario. 
C.2 Lobar Pneumonia Patient 
LOBAR PNEUMONIA 
Physiological Shunt (%) 
Time (min) Value Function 3S 
0 32 init value :i 30 ~ ~ 2S 120 30 ramp ..a 20 v.> . IS 
120 25 step 110 
S -240 23 ramp 0 200 400 600 800 1000 1200 1400 
360 21 ramp Time (min) 
360 16 step 
1440 7 ramp 
Body Temperature (OC) 
Time (min) Value Function 
""' 39 
0 35 init value ~ 
-
i 38 
120 37 ramp ~ 37 
--------~ 36 
0 200 400 600 800 1000 1200 1400 
Time (min) 
Table C.2 Continued Overleaf ... 
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LOBAR PNEUMONIA Continued ••• 
Metabolic Rate (%) 
Time (min) Value Function 
o 135 mit value 
1440 100 ramp 
Respiratory Quotient 
Time (min) Value Function 
o 0.75 mit value 
1440 0.8 ramp 
Airway Resistance (cmHzO/JIsec) 
Time (min) Value Function 
o 15 mit value 
1440 10 ramp 
Lung Compliance OIcmHzO) 
Time (min) Value Function 
o 0.02 mit value 
120 0.03 step 
360 0.04 step 
720 0.05 step 
Arterial Bicarbonate (mmol/l) 
Time (min) Value Function 
o 16 mit value 
1440 24 ramp 
Table C.2 Continues Overleaf ... 
~!~C:::;:I 
o 200 400 600 800 1000 1200 1400 
Time (min) 
0.81L:::J 0.80 0.79 
cy 0.78 
~ 0.77 
0.76 
0.75 
0.74 +---r--...,..---...----.----,r---r--.,.J 
o 200 400 600 800 1000 1200 1400 
Time (min) 
~ 16~--------------~ ! 14 r----------
] 12 
'-' 10 
~ 8~--T---T---~--~--~--~--~ 
o 200 400 600 800 1000 1200 1400 
Time (min) 
0'06~ Q;0.05 ~ ] 0.04 . 
C 0.03 .---...... 
~ 0.02 
u 0.01 " I , 
o 200 400 600 800 1000 1200 1400 
~ 2S 
120~ 
115 
~ 
Time (min) 
-
~ 10+---~--~--~--~--__ --__ --~ 
o 200 400 600 800 1000 1200 1400 
Time (min) 
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LOBAR PNEUMONIA Continued .•• 
Venous Bicarbonate (mmolll) 
Time (min) Value Function ~;;~ 0 17.8 init value ~ 23 
1440 25.8 ramp I;! 
~ 17 ~ IS 
0 200 400 600 800 1000 1200 1400 
Time (min) 
Table C.2: Event profiles for Lobar Pneumonia patient scenario. 
C.3 Acute Asthmatic Patient 
ACUTE ASTHMA TIC 
Physiological Shunt (%) 
Time (min) Value Function 
o 5 init value 
1440 0 ramp 
Airway Resistance (cmH10lllsec) 
Time (min) Value Function 
o 120 inil value 
360 50 ramp 
1080 10 ramp 
Lung Compliance (IIcmB1O) 
Time (min) Value Function 
0 0.04 inil value 
360 0.055 ramp 
1080 0.06 ramp 
o 200 400 600 800 1000 1200 1400 
Time (min) 
r~ ~+--'---r---r---r--=;:::::::;,=:::;:I, I 
o 200 400 600 800 1000 1200 1400 
Time (min) 
0.07 .,....-------------_. 
q: 0.06 1 0.05 I ./'" 5 0.04 V" 
0.03 +--.,...-_r_--.--....,...---..--.....,.----.J 
o 200 400 600 800 1000 1200 1400 
Time (min) 
Table C.3: Event profiles for Acute Asthmatic patient scenario. 
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C.4 Head Injury Patient 
HEAD INJURY 
Body Temperature COC) 
Time (min) Value Function i::k:: 0 34.5 init value I 120 37 ramp i 3S 34 • i i 
0 40 80 120 160 200 240 
Time (min) 
Table C.4: Event profiles for Head Injury patient scenario. 
C.S ARDS Patient 
ARDS 
Physiological Shunt (%) 
Time (min) Value Function 
o 40 init value 
360 50 ramp 
2880 20 ramp 
....... 
60t:::::d t so § 40 ~ 30 
&20 
10+---~--~--~--~--~--~--~ 
o 400 800 1200 1600 2000 2400 2800 
Time (min) 
Lung Compliance (I/cmH10) 
o 
Time (min) Value Function 
init value 0.015 
360 0.01 ramp 
1080 0.03 ramp 
0.046:: =:::j i .03 
e 0.02 _ 
~ 0.01 
u 0.00 +----r---r----r"i --r----r----~ 
o 400 800 1200 1600 2000 2400 2800 
Time (min) 
Table C.5: Event profiles for ARDS patient scenario. 
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C.6 Patient Initial Conditions 
Normal Lobar Acute Head ARDS 
Lungs Pneumon. Asthmatic Injury 
Patient Parameters 
Sex male female female male male 
Weight (kg) 75 60 60 85 75 
Height (cm) 165 150 150 190 180 
Age (years) 50 65 47 22 50 
Body Temperature (OC) 35 38.5 37 34.5 38 
Cardiac Output (Vrnin) t 4.82 6.15 4.65 5.35 6.90 
O2 Consum. (mVmin: STPD) t 213.2 343.8 222.7 220.6 317.3 
CO2 Prod. (ml/min: STPD) t 170.6 257.9 178.2 176.5 253.8 
Metabolic Rate (%) 100 135 100 100 110 
Respiratory Quotient 0.8 0.75 0.8 0.8 0.8 
Cardiac Efficiency (%) 100 100 100 100 100 
Tamponade Sensitivity (%) 100 100 100 100 100 
Dead Space (ml: ATPS) t 165 132 132 187 165 
Physiological Shunt rio) 8 32 5 3 40 
Fixed Shunt (%) 2 3 1 2 2 
PEEP Threshold (cmH2O) 6 60 100 4 70 
Haemoglobin (gil) 140 116 130 140 140 
Arterial Bicarbonate (mmol/l) 24 16 24 24 24 
Venous Bicarbonate (mmol/l) 25.8 17.8 25.8 25.8 25.8 
Packed Cell Volume (%)t 42 34.8 39 42 42 
Airway Resist. (cmH2OlVsec) 7 15 120 7 10 
Lung Compliance (VcmH2O) 0.08 0.02 0.04 0.07 0.015 
Ventilator Settings 
F102 (%: STPD) 60 50 50 70 50 
PEEP (cmH2O) 4 0 0 0 0 
VT (ml: ATPS) 750 600 600 700 700 
RR(rpm) 12 14 12 12 12 
TIN (%) 33 33 40 33 33 
TPAUSE (%) 10 10 10 10 10 
Atmospberic Conditions 
Barometric Pressure (kPa) 101.325 101.325 101.325 101.325 101.325 
Air Temperature (DC) 25 20 20 20 20 
Inspired FIC02 (%: STPD) 0.05 0.05 0.05 0.05 0.05 
Table C.6 continued overleaf ... 
248 
Continued ... Normal Lobar Acute Head ARDS 
Lungs Pneumon. Asthmatic Injury 
Fixed Parameters 
Hb O2 Binding Capacity (ml/g) 1.34 1.34 1.34 1.34 1.34 
Plasma ~ Solubility (ml/l/kPa) 0.225 0.225 0.225 0.225 0.225 
P50 (kPa) 3.5774 3.5774 3.5774 3.5774 3.5774 
O2 Lung Diff. (mJ/kPalmin) 450 450 450 450 450 
CO2 Lung Diff. (mJ/kPalmin) 1500 1500 1500 1500 1500 
Reference Only 
Systolic Blood Press. (mmHg) 135 120 120 120 120 
t Calculated from empirical formulae 
Table C.6: Initial patient parameters and ventilator settings for the Normal Lung, Lobar 
Pneumonia, Asthmatic, Head Injury and ARDS virtual patient scenarios. 
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Appendix D 
Closed Loop Decision History Data 
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1 2 3 4 5 6 
Time (hours) 0.0 0.5 1.0 2.5 5.5 8.5 
Patient Observations 
Pa02 (kPa) 42.90 27.24 21.67 21.82 23.86 19.28 
PaC02 (kPa) 3.08 4.68 5.36 5.93 4.73 5.23 
Arterial pH 7.60 7.43 7.38 7.34 7.43 7.39 
PIP (cmH2O) 16.6 15.5 12.7 12.7 13.2 13.0 
Sa02 (0/0) 99.9 99.5 99.1 99.0 99.3 98.8 
T BODY (OC) 35.0 35.5 36.0 37.0 37.0 37.0 
Cardiac Output (llmin) 4.82 5.06 5.46 5.95 5.95 5.95 
O2 Consump. (mllmin) 213 226 238 263 263 263 
CO2 Prod. (mllmin) 171 181 191 211 211 211 
Effective Shunt (0/0) 4.7 2.7 3.2 2.7 2.0 2.0 
Metab. Rate (%) 100 100 100 100 100 100 
Respiratory Quotient 0.80 0.80 0.80 0.80 0.80 0.80 
Raw (cmH2Oll/sec) 7.0 7.0 7.0 7.0 7.0 7.0 
Caw (lIcmH2O) 0.08 0.08 0.08 0.08 0.08 0.08 
Ventilator Settings 
FI02 (%) 60 40 35 35 35 30 
PEEP (cmH2O) 4.0 4.0 2.0 2.0 2.0 2.0 
Vr (ml) 750 750 700 700 700 700 
RR (rpm) 12.0 8.0 8.0 8.0 10.0 9.0 
Mv (llmin) 9.00 6.00 5.60 5.60 7.00 6.30 
TIN (%) 33 33 33 33 33 33 
Advised Ventilator Settings 
FI02 (%) 40 35 35 35 30 
PEEP (cmH 2O) 4.0 2.0 2.0 2.0 2.0 
Vr (ml) 750 700 700 700 700 
WEAN 
RR (rpm) 8.0 8.0 8.0 10.0 9.0 
Mv (llmin) 6.00 5.60 5.60 7.00 6.30 
TIN (%) 33 33 33 33 33 
Table 0.1: Anaesthetist decision history for Normal Lung patient. 
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1 2 3 4 5 6 
Time (hours) 0.0 0.5 1.0 2.5 5.5 8.5 
Patient Observations 
Pa02 (kPa) 42.90 21.26 18.14 17.74 19.14 19.22 
PaC02 (kPa) 3.08 5.11 5.49 5.93 5.41 5.32 
Arterial pH 7.60 7.39 7.37 7.34 7.38 7.38 
PIP (cmH2O) 16.6 11.7 11.1 10.7 11.0 11.2 
Sa02 (%) 99.9 99.2 98.7 98.4 98.8 98.8 
TaODY rC) 35.0 35.5 36.0 37.0 37.0 37.0 
Cardiac Output (I/min) 4.82 5.30 5.60 6.11 6.11 6.11 
O2 Consump. (ml/min) 213 226 239 263 263 263 
CO2 Prod. (ml/min) 171 181 191 211 211 211 
Effective Shunt (%) 4.7 3.6 3.6 3.1 2.0 2.0 
Metab. Rate (%) 100 100 100 100 100 100 
Respiratory Quotient 0.80 0.80 0.80 0.80 0.80 0.80 
Raw (cmH2O/l/sec) 7.0 7.0 7.0 7.0 7.0 7.0 
Caw (1/cmH2O) 0.08 0.08 0.08 0.08 0.08 0.08 
Ventilator Settings 
FI02 (%) 60 35 31 30 30 30 
PEEP (cmH2O) 4.0 1.0 0.5 0.0 0.0 0.0 
Vr (ml) 750 700 690 700 710 720 
RR (rpm) 12.0 8.0 8.0 8.0 8.5 8.5 
Mv (I/min) 9.00 5.60 5.52 5.60 6.04 6.12 
TIN (%) 33 33 33 33 33 33 
Advised Ventilator Settings 
FI02 (%) 35 31 30 30 30 30 
PEEP (cmH 2O) 1.0 0.5 0.0 0.0 0.0 0.0 
Vr (ml) 700 690 700 710 720 720 
RR (rpm) 8.0 8.0 8.0 8.5 8.5 8.5 
Mv (I/min) 5.60 5.52 5.60 6.04 6.12 6.12 
TIN (%) 33 33 33 33 33 33 
Table D.2: Prototype advisor decision history for Normal Lung patient. 
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1 2 3 4 5 6 
Time (hours) 0.0 0.5 1.0 2.5 5.5 8.5 
Patient Observations 
Pa02 (kPa) 42.90 25.57 21.04 21.71 23.34 23.35 
PaC02 (kPa) 3.08 5.34 5.49 5.70 5.31 5.31 
Arterial pH 7.60 7.38 7.37 7.35 7.38 7.38 
PIP (cmH2O) 16.6 12.8 11.1 11.2 11.3 10.8 
5a02 (0/0) 99.9 99.4 99.1 99.0 99.2 99.2 
T BODY (Oe) 35.0 35.5 36.0 37.0 37.0 37.0 
Cardiac Output (I/min) 4.82 5.22 5.60 6.07 6.07 6.11 
O2 Consump. (ml/min) 213 226 239 263 263 263 
CO2 Prod. (ml/min) 171 181 191 211 211 211 
Effective Shunt (%) 0.0 0.0 0.0 0.0 0.0 0.0 
Metab. Rate (%) 100 100 100 100 100 100 
Respiratory Quotient 0.80 0.80 0.80 0.80 0.80 0.80 
Raw (cmH2O/l/sec) 0.7 0.7 0.7 0.7 0.7 0.7 
Caw (1/cmH2O) 0.82 0.82 0.82 0.82 0.82 0.82 
Ventilator Settings 
FI02 (%) 60 40 35 35 35 35 
PEEP (cmH2O) 4.0 2.0 0.5 0.5 0.5 0.0 
Vr (ml) 750 710 690 690 690 690 
RR (rpm) 12.0 7.5 8.0 8.5 9.0 9.0 
Mv (I/min) 9.00 5.33 5.52 5.87 6.21 6.21 
TIN (%) 33 33 33 33 33 33 
Advised Ventilator Settings 
FI0 2 (%) 40 35 35 35 35 35 
PEEP (cmH2O) 2.0 0.5 0.5 0.5 0.0 0.0 
Vr (ml) 710 690 690 690 690 700 
RR (rpm) 7.5 8.0 8.5 9.0 9.0 9.0 
Mv (I/min) 5.33 5.52 5.87 6.21 6.21 6.30 
TIN (%) 33 33 33 33 33 33 
Table 0.3: Refined advisor decision history for Normal Lung patient. 
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1 2 3 4 5 6 7 8 9 10 11 
lirre (hcus) 0.0 0.5 1.5 2.5 4.5 6.5 9.5 12.5 18.5 24.5 25.5 
Palent ObsefvatIoos 
~(kPa) 9.54 9.79 9.91 11.11 11.65 18.05 16.00 15.25 20.22 19.70 14.93 
~(kPa) 8.58 6.88 6.17 5.31 4.91 4.16 4.61 4.68 4.54 4.55 5.38 
Merial pH 7.02 7.12 7.17 7.24 7.29 7.37 7.35 7.37 7.42 7.45 7.38 
PIP (art-iP) 36.4 42.1 42.9 32.8 32.5 27.3 25.3 22.0 19.3 16.3 15.8 
SaOz(%) 80.5 86.2 88.7 93.4 94.9 98.5 98.2 97.8 98.9 99.0 97.9 
TIDJI'(°C) 38.5 38.5 38.4 38.3 38.2 38.1 37.9 37.7 37.3 37.0 37.0 
Qrda:: QJtput (linin) 6.15 6.05 5.98 5.88 5.75 5.59 5.40 5.18 4.82 4.57 4.57 
Oz Cmsurrp. (n1/nin) 344 341 335 3:D 319 309 293 278 248 223 223 
~ Prod. (n1/mn) 258 256 253 249 243 213 Z!3 216 100 178 178 
Effective SU1t (%) 35.0 32.4 31.5 25.9 24.0 17.7 16.3 14.9 121 9.8 9.8 
MetaI:>. Rate (%) 135 134 133 131 128 1:;E 121 117 108 100 100 
Respiratory OJotiert 0.75 0.75 0.75 0.76 0.76 0.76 0.77 0.78 0.79 0.80 0.80 
Raw (CI"f""I-1PI/sec) 15.0 14.9 14.7 14.5 14.1 13.6 13.0 124 11.1 10.0 10.0 
CaN (lIartiPl 0.02 0.02 0.02 0.03 0.03 0.04 0.04 0.05 0.05 0.05 0.05 
VentIlator SettIngs 
FIOz(%) 50 70 80 80 80 80 70 60 60 50 40 
PEEP (c:rrHP) 0.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 2.0 2.0 
Vr(n1) 600 600 600 600 600 600 600 600 550 550 550 
RR(lPnV 14.0 18.0 20.0 20.0 20.0 20.0 16.0 16.0 14.0 120 10.0 
MlOImn) 8.40 10.00 1200 1200 1200 1200 9.60 9.60 7.70 6.60 5.50 
T1N (%) 33 33 33 33 33 33 33 33 33 33 33 
AdvIsed VentIlator SettIngs 
FIOz(%) 70 80 80 80 80 70 60 60 50 40 
PEEP (art-iP) 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 2.0 2.0 
Vr(n1) 600 600 600 600 600 600 600 550 550 550 
VI.EAN 
RR(rpnV 18.0 20.0 20.0 20.0 20.0 16.0 16.0 14.0 120 10.0 
M.t (limn) 10.00 12.00 12.00 1200 1200 9.60 9.60 7.70 6.60 5.50 
TIN(%) 33 33 33 33 33 33 33 33 33 33 
Table 0.4: Anaesthetist decision history for Lobar Pneumonia patient. 
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1 2 3 4 5 6 7 8 9 10 11 
lirre (hcus) 0.0 0.5 1.5 25 4.5 6.5 9.5 125 1&5 24.5 25.5 
pajert Q:xser\&joos 
PaQ(kPa) 9.54 9.70 10.18 1228 1279 20.23 13.43 13.80 15.00 15.64 13.83 
~(kPa) 8.58 7.00 6.44 5.45 4.83 4.15 4.13 4.20 4.03 4.20 5.00 
Melia P-l 7.(12 7.11 7.15 7.23 7.:1> 7.'51 7.40 7.41 7.C 7.48 7.41 
Ap(arHP) 35.4 41.0 41.0 31.8 34.7 2&7 ZT.3 22.8 21.0 19.7 18.1 
SaO.z(o/~ 80.5 85.5 88.9 94.7 00.0 98.8 97.3 97.6 98.4 98.5 97.7 
TEJ::Vv(°C) 38.5 38.5 38.4 38.3 38.2 38.1 '51.9 '51.7 37.3 37.0 37.0 
Cadac 0JIp..t Olrrin) 6.15 6.(l; 5.98 5.ff7 5.74 5.57 5.40 5.18 4.82 4.50 4.54 
D.1 Corsurrp. (mlrrin) 344 341 335 3:l) 319 :m 293 ZT8 248 223 223 
CD.1 Prod. (m/nin) 258 256 253 249 243 235 223 216 100 178 178 
Effective Sui (%~ 35.0 327 31.4 25.6 23.8 17.6 16.3 14.9 121 9.5 9.7 
~Ra:eW~ 135 134 133 131 128 123 121 117 100 100 100 
ResPratay Q..diert 0.75 075 075 0.76 0.76 076 0.77 078 0.79 080 080 
RaN (aTtWIlsec) 15.0 14.9 14.7 14.5 14.1 13.6 13.0 124 11.1 10.0 10.0 
C:aN(I/cntiP) 0.02 0.02 0.02 0.03 0.03 0.04 0.04 O.(l; O.(l; O.(l; O.(l; 
Vertilcmr Settirv; 
FID.1(o/~ 50 67 82 00 88 84 00 55 51 42 '51 
PeEP(arHP) 0.0 3.5 4.0 4.5 4.5 4.5 4.0 4.0 4.0 4.0 3.0 
VT(m) OOJ 500 570 fro 650 640 650 640 610 610 610 
RR(~ 14.0 18.0 20.0 21.0 18.5 18.5 16.5 15.0 14.0 11.5 9.5 
MJ O/nin) 8.40 10.62 11.40 11.76 1203 11.84 10.73 9.00 8.54 7.02 5.80 
TINW~ 33 33 33 33 33 33 33 33 33 33 33 
Pdvised Veliilaa Settirv; 
FID.1(o/~ 67 82 00 88 84 00 55 51 42 '51 35 
PeEP(arHP) 3.5 4.0 4.5 4.5 4.5 4.0 4.0 4.0 4.0 3.0 20 
VT(m) 500 570 fro 650 640 650 640 610 610 610 500 
RR(~ 18.0 20.0 21.0 18.5 1&5 16.5 15.0 14.0 11.5 9.5 9.5 
MJO/nin) 10.62 11.40 11.76 1203 11.84 10.73 9.00 8.54 7.02 5.80 5.61 
liNW~ 33 33 33 33 33 33 33 33 33 33 33 
Table D.5: Prototype advisor decision history for Lobar Pneumonia patient. 
255 
1 2 3 4 5 6 7 8 9 10 11 
lirre(hcus) 0.0 0.5 1.5 25 4.5 6.5 9.5 125 18.5 24.5 25.5 
?Uri Cllservc:mms 
f>aO.1 (kPa) 9.54 9.65 9.69 10.97 11.56 17.78 15.49 15.65 20.23 21.74 16.14 
~(kPa) 8.58 6.91 6.03 5.21 4.91 4.43 4.73 4.78 4.55 4.46 5.33 
Melia p-i 7.02 7.11 7.18 7.25 7.':!J 7.35 7.34 7.33 7.42 7.46 7.38 
AP(art-W) 33.4 40.2 41.5 31.4 31.0 25.3 24.0 21.3 20.2 18.3 16.7 
SaD.! (o/~ 80.5 85.5 88.2 93.3 94.8 98.3 97.8 97.9 00.0 00.2 98.3 
TIOJ'((°C) 38.5 38.5 38.4 38.3 38.2 38.1 37.9 37.7 37.3 37.0 37.0 
Cadac Q.JIplt (Ilrrin) 6.15 6.05 5.98 5.88 5.75 5.59 5.40 5.18 4.82 4.54 4.57 
~ CorsuTp. (rrllrrin) 344 341 333 3:I) 319 :m 293 278 248 223 223 
CX>z Prod. (rrl/nin) 258 253 253 249 243 233 2a3 216 193 178 178 
Bfedive Sui (%~ 0.4 0.3 0.3 0.3 0.2 0.2 0.2 0.1 0.1 0.1 0.1 
M:.ta>. Rae (O/~ 135 134 133 131 128 123 121 117 108 100 100 
ResPratay Q.diert 075 0.75 075 076 076 076 077 078 079 0.80 080 
Ra.v{arHPllsec) 1.5 1.5 1.4 1.4 1.4 1.3 1.3 1.2 1.1 1.0 1.0 
CaN (I/art-W) 0.20 0.20 0.20 0.31 0.31 0.41 0.41 0.51 0.51 0.51 0.51 
Vertilatcr Settirvo 
FI~(o/~ 50 fJ1 76 79 79 79 as 61 00 53 43 
A:B> (art-W) 0.0 3.5 4.0 4.0 4.0 4.0 4.0 4.0 4.0 3.0 20 
Vr(n1) Em Em Em 600 600 600 600 Em Em Em Em 
RR(fPTO 14.0 18.0 20.5 20.5 20.0 18.5 15.5 14.0 125 11.0 9.0 
MtOlnin) 8.40 10.80 12]) 12]) 1200 11.10 9.]) 8.40 7.50 6.00 5.40 
liN(o/~ 33 40 40 40 40 40 40 33 33 33 33 
PdIised VertiI<*J" Settirvo 
FI~(O/~ fJ1 76 79 79 79 as 61 00 53 43 33 
A:B> (art-W) 3.5 4.0 4.0 4.0 4.0 4.0 4.0 4.0 3.0 20 25 
Vr(n1) 600 600 Em 600 600 600 Em Em Em Em Em 
RR(fPTO 18.0 20.5 20.5 20.0 18.5 15.5 14.0 125 11.0 9.0 9.0 
Mt (linin) 10.80 12]) 12]) 1200 11.10 9.]) 8.40 7.50 6.00 5.40 5.40 
liN (O/~ 40 40 40 40 40 40 33 33 33 33 33 
Table D.6: Revised advisor decision history for Lobar Pneumonia patient. 
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1 2 3 4 5 
Time (hours) 0.0 0.5 2.5 8.5 10.5 
Patient Observations 
Pa02 (kPa) 28.68 20.43 21.01 23.08 20.58 
PaC02 (kPa) 3.93 5.55 5.57 5.49 4.68 
Arterial pH 7.51 7.37 7.36 7.37 7.44 
PIP (cmH2O) 51.1 31.5 25.6 14.9 15.2 
Sa02 (%) 99.6 98.9 98.9 99.1 99.1 
T BODY (0C) 37.0 37.0 37.0 37.0 37.0 
Cardiac Output (llmin) 4.65 4.65 4.65 4.65 4.65 
O2 Consump. (mllmin) 223 223 223 223 223 
CO2 Prod. (mllmin) 178 178 178 178 178 
Effective Shunt (%) 6.0 5.9 5.5 4.2 3.8 
Metab. Rate (%) 100 100 100 100 100 
Respiratory Quotient 0.80 0.80 0.80 0.80 0.80 
Raw (cmH2Oll/sec) 120.3 114.2 90.8 41.8 34.7 
Caw (lIcmH2O) 0.04 0.04 0.05 0.06 0.06 
Ventilator Settings 
FI02 (%) 50 40 40 40 35 
PEEP (cmH2O) 0.0 0.0 0.0 0.0 0.0 
VT (ml) 600 450 400 400 450 
RR (rpm) 12.0 12.0 14.0 14.0 14.0 
Mv (llmin) 7.20 5.40 5.60 5.60 6.30 
TIN (%) 40 50 50 50 50 
Advised Ventilator Settings 
FI02 (%) 40 40 40 35 
PEEP (cmH2O) 0.0 0.0 0.0 0.0 
Vr (ml) 450 400 400 450 
WEAN 
RR (rpm) 12.0 14.0 14.0 14.0 
Mv (llmin) 5.40 5.60 5.60 6.30 
TIN (%) 50 50 50 50 
Table D.7: Anaesthetist decision history for Acute Asthmatic patient. 
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1 2 3 4 5 
Time (hours) 0.0 0.5 2.5 8.5 10.5 
Patient Observations 
Pa02 (kPa) 28.68 14.97 15.32 16.57 17.03 
PaC02 (kPa) 3.93 5.25 5.22 5.06 5.09 
Arterial pH 7.51 7.39 7.39 7.40 7.40 
PIP (cmH2O) 51.0 38.6 31.9 19.5 18.1 
5a02 (0/0) 99.6 98.0 98.1 98.4 98.5 
T BODY (DC) 37.0 37.0 37.0 37.0 37.0 
Cardiac Output (I/min) 4.65 4.65 4.65 4.65 4.65 
O2 Consump. (ml/min) 223 223 223 223 223 
CO2 Prod. (ml/min) 178 178 178 178 178 
Effective Shunt (0/0) 6.0 5.9 5.5 4.2 3.8 
Metab. Rate (%) 100 100 100 100 100 
Respiratory Quotient 0.80 0.80 0.80 0.80 0.80 
Raw (cmH2O/l/sec) 120.0 114.1 90.7 41.6 34.9 
Caw (lIcmH2O) 0.04 0.04 0.05 0.06 0.06 
Ventilator Settings 
FI02 (%) 50 30 30 30 30 
PEEP (cmH2O) 0.0 0.0 0.0 0.0 0.0 
Vr (ml) 600 520 520 570 590 
RR (rpm) 12.0 10.5 10.5 9.5 9.0 
Mv (I/min) 7.20 5.46 5.46 5.42 5.31 
TIN (%) 40 40 40 40 40 
Advised Ventilator Settings 
FI02 (%) 30 30 30 30 30 
PEEP (cmH2O) 0.0 0.0 0.0 0.0 0.0 
VT (ml) 520 520 570 590 580 
RR (rpm) 10.5 10.5 9.5 9.0 9.0 
Mv (I/min) 5.46 5.46 5.42 5.31 5.22 
TIN (%) 40 40 40 40 40 
Table 0.8: Prototype advisor decision history for Acute Asthmatic patient. 
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1 2 3 4 5 
Time (hours) 0.0 0.5 2.5 8.5 10.5 
Patient Observations 
Pa02 (kPa) 28.68 20.43 17.98 19.68 20.38 
PaC02 (kPa) 3.93 5.55 5.46 5.24 5.07 
Arterial pH 7.51 7.37 7.37 7.39 7.40 
PIP (cmH2O) 51.0 31.5 26.6 16.3 17.3 
5a02 (%) 99.6 98.9 98.6 98.9 99.0 
T BODY (OC) 37.0 37.0 37.0 37.0 37.0 
Cardiac Output (limin) 4.65 4.65 4.63 4.63 4.63 
O2 Consump. (mllmin) 223 223 223 223 223 
CO2 Prod. (ml/min) 178 178 178 178 178 
Effective Shunt (%) 0.1 0.1 0.1 0.0 0.0 
Metab. Rate (%) 100 100 100 100 100 
Respiratory Quotient 0.80 0.80 0.80 0.80 0.80 
Raw (cmH2O/l/sec) 11.8 11.2 8.9 4.1 3.4 
Caw (IIcmH2O) 0.41 0.42 0.47 0.57 0.58 
Ventilator Settings 
FI02 (%) 50 40 35 35 35 
PEEP (cmH2O) 0.0 0.0 0.5 0.5 0.5 
VT (ml) 600 450 440 450 490 
RR (rpm) 12.0 12.0 12.5 12.5 11.5 
Mv (I/min) 7.20 5.40 5.50 5.63 5.64 
TIN (%) 40 50 50 50 40 
Advised Ventilator Settings 
FI02 (%) 40 35 35 35 35 
PEEP (cmH2O) 0.0 0.5 0.5 0.5 0.5 
VT (ml) 450 440 450 490 500 
RR (rpm) 12.0 12.5 12.5 11.5 11.0 
Mv (I/min) 5.40 5.50 5.63 5.64 5.50 
TIN (%) 50 50 50 40 33 
Table 0.9: Revised advisor decision history for Acute Asthmatic patient. 
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1 2 3 4 5 6 
Time (hours) 0.0 0.5 2.5 3.5 5.5 11.5 
Patient Observations 
Pa02 (kPa) 51.82 32.04 22.88 23.58 19.66 19.66 
PaC02 (kPa) 3.47 4.42 5.42 3.90 4.50 4.50 
Arterial pH 7.55 7.45 7.38 7.51 7.45 7.45 
PIP (cmH 2O) 13.0 12.5 12.5 13.5 13.0 13.0 
Sa02 (%) 99.9 99.7 99.1 99.4 99.0 99.0 
TBODY(OC) 34.5 35.1 37.0 37.0 37.0 37.0 
Cardiac Output (I/min) 5.35 5.69 6.71 6.71 6.71 6.71 
O2 Consump. (ml/min) 221 238 289 289 289 289 
CO2 Prod. (ml/min) 176 190 231 231 231 231 
Effective Shunt (%) 5.0 5.0 5.0 5.0 5.0 5.0 
Metab. Rate (%) 100 100 100 100 100 100 
Respiratory Quotient 0.80 0.80 0.80 0.80 0.80 0.80 
Raw (cmH 2O/l/sec) 7.0 7.0 7.0 7.0 7.0 7.0 
Caw (lIcmH2O) 0.07 0.07 0.07 0.07 0.07 0.07 
Ventilator Settings 
FI0 2 (%) 70 50 40 40 35 35 
PEEP (cmH 2O) 0.0 0.0 0.0 0.0 0.0 0.0 
Vr (ml) 700 700 700 700 700 700 
RR (rpm) 12.0 10.0 10.0 14.0 12.0 12.0 
Mv (llmin) 8.40 7.00 7.00 9.80 8.40 8.40 
TIN (%) 33 33 33 33 33 33 
Advised Ventilator Settings 
FI0 2 (%) 50 40 40 35 35 
:::!CJ) 
PEEP (cmH 2O) 0.0 0.0 0.0 0.0 0.0 I-UJ < z~ :::E ::::>< Vr (ml) 700 700 700 700 700 UJ~ 0 u 
RR (rpm) 10.0 10.0 14.0 12.0 12.0 ::::>I-:::E ~ZO I-UJ~ Mv (I/min) 7.00 7.00 9.80 8.40 8.40 z-o~LL. 
TIN (%) 33 33 33 33 33 ua.. 
Table 0.10: Anaesthetist decision history for Head Injury patient. 
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1 2 3 4 5 6 7 
Time (hours) 0.0 0.5 2.5 3.5 5.5 11.5 17.5 
Patient Observations 
Pa02 (kPa) 51.82 23.38 16.81 16.43 16.45 16.47 16.47 
PaC02 (kPa) 3.47 4.73 5.70 4.76 4.69 4.63 4.63 
Arterial pH 7.55 7.43 7.35 7.43 7.44 7.44 7.44 
PIP (cmH 2O) 13.0 13.0 13.1 14.1 14.3 14.5 14.5 
8a02 (%) 99.9 99.4 98.3 98.5 98.5 98.5 98.5 
T BODY (DC) 34.5 35.1 37.0 37.0 37.0 37.0 37.0 
Cardiac Output (I/min) 5.35 5.70 6.71 6.71 6.71 6.71 6.71 
O 2 Consump. (ml/min) 221 238 289 289 289 289 289 
C02 Prod. (ml/min) 176 190 231 231 231 231 231 
Effective Shunt (%) 5.0 5.0 5.0 5.0 5.0 5.0 5.0 
Metab. Rate (%) 100 100 100 100 100 100 100 
Respiratory Quotient 0.80 0.80 0.80 0.80 0.80 0.80 0.80 
Raw (cmH 2Oll/sec) 7.0 7.0 7.0 7.0 7.0 7.0 7.0 
Caw (lIcmH 2O) 0.07 0.07 0.07 0.07 0.07 0.07 0.07 
Ventilator Settings 
FI0 2 (%) 70 40 31 30 30 30 30 
PEEP (cmH 2O) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Vr (ml) 700 750 760 800 810 820 820 
RR (rpm) 12.0 8.5 8.5 9.5 9.5 9.5 9.5 
Mv (I/min) 8.40 6.38 6.46 7.60 7.70 7.79 7.79 
TIN (%) 33 33 33 33 33 33 33 
Advised Ventilator Settings 
FI0 2 (%) 40 31 30 30 30 30 30 
PEEP (cmH 2O) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Vr (ml) 750 760 800 810 820 820 820 
RR (rpm) 8.5 8.5 9.5 9.5 9.5 9.5 10.0 
Mv (I/min) 6.38 6.46 7.60 7.70 7.79 7.79 8.20 
TIN (%) 33 33 33 33 33 33 33 
Table 0.11: Prototype advisor decision history for Head Injury patient. 
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1 2 3 4 5 6 7 
Time (hours) 0.0 0.5 2.5 3.5 5.5 11.5 17.5 
Patient Observations 
Pa02 (kPa) 51.82 31.60 22.88 19.66 20.15 20.15 20.15 
PaC02 (kPa) 3.47 4.88 5.42 4.50 4.49 4.49 4.49 
Arterial pH 7.55 7.41 7.38 7.45 7.45 7.45 7.45 
PIP (cmH 2O) 13.0 12.2 12.5 13.0 13.5 13.5 13.5 
Sa02 (%) 99.9 99.7 99.1 99.0 99.0 99.0 99.0 
TeODY (OC) 34.5 35.1 37.0 37.0 37.0 37.0 37.0 
Cardiac Output (llmin) 5.35 5.70 6.71 6.71 6.67 6.67 6.67 
O2 Consump. (mllmin) 221 238 289 289 289 289 289 
C02 Prod. (mllmin) 176 190 231 231 231 231 231 
Effective Shunt (%) 0.1 0.1 0.1 0.1 0.0 0.0 0.0 
Metab. Rate (%) 100 100 100 100 100 100 100 
Respiratory Quotient 0.80 0.80 0.80 0.80 0.80 0.80 0.80 
Raw (cmH 2Olllsec) 0.7 0.7 0.7 0.7 0.7 0.7 0.7 
Caw (lIcmH2O) 0.71 0.71 0.71 0.71 0.71 0.71 0.71 
Ventilator Settings 
FI0 2 (%) 70 50 40 35 35 35 35 
PEEP (cmH 2O) 0.0 0.0 0.0 0.0 0.5 0.5 0.5 
Vr (ml) 700 700 700 700 700 700 700 
RR (rpm) 12.0 9.0 10.0 12.0 12.0 12.0 12.0 
Mv (I/min) 8.40 6.30 7.00 8.40 8.40 8.40 8.40 
TIN (%) 33 33 33 33 33 33 33 
Advised Ventilator Settings 
FI0 2 (%) 50 40 35 35 35 35 35 
PEEP (cmH 2O) 0.0 0.0 0.0 0.5 0.5 0.5 0.5 
Vr (ml) 700 700 700 700 700 700 700 
RR (rpm) 9.0 10.0 12.0 12.0 12.0 12.0 12.0 
Mv (llmin) 6.30 7.00 8.40 8.40 8.40 8.40 8.40 
TIN (%) 33 33 33 33 33 33 33 
Table 0.12: Revised advisor decision history for Head Injury patient. 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Time (hours) 0.0 0.5 1.5 3.5 4.5 5.5 7.5 11.5 17.5 23.5 26.5 34.5 42.5 46.5 50.5 
Patient Observations 
Pa02 (kPa) 8.00 8.76 8.54 8.03 8.41 8.73 8.75 9.01 9.49 10.12 10.29 11.27 12.82 14.00 12.69 
PaC0 2 (kPa) 8.04 8.20 8.35 8.36 8.35 9.19 9.16 8.72 8.14 7.64 7.99 7.50 6.09 5.55 5.33 
Arterial pH 7.21 7.21 7.20 7.20 7.20 7.16 7.16 7.18 7.21 7.24 7.22 7.24 7.33 7.37 7.39 
PIP (cmH 2O) 50.9 47.9 46.8 48.1 52.9 53.5 52.3 46.3 40.0 35.8 33.8 28.4 28.0 25.8 27.6 
Sa02 (%) 82.2 85.7 84.3 81.5 83.7 83.4 83.6 85.7 88.6 91.2 91.2 93.6 96.3 97.3 96.7 
T BODY ("C) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 
Cardiac Output (11m in) 6.90 6.84 6.84 6.85 6.78 6.79 6.78 6.76 6.73 6.70 6.69 6.70 6.67 6.71 6.71 
O 2 Con sump. (ml/min) 317 317 317 317 317 317 317 317 317 317 317 317 317 317 317 
CO2 Prod. (ml/min) 254 254 254 254 254 254 254 254 254 254 254 254 254 254 254 
Effective Shunt (%) 42.0 40.5 42.1 45.2 42.7 44.1 43.9 41.5 37.8 34.1 32.3 28.3 23.2 21.3 20.3 
Metab. Rate (G,{,) 110 110 110 110 110 110 110 110 110 110 110 110 110 110 110 
Respiratory Quotient 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 
Raw (cmH 2Olllsec) 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 
Caw (1/cmH 2O) 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.03 0.03 0.03 
Ventilator Settings 
FI0 2 (%) 50 70 70 70 70 80 80 80 80 80 70 70 70 70 60 
PEEP (cmH 2O) 0.0 4.0 4.0 4.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 8.0 8.0 6.0 6.0 
VT (ml) 700 600 550 500 450 425 425 425 425 425 425 425 475 500 550 
R R (rpm) 12.0 14.0 16.0 20.0 22.0 22.0 22.0 22.0 22.0 22.0 20.0 20.0 20.0 20.0 18.0 
Mv (I/min) 8.40 8.40 8.80 10.00 9.90 9.35 9.35 9.35 9.35 9.35 8.50 8.50 9.50 10.00 9.90 
TIN (%) 33 50 50 60 60 60 60 60 60 60 60 60 60 60 50 
Advised Ventilator Settings 
FI0 2 (%) 70 70 70 70 80 80 80 80 80 70 70 70 70 60 
PEEP (cmH 2O) 4.0 4.0 4.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 8.0 8.0 6.0 6.0 
550 500 450 425 425 425 425 425 425 425 475 500 550 
w 
VT (ml) 600 :::I 
z 
RR (rpm) 14.0 16.0 20.0 22.0 22.0 22.0 22.0 22.0 22.0 20.0 20.0 20.0 20.0 18.0 i= 
z 
Mv (11m in) 8.40 8.80 10.00 9.90 9.35 9.35 9.35 9.35 9.35 8.50 8.50 9.50 10.00 9.90 0 0 
TIN (%) 50 50 60 60 60 60 60 60 60 60 60 60 60 50 
- - - -
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Table 0.13: Anaesthetist decision history for ARDS patient. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Time (hours) 0.0 0.5 1.5 3.5 4.5 5.5 7.5 11.5 17.5 23.5 26.5 34.5 42.5 46.5 50.5 
Patient Observations 
Pa02 (kPa) 8.00 8.49 8.99 9.15 9.70 10.01 10.49 11.20 12.02 12.08 11.78 15.20 15.52 13.19 12.99 
PaC0 2 (kPa) 8.05 7.34 7.69 8.23 8.88 9.80 10.68 11.23 11.12 8.40 6.41 5.60 4.96 4.89 5.06 
Arterial pH 7.21 7.25 7.23 7.20 7.17 7.13 7.10 7.07 7.08 7.20 7.31 7.37 7.42 7.42 7.41 , 
PIP (cmH 2O) 50.9 54.6 56.4 62.1 66.1 69.1 65.9 56.9 48.2 44.7 47.2 43.4 40.9 37.7 35.0 
Sa02 (%) 82.2 86.4 87.7 87.3 88.1 87.7 88.0 89.3 91.4 93.9 95.3 97.7 98.0 97.3 97.1 
T BODY (OC) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 
Cardiac Output (I/min) 6.90 6.84 6.83 6.80 6.76 6.75 6.74 6.72 6.69 6.66 6.65 6.60 6.61 6.68 6.72 
O 2 Consump. (ml/min) 317 317 317 317 317 317 317 317 317 317 317 317 317 317 317 
CO 2 Prod. (mllmin) 254 254 254 254 254 254 254 254 254 254 254 254 254 254 254 
Effective Shunt (%) 42.0 40.5 41.5 42.6 41.4 41.7 41.1 39.2 36.3 33.1 31.3 26.5 22.5 20.9 20.4 
M etab. Rate (%) 110 110 110 110 110 110 110 110 110 110 110 110 110 110 110 
Respiratory Quotient 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 
Raw (cmH 2Olllsec) 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 
Caw (1/cmH20) 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.03 0.03 0.03 
Ventilator Settings 
F 102 (%) 50 75 94 100 100 100 100 100 100 100 99 99 83 67 63 
PEEP (cmH 2O) 0.0 4.0 5.0 8.0 12.0 13.5 14.0 13.5 12.5 12.0 12.0 12.0 10.0 7.0 5.5 
VT (ml) 700 670 640 600 560 540 520 510 510 530 600 620 700 750 740 
RR (rpm) 12.0 14.0 14.5 15.0 14.5 13.5 12.5 11.5 11.0 14.0 16.0 16.5 15.0 13.5 13.0 
M v (11m in) 8.40 9.38 9.28 9.00 8.12 7.29 6.50 5.87 5.61 7.42 9.60 10.23 10.50 10.13 9.62 
TIN (%) 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 
Advised Ventilator Settings 
F 102 (%) 75 94 100 100 100 100 100 100 100 99 99 83 67 63 60 
PEEP (cmH20) 4.0 5.0 8.0 12.0 13.5 14.0 13.5 12.5 12.0 12.0 12.0 10.0 7.0 5.5 4.5 
VT (m I) 670 640 600 560 540 520 510 510 530 600 620 700 750 740 750 
RR (rpm) 14.0 14.5 15.0 14.5 13.5 12.5 11.5 11.0 14.0 16.0 16.5 15.0 13.5 13.0 12.5 
Mv(lImin) 9.38 9.28 9.00 8.12 7.29 6.50 5.87 5.61 7.42 9.60 10.23 10.50 10.13 9.62 9.38 
TIN (%) 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 
~~ 
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Table D.14: Prototype advisor decision history for ARDS patient. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Time (hours) 0.0 0.5 1.5 3.5 4.5 5.5 7.5 11.5 17.5 23.5 26.5 34.5 42.5 46.5 50.5 
Patient Observations 
Pa02 (k Pal 8.00 8.62 8.69 8.47 8.44 8.52 8.73 9.19 9.75 10.34 10.55 11.92 14.79 15.05 13.66 
PaC0 2 (kPa) 8.05 7.91 7.87 8.36 8.60 8.97 9.03 8.71 8.10 7.65 7.24 6.50 5.86 5.43 5.15 
Arterial pH 7.21 7.22 7.22 7.20 7.19 7.17 7.17 7.18 7.21 7.24 7.26 7.30 7.35 7.38 7.40 
PIP (cmHzO) 50.9 44.7 46.0 49.3 51.6 54.5 53.1 47.1 41.3 37.0 35.4 32.2 29.5 28.9 29.5 
Sa02 (%) 82.2 85.7 86.1 84.0 83.2 82.8 83.8 86.5 89.5 91.7 92.7 95.3 97.5 97.7 97.3 
TaODyeC) 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 38.0 
Cardiac Output (11m in) 6.90 6.84 6.83 6.82 6.81 6.80 6.79 6.76 6.72 6.69 6.69 6.66 6.67 6.70 6.72 
0z Consump. (mllmin) 317 317 317 317 317 317 317 317 317 317 317 317 317 317 317 
CO 2 Prod. (mllmin) 254 254 254 254 254 254 254 254 254 254 254 254 254 254 254 
Effective Shunt (%) 0.4 0.4 0.4 0.4 0.4 0.5 0.4 0.4 0.4 0.3 0.3 0.3 0.2 0.2 0.2 
Metab. Rate (%) 110 110 110 110 110 110 110 110 110 110 110 110 110 110 110 
Respiratory Quotient 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 
Raw (cm H2Oll/sec) 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
Caw (ltcm HzO) 0.15 0.15 0.14 0.12 0.11 0.11 0.11 0.13 0.16 0.19 0.20 0.24 0.28 0.30 0.31 
Ventilator Settings 
F!02 (%) 50 70 80 81 82 83 84 84 84 83 82 81 81 74 66 I 
PEEP (cmHzO) 0.0 4.0 5.0 6.0 7.0 8.5 9.5 10.5 11.0 10.5 10.0 9.5 8.0 6.5 5.5 
VT (ml) 700 550 520 490 470 450 440 430 430 430 440 460 500 560 620 
RR (rpm) 12.0 16.5 18.5 20.0 21.0 21.5 21.5 21.5 21.5 21.5 21.5 21.0 19.5 17.5 16.0 
M v (11m in) 8.40 9.08 9.62 9.80 9.87 9.68 9.46 9.25 9.25 9.25 9.46 9.66 9.75 9.80 9.92 I 
TIN (%) 33 50 50 60 60 60 60 60 60 50 50 50 50 50 50 
Advised Ventilator Settings 
F!02 (%) 70 80 81 82 83 84 84 84 83 82 81 81 74 66 63 
PEEP (cmHzO) 4.0 5.0 6.0 7.0 8.5 9.5 10.5 11.0 10.5 10.0 9.5 8.0 6.5 5.5 4.5 
VT (ml) 550 520 490 470 450 440 430 430 430 440 460 500 560 620 620 
RR (rpm) 16.5 18.5 20.0 21.0 21.5 21.5 21.5 21.5 21.5 21.5 21.0 19.5 17.5 16.0 15.5 
Mv (llmin) 9.08 9.62 9.80 9.87 9.68 9.46 9.25 9.25 9.25 9.46 9.66 9.75 9.80 9.92 9.61 
TIN (%) 50 50 60 60 60 60 60 60 50 50 50 50 50 50 50 
--
Table 0.15: Refined advisor decision history for ARDS patient 
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E.t Prototype Control Rules 
FI02 Prototvpe Control Rules 
[I] If(Pa02 = VHI) AND (Fi02 = VHI-MAX) mEN [dFi02 = N6 (-50)] 
[2] If(Pa02= Ill) AND (Fi02= VHI-MAX)nJEN [dFi02= N5 (-35)] 
[3] If (Pa02 = VHI) AND (Fi02 = Ill) mEN [dFi02 = N4 (-30)] 
[4] If(Pa02= HI-VHI) AND (Fi02= MED)THEN [dFi02= N3 (-20)] 
[5] If (Pa02 = Ill) AND (Fi02 = Ill) mEN [dFi02 = N3 (-20)] 
[6) If (Pa02 = SHI) AND (Fi02 = VHI-MAX) mEN [dFi02 = N3 (-20)] 
[7] 1f(Pa02 = SHI) AND (Fi02 = HI) mEN [dFi02= N2 (-15)] 
[8] If(Pa02 = SHI) AND (Fi02 = MED) mEN [dFi02 = NI (-10)] 
[9] 1f(Pa02 = N) mEN [dFi02 = Z (0)] 
[10] If(Pa02= SID-VHI) AND (Fi02= MIN) mEN [dFi02 = Z(O)] 
[U] If(Pa02= VLO-SLO) AND (Fi02 = MAX) mEN [dFi02 = Z (0)] 
[12] If(Pa02 = VLO-SLO) AND (Fi02 = VHI) mEN [dFi02 = PI (10)] 
[13] If(Pa02 = SLO) AND (Fi02 = MIN-Ill) mEN [dFi02 = P2 (20)] 
[14] If(Pa02 = LO) AND (Fi02 = MED-HI) mEN [dFi02 = P3 (30)] 
[15] If(Pa02 = VLO) AND (Fi02 = Ill) mEN [dFi02 = P3 (30)] 
[16) If(Pa02 = LO) AND (Fi02 = MIN) mEN [dFi02 = P4 (40)] 
[17] If(Pa02 = VLO) AND (Fi02 = MED) THEN [dFi02 = P5 (50)] 
[18] If(Pa02= VLO) AND (Fi02 = MIN) mEN (dFi02 = P6 (70)] 
PEEP Prototvpe Control Rules 
[I] If(Pa02 = VHI) AND (Fi02 = MIN) AND (PEEP = MAX) TI-IEN (dPEEP = N8 (-16)] 
[2] If (Pa02 = SID-Ill) AND (Fi02 = MIN) AND (PEEP = MAX) mEN [dPEEP = N7 (-12)] 
[3] If (Pa02 = VHI) AND (Fi02 = MED-MAX) AND (PEEP = MAX) mEN [dPEEP = N7 (-12)] 
[4] If (Pa02 = VHI) AND (PEEP = IDGH) TI-IEN [dPEEP = N6 (-S)] 
[5] If (Pa02 = N) AND (Fi02 = MIN) AND (PEEP = MAX) 1HEN (dPEEP = N6 (-S)] 
(6) 1f(Pa02 = SID-Ill) AND (Fi02 = MED-MAX) AND (PEEP = MAX) mEN [dPEEP= N6 (-S)] 
[7] If(Pa02 = VHI) AND (PEEP = MED) mEN [dPEEP = N5 (~)] 
[8] If (Pa02 = SHI-Ill) AND (Fi02 = MIN) AND (PEEP = IDGH) 1HEN [dPEEP = N5 (~)] 
[9] If(p"a02 = Ill) AND (Fi02 = MED-Ill) AND (PEEP = HIGH) mEN [dPEEP = N5 (-6)] 
[IOJ If(Pa02 = N) AND (Fi02 = MED) AND (PEEP = MAX) mEN [dPEEP = N5 (~)J 
[l1J If(Pa02 = VHI) AND (Fi02 = MIN) AND (PEEP = LOW) mEN [dPEEP = N4 (4)] 
[12] If(Pa02 = N-Ill) AND (Ft02 = MIN-MED) AND (PEEP = MED) 1HEN [dPEEP= N4 (4)J 
[13] If(Pa02=HI) AND (Fi02 =ID-VHI) AND (PEEP = MED) mEN [dPEEP=N4(4)] 
[14] If(Pa02=N)AND (Fi02=MIN-1ll) AND (PEEP = IDGH)mEN [dPEEP=N4 (-4)] 
[15] If(Pa02 = Sill) AND (Fi02 = MED-VHI) AND (PEEP = IDGH) mEN [dPEEP = N4 (4)] 
[16) If(Pa02 = Ill) AND (Ft02 = VHI-MAX) AND (PEEP = IDGH) THEN [dPEEP = N4 (4)] 
[17] If(Pa02 = LO-SLO) AND (Fi02 = MIN-MED) AND (PEEP = MAX) TIiEN [dPEEP = N4 (-4)] 
[18] If(Pa02 = N) AND (Fi02 = HI-MAX) AND (PEEP = MAX) 1HEN [dPEEP = N4 (4)] 
[19] If(Pa02 = SID-HI) AND (Ft02 = MIN) AND (PEEP = LOW) 1HEN (dPEEP = N3 (-3)] 
[20] If(Pa02= VHl)AND (Fi02= MED-HI)AND (PEEP = LOW)TIIEN [dPEEP= N3 (-3)] 
[21] If(Pa02 = N) AND (Fi02 = MIN) AND (PEEP = LOW) mEN [dPEEP = N2 (-2)] 
[22] If(Pa02 = Ill) AND (Fi02 = MED) AND (PEEP = LOW) mEN [dPEEP= N2 (-2)] 
[23] If(Pa02 = VHI) AND (Fi02 = VHI-MAX) AND (PEEP = LOW) TIIEN (dPEEP = N2 (-2)] 
[24] If (Pa02 = LO-SLO) AND (Fi02 = MIN) AND (pEEP = MED-IDGH) TIiEN [dPEEP = N2 (-2)] 
[25] If(Pa02 = N-SID) AND (Fi02 = Ill) AND (PEEP = MEO) THEN [dPEEP = N2 (-2)] 
[26) If(Pa02 = SID) AND (Fi02= VHI) AND (PEEP = MED)THEN [dPEEP= N2 (-2)] 
[27] 1f(Pa02 = ID) AND (Fi02 = MAX) AND (PEEP = MEO) TIIEN (dPEEP = N2 (-2)] 
[28J 1f(Pa02 = LO-SLO) AND (Fi02 = MEO) AND (PEEP = IDGH) TIIEN [dPEEP = N2 (-2)] 
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[29] If(Pa02 = N) AND (Fi02 = VIll) AND (PEEP = HIGH) 1HEN [dPEEP = N2 (-2)] 
[30J If(Pa02 = SHI) AND (Fi02 = MAX) AND (PEEP = HIGH) 1HEN [dPEEP = N2 (-2)J 
[31 J If(Pa02 = VLO) AND (Fi02 = MIN) AND (PEEP = MAX) 1HEN [dPEEP = N2 (-2)] 
[32J If(Pa02 = HI) AND (Fi02 = HI) AND (PEEP = LOW) 1HEN [dPEEP = Nl (-I)J 
[33J If(Pa02 = SLO-VIll) AND (Fi02 = MIN) AND (PEEP = OFF) 1HEN [dPEEP= Z (0)] 
[34] If(Pa02= N-SHI) AND (Fi02 = MID-HI) AND (PEEP = OFF-LOW)1HEN [dPEEP= Z(O)] 
[35] If(Pa02= HI-VIll) AND (Fi02= MED-MAX) AND (PEEP = OFF) 1HEN [dPEEP= Z (0)] 
[36] If(Pa02= SHI) AND (Fi02= VHI-MAX) AND (PEEP = OFF-LOW)1HEN [dPEEP= Z(O)] 
[37] If(Pa02 = LO-SLO) AND (Fi02 = MIN) AND (PEEP = LOW) 1HEN [dPEEP = Z (O)J 
[38J If(Pa02 = SLO) AND (Fi02 = MED-HI) AND (PEEP = LOW-MED) 1HEN [dPEEP = Z (0)] 
[39J If(Pa02 = N) AND (Fi02 = VHI-MAX) AND (PEEP = LOW) mEN [dPEEP = Z (O)J 
[40] If(Pa02 = HI) AND (Fi02 = VHI-MAX) AND (PEEP = LOW) 1HEN [dPEEP = Z (O)J 
[41] If(Pa02 = VLO) AND (Fi02 = MIN) AND (PEEP = MED-HIGH) 1HEN [dPEEP= Z (0)] 
[42J If(Pa02 = LO) AND (Fi02 = MFD-HI) AND (PEEP = MED) mEN [dPEEP = Z (0») 
[43] If(Pa02 = N) AND (Fi02 = VIll) AND (PEEP = MED) 1HEN [dPEEP = Z (0») 
[44J If(Pa02 = VLO) AND (Fi02 = MED) AND (PEEP = HIGH-MAX) 1HEN [dPEEP = Z (0)] 
[45J Jf(Pa02 = LO-SLO) AND (Fi02 = HI-VHI) AND (PEEP = IDGH-MAX) THEN [dPEEP = Z (0)] 
[46] If(Pa02 = N) AND (Fi02 = MAX) AND (PffiP= HIGH) 1HEN [dPEEP= Z (0)] 
[47] Jf(Pa02 = VLO) AND (Fi02 = HI-MAX) AND (PEEP = MAX) 1HEN [dPEEP = Z (0)] 
[48] Jf(Pa02 = LO-SLO) AND (Fi02 = MAX) AND (PEEP = MAX) 1HEN [dPEEP = Z (0)] 
[49J If(Pa02 = VLO) AND (Fi02 = MlN-MED) AND (PEEP = LOW) 1HEN [dPEEP = PI (2)] 
[50] If(Pa02 = LO) AND (Fi02 = MED-HI) AND (PEEP = LOW) mEN [dPEEP = PI (2)J 
[51] If(Pa02 = SLO) AND (Fi02 = VHI) AND (PEEP = LOW-MED) 1HEN [dPEEP = PI (2)] 
[52] Jf(Pa02 = VLO) AND (Fi02 = MED-HI) AND (PEEP = MED) 1HEN [dPEEP = PI (2)] 
[53] Jf(Pa02 = LO) AND (Fi02 = VIll) AND (PEEP = MED) 1HEN [dPEEP = PI (2») 
[54] If(Pa02 = N-SHI) AND (Fi02 = MAX) AND (PEEP = MED) mEN [dPEEP = PI (2)] 
[55] If(Pa02 = VLO) AND (Fi02 = HI-VIll) AND (PEEP = HIGH) 1HEN [dPEEP = PI (2») 
[56J If(Pa02= LO-SLO) AND (Fi02= MAX) AND (PEEP = HIGH) mEN [dPEEP= PI (2») 
[57] If(Pa02= VLO-LO) AND (Fi02 = MlN-HI) AND (PEEP = OFF) mEN [dPEEP= P2 (4)J 
[58] If(Pa02= SLO) AND (Fi02 = MED-MAX) AND (PEEP = OFF) 1HEN [dPEEP = P2 (4)] 
[59] If(Pa02 = LO) AND (Fi02 = VIll) AND (PEEP = OFF-LOW) 1HEN [dPEEP = P2 (4») 
[60] If(Pa02=N) AND (Fi02= VHI-MAX) AND (PEEP = OFF) mEN [dPEEP= P2 (4») 
[61] If(Pa02 = VLO) AND (Fi02 = HI-MAX) AND (PEEP = LOW) 1HEN [dPEEP = P2 (4)] 
[62J If(Pa02 = LO-SLO) AND (Fi02 = MAX) AND (PEEP = LOW-MED) mEN [dPEEP = P2 (4)J 
[63] If(Pa02 = VLO) AND (Fi02 = VHI-MAX) AND (PEEP = MED) 1HEN [dPEEP = P2 (4)] 
[64] If(Pa02 = VLO) AND (Fi02 = MAX) AND (PEEP = HIGH) mEN [dPEEP = P2 (4)] 
[65] If(Pa02= VLO) AND (Fi02 = VHI-MAX) AND (PEEP = OFF) TI-IEN [dPEEP= P3 (8)] 
[66] If(Pa02 = LO) AND (Fi02 = MAX) AND (PEEP = OFF) 1HEN [dPEEP = P3 (8») 
Mv PrototyPe Control Rules 
[1] Jf(cPaC02 = NB) AND (cPh= VALK)1HEN[dMv= N6 (-60)] 
[2] Jf(ePaC02 = NB) AND (cPh = ALK) 1HEN [dMv = N5 (-45)] 
[3] Jf(ePaC02 = NB) AND (cPh=NORM)1HEN [dMv=N4 (-30)] 
[4] Jf(ePaC02 =NS) AND (cPh=ALK-VALK)1HEN [dMv= N4 (-30)] 
[5] Jf(ePaC02=NS) AND (ePh= NORM) 1HEN [dMv=N3 (-15)] 
[6] Jf(ePaC02=Z) AND(ePh=VALK)1HEN[dMv= N3 (-15)] 
[7] Jf(ePaC02 = NB-Z) AND (ePh = VACID-ACID) AND (ePip = VHIGH) TIffiN [dMv = N3 (-15)] 
[8] Jf(ePaC02=Z) AND (ePh = NORM-ALK) AND (ePip=VHIGH)1HEN[dMv=N3 (-15)] 
[9] Jf(ePaC02 =PS-PB) AND (ePh=ALK-VALK) AND(ePip=VHIGH)1HEN[dMv=N3 (-15)] 
(lO]Jf(ePaC02=NB-Z)AND(ePh=VACID-ACID)AND(cPip=HIGH)1HEN[dMv=N2(-IO)] 
[11] If(ePaC02 = Z) AND (cPh = NORM-ALK) AND (ePip= HIGH) mEN [dMv= N2 (-10)] 
[12] Jf(ePaC02 = PS-PB) AND (ePh = ALK-V ALK) AND (ePip= HIGH) 1HEN [dMv= N2 (-10)] 
[13] Jf(ePaC02 = PS-PB) AND (ePh = VACID-NORM) AND (ePip= VHIGH) THEN [dMv= N2 (-10)] 
[14] If(ePaC02 = Z) AND (ePh = ALK) AND (ePip = OKA Y-ALARM) mEN [dMv= Nl (-5)] 
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[15] Jf(ePa(X)2= NB-NS) AND (ePh = VACID-ACID) AND (ePip=OK-ALARM) mEN [dMv= Z(O)] 
[16] Jf(cPa(X)2=Z) AND (ePh=ACID-NORM) AND (cPip=OKAY-ALARM)TIffiN [dMv= Z (0)] 
[17] Jf(cPa(X)2 = PS-PB) AND (ePh = ALK-VALK) AND (cPip=OK-ALARM) THEN [dMv=Z (0)] 
[18] Jf(ePa(X)2=Z) AND (ePh= VACID) AND (ePip= ALARM) TIffiN [dMv= Z (0)] 
[19] Jf(ePa(X)2= PS) AND (ePh = NORM) AND (ePip= ALARM-HIGH)TI-JEN [dMv= Z (0)] 
[20] Jf(ePa(X)2 = PS-PB) AND (ePh = VACID-ACID) AND (ePip= HIGH) mEN [dMv = Z (0)] 
[21] Jf(ePa(X)2 = PB) AND (ePh = NORM) AND (ePip = HIGH) 1HEN [dMv= Z (0)] 
[22] Jf(cPa(X)2 = Z) AND (ePh = VACID) AND (ePip = OKA Y-NRALARM) TI-JEN [dMv = PI (15)] 
[23] Jf(cPa(X)2 = PS) AND (ePh = V ACID-ACID) AND (cPip = ALARM) mEN [dMv = PI (15)] 
[24] Jf(cPa(X)2 = PB) AND (ePh= ACID-NORM) AND (cPip= ALARM) mEN [dMv= PI (15)] 
[25] Jf(ePaC02 = PS) AND (ePh = NORM) AND (cPip = OKA Y-NRALARM) mEN [dMv= P2 (25)] 
[26] Jf(cPaC02 = PS) AND (ePh = VACID-ACID) AND (cPip = NRALARM) mEN [dMv = P2 (25)] 
[27] Jf(cPa(X)2 = PB) AND (ePh = ACID-NORM) AND (cPip = NRALARM) TI-JEN [dMv = P2 (25)] 
[28] Jf(ePaC02 = PB) AND (ePh = VACID) AND (ePip = ALARM) TIffiN [dMv = P2 (25)] 
[29] Jf(ePaC02= PS)AND (ePh= VACID-ACID) AND (cPip= OKAy) mEN [dMv= P3 (50)] 
[30] Jf(ePa(X)2 = PB) AND (ePh = NORM) AND (ePip= OKAy) TIffiN [dMv= P3 (50)] 
[31] Jf(ePaC02 = PB) AND (ePh= VACID) AND(cPip= NRALARM) TIffiN [dMv= P3 (50)] 
[32] Jf(ePa(X)2 = PB) AND (cPh= ACID) AND (cPip= OKAy) mEN [dMv= P4 (7S)] 
[33] Jf(ePaC02 = PB) AND (cPh = VACID) AND (ePip= OKAy) TIffiN [dMv= PS (100)] 
VT-RR Prototvpe Control Rules 
[1] Jf(RR = MIN-LOW) AND (eVfnonn = PB)TIffiN [dVt= N7 (-35)] 
[2] If(RR = MIN) AND (eVfoonn = PS) 1lIEN [dVt= N6 (-30)J 
[3J If(RR = MED) AND (eVfnonn = PB) 1lIEN [dVt = N5 (-25)J 
[4] If(RR= VLOW-LOW) AND (eVfnonn=ps)1lIEN [dVt=N4(-20)] 
[5] Jf(RR = MIN) AND (eVfnonn=Z)1HEN [dVt=N3 (-IS)] 
[6] Jf(RR =MED) AND (eVfnonn=PS)1HEN [dVt= N3 (-15)] 
[7] Jf(RR= HIGH) AND (eVfnonn=PB)1HEN [dVt=N3 (-15)] 
[8] Jf{RR=VLOW-VHIGH)AND (eVfnonn=Z) AND (cPip= VHIGH)1HEN [dVt=N3 (-15)] 
[9] Jf(RR=VLOW)AND (cVfnonn=Z) AND (cPip= ALARM-HIGH)1H8N [dVt= N2(-10)] 
[10] Jf(RR = LOW-MED) AND (eVfnonn=Z) AND (ePip = HIGH) mEN [dVt=N2 (-10)] 
[11] Jf(RR=M1N-VHIGH)AND (eVfnonn= NS)AND (cPip=VHIGH)TI-JEN [dVt=N2 (-10)] 
[12] Jf(RR=HIGH-MAX) AND (eVfnonn=PS) AND (cPip= VHIGH)mEN [dVt=N2 (-10)] 
[13] Jf(RR = VHIGH-MAX) AND (eVfnonn = PB) AND (cPip = VHIGH) mEN [dVt = N2 (-10)] 
[14] Jf(RR=MIN) AND (eVfnonn=NS)AND (cPip=OKAY-HIGH)mEN [dVt=Nl (-S)] 
[15] If{RR=VLOW) AND (eVfnonn=Z) AND (cPip=OKAY-NRALARM)1HEN[dVt=Nl (-S)] 
[16] Jf(RR = HIGH) AND (eVfnonn=PS) AND (cPip= OKAY-HIGH)1lIEN [dVt=Nl (-5)] 
[17] Jf(RR= VHIGH-MAX) AND (eVfnonn=PB) AND (cPip=OKAY-HIGH)1HEN [dVt= Nl (-5)] 
[18] Jf(RR=VLOW-LOW) AND (eVfnonn=NS) AND (cPip=ALARM-HIGH)1HEN[dVt=Nl (-S») 
[19] Jf(RR=LOW-HIGH) AND (eVfnonn=Z) AND (cPip=ALARM)1H8N [dVt=Nl (-5)] 
[20] Jf(RR=VHIGH) AND (eVfnonn = PS) AND (cPip=ALARM-HIGH)TI-JEN [dVt=NI (-5») 
[21] Jf(RR = MED-VHIGH) AND (eVfnonn=NS) AND (cPip= HIGH) 1HEN [dVt=Nl (-S)] 
[22] Jf(RR =HIGH-VHIGH) AND (eVfnonn=Z) AND (cPip= HIGH) mEN [dVt=Nl (-S)J 
[23] Jf(RR=MAX) AND (eVfnonn=PS) AND (cPip= HIGH) 1lIEN [dVt=Nl (-S)J 
[24] Jf(RR=LOW-MED) AND (eVfnonn=Z) AND (ePip=OKAY-NRALARM)1HEN [dVt=Z(O)] 
[25] Jf(RR = VLOW) AND (eVfnonn = NS) AND (cPip = NRALARM) mEN [dVt = Z (O)J 
[26] Jf(RR = HIGH) AND (eVfnonn = Z) AND (ePip= NRALARM) mEN [dVt = Z (0)] 
[27] Jf(RR=VHIGH) AND (eVfnonn = PS) AND (cPip=NRALARM)mEN [dVt=Z(O)J 
[28] Jf(eVfnonn = NB) AND (cPip= ALARM-VHIGH) 1lIEN [dVt= Z (0)] 
[29] Jf(RR = MED-MAX) AND (eVfnonn = NS) AND (cPip= ALARM) mEN [dVt = Z (0)] 
[30] Jf(RR = VHIGH-MAX) AND (eVfnonn = Z) AND (ePip = ALARM) lliEN [dVt = Z (0)] 
(31] Jf(RR = MAX) AND (eVfnonn = PS) AND (cPip= ALARM) mEN [dVt = Z (0)] 
(32] Jf(RR = MAX) AND (eVfnonn=NS-Z) AND (cPip= HIGH-VHIGH)lliEN [dVt= Z (0)] 
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[33] If(RR = VLOW) AND (eVfoonn = NS) AND (ePip = OKAy) TI-IEN [dVt = PI (2)] 
[34] If(RR= VIllGH) AND (eVfnonn=PS) AND (cl>ip=OKAy)1HEN [dVt=Pl (2)] 
[35] If(RR = MIN) AND (eVfnonn = NB) AND (ePip= OKA Y-NRALARM) mEN [dVt = P2 (5)] 
[36] If(RR = IDGH) AND (eVfoonn = Z) AND (ePip = OKAy) TI-IEN [dVt = P2 (5)] 
[37] If(RR = LOW) AND (eVfnonn = NS) AND (cPip = NRALARM) 1HEN [dVt = P2 (5)] 
[38] If(RR = MAX) AND (eVfnonn = PS) AND (ePip = NRALARM) mEN [dVt = P2 (5)] 
[39] If(RR = LOW) AND (eVfnonn = NS) AND (cPip = OKAy) 1HEN [dVt = P3 (10)] 
[40] If(RR = MAX) AND (eVfnonn = PS) AND (cPip = OKAy) 1HEN [dVt = P3 (10)] 
[41] If(RR = VLOW-MAX) AND (eVfoonn = NB) AND (cl>ip=NRALARM) mEN [dVt= P3 (10)] 
[42] If(RR = MED-MAX) AND (eVfoonn = NS) AND (ePip = NRALARM) 1HEN [dVt = P3 (10)] 
[43] If(RR=VIllGH-MAX) AND (cVfnonn=Z) AND (cPip=NRALARM)mEN [dVt=P3 (10)] 
[44] If(RR=VLOW) AND (eVfnonn =NB) AND (ePip=OKAy)TI-IEN[dVt=P4(lS)] 
[45] If(RR = MED-IDGH) AND (eVfnonn = NS)AND (cPip=OKA Y)TI-IEN [dVt= P4 (IS)] 
[46] If(RR=VIllGH) AND (eVfnonn=Z) AND (ePip= OKAY)1HEN [dVt= P4 (15)] 
[47] If(RR = LOW) AND (eVfnonn = NB) AND (cPip = OKAy) 1HEN [dVt = PS (25)] 
[48] If(RR = VIllGH) AND (eVfnonn = NS)AND (cPip=OKAY)1HEN [dVt= P5 (25)] 
[49] If(RR = MAX) AND (eVfnonn = Z) AND (ePip = OKAy) mEN [dVt = PS (25)] 
[50] If(RR = MAX) AND (eVfnonn=NS) AND (cPip=OKAY)1HEN [dVt=fY) (3S)] 
[SI] If(RR = MED-VIllGH) AND (eVfnonn = NB) AND (cPip= OKAy) mEN [dVt = P7 (40)] 
[52] If(RR = MAX) AND (eVfnonn = NB) AND (cPip= OKA Y)1HEN [dVt= P8 (50)] 
E.2 Refined Control Rules 
FI02 Refined Control Rules 
[I] If (Pa02 = VIll) AND (Fi02 = MAX) mEN [dFi02 = N9 (-50)] 
[2] If(Pa02 = VIll) AND (Fi02 = EHI) 1HEN [dFi02 = N8 (-40)] 
[3] If(Pa02 = Ill) AND (Fi02= EIll-MAX)mEN [dFi02= N7 (-35)] 
[4] If(Pa02 = VIll) AND(Fi02 = VHI) 1HEN [dFi02= N6 (-30)] 
[5] If(Pa02 = Ill) AND (Fi02= VHl)TI-IEN [dFi02= NS (-25)] 
[6] If(Pa02 = VIll) AND (Fi02 = MED_ID-HI)1HEN [dFi02= N4 (-20)] 
[7] If(Pa02 = Ill) AND (Fi02 = ID) TIffiN [dFi02 = N4 (-20)] 
[8] If(Pa02 = SHI) AND (Fi02 = MAX)1HEN [dFi02 = N4 (-20)] 
[9] If(Pa02 = Ill) AND (Fi02 = MED _HI) TI-IEN [dFi02 = N3 (-IS)] 
[10] If(Pa02= SID-VHI) AND (Fi02 =MED)1HEN [dFi02=N2 (-10)] 
[U] If(Pa02= Sill) AND (Fi02= ID-EHI)1HEN [dFi02 = N2 (-10)] 
[12] If(Pa02= VHI) AND (Fi02= VLOW-LOW)1HEN [dFi02= NI (-S)] 
[13] If(Pa02= SID-HI) AND (Fi02=LOW)TI-IEN [dFi02=NI (-S)] 
[14] If(Pa02 = N) AND (Fi02 = Ern-MAX) TI-IEN [dFi02 = NI (-5)] 
[15] If(Pa02 = N) AND (Fi02 = MIN-VHl) TIffiN [dFi02 = Z (0)] 
[16) If(Pa02 = SID-HI) AND (Fi02 = MIN-VLOW) TI-IEN [dFi02 = Z (0)] 
[17] If(Pa02= VHl)AND (Fi02 = MlN)1HEN [dFi02 = Z(O)] 
[18] If(Pa02= SID) AND (Fi02= MED _HI)TI-IEN [dFi02 = Z(O)] 
[19] If(Pa02 = SLO) AND (Fi02 = VID-MAX) TI-IEN [dFi02 = Z (0)] 
[20] If(Pa02 = 10) AND (Fi02 = Ern-MAX) 1HEN [dFi02 = Z (0)] 
[21] If(Pa02= VLO) AND (Fi02= MAX) TIffiN [dFi02= Z(O)] 
[22] If(Pa02 = LO) AND (Fi02 = VHI) TIffiN [dFi02 = PI (5)] 
[23] If(Pa02 = LO-SLO) AND (Fi02 = HI) TI-IEN [dFi02 = P2 (10)] 
[24] If(Pa02 = VLO) AND (Fi02 = VIll-EHI) TI-IEN [dFi02 = P2 (10)] 
[25] If(Pa02 = SLO) AND (Fi02 = MED _Ill) TI-IEN [dF102 = P3 (IS)] 
[26] If(Pa02 = SLO) AND (Fi02 = MIN-MED) TI-IEN [dFi02 = P4 (20)] 
[27] If(Pa02 = LO) AND (Fi02 = LOW-MED _ HI) TI-IEN [dFi02 = P4 (20)] 
[28] If(Pa02 = VLO) AND (Fi02 = HI) TIffiN [dFi02 = P5 (30)] 
[29] If(Pa02 = LO) AND (Fi02 = VLOW) TI-IEN [dFi02 = fY) (35)] 
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[30] If(Pa02 = LO) AND (Fi02 = MIN) TIIEN [dFi02 = P7 (40)] 
[31] If(Pa02= VLO) AND (Fi02 = MED_HI)1HEN [dFi02 = P7 (40)] 
[32] If(Pa02 = VLO) AND (Fi02 = LOW-MED) TIIEN [dFi02 = P8 (50)] 
[33] If(Pa02 = VLO) AND (Fi02 = VLOW) TIIEN [dFi02 = P9 (65)] 
[34] If(Pa02 = VLO) AND (Fi02 = MIN) TIIEN [dFi02 = PIO (70)] 
PEEP Refined Control Rules 
[1] Jf(Pa02 = VHI) AND (Fi02 = MIN) AND (PEEP = MAX) THEN [dPEEP = N6 (-16)] 
[2] Jf(Pa02 = SHI-HI) AND (Fi02 = MIN) AND (PEEP = MAX) 1HEN [dPEEP = N5 (-12)] 
[3] Jf(Pa02 = VHI) AND (Fi02 = MEO-MAX) AND (PEEP = MAX) 1HEN [dPEEP = N5 (-12)] 
[4] If(Pa02 = VHI) AND (PEEP = HIGH) TIIEN [dPEEP = N4 (~)] 
[5] If(Pa02 = N) AND (Fi02 = MIN) AND (PEEP = MAX) TIIEN [dPEEP = N4 (~)] 
[6] Jf(Pa02 = SHI-HI) AND (Fi02 = MED-MAX) AND (PEEP = MAX) TIIEN [dPEEP= N4 (~)] 
[7] If(Pa02 = VHI) AND (PEEP = MED) mEN [dPFEP = N3 (-6)] 
[8] If (Pa02 = SHI-HI) AND (Fi02 = MIN) AND (PEEP = IDGH) 1HEN [dPEEP = N3 (-6)] 
[9] If (Pa02 = HI) AND (Fi02 = MEO-HI) AND (PEEP = HIGH) 1HEN [dPEEP = N3 (-6)] 
[10] If(Pa02 = N) AND (Fi02 = MED) AND (PEEP = MAX) mEN [dPEEP = N3 (-6)] 
[11] If(Pa02 = ID-VHI) AND (Fi02 = MIN) AND (PEEP = LOW) TIIEN [dPEEP = N2 (4)] 
[12] Jf(Pa02= N-HI) AND (H02 = MIN-MED) AND (PEEP = MED)1HEN [dPEEP= N2 (4)] 
[13] If(Pa02 = HI) AND (Fi02 = HI-VHI) AND (PEEP = MED) 1HEN [dPEEP = N2 (4)] 
[14] If(Pa02=N) AND (Fi02=MIN-HI) AND (PEEP = HIGH) TIIEN [dPEEP=N2 (4)] 
[15] If(Pa02 = SHI) AND (Fi02 = MEO-VHI) AND (PEEP = IDGH) mEN [dPEEP = N2 (4)] 
[16] If(Pa02 = HI) AND (Fi02 = VIII-MAX) AND (PEEP = HIGH) TIIEN [dPEEP = N2 (4)] 
[17] If(Pa02 = LO-SLO) AND (Fi02 = MIN-MED) AND (PEEP = MAX) mEN [dPEEP = N2 (4)] 
[18] If(Pa02 = N) AND (Fi02 = HI-MAX) AND (PEEP = MAX) mEN [dPEEP = N2 (4)] 
[19] If(Pa02 = N-SHI) AND (Fi02 = MIN) AND (PEEP = LOW) mEN [dPFEP = Nl (-2)] 
[20] If(Pa02= HI-VHI) AND (Fi02 =MEO-HI) AND (PEEP = LOW)TI-fEN [dPEEP= Nl (-2)] 
[21] If(Pa02 = LO-SLO) AND (Fi02 = MIN) AND (PEEP = MED-HIGH) mEN [dPEEP = Nl (-2)] 
[22] If(Pa02 = N-SHI) AND (Fi02 = HI) AND (PEEP = MED) mEN [dPEEP = Nl (-2)] 
[23] If(Pa02= SHI) AND (Fi02= VHI) AND (PEEP = MED) mEN [dPEEP= Nt (-2)] 
[24] If(Pa02 = HI) AND (VI02 = MAX) AND (PEEP = MED) TIIEN [dPEEP = Nl (-2)] 
[25] If(Pa02=LO-SLO) AND (Fi02=MED) AND (PEEP = HIGH) mEN [dPEEP=Nt (-2)] 
[26] If(Pa02 = N) AND (Fi02 = VHI) AND (PEEP = HIGH) mEN [dPEEP = Nl (-2)] 
[27] If(Pa02 = SHI) AND (Fi02 = MAX) AND (PEEP = HIGH) 1HEN [dPEEP = Nt (-2)] 
[28] If(Pa02= VLO) AND (Fi02 = MIN) AND (PEEP = MAX) mEN [dPEEP= Nt (-2)] 
[29] If(Pa02 = SL(). VHI) AND (Fi02 = MIN) AND (PEEP = OFF) TIIEN [dPEEP = Z (0)] 
(30] If(Pa02 = HI-VHI) AND (Fi02 = MED-MAX) AND (PEEP = OFF) TIIEN [dPEEP = Z (0)] 
(31] If(Pa02 = N-SHI) AND (Fi02 = HI) AND (PEEP = OFF-LOW) 1HEN [dPEEP = Z (0)] 
(32] If(Pa02 = SHI) AND (Fi02 = VIII-MAX) AND (PEEP = OFF-LOW) 1HEN [dPEEP = Z (0)] 
[33] If(Pa02 = LO-SLO) AND (Fi02 = MIN) AND (PEEP = LOW) TIIEN [dPEEP = Z (0)] 
[34] If(Pa02 = SLO) AND (Fi02 = MEO-HI) AND (PEEP = LOW-MED) TIIEN [dPEEP = Z (0)] 
[35] If(Pa02 = N-SHI) AND (Fi02 = MEn) AND (PEEP = LOW) mEN [dPEEP = Z (0)] 
(36] If(Pa02 = SL().N) AND (Fi02 = VHI) AND (PEEP = LOW) mEN [dPEEP = Z (0)] 
(37] If(Pa02 = HI-VHI) AND (V02 = VHI-MAX) AND (PEEP = LOW) 1HEN [dPEEP = Z (0)] 
[38] If(Pa02 = N) AND (Fi02 = MAX) AND (PEEP = LOW) mEN [dPEEP = Z (0)] 
[39] If(Pa02 = VLO) AND (Fi02 = MIN) AND (PEEP = MED-HIGH) TI-IEN [dPEEP = Z (0)] 
[40] If(Pa02= LO) AND (Fi02 = MEn-HI) AND (PEEP = MED)1HEN [dPEEP= Z(O)] 
[41] If(Pa02 = N) AND (Fi02 = VHI) AND (PEEP = MED) mEN [dPEEP = Z (0)] 
[42] If(Pa02 = VLO) AND (Fi02 = MED) AND (PEEP = HIGH-MAX) TI-fEN [dPEEP = Z (0)] 
[43] If(Pa02 = LO-SLO) AND (Fi02 = HI-VHI) AND (PEEP = HIGH-MAX) mEN [dPEEP = Z (0)] 
[44] If(Pa02 = N) AND (Fi02 = MAX) AND (PEEP = HIGH) TIIEN [dPEEP = Z (0)] 
[45] If(Pa02 = VLO) AND (Fi02 = HI-MAX) AND (PEEP = MAX) 1HEN [dPEEP = Z (0)] 
[46] If(Pa02 = LO-SLO) AND (Fi02 = MAX) AND (PEEP = MAX) 1HEN [dPEEP = Z (0)] 
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[47] 1f(Pa02 = N-SHI) AND (Fi02 = MED) AND (PEEP = OFF) 1HEN [dPEEP = PI (2)] 
[48] 1f(Pa02= VLO) AND (Fi02=MIN-MED) AND (PEEP = LOW) THEN [dPEEP= PI (2)] 
[49] 1f(Pa02= LO) AND (Fi02= MED) AND (PEEP = LOW)1HEN [dPEEP= PI (2)] 
[SO] 1f(Pa02 = VLO) AND (Fi02 = MED-HI) AND (PEEP = MED) 1HEN [dPEEP = PI (2)] 
[51] 1f(Pa02 = LO-SLO) AND (Fi02 = VHl) AND (PEEP = MEO) THEN [dPEEP = PI (2)] 
[52] 1f(Pa02 = N-SHI) AND (Fi02 = MAX) AND (PEEP = MEO) 1HEN [dPEEP = PI (2)] 
[53] 1f(Pa02 = VLO) AND (Fi02 = Ill-VHl) AND (PEEP = IllGH) 1HEN [dPEEP = PI (2)] 
[54] 1f(Pa02= LO-SLO) AND (Fi02 = MAX) AND (PEEP=IllGH) mEN [dPEEP=PI (2)] 
[55] 1f(Pa02= VLO-LO) AND (Fi02=MIN-HI) AND (PEEP = 0FF)1HEN (dPEEP=P2 (4)] 
[56] 1f(Pa02 = SLO) AND (Fi02 = MED-MAX) AND (PEEP = OFF) THEN (dPEEP = P2 (4)] 
[57] 1f(Pa02 = LO) AND (Fi02 = VHl) AND (PEEP = OFF) 1HEN [dPEEP = P2 (4)] 
[58] 1f(Pa02 = N) AND (Fi02 = VIll-MAX) AND (PEEP = OFF) mEN [dPEEP = P2 (4)] 
[59] 1f(Pa02 = LO) AND (Fi02 = HI) AND (PEEP = LOW) 1HEN [dPEEP = P2 (4)] 
(60] 1f(Pa02 = SLO) AND (Fi02 = MAX) AND (PEEP = LOW-MEO) THEN [dPEEP = P2 (4)] 
[61] 1f(Pa02 = VLO) AND (Fi02 = VIll-MAX) AND (PEEP = MED) 1HEN [dPEEP = P2 (4)] 
[62] 1f(Pa02 = LO) AND (Fi02 = MAX) AND (PEEP = MEO) mEN [dPEEP = P2 (4)] 
[63] 1f(Pa02 = VLO) AND (Fi02 = MAX) AND (PEEP = IllGH) 1HEN [dPEEP = P2 (4)] 
[64] 1f(Pa02 = VLO) AND (Fi02 = Ill-MAX) AND (PEEP = LOW) 1HEN [dPEEP = P3 (6)] 
[65] 1f(Pa02 = LO) AND (Fi02 = VIll-MAX) AND (PEEP = LOW) mEN [dPEEP = P3 (6)] 
[66] 1f(Pa02 = VLO) AND (Fi02 = VIll-MAX) AND (PEEP = OFF) THEN [dPEEP = P4 (8)] 
[67] If(P'd02 = LO) AND (Fi02 = MAX) AND (PEEP = OFF) 1HEN [dPEEP = P4 (8)] 
Mv Refined Control Rules 
[1] If(ePaC02 = NB) AND (Pip = VHIGH-EIDGH) 1HEN [dMv = N6 (-60)] 
[2] If(ePaC02 = NB) AND (Pip = LOW-HIGH)1HEN [dMv= N5 (-55)] 
[3] If(ePaC02=NM) THEN [dMv=N4 (-30)] 
[4] If(ePaC02 = NS) 1HEN [dMv = N3 (-15)] 
[5] If(ePaC02= ZrPM) AND (Pip=EHIGH) THEN [dMv= N3 (-15)] 
[6] If(cPaC02= PB) AND (Pip = EHIGH)1HEN [dMv= N2 (-10)] 
[7] If(ePaC02 = Z) AND (Pip = VIllGH) mEN [dMv = Nl (-5)] 
[8] If(ePaC02 = Z) AND (Pip = LOW-IllGH) 1HEN [dMv = Z (0)] 
[9] If (ePaC02 = PS-PM) AND (Pip = MED-VIDGH) AND (eVI'nonn = NB) 1HEN [dMv = Z (0)] 
[10] If(ePaC02 = PB-PVB) AND (Pip = IllGH-VHIGH) AND (eVI'nonn = NB) 1HEN [dMv = Z (0)] 
[11] If(ePaC02 = PVB) AND (Pip = EHIGH) AND (eVI'oonn = NB) mEN [dMv= Z(O)] 
[12] If(ePaC02 = PS) AND (Pip = IllGH-VHIGH) AND (eVI'oonn=OK)THEN [dMv= Z (0)] 
[13] If(ePaC02= PS)AND (Pip=MED) AND (eVI'oonn= OK) 1HEN [dMv=PI (5)] 
[14] If(ePaC02 = PM) AND (Pip=VHIGH) AND (eVI'nonn= OK) 1HEN [dMv=PI (5)] 
[15] If(ePaC02 = PVB) AND (Pip = EHIGH) AND (eVI'oonn = OK) THEN [dMv= PI (5)] 
[16] If(ePaC02 = PB) AND (Pip=MED) AND (eVI'nonn=NB)1HEN[dMv=P2 (10)] 
[17] If(ePaC02=PB-PVB) AND (Pip = VIDGH) AND (eVI'nonn = OK) mEN [dMv= P2 (10)] 
[18] If(ePaC02= PS)AND (Pip=LOW)1HEN [dMv=P3 (15)] 
[19] If(ePaC02 = PM) AND (Pip = MED-IllGH) AND (eVI'nonn = OK) 1HEN [dMv = P3 (15)] 
[20] If(ePaC02 = PVB) AND (Pip = MEO) AND (eVI'oonn = NB) mEN [dMv = P4 (20)] 
[21] If(ePaC02 = PB-PVB) AND (Pip = IllGH) AND (eVI'nonn = OK) 1HEN [dMv= P5 (25)] 
[22] If(ePaC02 = PM) AND (Pip = LOW) 1HEN [dMv = P6 (30)] 
[23] If(ePaC02 = PB-PVB) AND (Pip = MEO) AND (eVI'nonn = OK) 1HEN [dMv = P6 (30)] 
[24] If(ePaC02 = PB) AND (Pip = LOW) 1HEN [dMv = P7 (60)] 
[25] If(ePaC02 = PVB) AND (Pip = LOW) mEN [dMv= P8 (90)] 
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VT-RR Refined Control Rules 
[I] If(RR = MIN-LOW) AND (eVTnonn = PM) AND (Pip = EillGH) mEN [dVt = N7 (-35)] 
[2] If(RR = MIN) AND (eVTnonn = PM) AND (Pip = LOW-VlllGH) THEN [dVt = N6 (-30)] 
[3] If(RR=MIN-MED)AND (eVTnonn= Z-PS) AND (Pip = VlllGH-EHIGH) mEN [dVt=N5 (-25)] 
[4] If(RR= IllGH) AND (eVTnonn=P5-PM) AND (Pip = VlllGH-EHIGH) THEN [dVt= N5 (-25)] 
[5) If(RR=VLOW-MED) AND (eVTnonn=PM) AND (Pip = VlllGH) THEN [dVt= N5 (-25)] 
[6) If(RR=IllGH)AND (eVTnonn=Z) AND (Pip=EillGH)TIJEN [dVt=N5 (-25)] 
[7] If(RR = MED) AND (eVfnonn = PM) AND (Pip = El-llGH) THEN [dVt = N5 (-25)] 
[8] If(RR=MIN) AND (eVfnonn=PS) AND (Pip = LOW-HIGH) TIffiN [dVt=N4 (-20)] 
[9] If(RR=VLOW-LOW) AND (eVTnonn=PM) AND (Pip = LOW-HIGH) mEN [dVt=N4 (-20)] 
[10] If(RR = MIN-HIGH) AND (eVTnonn= NM-NS) AND (Pip = El-llGH) TIffiN [dVt = N4 (-20)] 
[11] If(RR=MIN) AND (eVTnonn=Z) AND (Pip=LOW-IllGH)1lIEN [dYt=N3 (-15)] 
[12] If(RR = MED) AND (eVTnonn= PM) AND (Pip = LOW-I-UGH) mEN [dVt=N3 (-15)] 
[13] If(RR=MIN-HIGH) AND (eVTnonn=NS) AND (Pip=VlllGH)1lIEN [dVt= N3 (-15)] 
[14] If(RR = VlllGH) AND (eVTnonn =Z-PS) AND (Pip = EillGH) THEN [dVt=N3 (-I5)J 
[15JIf(RR=VLOW-LOW)AND(eVTnonn=PS)AND(Pip=LOW-HIGH)THEN[dVt=N2(-1O)] 
[16) If(RR = MED) AND (eVfnonn=PS) AND (Pip = MEO)1lIEN [dVt=N2 (-10)] 
[17] If(RR = MIN-VLOW) AND (eVTnonn = NM-NS) AND (Pip = HIGH) THEN [dVt = N2 (-10)] 
[18] If(RR=LOW-MED) AND (eVTnonn= NS) AND (Pip=HIGH)THEN[dVt=N2(-lO)] 
[19] If(RR= VLOW-LOW) AND (eVTnonn=Z) AND (Pip = HlGH) THEN [dVt=N2 (-10)] 
[20] If(RR = MIN-HIGH) AND (eVfoonn = NM) AND (Pip = VlllGH) THEN [dVt = N2 (-10)] 
[21] If(RR = VlllGH) AND (eVTnonn=NM-NS) AND (Pip = EillGH) THEN [dVt=N2 (-10)] 
[22] If(RR = MAX) AND (eVTnonn = PS-PM) AND (Pip = EillGH) 1lIEN [dVt = N2 (-10)] 
[23] If(RR = VlllGH) AND (eVTnonn = PM) AND (Pip = EHIGH) 1lIEN [dVt = N2 (-10)] 
[24] If(RR = MIN) AND (eVTnonn = NS) AND (Pip=LOW-MED)1lIEN [dVt=NI (-5)] 
[25] If(RR =MED) AND (eVTnonn= PS) AND (Pip = LOW)lHEN [dVt=NI (-5)] 
[26) If(RR = HIGH) AND (eVTnonn=PM) AND (Pip = LOW-HIGH) TIffiN [dVt= Nl (-5)] 
[27] If(RR = VLOW-LOW) AND (eVfnonn= NS-Z) AND (Pip = MED) TIffiN IdYl = Nl (-5)] 
[28] If(RR = MED) AND (eVTnonn=NS) AND (Pip = MED) TIffiN [dVt=NI (-5)] 
[29] If(RR=LOW-MED) AND (eVfnonn=NM) AND (Pip = HlGH) TIffiN [dVt= NI (-5)] 
[30] If(RR = MED) AND (eVfnonn=PS) AND (Pip = I-UGH)lHEN [dVt=NI (-5)] 
[31] If(RR= VlllGH) AND (eVfnonn= PM) AND (Pip = HIGH-VlllGH)1lIEN [dVt= Nl (-5)] 
[32] If(RR = VlllGH) AND (eVTnonn = NM-NS) AND (Pip = VlllGH) 1lIEN [dVt= NI (-5)] 
[33] If(RR = VlllGH-MAX) AND (eVTnonn = PS) AND (Pip = VlllGH) THEN [dVt = Nl (-5)J 
[34] If(RR = MAX) AND (eVTnonn= PM) AND (Pip = VlllGH)nIEN [dVt=NI (-5)] 
(35) If(RR = MIN) AND (eVTnonn = NB) 1lIEN [dYt = Z (0)] 
[36) If(RR=MIN-VLOW) AND (eVTnonn=NM) AND (Pip=LOW-MED)1lIEN[dVt=Z(O)] 
[37] If(RR = VLOW-MED) AND (eVTnonn=Ns-Z) AND (Pip = LOW)1lIEN [dYt= Z (0)] 
[38] If(RR = HlGH-VlllGH) AND (eVTnonn = PS) AND (Pip = LOW-HlGH) 1lIEN [dVt = Z (0)] 
[39] If(RR = LOW-MED) AND (eVTnonn = NM) AND (Pip = MEO) THEN [dVt = Z (0)] 
[40] If(RR = MED-VlllGH) AND (eVTnonn = Z) AND (Pip = MED-HIGH) mEN [dVt = Z (0)] 
[4l] If(RR=VlllGH) AND (eVTnonn=PM) AND (Pip = MED) nIEN [dVt= Z (0)] 
[42] If(RR = VLOW-MAX) AND (eVTnonn = NB) AND (Pip = HlGH-EHIGH) mEN [dVt = Z (0)] 
[43] If(RR = HIGH-MAX) AND (eVfnonn= NM-NS) AND (Pip = I-UGH) THEN [dVt=Z(O)] 
[44] If(RR = MAX) AND (eVTnonn = Z-PM) AND (Pip = HlGH) nIEN [dVt = Z (0)] 
(45) If(RR = MAX) AND (eVTnonn = NM-Z) AND (Pip = VlllGH-EHIGH) 1lIEN [dYt = Z (0)] 
[46] If(RR = HlGH-VlllGH) AND (eVTnonn = Z) AND (Pip = VlllGH) THEN [dVt = Z (0)] 
[47] If(RR = VlllGH) AND (eVTnonn = PM) AND (Pip = LOW) nIEN [dYt= PI (2)] 
[48] If(RR = LOW) AND (eVTnonn = NM) AND (Pip = LOW) THEN [dVt = P2 (5)] 
[49] If(RR = HIGH) AND (eVTnonn =Z) AND (Pip = LOW) TIffiN [dVt= P2 (5)] 
[50] If(RR = HlGH-VlllGH) AND (eVTnonn = NS) AND (Pip = MED)lliEN [dVt=P2 (5)] 
[51] If(RR = MAX) AND (eVTnonn = PS-PM) AND (Pip = MED) TIffiN [dVt = P2 (5)] 
[52] If(RR = MAX) AND (eVfnonn = PM) AND (Pip = LOW) mEN [dYt = P3 (10)] 
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[53] Jf(RR=VLOW-MAX) AND (eVToonn= NB) AND (Pip=MED)mEN[dVt=P3 (10)] 
[54] Jf(RR=IDGH-MAX) AND (eVTnonn=NM) AND (Pip=MED)1HEN [dVt=P3 (10)] 
[55] Jf(RR = MAX) AND (eVTnonn = NS-Z) AND (Pip = MED) mEN [dVt = P3 (10)] 
(56) Jf(RR = VLOW) AND (eVTnonn = NB) AND (Pip = LOW) 1HEN [dVt = P4 (15)] 
[57] Jf(RR = IDGH) AND (eVTnonn = NS) AND (Pip = LOW) TI-IEN [dVt = P4 (15)] 
[58] Jf(RR = VIDGH) AND (eVTnonn = Z) AND (Pip = LOW) THEN [dVt= P4 (15)] 
[59] Jf(RR = MAX) AND (eVTnonn = PS) AND (Pip = LOW) 1HEN [dVt = P4 (15)J 
[60J Jf(RR=MED) AND (eVTnonn=NM) AND (Pip = LOW) THEN [dVt=P5 (20)] 
[6IJ Jf(RR = LOW) AND (eVTnonn = NB) AND (Pip = LOW) THEN [dVt= P6 (25)J 
[62] Jf(RR= VIDGH) AND (eVTnonn= NS) AND (Pip=LOW)1HEN [dYt=P6 (25)J 
[63] Jf(RR = MAX) AND (eVTnonn = Z) AND (Pip = LOW) TIffiN [dVt= P6 (25)] 
[64] Jf(RR = MAX) AND (eVTnonn = NS) AND (Pip = LOW) 1HEN [dYt = P7 (35)] 
[65] Jf(RR = MED) AND (eVTnonn = NB) AND (Pip = LOW) 1HEN [dYt = P8 (4O)J 
[66] Jf(RR = IDGH-VIDGH) AND (eVTnonn = NM) AND (Pip = LOW) THEN [dVt= P8 (40») 
[67] Jf(RR = IDGH) AND (eVToonn = NB) AND (Pip = LOW) 1HEN [dVt = P9 (50)] 
[68] Jf(RR = MAX) AND (eVTnonn = NM) AND (Pip = LOW) 1HEN [dVt = P9 (50)J 
[69] Jf(RR = VIDGH-MAX) AND (eVTnonn = NB) AND (Pip = LOW) THEN [dVt = PIO «(ll)J 
TIN New Control Rules 
[1] Jf(Pip= OKAy) AND (Tm = MAX) THEN [dTin = N2 (-20)J 
[2] Jf(Pip= OKAy) AND (Tm = MED-ID)mEN [dTin = NI (-10)] 
[3] Jf(Pip= MED-ID) AND (fin = MAX) mEN [dTin = NI (-10») 
[4J Jf(Pip= OKAY -MED) AND(Tm= NORM) mEN [dTin= Z (0)] 
[5] Jf (Pip = MED-ID) AND (fin = MEO-ID) mEN [arm = Z (0)] 
[6] Jf (Pip = VID) AND (fin = MAX) mEN [dTin = Z (0)] 
[7] Jf(Pip= ID) AND (Tm = NORM) mEN [dTin = PI (10)] 
[8J Jf (Pip = VID) AND (fin = MEO-ID) TI-IEN [arm = PI (10)] 
[9] Jf(Pip = VID) AND (Tm = NORM) mEN [arm = P2 (20») 
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Figure E.2: The output behaviour of the prototype PEEP advisor, for all possible combinations 
of Pa02 and FI02 input. Control space plots are shown for each PEEP fuzzy linguistic class; 
(a) OFF (0 cmH20), (b) LOW (4 cmH20), (c) MEDIUM (8 cmH20), (d) IlIOII 
(12 cmH20) and (e) MAX (16 cmH20). 
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Figure E.3: The output behaviour of the modified PEEP advisor, for all possible combinations of 
Pa0 2 and FI02 input. Control space plots are shown for the PEEP fuzzy linguistic classes; 
(a) OFF (0 cmH20) and (b) LOW (4 cmH20). The plots for MEDIUM, HIGH, and MAX are not 
shown since they are identical to those of Figure E.2 (c) to (e). 
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Figure continued overleaf ... 
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Figure E.4: The output behaviour of the prototype Mv advisor, for all possible combinations of 
ePaC02 and ePIP input. Control space plots are shown for the epH fuzzy linguistic classes; 
(a) V.ACID (-0.29), (b) ACID (-0.17), (c) NORMAL (0), (d) ALK (+0.15) and (e) V.ALK (+0.38). 
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(c) 
•. Figure E.5: The output 
•• behaviour of the modified Mv 
•.. advisor, for all possible 
Combinations of ePaC(h and 
rIP input. Control space plots 
.. are shown for each e VI NORM 
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i 15 %) and 
\~) NB (-35 %). The region of 
output between ±30 % has 
. been expanded in (c) and (d) 
to give a c1eare picture of the 
controller behaviour due to the 
variability of scale in the 
&tvice given. 
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Figure E.6: The output behaviour of the prototype VT-RR advisor, for all possible combinations of 
eVTNORM and RR input. Control space plots are shown for the ePIP fuzzy linguistic classes; 
(a) OKAY (-10 cmH20), (b) NEAR ALARM (-5 cmH20), (c) ALARM (0 cmH20), (d) mGH (+5 cmH20) and 
(e) V.HIGH (+ 10 cmH20). 
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Figure continued overleaf. .. 
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Figure E.7: The output behaviour of the modified VT-RR advisor, for all possible combinations of 
eVTNORM and RR input. Control space plots are shown for the PIP fuzzy linguistic classes; 
(a) LOW (20 cmH20), (b) MEDillM (30 cmH20), (c) mGH (40 cmH20), (d) v.mGH (50 cmH20) and (c) 
E.tnGH (60 cmH20). 
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Figure E.8: The output behaviour of the modified TIN advisor, for all possible combinations of TIN and 
PIP input. This advisor subsystem was not present in the prototype advisor. 
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Appendix F 
Advisor Responses to Clinical Data 
and Decision Scoring 
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Patient 1: 
, 1 2 
Observations 
Pa~(kPa) 25.8 23.5 
PaC02 (kPa) 5.14 5.02 
pH 7.36 7.37 
PIP (cmHP) 13.0 11.0 
Weight (kg) 60.3 60.3 
Fi02 (%) 40 35 
Peep (cmHP) 0 0 
Mv(lImin) 7.50 8.00 
RR (rpm) 11 11 
vt(ml) 682 727 
Tin(%) 
- -
Target PaC02 (kPa) 5.3 5.3 
Anaesthetisfs New Settings 
Fi02 (%) 35 35 
Peep (cmHP) 0.0 0.0 
Mv(lImin) 8.00 7.50 
RR (rpm) 11.0 11.0 
Vt(ml) 727 682 
Tin(%) 
- -
Advisor New Settings 
Fi02 (%) 35 35 
PEEP (cmHP) 0.0 0.0 
MY (llmin) 7.28 7.56 
RR (rpm) 11.5 12.0 
vt(ml) 630 630 
Tin(%) 33 33 
Decision Difference 
Fi02 (%) 0 0 
Peep (cmHP) 00 0.0 
Mv(lImin) -0.72 0.06 
RR (rpm) 0.5 1.0 
vt(ml) -97 -52 
Tin(%) - -
Scoring 
Fi02 score exact exact 
Peep score exact exact 
Mvsoore X good 
RR score good good 
VI soore X mod 
Tin score nla nla 
3 I 4 
20.3 12.9 
5.50 5.53 
7.39 7.38 
11.0 11.0 
60.3 60.3 
35 30 
0 0 
7.50 7.50 
11 11 
682 682 
- -
5.3 5.3 
30 30 
0.0 0.0 
7.50 7.50 
11.0 11.0 
682 682 
- -
35 30 
0.5 0.0 
7.80 7.84 
12.5 12.5 
630 630 
33 33 
5 0 
0.5 00 
0.30 0.34 
1.5 1.5 
-52 -52 
- -
good exact 
good exact 
good good 
good good 
mod mod 
nJa nla 
I Patient 2: 
I 5 I 6 I 1 I 2 I 3 I 
15.0 16.0 20.6 20.0 16.3 
5.18 5.27 8.87 6.60 7.04 
7.42 7.40 7.10 7.25 7.24 
12.0 14.0 22.0 27.0 29.0 
60.3 60.3 65.0 65.0 65.0 
30 30 100 90 80 
0 0 0 5 5 
7.50 7.50 7.99 10.50 10.50 
11 11 14 14 14 
682 682 571 750 750 
- -
33 33 33 
5.3 5.3 3.8 3.8 3.8 
30 30 90 80 70 
0.0 0.0 5.0 5.0 5.0 
7.50 7.50 10.50 10.50 15.00 
110 11.0 14.0 14.0 15.0 
682 682 750 750 1000 
- -
33 33 33 
30 30 72 69 69 
0.0 0.0 0.0 4.5 4.5 
7.31 7.46 14.23 15.02 14.23 
115 12.0 20.0 20.0 19.0 
630 630 720 750 750 
33 33 33 33 33 
0 0 -18 -11 -1 
0.0 0.0 -5.0 -0.5 -0.5 
-0.19 -0.04 3.73 4.52 -0.77 
0.5 1.0 60 6.0 40 
-52 -52 -30 0 -250 
- -
0 0 0 
exact exact X X good 
exact exact X good good 
good good X X mod 
good good X X X 
mod mod good exact X 
nla nla exact exact exact 
4 5 6 I 7 8 9 I 10 I 11 I 12 I 13 I 14 I 
21.8 17.5 18.1 17.6 18.5 13.1 10.4 13.1 11.8 9.1 17.3 
4.87 4.47 4.20 3.60 3.69 3.70 3.83 3.80 3.75 3.73 3.50 
7.40 7.45 7.47 7.53 7.56 7.55 7.50 7.53 7.53 7.56 7.59 
32.0 31.0 28.0 30.0 30.0 28.0 28.0 30.0 30.0 27.5 27.4 
65.0 65.0 65.0 65.0 65.0 65.0 65.0 65.0 65.0 65.0 65.0 
70 60 60 60 50 40 40 40 40 40 40 
5 5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 
15.00 15.00 15.00 16.50 16.50 14.54 14.54 14.54 14.54 14.54 14.54 
15 15 15 15 15 16 16 16 16 16 16 
1000 1000 1000 1100 1100 938 938 938 938 938 938 
33 33 33 33 33 33 33 33 33 33 33 
3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 
60 60 60 50 40 40 40 40 40 40 40 
5.0 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 
15.00 15.00 1650 16.50 14.54 14.54 14.54 14.54 14.54 14.54 14.54 
15.0 15.0 15.0 15.0 15.5 15.5 15.5 15.5 15.5 15.5 15.5 
1000 1000 1100 1100 938 938 938 938 938 938 938 
33 33 33 33 33 33 33 33 33 33 33 
54 57 56 57 40 39 51 39 41 59 35 
3.0 4.0 4.5 4.5 4.0 4.0 5.5 4.0 4.0 6.5 4.0 
17.03 15.94 15.74 15.59 16.01 14.63 15.08 15.01 14.78 14.71 13.81 
18.5 17.5 17.5 16.5 17.0 17.5 17.5 18.0 17.5 17.5 17.0 
930 900 890 940 950 830 850 840 840 840 810 
33 33 33 33 33 33 33 33 33 33 33 
-6 -3 -4 7 0 -1 11 -1 1 19 -5 
-2.0 -3.5 -3.0 -3.0 -3.5 -3.5 -2.0 -3.5 -3.5 -1.0 -3.5 
2.03 0.94 -0.77 -0.91 1.47 0.09 0.54 0.47 0.24 0.17 -0.73 
35 2.5 2.5 1.5 15 2.0 2.0 2.5 2.0 2.0 1.5 
-70 -100 -210 -160 12 -108 -88 -98 -98 -98 -128 
0 0 0 0 0 0 0 0 0 0 0 
mod good good mod exact good X good good X good 
mod X X X X X mod X X good X 
X mod mod mod X good mod good good good mod 
X mod mod good good mod mod mod mod mod good 
mod mod X X good X mod mod mod mod X 
exact exact exact exact exact exact exact exact exact exact exact 
tv 
00 
\0 
~ 
G 
(') 
o g. 
S 
(t> 
Q.. 
~ (t> 
::!.. 
~ 
I 15 I 16 I 
Observations 
Pa02(kPa) 21.4 10.3 
Pa~(kPa) 3.70 3.54 
pH 7.57 7.57 
PIP (cmHzO) 27.0 28.0 
Weight (kg) 65_0 65.0 
FiOz(%) 40 35 
Peep (cmHzO) 7_5 7_5 
MY (llmin) 14.54 15_01 
RR (rpm) 16 16 
vt(ml) 938 938 
Tin(%) 33 33 
Target PaCOz (kPa) 3.8 3_8 
Anaesthetist's New Settings 
FiOz(%) 35 35 
Peep(cmH~) 7.5 7.5 
MY (I/min) 1501 15_01 
RR (rpm) 16.0 16_0 
vt(ml) 938 938 
Tin(%) 33 33 
Advisor New Settings 
Fi02 (%) 35 46 
PEEP (cmHp) 3.5 5_0 
MV(Vmin) 14.63 13_96 
RR (rpm) 17.5 17_0 
vt(ml) 830 820 
Tin(%) 33 33 
Decision Difference 
Fi02 (%) 0 11 
Peep(cm~) -4.0 -2_5 
MY (Vmin) -0_38 -105 
RR(rpm) 1.5 1_0 
vt(ml) -108 -118 
Tin(%) 0 0 
Scoring 
Fi02score exact X 
Peep score X X 
MY score good X 
RRscore good good 
vt score X X 
Tin score exact exact 
-
171 18 I 
13.1 10.3 
3.40 3.50 
7_60 7_58 
27.0 27.0 
65_0 65_0 
35 35 
7_5 0 
15_01 15.01 
16 16 
938 938 
33 33 
3_8 3_8 
35 40 
0_0 0.0 
15_01 1501 
16_0 16.0 
938 938 
33 33 
35 46 
4_0 1_0 
13_43 13_81 
17_0 17_0 
800 610 
33 33 
0 6 
40 1_0 
-1_58 -1.20 
1.0 to 
-138 -128 
0 0 
exact mod 
X good 
X X 
good good 
X X 
exact exact 
19 I 20 21 I 22 I 23 I 24 I 
18.0 10.9 19.7 12.5 14.3 10.6 
3.82 3.70 4.18 3.63 4.17 4.00 
7_54 7_57 7.56 7_54 7_53 7_51 
29.0 25_0 25.0 24.0 25.0 29_0 
65.0 65_0 65_0 65.0 65_0 65_0 
40 40 45 45 45 45 
0 0 0 0 0 0 
1501 15.01 1501 1501 1501 15_01 
16 16 16 16 16 16 
938 938 938 938 938 938 
33 33 33 33 33 33 
3.6 3_6 3.8 3.8 3.8 3.8 
40 45 45 45 45 45 
0.0 0.0 00 0.0 0.0 0_0 
1501 15_01 15_01 15_01 15.01 15_01 
16.0 16_0 16_0 160 16.0 16.0 
938 938 938 938 938 938 
33 33 33 33 33 33 
35 47 37 44 41 54 
1_0 1_5 1_0 1.5 1_5 2_0 
15.04 14_63 1601 15_12 15_96 15_34 
18.0 17_5 18_5 18.0 18.5 18.0 
840 830 870 850 870 850 
33 33 33 33 33 33 
-5 2 -8 -1 -4 9 
1.0 1_5 1_0 1_5 1_5 2.0 
0.03 -0.38 1_00 0_11 0.95 0_33 
2.0 1.5 2.5 2.0 2.5 2.0 
-98 -108 -68 -88 -68 --88 
0 0 0 0 0 0 
good good mod good good mod 
good mod good mod mod mod 
good good X good mod good 
mod good mod mod mod mod 
mod X mod mod mod mod 
exact exact exact exact exact exact 
25 I 26 I 27 I 28 I 29 30 31 I 32 33 341 
11.7 11.1 11.1 10.1 10.1 14.1 14.1 13.8 10.7 9.8 ' 
4.10 400 4.00 4.35 4.35 4.90 4.67 4.64 4.86 4.93 
7.49 7_51 7.51 7.50 7_50 7.43 7.44 7.45 7_43 7.42 
29.0 29_0 29.0 29.0 29.0 28.0 29_0 38.0 29.0 35_0 
65_0 65_0 65.0 65_0 65_0 65_0 65.0 65_0 65.0 65.0 
45 50 55 50 55 80 75 70 70 70 
0 0 0 0 0 0 0 0 0 0 
15_01 15_01 1501 15_01 15.Q1 15_01 15_01 16.50 16.50 16_50 
16 16 16 16 16 16 16 16 16 16 
938 938 938 938 938 938 938 1031 1031 1031 
33 33 33 33 33 33 33 33 33 33 
3_8 3.8 3.8 38 3_8 3.8 3_8 3.8 3_8 3.8 
50 55 50 55 80 75 70 70 70 70 
0.0 0.0 0_0 0_0 0_0 0_0 0_0 0.0 0.0 0_0 
15.01 15_01 15.01 15.01 15.01 15_01 16.50 16.50 16_50 20.00 
16_0 16_0 16_0 16.0 16.0 16.0 16.0 16_0 16_0 16.0 
938 938 938 938 938 938 1031 1031 1031 1250 
33 33 33 33 33 33 33 33 33 33 
47 56 60 63 66 75 70 65 74 77 
1_5 25 2_0 3_5 3_0 1_0 0.5 0.0 1_5 3_0 
15_49 15.34 15_34 15_88 15.88 17_80 16_75 18.59 18_99 18.90 
18.0 18.0 18.0 185 18_5 195 19.0 19.0 19.5 19.5 
860 850 850 870 870 900 890 980 980 980 
33 33 33 33 33 33 33 40 33 40 
-3 1 10 8 -14 0 0 -5 4 7 
1.5 2.5 2.0 3.5 3.0 1_0 0_5 00 1.5 3_0 
0.48 0_33 0.33 0.87 0_87 2.59 0.25 2_09 2.49 -1.10 
2_0 2.0 2_0 2.5 2.5 3.5 3_0 3.0 3_5 3_5 
-78 -88 -88 -68 -68 -38 -141 -51 -51 -270 
0 0 0 0 0 0 0 7 0 7 
good good X mod X exact exact good good mod 
mod X mod X X good good exact mod X 
good good good mod mod X good X X X 
mod mod mod mod mod X mod mod X X 
mod mod mod mod mod good X mod mod X 
exact exact exact exact exact exact exact mod exact mod 
tv 
\0 
o 
~ (j) 
(') 
o 
E-. g 
(1) 
c. 
o 
-< (1) 
:L 
(1) 
~ 
I 
I 35 I 36 I 37 I 
Observations 
Pa02(kPa) 12.6 29.5 11.6 
PaC~(kPa) 4.90 5.20 4.80 
pH 7.42 7.42 7.45 
PIP (cmH2O) 27.0 26.0 25.0 
Weight (kg) 65.0 65.0 65.0 
Fi02(%) 85 85 75 
Peep (cmHp) 0 0 0 
MY (Vmin) 19.00 19.00 18.00 
RR (rpm) 20 20 20 
Vt(ml) 950 950 900 
Tin(%) 33 33 33 
Target PaC02 (kPa) 3.8 3.8 3.8 
Anaesthetist's New Settings 
Fi02(%) 85 75 75 
Peep (cmHP) 0.0 00 0.0 
MY (Vmin) 19.00 18.00 18.00 
RR(rpm) 20.0 20.0 20.0 
Vt(ml) 950 900 900 
Tin(%) 33 33 33 
Advisor New Settings 
Fi02 (%) 81 54 76 
PEEP (cmHp) 2.5 0.0 1.5 
MV(Vmin) 22.56 23.40 21.53 
RR(rpm) 23.0 23.5 23.0 
Vt(ml) 980 1000 940 
Tin(%) 33 33 33 
Decision Difference 
Fi02(%) -4 -21 1 
Peep(cmH~) 2.5 0.0 1.5 
MY (Vmin) 3.56 5.40 3.53 
RR (rpm) 3.0 3.5 3.0 
Vt(ml) 30 100 40 
Tin(%) 0 0 0 
Scoring 
Fi02scone good X good 
Peep score X exact mod 
MY scone X X X 
RRscone mod X mod 
Vt score good X good 
Tin score exact exact exact 
I Patient 3: 
38 I 39 I 1 I 2 I 3 4 
31.7 25.4 60.5 40.0 23.3 19.8 
4.70 4.70 5.85 5.12 4.90 5.56 
7.46 7.45 7.27 7.30 7.35 7.32 
25.0 27.0 34.0 34.0 28.0 28.0 
65.0 65.0 50.5 50.5 50.5 50.5 
75 60 100 50 45 45 
0 0 1 1 1 1 
18.00 18.00 14.00 14.00 12.75 12.75 
20 20 20 20 15 15 
900 900 700 700 850 850 
33 33 25 25 25 25 
3.8 3.8 5.50 5.50 5.50 5.50 
60 60 50 45 45 45 
00 00 1.0 1.0 1.0 1.0 
18.00 18.00 14.00 12.75 12.75 12.75 
20.0 20.0 20.0 15.0 15.0 15.0 
900 900 700 850 850 850 
33 33 25 25 25 25 
51 45 50 40 37 37 
0.0 0.0 1.0 0.5 0.5 1.5 
21.08 20.61 14.18 13.02 11.35 12.81 
22.5 22.5 21.0 19.5 16.0 17.0 
930 920 680 670 720 750 
33 33 33 33 33 33 
-9 -15 0 -5 .a ..a 
0.0 0.0 0.0 '()5 '()5 0.5 
3.08 2.61 0.18 0.27 -1.40 0.06 
2.5 25 1.0 4.5 1.0 2.0 
30 20 -20 -180 -130 -100 
0 0 8 8 8 8 
mod X exact good mod mod 
exact exact exact good good good 
X X good good X good 
mod mod good X good mod 
good good good X X mod 
exact exact mod mod mod mod 
5 6 I 7 I 8 I 9 I 10 I 11 I 12 I 13 I 14 I 15 I 
24.8 17.1 25.0 16.4 17.6 13.7 14.7 15.4 13.6 13.0 14.4 
5.21 5.05 5.94 5.30 3.17 4.53 4.47 4.76 503 4.90 4.49 
7.36 7.38 7.30 7.33 7.31 7.45 7.48 7.43 7.39 7.41 7.49 
25.0 25.0 31.0 31.0 30.0 30.0 32.0 27.0 30.0 27.0 26.0 
50.5 50.5 50.5 50.5 50.5 50.5 50.5 50.5 50.5 50.5 50.5 
45 35 50 40 35 35 35 35 35 35 35 
1 1 1 1 1 1 1 1 5 5 5 
12.75 12.75 12.75 12.75 12.75 12.75 12.75 12.75 12.75 12.75 12.75 
15 15 15 15 15 15 15 15 15 15 15 
850 850 850 850 850 850 850 850 850 850 850 
25 25 25 25 25 25 25 25 25 25 25 
5.50 5.50 550 5.50 5.50 5.50 5.50 5.50 5.50 5.50 5.50 
35 35 40 35 35 35 35 35 35 35 35 
1.0 1.0 1.0 1.0 1.0 1.0 1.0 5.0 5.0 5.0 5.0 
12.75 12.75 12.75 12.75 12.75 12.75 12.75 12.75 12.75 12.75 12.75 
15.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0 
850 850 850 850 850 850 850 850 850 850 850 
25 25 25 25 25 25 25 25 25 25 25 
37 35 40 35 35 35 35 35 35 35 35 
0.5 1.0 0.5 1.5 1.0 1.0 1.0 1.0 3.0 3.0 3.0 
12.05 11.73 13.06 12.30 7.60 10.52 10.39 11.03 11.67 11.35 10.39 
16.5 16.5 17.5 17.0 11.0 15.0 15.0 15.5 16.0 16.0 15.0 
730 720 750 730 680 710 700 710 720 720 700 
33 33 33 33 33 33 33 33 33 33 33 
2 0 0 0 0 0 0 0 0 0 0 
'()5 00 '()5 0.5 0.0 0.0 0.0 -4.0 -2.0 -2.0 -2.0 
.().70 
-1.02 0.31 '()45 -5.15 -2.23 -2.36 -1.72 -1.08 -1.40 -2.36 
1.5 1.5 25 2.0 -4.0 0.0 0.0 0.5 1.0 1.0 00 
-120 -130 -100 -120 -170 -140 -150 -140 -130 -130 -150 
8 8 8 8 8 8 8 8 8 8 8 
good exact exact exact exact exact exact exact exact exact exact 
good exact good good exact exact exact X mod mod mod 
mod X good good X X X X X X X 
good good mod mod X exact exact good good good exact 
X X mod X X X X X X X X 
mod mod mod mod mod mod mod mod mod mod mod 
tv 
1.0 
-
~ 
G 
o 
o 
:l e. 
2 
C1> p. 
o 
-< C1> 
::l. 
~ 
I 
I 16 
Observations 
Pa02(kPa) 15.3 
Pa~(kPa) 4.52 
pH 7.50 
PIP (anHp) 28.0 
Weight (kg) 50.5 
Fi02(%) 35 
Peep (anH2O) 5 
MY (Vmin) 12.75 
RR(rpm) 15 
Vt(ml) 850 
Tin(%) 25 
Target Pa~ (!<Pol) 550 
Anaesthetisfs New Settings 
Fi02(%) 35 
Peep (anH2O) 5.0 
Mv (Vmin) 12.75 
RR (rpm) 15.0 
Vt(ml) 850 
Tin(%) 25 
Advisor New Settings 
Fi02 (%) 35 
PEEP (anHp) 3.0 
MV (llmin) 1046 
RR (rpm) 15.0 
Vt(ml) 700 
Tin (%) 33 
Decision Difference 
Fi02 (%) 0 
Peep (anH,o) -2.0 
Mv (Vmin) -2.30 
RR(rpm) 00 
Vt(ml) -150 
Tin(%) 8 
Scoring 
Fi02score exact 
Peep score mod 
Mv score X 
RRscore exact 
Vt score X 
Tin score mod 
17 I 18 I 
14.7 16.9 
4.52 4.18 
7.53 7.52 
27.0 28.0 
50.5 50.5 
35 35 
5 5 
12.75 12.75 
15 15 
850 850 
25 25 
5.50 5.50 
35 35 
5.0 5.0 
12.75 12.75 
15.0 15.0 
850 850 
25 25 
35 35 
3.0 2.5 
10.46 9.69 
15.0 14.0 
700 690 
33 33 
0 0 
-2.0 -2.5 
-230 -3.06 
0.0 -1.0 
-150 -160 
8 8 
exact exact 
mod X 
X X 
exact good 
X X 
mod mod 
I Patient 4: 
19 I 20 I 21 I 22 I 23 I 24 I 25 I 1 I 2 I 
16.2 17.0 19.4 12.7 15.9 12.5 12.0 31.5 16.8 
4.57 4.80 5.30 5.20 5.10 5.00 4.70 4.50 4.03 
7.52 7.49 7.45 7.45 7.47 7.45 7.47 7.36 7.35 
29.0 21.0 22.0 22.0 23.0 24.0 23.0 30.0 26.0 
50.5 50.5 50.5 50.5 50.5 50.5 50.5 70.0 70.0 
35 35 35 30 30 30 30 50 45 
5 5 5 5 5 5 5 0 0 
12.75 9.00 9.00 9.00 9.00 9.00 9.00 12.60 12.60 
15 12 12 12 12 12 12 14 14 
850 750 750 750 750 750 750 900 900 
25 25 25 25 25 25 25 
- -
5.50 5.50 550 5.50 5.50 5.50 5.50 4.00 4.00 
35 35 30 30 30 30 30 45 45 
5.0 5.0 5.0 5.0 5.0 5.0 5.0 0.0 0.0 
9.00 9.00 9.00 9.00 9.00 9.00 9.00 12.60 12.60 
12.0 12.0 12.0 12.0 12.0 12.0 12.0 14.0 14.0 
750 750 750 750 750 750 750 900 900 
25 25 25 25 25 25 25 - -
35 35 35 30 30 30 30 40 37 
3.0 2.5 2.5 2.5 2.5 2.5 2.5 0.0 1.5 
10.58 7.68 8.69 8.51 8.33 8.19 7.70 13.13 12.68 
15.0 13.0 14.0 14.0 13.5 13.5 130 17.0 16.5 
710 600 620 610 610 610 600 780 770 
33 33 33 33 33 33 33 33 33 
0 0 5 0 0 0 0 -5 -8 
-2.0 -2.5 -2.5 -25 -2.5 -2.5 -2.5 0.0 1.5 
1.58 -1.13 -0.32 -049 -0.68 -081 -1.31 053 0.08 
30 1.0 2.0 2.0 1.5 1.5 1.0 3.0 2.5 
-40 -150 -130 -140 -140 -140 -150 -120 -130 
8 8 8 8 8 8 8 - -
exact exact good exact exact exact exact good mod 
mod X X X X X X exact mod 
X X good good mod mod X mod good 
mod good mod mod good good good mod mod 
good X X X X X X X X 
mod mod mod mod mod mod mod nla nJa 
3 I 4 I 5 I 6 I 7 I 8 I 9 I 10 I 
25.3 24.5 20.2 14.6 21.1 17.9 21.2 18.3 
4.04 4.10 4.40 4.00 4.03 3.58 3.59 3.17 
7.37 7.38 7.40 7.48 7.48 7.51 7.56 7.57 
24.0 23.0 27.0 27.0 33.00 23.00 30.00 28.00 
70.0 70.0 70.0 70.0 70.0 70.0 70.0 70.0 
45 50 50 50 40 40 40 40 
0 0 0 0 0 0 0 0 
12.60 12.60 12.80 13.60 16.80 16.50 16.50 16.50 
14 14 16 16 21 22 22 22 
900 900 800 850 800 750 750 750 
- - - - - - - -
4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 
50 50 50 40 40 40 40 40 
0.0 0.0 0.0 0.0 0 0 0 0 
12.60 12.80 13.60 15.30 16.50 16.50 16.50 16.50 
14.0 16.0 16.0 18.0 22 22 22 22 
900 800 850 850 750 750 750 750 
- - - - - - - -
37 40 40 43 35 35 35 35 
0.0 00 1.0 2.0 0.5 1.0 0.5 0.5 
1269 12.85 13.48 13.60 16.84 14.77 14.77 13.12 
16.5 16.5 17.5 17.0 21.0 19.0 19.5 17.5 
770 780 780 790 800 780 750 750 
33 33 33 33 40 33 33 33 
-13 -10 -10 3 -5 -5 -5 -5 
0.0 00 1.0 2.0 05 1.0 0.5 0.5 
0.09 0.05 -0.12 -1.70 034 -1.73 -1.73 -3.38 
2.5 0.5 15 -1.0 -1.0 -3.0 -2.5 -4.5 
-130 -20 -70 -60 50 30 0 0 
- - - - - - - -
X mod mod good good good good good 
exact exact good mod good good good good 
good good good X good X X X 
mod good good good good mod mod X 
X good X mod good good exact exact 
nJa nla nJa nJa nJa nJa nla nla 
N 
\0 
N 
~ 
G 
(') 
o g. 
E 
C'D 
Q. 
~ 
::!.. 
~ 
I 
I 11 
Observations 
Pa02(kPa) 18.3 
PaCC>,(kPa) 3.33 
pH 7.58 
PIP (cmH2O) 36.00 
Weight (kg) 70.0 
Fi02 (%) 40 
Peep (cmH2O) 0 
Mv (Vrnin) 16.50 
RR(rpm) 22 
vt(ml) 750 
Tin(%) 
-
Target PaC02 (kPa) 4.00 
Anaesthetisfs New Settings 
Fi02 (%) 40 
Peep (cmHp) 0 
Mv(Vmin) 16.50 
RR(rpm) 22 
vt(ml) 750 
Tin(%) 
-
Advisor New Settings 
Fi02 (%) 35 
PEEP (cmHp) 0.5 
MV(Vmin) 13.78 
RR(rpm) 18.5 
vt(ml) 750 
Tin(%) 40 
Decision Difference 
Fi02 (%) -5 
Peep (cmHP) 05 
Mv(Vmin) -2.72 
RR(rpm) -3.5 
vt(ml) 0 
Tin(%) 
-
Scoring 
Fi02 score good 
Peep score good 
Mvscore X 
RRscore X 
vt score exact 
Tin score nJa 
12 13 
24.2 14.3 
3.50 404 
7.56 7.50 
34.00 32.00 
70.0 70.0 
40 40 
0 0 
16.50 16.50 
22 22 
750 750 
- -
4.00 4.00 
40 40 
0 0 
16.50 16.50 
22 22 
750 750 
. 
-
35 37 
00 1.0 
14.44 16.54 
195 22.0 
750 750 
40 33 
-5 -3 
00 10 
-2.06 0.04 
-2.5 00 
0 0 
. 
-
good good 
exact good 
X good 
mod exact 
exact exact 
n/a nJa 
Patient 5: 
1 I 2 I 3 I 4 5 6 
78.5 26.4 24.6 13.6 9.9 9.2 
2.74 3.39 2.88 3.80 4.19 4.72 
7.54 7A5 7.41 7.34 7.30 7.27 
33.0 25.0 24.0 21.0 24.0 23.0 
78.3 78.3 78.3 78.3 78.3 78.3 
80 50 50 45 45 45 
0 0 0 0 0 0 
12.50 9.00 9.00 7.99 7.99 7.99 
17 12 12 12 12 12 
735 750 750 666 666 666 
25 25 25 25 25 25 
4.00 4.00 4.00 4.00 4.00 4.00 
50 50 45 45 45 60 
0.0 0.0 0.0 0.0 0.0 0.0 
9.00 9.00 7.99 7.99 7.99 8.00 
12.0 12.0 12.0 12.0 12.0 130 
750 750 666 666 666 615 
25 25 25 25 25 25 
50 40 40 42 59 64 
0.0 0.0 0.0 1.5 2.5 3.0 
8.59 7.65 6.48 7.59 8.29 9.17 
12.5 10.5 9.0 11.5 12.5 14.0 
700 730 740 660 650 660 
33 33 33 33 33 33 
0 -10 -5 -3 14 4 
00 0.0 0.0 1.5 2.5 3.0 
-0.41 -1.35 -1.51 -0.40 0.29 1.17 
0.5 -1.5 -3.0 -0.5 0.5 1.0 
-50 -20 74 ~ -16 45 
8 8 8 8 8 8 
exact mod good good X good 
exact exact exact mod X X 
good X X good good X 
good good mod good good good 
good good mod good good good 
mod mod mod mod mod mod 
Patient 6: 
7 8 9 I 10 11 12 1 2 3 4 5 
10.2 10.6 10.5 11.8 12 11.8 14.7 14.6 15.1 11.8 11.2 
4.00 3.92 4.00 3.93 3.98 406 4.17 3.71 3.64 3.47 3.43 
7.33 7.32 7.28 7.26 7.24 7.18 7.18 7.22 7.24 7.27 7.37 
26.0 26.0 26.0 26.0 26.0 27.0 44.0 31.0 32.0 31.0 29.0 
78.3 78.3 78.3 78.3 78.3 78.3 54.0 54.0 54.0 54.0 54.0 
60 70 70 70 70 70 95 95 80 70 60 
0 0 0 5 5 5 4 4 4 4 4 
8.00 9.49 9.49 9.49 9.49 9.49 10.50 11.20 10.50 10.50 10.50 
13 13 13 13 13 13 15 16 15 15 15 , 
615 730 730 730 730 730 700 700 700 700 700 
25 25 25 25 25 25 25 25 25 25 25 
4.00 400 400 400 4.00 4.00 5.3 5.3 5.3 5.3 5.3 
70 70 70 70 70 70 95 80 70 60 50 
0.0 0.0 5.0 5.0 5.0 5.0 4.0 4.0 4.0 4.0 4.0 
9.49 9.49 9.49 9.49 9.49 9.49 11.20 10.50 10.50 10.50 7.00 
13.0 13.0 13.0 13.0 13.0 13.0 16.0 15.0 15.0 15.0 10.0 
730 730 730 730 730 730 700 700 700 700 700 
25 25 25 25 25 25 25 25 25 25 25 
69 75 75 71 70 71 83 84 72 71 64 
3.0 2.0 2.0 4.5 4.5 4.5 4.0 4.0 4.0 4.0 4.0 
8.00 9.30 9.49 9.35 9.44 9.57 8.24 7.84 7.22 6.96 6.87 
13.0 130 13.0 13.0 13.0 13.5 14.5 14.0 130 12.5 12.5 
610 720 720 720 720 720 560 570 560 560 560 
33 33 33 33 33 33 40 33 33 33 33 
-1 5 5 1 0 1 -12 4 2 11 14 
3.0 2.0 -3.0 -0.5 -0.5 -0.5 00 0.0 00 00 00 
-1.50 -0.19 0.00 -0.14 -0.05 0.08 -2.96 -2.66 -3.28 -3.54 -0.13 
0.0 00 00 00 00 0.5 -1.5 -1.0 -2.0 -2.5 2.5 
-120 -10 ·10 -10 -10 -10 -140 -130 -140 -140 -140 
8 8 8 8 8 8 15 8 8 8 8 
good good good good exact good X good good X X 
X mod X good good good exact exact exact exact exact 
X good exact good good good X X X X good 
exact exact exact exact exact good good good mod mod mod 
X good good good good good X X X X X 
mod mod mod mod mod mod X mod mod mod mod 
I'..J 
1.0 
W 
~ ~ 
G 
() g, 
E 
~ 
0.. 
o 
< a. 
~ 
, Observations 
Pa02(kPa) 11.2 
Pa~(kPa) 4.50 
pH 7.30 
PIP (cmH2O) 25.0 
Weight (kg) 54.0 
Fi02(%) 50 
Peep (cmH2O) 4 
MY (I/min) 7.00 
RR(rpm) 10 
Vt(ml) 700 
Tin(%) 25 
Target PaOO, (kPa) 5.3 
Anaesthetist's New Settings 
Fi02(%) 60 
Peep (cmH,o) 4.0 
MY (I/min) 7.00 
RR(rpm) 10.0 
Vt(ml) 700 
Tin(%) 25 
Advisor New Settings 
Fi02 (%) 55 
PEEP (cmHp) 4.0 
MY (I/min) 5.95 
RR(rpm) 10.5 
Vt(ml) 560 
Tin(%) 33 
Decision Difference 
Fi02(%) -5 
Peep (cmH,o) 00 
MY (I/min) -1.05 
RR(rpm) 0.5 
Vt(ml) -140 
Tin(%) 8 
Scoring 
Fi02score good 
Peep score exact 
MY score X 
RR score good 
Vt score X 
Tin score mod 
13.9 20.2 15.7 
4.62 4.39 4.60 
7.32 7.21 7.36 
25.0 23.0 23.0 
54.0 54.0 54.0 
60 60 55 
4 5 4 
7.00 7.00 7.00 
10 10 10 
700 700 700 
25 25 25 
5.3 5.3 5.3 
60 55 55 
4.0 4.0 4.0 
7.00 7.00 7.00 
10.0 10.0 10.0 
700 700 700 
25 25 25 
60 53 50 
4.0 3.5 4.0 
609 5.81 6.09 
11.0 10.5 11.0 
560 560 560 
33 33 33 
0 -2 -5 
0.0 -0.5 0.0 
-0.91 -1.19 -0.91 
1.0 0.5 1.0 
-140 -140 -140 
8 8 B 
exact good good 
exact good exact 
mod X mod 
good good good 
X X )( 
mod mod mod 
18.6 19 15.6 7.8 11.4 
4.58 4.82 4.63 5.54 5.70 
7.30 7.28 7.29 7.38 7.36 
22.0 230 23.0 21.0 21.0 
54.0 54.0 54.0 80.0 80.0 
55 55 50 60 70 
4 4 4 5 5 
7.00 7.00 7.00 9.80 9.80 
10 10 10 14 14 
700 700 700 700 700 
25 25 25 25 25 
5.3 5.3 5.3 5.50 5.50 
55 50 45 70 70 
4.0 4.0 4.0 5.0 7.0 
7.00 7.00 7.00 980 9.80 
10.0 10.0 10.0 14.0 14.0 
700 700 700 700 700 
25 25 25 25 25 
48 48 41 78 72 
3.5 3.5 4.0 6.5 4.5 
6.06 6.37 6.13 9.85 10.12 
11.0 11.5 11.0 14.0 14.5 
560 560 560 700 710 
33 33 33 33 33 
-7 -2 -4 8 2 
-0.5 -0.5 00 1.5 -2.5 
-0.95 -0.63 -0.88 0.05 0.32 
1.0 1.5 1.0 00 0.5 
-140 -140 -140 0 10 
B B B B 8 
mod good good mod good 
good good exact mod X 
mod mod mod good good 
good good good exact good 
X )( X exact good 
mod mod mod mod mod 
9.3 11.6 9.2 7.3 7.9 8.4 22.5 19.7 13.4 9.8 
6.00 5.68 6.50 6.11 5.94 5.15 5.60 4.81 4.88 4.70 
7.31 7.35 7.31 7.38 7.38 7.43 7.47 7.42 7.42 7.40 
21.0 22.0 21.0 23.0 23.0 25.0 29.0 19.0 19.0 18.0 
80.0 80.0 80.0 80.0 80.0 80.0 55.0 97.9 97.9 97.9 
70 70 65 70 80 80 55 45 40 40 
7 7 7 7 7 7 5 0 0 0 
9.80 9.80 9.80 10.50 10.50 12.00 6.00 9.00 9.00 9.00 
14 14 14 15 15 15 10 12 12 12 
700 700 700 700 700 800 600 750 750 750 
25 25 25 25 25 25 - - - -
5.50 5.50 5.50 5.50 5.50 5.50 4.60 460 4.60 4.60 
70 65 70 80 80 80 45 40 40 45 
7.0 7.0 7.0 7.0 7.0 15.0 5.0 0.0 0.0 0.0 
9.80 9.80 10.50 10.50 12.00 12.00 6.00 9.00 9.00 900 
14.0 14.0 15.0 15.0 15.0 15.0 10.0 12.0 12.0 12.0 
700 700 700 700 800 800 600 750 750 750 
25 25 25 25 25 25 
- - - -
79 71 77 80 83 81 45 37 38 55 
7.0 5.5 7.0 8.0 8.5 8.0 3.0 1.0 1.0 1.5 
10.62 10.10 11.46 11.42 11.17 11.22 6.63 9.41 9.54 9.18 
15.0 14.5 15.5 15.5 155 14.5 12.0 12.5 12.5 12.0 
720 700 740 730 720 770 560 750 750 750 
33 33 33 33 33 33 33 33 33 33 
9 6 7 0 3 1 0 -3 -2 10 
0.0 -1.5 00 1.0 1.5 -7.0 -2.0 1.0 1.0 1.5 
082 030 0.96 0.92 -083 -0.78 0.63 0.40 0.54 0.18 
1.0 0.5 0.5 0.5 0.5 -0.5 2.0 0.5 0.5 00 
20 0 40 30 -80 -30 -40 0 0 0 
B 8 8 8 8 8 
- - - -
mod X mod exact good good exact good good mod 
exact mod exact good mod X mod good good mod 
mod good mod mod mod mod mod good mod good 
good good good good good good mod good good exact 
good exact good good mod good good exact exact exact 
mod mod mod mod mod mod nla nla nla nla 
IV 
\0 
"'" 
I Patient 10: 
I 1 I 2 
Observations 
Pa~(kPa) 12.9 19.6 
Pa~(kPa) 4.87 4.09 
pH 7A3 7.50 
PIP (cmHPl 37.0 37.0 
Weight (kg) 54.2 54.2 
Fi02 (%) 75 75 
Peep (cmHPl 9 9 
MY (I/min) 9.60 9.60 
RR (rpm) 12 12 
Vt(ml) 800 800 
Tin(%l 50 50 
Target PaCO. (kPa) 4.60 4.60 
Anaesthetist's New Settings 
Fi02 (%) 75 75 
Peep (cmHP) 9.0 9.0 
MY (llmin) 9.60 9.60 
RR (rpm) 12.0 12.0 
Vt(ml) 800 800 
Tin(%) 50 50 
Advisor New Settings 
Fi02 (%) 73 60 
PEEP (cmHP) 7.0 5.5 
MY (11m in) 9.66 8.54 
RR (rpm) 14.5 13.0 
Vt(ml) 660 650 
Tin(%) 50 50 
Decision Difference 
Fi02 (%) -2 -15 
Peep (cmHP) -2.0 -3.5 
Mv (llmin) 006 -1.06 
RR (rpm) 2.5 1.0 
Vt(ml) -140 -150 
Tin(%) 0 0 
Scoring 
Fi02 score good X 
Peep score mod X 
Mvscore good X 
RRscore mod good 
Vtscore X X 
Tin score exact exact 
I 3 I 
17.3 
4.38 
7.51 
38.0 
54.2 
75 
9 
9.60 
12 
800 
50 
4.60 
65 
9.0 
9.00 
12.0 
750 
50 
63 
6.0 
9.12 
14.0 
650 
50 
-2 
-3.0 
0.12 
2.0 
-100 
0 
good 
X 
good 
mod 
mod 
exact 
4 I 
14.1 
4.50 
7.52 
35.0 
54.2 
65 
9 
900 
12 
750 
50 
4.60 
65 
9.0 
9.00 
12.0 
750 
50 
62 
6.0 
8.82 
14.0 
620 
50 
-3 
-3.0 
-0.18 
2.0 
-130 
0 
good 
X 
good 
mod 
X 
exact 
I Patient 11: 
5 I 1 I 2 
13.2 11.9 12.3 
4.73 6.55 5.81 
7.50 7.12 7.18 
36.0 28.0 31.0 
54.2 76.0 76.0 
65 40 40 
9 4 4 
9.00 5.72 7.80 
12 11 15 
750 520 520 
50 
- -
4.60 4.80 4.80 
, 
55 40 40 ! 
9.0 4.0 4.0 ! 
9.00 7.80 9.36 I 
12.0 15.0 18.0 
750 520 520 
50 
- -
63 41 40 
6.0 3.0 3.0 
9.04 6.40 7.95 
14.5 120 15.0 
620 540 530 
50 33 33 
8 1 0 
-3.0 -1.0 -1.0 
004 -1.40 -1.41 
2.5 -3.0 -3.0 
-130 20 10 
0 - -
mod good exact 
X good good 
good X X 
mod mod mod 
X good good 
exact nla nla 
Table F.l: The observation data required by the modified advisor 
exstracted from the clinical records collected (see Section 8.2 for a brief 
synopsis of the patients recorded). All records were from patients on VC 
or PRVC modes of ventilation. The changes to the ventilator settings made 
by the attending anaesthetist are compared against those proposed by the 
advisor. The decision difference is shown together with the results of the 
qualitative scoring, see Section 8.4. 
Frequency 
Exact Good Moderate Poor 
F10l 36 54 20 16 
PEEP 32 33 26 35 
Mv 1 48 25 52 
RR 13 55 46 12 
VT 11 30 29 56 
TIN 42 0 58 1 
Total 135 220 204 172 
Percentage of Total 
Exact Good Moderate Poor 
FI01 28.6 42.9 15.9 12.6 
PEEP 25.4 26.2 20.6 27.8 
Mv 0.9 38.1 19.8 41.2 
RR 10.3 43.7 36.5 9.5 
VT 8.8 23.8 23.0 44.4 
TIN 41.6 0.0 57.4 1.0 
Total 18.5 30.1 27.9 23.5 
Table F.2: The qualitative scoring frequency distribution of the decision 
matching achieved by the advisor in response to the clinical data. 
Frequency 
Exact Good Moderate Poor 
FI01 20 13 5 0 
PEEP 18 14 5 1 
Mv 14 19 5 0 
RR 19 16 3 0 
VT 4 23 8 3 
TIN 28 0 10 0 
Total 103 85 36 4 
Percentage of Total 
Exact Good Moderate Poor 
FI01 52.6 34.2 13.2 0.0 
PEEP 47.4 36.8 13.2 2.6 
Mv 36.8 50.0 13.2 0.0 
RR 50.0 42.1 7.9 0.0 
VT 10.5 60.5 21.1 7.9 
TIN 73.7 0.0 26.3 0.0 
Total 45.2 37.3 15.8 1.7 
Table F.3: The qualitative scoring frequency distribution of the decision 
matching achieved by the advisor in response to the simulated closed-
loop data. 
Nomenclature 
Ph 
2,3-DPG 
ARDS 
ATPS 
BC02 
BPDIAS 
BPsyS 
BROPUS 
BTPS 
C.O. 
CaC02 
CAC02 
Ca02 
CA0 2 
CAW 
CC0 2 / C( C02) 
CetC02 
CMV 
C02 / C(0 2) 
CoG 
CoLA 
COPD 
CoS 
CP 
CPAP 
CpC02 
Cp02 
CRI 
CtC02 
Ct02 
CVC 
CVC02 
CV02 
DC02 
002 
oxygen carrying capacity of the blood plasma 
oxygen combining capacity of haemoglobin 
organ ic phosphate 2,3-d iphosphoglycerate 
adult respiratory distress syndrome 
atmospheric temperature pressure saturated 
diffusion capacity of the lung for carbon dioxide (per litre of blood flowing in 
pulmonary capillaries) 
diffusion capacity of the lung for oxygen (per litre of blood flowing in 
pulmonary capillaries) 
diastolic blood pressure 
systolic blood pressure 
block diagram representations of patient under simulation 
body temperature pressure saturated 
cardiac output (same as Qt) 
concentration of carbon dioxide in arterial blood 
concentration of carbon dioxide in alveolar gas 
concentration of oxygen in arterial blood 
concentration of oxygen in alveolar gas 
airway compliance 
concentration of carbon dioxide 
end-tidal concentration of carbon dioxide 
continuous mandatory ventilation 
concentration of oxygen 
centre-of-gravity 
centre-of-Iargest area 
chronic obstructive pulmonary disease 
centre-of-sums 
percentage of normal cardiac output 
continuous positive airway pressure 
concentration of carbon dioxide in pulmonary blood 
concentration of oxygen in pulmonary blood 
compositional rule of inference 
concentration of carbon dioxide in tissue blood 
concentration of oxygen in tissue blood 
central venous catheter 
concentration of carbon dioxide in venous blood 
concentration of oxygen in venous blood 
diffusion capacity of the lung for carbon dioxide 
diffusion capacity of the lung for oxygen 
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ePaC02 
epH 
ePIP 
eVTNORM 
FAC 
FAVeM 
FrC02 
FrOz 
FrSMAT 
FKBC 
FoM 
FRC 
GDF 
GUI 
[If] 
Hb 
HCOj 
HR 
I:E 
ICU 
IGDF 
IPPV 
IRI 
LoM 
LVF 
MATLAB 
MIDoM 
MoM 
MR 
Mv 
ODC 
OPM 
P50 
PAC 
PaC02 
PAC02 
Pa02 
PA0 2 
PB 
error from PaC02 set-point 
error from normal pH 
error from PIP set-point 
error from normal tidal volume 
femoral artery catheter 
fuzzy-logic based advisor for ventilation management 
fractional concentration of inspired carbon dioxide 
fractional concentration of oxygen in inspired breath 
fuzzy logic public domain toolbox for MATLAB 
fuzzy knowledge based controller 
first of maxima 
functional residual capacity 
gas dissociation function 
graphical user interface 
concentration of hydrogen ions 
haemoglobin concentration 
bicarbonate 
heart rate 
inspiratory-expiratory time ratio 
intensive care unit 
inverse gas dissociation function 
intermittent positive pressure ventilation 
individual rule of inference 
last of maxima 
left ventricular failure 
Matrix Laboratory - proprietary software for mathematical development 
middle of maxima 
mean of maxima 
percentage of normal metabolic rate 
minute volume 
normal minute volume (based on weight) 
oxygen dissociation curve 
observation processing module 
50 % saturation normal operating point of the oxygen dissociation curve 
pulmonary artery catheter 
partial pressure of carbon dioxide in arterial blood 
partial pressure of carbon dioxide in alveolar gas 
partial pressure of oxygen in arterial blood 
partial pressure of oxygen in alveolar gas 
atmospheric pressure 
297 
Pbco2 
Pbo2 
Pc~ 
PCV 
PEEP 
PH20 
PlP 
pK 
PMEAN 
P02 
PpC02 
Pp~ 
PRVC 
PSS 
PVC02 
PV C02 
PV02 
Qs/Qt 
Qs 
Qt 
RAC 
RAW 
RH 
RQ 
RR 
RTA 
SA 
SHBODC 
SIMULINK 
SIMV 
S0 2 
SOPAVent 
STPD 
TLC 
TIN 
TPAUSE 
UoD 
partial pressure of carbon dioxide in brain tissue 
partial pressure of oxygen in brain tissue 
partial pressure of carbon dioxide 
packed cell volume or haematocrit 
positive end expiratory pressure 
partial pressure of water 
peak inspiratory pressure 
logarithm of the inverse of the apparent first dissociation constant 
mean alveolar or airway pressure 
partial pressure of oxygen 
partial pressure of carbon dioxide in pulmonary blood 
partial pressure of oxygen in pulmonary blood 
pressure regulated volume control 
parameter sensitivity score 
partial pressure of carbon dioxide in venous blood 
partial pressure of carbon dioxide in mixed venous blood 
partial pressure of oxygen in venous blood 
shunt fraction (same as X) 
shunt blood flow 
cardiac output (same as C.O.) 
radial artery catheter 
airway resistance 
relative humidity 
respiratory gas exchange ratio or respiratory quotient 
respiratory rate 
road traffic accident 
sensitivity analysis 
standard human blood oxygen dissociation curve 
proprietary software for block diagram model development and simulation 
synchronised intermittent mandatory ventilation 
percent saturation of haemoglobin with oxygen 
simulation of patient under artificial ventilation 
standard temperature pressure dry 
total lung capacity 
expiratory time 
inspiratory time 
inspiratory time as percentage of whole breath 
pause time after inspiration as percentage of whole breath 
universe of discourse 
298 
Va 
VA 
VA 
VC 
V C02 
VD 
VD 
V0 2 
Vp 
VT 
Vt 
VTNORM 
Vv 
VWB 
V/Q 
WT 
X 
volume of ventilation per minute 
arterial blood volume 
alveolar gas volume 
alveolar ventilation per minute 
volume control 
rate of carbon dioxide production per minute 
dead space volume 
dead space ventilation per minute 
rate of oxygen consumption per minute 
pulmonary blood volume 
tidal volume 
tissue blood volume 
normal tidal volume (based upon patient weight) 
venous blood volume 
whole blood volume 
ventilation-perfusion ratio 
weight 
shunt fraction (same as Qs/Qt ) 
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